<SEC-DOCUMENT>0001213900-24-076184.txt : 20240905
<SEC-HEADER>0001213900-24-076184.hdr.sgml : 20240905
<ACCEPTANCE-DATETIME>20240905171825
ACCESSION NUMBER:		0001213900-24-076184
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		36
CONFORMED PERIOD OF REPORT:	20240829
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
ITEM INFORMATION:		Change in Shell Company Status
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240905
DATE AS OF CHANGE:		20240905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		241282218

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0213193-8k_orukathera.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ORKA="http://arcabio.com/20240829">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ORKA_arcabio.com_20240829 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20240829_20240829 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000907654 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000005" name="dei:EntityCentralIndexKey">0000907654</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="orka-20240829.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-29</xbrli:startDate>
        <xbrli:endDate>2024-08-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-292024-08-29_dei_FormerAddressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-29</xbrli:startDate>
        <xbrli:endDate>2024-08-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20240829__20240829_zMt1PMJM9Hc4"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding-right: 2.15pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of Report (Date of earliest event reported): <span id="xdx_905_edei--DocumentPeriodEndDate_c20240829__20240829_zVIplqzAskv4"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">August 29, 2024</ix:nonNumeric></span></b></span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20240829__20240829_zN6xBwvrRU74"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000012" name="dei:EntityRegistrantName">Oruka Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as Specified in its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 34%"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20240829__20240829_zsCtQ9xelB5c"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_90E_edei--EntityFileNumber_c20240829__20240829_zecAKVGGQXzg"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000014" name="dei:EntityFileNumber">000-22873</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20240829__20240829_zuB2t1NHXHrd"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000015" name="dei:EntityTaxIdentificationNumber">36-3855489</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(State or other jurisdiction<br/>
of incorporation)</b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Commission File Number)</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(IRS Employer<br/>
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20240829__20240829_zap5EBh3sIG"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000016" name="dei:EntityAddressAddressLine1">855 Oak Grove Avenue</ix:nonNumeric></span></b></span></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityAddressAddressLine2_c20240829__20240829_zz9ypLlCDXW1"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span><br/>
                                            <span id="xdx_900_edei--EntityAddressCityOrTown_c20240829__20240829_zdP05UHkBqQ4"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000018" name="dei:EntityAddressCityOrTown">Menlo Park</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20240829__20240829_z16V5kcezDxb"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240829__20240829_zgdTsImpNG26"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000020" name="dei:EntityAddressPostalZipCode">94025</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Address of principal executive offices)
    </b>&#160; </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="padding-right: 2.15pt; text-align: center"/></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code:</b>&#160;<b><span>(<span id="xdx_90B_edei--CityAreaCode_c20240829__20240829_zdJYHgSJrspj"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000021" name="dei:CityAreaCode">650</ix:nonNumeric></span>)</span> <span id="xdx_905_edei--LocalPhoneNumber_c20240829__20240829_zUDQqI2UKjhh"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000022" name="dei:LocalPhoneNumber">606-7910</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_906_edei--EntityRegistrantName_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_z9gcuKpiS7Qk"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" id="Fact000023" name="dei:EntityRegistrantName">ARCA biopharma, Inc.</ix:nonNumeric></span> </span><br/>
<span><span id="xdx_902_edei--EntityAddressAddressLine1_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zSooRrS0fGg6"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" id="Fact000024" name="dei:EntityAddressAddressLine1">10170 Church Ranch Way</ix:nonNumeric></span></span><br/>
<span><span id="xdx_904_edei--EntityAddressAddressLine2_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zDi1vq9M2qSd"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></span><span><br/> <span id="xdx_90B_edei--EntityAddressCityOrTown_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zP71dNbR2TM3"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" id="Fact000026" name="dei:EntityAddressCityOrTown">Westminster</ix:nonNumeric></span></span>, <span><span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_z8lW6CapMEw8"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" format="ixt-sec:stateprovnameen" id="Fact000027" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span>&#160;<span id="xdx_904_edei--EntityAddressPostalZipCode_c20240829__20240829__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_z2Ek2GkJi8J6"><ix:nonNumeric contextRef="From2024-08-292024-08-29_dei_FormerAddressMember" id="Fact000028" name="dei:EntityAddressPostalZipCode">80021</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--WrittenCommunications_c20240829__20240829_z4kw3BvWaGe3"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:booleanfalse" id="Fact000029" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--SolicitingMaterial_c20240829__20240829_zcLI9Iw2BKFl"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:booleanfalse" id="Fact000030" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--PreCommencementTenderOffer_c20240829__20240829_zTxvLJBCYax4"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:booleanfalse" id="Fact000031" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20240829__20240829_zpLjXxuhoBKe"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:booleanfalse" id="Fact000032" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    <b>Title of each class</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    <b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20240829__20240829_zd9MOnaNAUCa"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000033" name="dei:Security12bTitle">Common Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20240829__20240829_zmua4K8nsiV1"><ix:nonNumeric contextRef="AsOf2024-08-29" id="Fact000034" name="dei:TradingSymbol">ORKA</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The <span id="xdx_90F_edei--SecurityExchangeName_c20240829__20240829_zIIPjN88RKT1"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt-sec:exchnameen" id="Fact000035" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20240829__20240829_zPErBIIXosch"><ix:nonNumeric contextRef="AsOf2024-08-29" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024 (the &#8220;<b>Closing Date</b>&#8221;), Oruka Therapeutics, Inc., a Delaware corporation (formerly known as ARCA
biopharma, Inc.) (prior to the Closing Date, unless context otherwise requires, &#8220;<b>ARCA</b>&#8221; and, after the Closing
Date, the &#8220;<b>Company</b>&#8221;), consummated the previously announced business combination (the
&#8220;<b>Closing</b>&#8221;) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024
(the &#8220;<b>Merger Agreement</b>&#8221;), by and among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned
subsidiary of ARCA (&#8220;<b>First Merger Sub</b>&#8221;), Atlas Merger Sub II, LLC, a Delaware limited liability company and
wholly owned subsidiary of ARCA (&#8220;<b>Second Merger Sub</b>&#8221;), and Oruka Therapeutics, Inc., a private Delaware
corporation (&#8220;<b>Oruka</b>&#8221;) prior to the consummation of the Merger (as defined herein).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of and upon the effective time of the First Merger (as defined herein) (the &#8220;<b>First Effective Time</b>&#8221;), among
other things, (i) each then-issued and outstanding share of common stock, par value $0.0001 per share, of Oruka (the &#8220;<b>Oruka
Common Stock</b>&#8221;) (including any shares of Oruka Common Stock issued pursuant to Oruka&#8217;s Pre-Closing&#160;Financing, described
in more detail below) immediately prior to the First Effective Time (excluding shares cancelled pursuant to the Merger Agreement and
excluding dissenting shares) automatically converted solely into the right to receive a number of shares of ARCA common stock, par value
$0.001 (the &#8220;<b>Company Common Stock</b>&#8221; and prior to the effective time of the Merger, the &#8220;<b>ARCA Common Stock</b>&#8221;),
equal to the Exchange Ratio (as defined herein) of 6.8569 shares of ARCA Common Stock (described in more detail below), (ii) each share
of Oruka&#8217;s Series A convertible preferred stock, par value $0.0001 (the &#8220;<b>Oruka Series A Preferred Stock</b>&#8221;), outstanding
immediately prior to the First Effective Time (excluding shares cancelled pursuant to the Merger Agreement and excluding dissenting shares)
automatically converted solely into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock,
par value $0.001 per share (the &#8220;<b>Company Preferred Stock</b>&#8221;), which are each convertible into 1,000 shares of Company
Common Stock, and further adjusted for the Exchange Ratio divided by 1,000, (iii) each outstanding option to purchase Oruka Common Stock
was assumed by ARCA and converted into an option to purchase shares of Company Common Stock, subject to adjustment as set forth in the
Merger Agreement, (iv)&#160;each outstanding&#160;warrant to purchase shares of Oruka Common Stock was converted into a warrant to purchase
shares of Company Common Stock, subject to adjustment as set forth in the Merger Agreement, (v)&#160;each outstanding in-the-money&#160;option
to acquire shares of ARCA Common Stock (whether vested or unvested) was cancelled and converted into the right to receive an amount in
cash equal to the excess of $3.9489, the volume weighted average closing price of ARCA Common Stock on The Nasdaq Stock Market LLC (&#8220;<b>Nasdaq</b>&#8221;)
for the five (5) consecutive&#160;trading days ending three (3)&#160;trading days prior to the closing of the First Merger, over the
option&#8217;s exercise price and (vi)&#160;each share of ARCA Common Stock issued and outstanding at the First Effective Time remain
issued and outstanding in accordance with its terms and such shares, subject to the reverse stock split of 1-for-12 effected on September
3, 2024. The amounts described above do not give effect to the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of ARCA Common Stock were issued in connection with the Merger, and no certificates or scrip for any such fractional
shares were issued. Any fractional shares of ARCA Common Stock resulting from the conversion of shares of Oruka Common Stock (including
shares of Oruka Common Stock issued in the Oruka Pre-Closing&#160;Financing) were issued as follows: (i)&#160;one share of ARCA Common
Stock if the aggregate amount of fractional shares of ARCA Common Stock of any individual holder of Oruka capital stock if upon conversion
was equal to or exceeded 0.50 or (ii)&#160;no shares of ARCA Common Stock if the aggregate amount of fractional shares of ARCA Common
Stock of any individual holder of Oruka capital stock if upon conversion was less than 0.50. Any fractional shares of Company Preferred
Stock otherwise entitled to be received was aggregated with all fractional shares of Company Preferred Stock issuable to such holder
and rounded up to the nearest whole share of Company Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exchange Ratio was calculated using a formula intended to allocate existing ARCA and Oruka securityholders a percentage of the combined
company. Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of August 29, 2024, the Exchange Ratio was 6.8569 shares of ARCA
Common Stock. After giving effect to the Oruka Pre-Closing Financing, immediately following the completion of the Merger, ARCA securityholders
own approximately 2.39% of the capital stock of the combined company, and Oruka securityholders, including shares of Oruka Common Stock
and Oruka pre-funded warrants purchased in the Oruka Pre-Closing Financing, own approximately 97.61% of the capital stock of the combined
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on August 28, 2024, the Company paid a special cash dividend (the &#8220;<b>special cash dividend</b>&#8221;) of an aggregate
amount of cash total of approximately $23.4&#160;million and distributed $1.613 per share of ARCA Common Stock to stockholders of record
of outstanding shares of ARCA Common Stock as of a record date of August 26, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, First Merger Sub merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving
corporation of the merger (the &#8220;<b>First Merger</b>&#8221;), and Oruka merged with and into Second Merger Sub, with Second Merger
Sub being the surviving entity of the merger (the &#8220;<b>Second Merger</b>&#8221; and, together with the First Merger, the &#8220;<b>Merger</b>&#8221;),
whereby the bylaws of the Company, dated August 29, 2024, were amended and restated in the form attached hereto as Exhibit 3.6. In connection
with the completion of the Merger, Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;
and ARCA changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; (the &#8220;<b>Company Name Change</b>&#8221;). The Merger is intended
to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue
Code of 1986, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material provisions of the Merger Agreement are described in ARCA&#8217;s definitive proxy statement/prospectus filed on Form S-4 with
the U.S. Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) and declared effective on July 24, 2024 (the &#8220;<b>Proxy
Statement/Prospectus</b>&#8221;) in the section entitled &#8220;<i>The Merger Agreement</i>&#8221; beginning on page 135 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Merger Agreement is not complete and is subject to and qualified in its entirety by reference to the complete
text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1 and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Support
and Lock-Up Agreements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the execution of the Merger Agreement, (a) certain stockholders of ARCA (solely in their respective capacities as ARCA stockholders)
holding approximately 28.5% of the outstanding shares of ARCA Common Stock entered into support agreements with ARCA and Oruka to vote
all of their shares of ARCA Common Stock in favor of the adoption and approval of the Merger Agreement, and the transactions contemplated
thereby, and against any alternative acquisition proposals (the &#8220;<b>ARCA Support Agreements</b>&#8221;) and (b) certain stockholders
of Oruka (solely in their respective capacities as Oruka stockholders) holding approximately 90% of the outstanding shares of Oruka capital
stock entered into support agreements with ARCA and Oruka to vote all of their shares of ARCA Common Stock in favor of Proposals 1, 2
and 3 of the stockholder proposals further described in Item 5.07 of this Current Report on Form 8-K under the heading &#8220;<i>Submission
of Matters to a Vote of Security Holders</i>,&#8221; which is incorporated herein by reference, and against any alternative acquisition
proposals (the &#8220;<b>Oruka Support Agreements</b>,&#8221; and, together with the ARCA Support Agreements, the &#8220;<b>Support Agreements</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the execution of the Merger Agreement, certain executive officers, directors and stockholders of Oruka entered into lock-up agreements
(the &#8220;<b>Lock-Up Agreements</b>&#8221;) pursuant to which such parties have agreed not to, except in limited circumstances, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA Common Stock or any securities
convertible into or exercisable or exchangeable for ARCA Common Stock, currently or thereafter owned, including shares of ARCA Common
Stock issuable upon conversion of Company Preferred Stock issued in exchange for shares of Oruka Series A Preferred Stock in the Merger,
but excluding, as applicable, shares purchased in the Oruka Pre-Closing&#160;Financing (including any shares of ARCA Common Stock issuable
upon exercise of pre-funded&#160;warrants issued in exchange for pre-funded&#160;warrants to purchase shares of Oruka Common Stock sold
in the Oruka Pre-Closing&#160;Financing), until 180&#160;days following the Closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Descriptions
of the Support Agreements and the Lock-Up Agreements are included in the Proxy Statement/Prospectus in the sections entitled &#8220;<i>Agreements
Related to the Merger-Support Agreements</i>&#8221; and &#8220;<i>Agreements Related to the Merger-Lock-Up Agreements</i>&#8221; on page
153 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Support Agreements and the Lock-Up Agreements are not complete and are subject to and qualified in their
entirety by reference to the complete text of the Form of Oruka Support Agreement, the Form of ARCA Support Agreement and the Form of
Lock-Up Agreement, copies of which are attached hereto as Exhibits 10.7, 10.8 and 10.9, respectively, and are incorporated herein by
reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Transaction </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka (the &#8220;<b>Financing Investors</b>&#8221;)
entered into a subscription agreement with Oruka (the &#8220;<b>Subscription Agreement</b>&#8221;), pursuant to which, and on the terms
and subject to the conditions of which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Oruka
Common Stock and 9,664,208 Oruka pre-funded&#160;warrants (collectively, the &#8220;<b>Financing Securities</b>&#8221;) for gross proceeds
of approximately $275.0&#160;million (which includes $25.0&#160;million of proceeds previously received from the issuance of the Convertible
Note and accrued interest on such note which converted to 4,764,032 shares of Oruka Common Stock), immediately prior to the Closing and before the effect of the Reverse
Stock Split (as defined below) (the &#8220;<b>Pre-Closing Financing</b>&#8221;).
At the Closing, the shares of Oruka Common Stock and Oruka pre-funded&#160;warrants issued in the Pre-Closing&#160;Financing were converted
into shares of ARCA Common Stock in accordance with the Exchange Ratio (as defined herein).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties
of the purchaser parties thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of the Subscription Agreement is included in the Proxy Statement/Prospectus in the section entitled &#8220;<i>Agreements
Related to the Merger-Subscription Agreement</i>&#8221; beginning on page 153 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Subscription Agreement is not complete and is subject to and qualified in its entirety by reference to the
complete text of the Subscription Agreement, a copy of which is attached hereto as Exhibit 10.25 and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indemnification
Agreements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, the Company entered into indemnification agreements with each of its directors and executive officers (collectively,
the &#8220;<b>Indemnitees</b>&#8221; and, the &#8220;<b>Indemnification Agreements</b>&#8221;), which replaced and superseded any previous
indemnification agreements between the Company and each such individual. The Indemnification Agreements provide for certain indemnification
and advancement of expenses by the Company in connection with actions or proceedings arising out of the Indemnitees&#8217; service as
directors or officers of the Company or service to other entities at the Company&#8217;s request, on the terms and subject to the conditions
set forth therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Indemnification Agreements is not complete and is subject to and qualified in its entirety by reference
to the complete text of the Indemnification Agreements, the form of which is attached hereto as Exhibit 10.9 and incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Antibody
Discovery and Option Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2024, Oruka entered into the license agreements, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;<b>Paragon</b>&#8221;)
and Paruka Holding LLC (&#8220;<b>Paruka</b>&#8221;), subsequently amended and restated on March 28, 2024 (the &#8220;<b>Paragon Option
Agreements</b>&#8221;). Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain
mutually agreed therapeutic targets of interest to Oruka. Under the Paragon Option Agreements, Oruka has the exclusive option to, on
a research program-by-research&#160;program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title,
and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize
the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;<b>Option</b>&#8221;).&#160;From time to time, Oruka
can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. As of the date hereof, Oruka has
not exercised any Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of the Paragon Option Agreements&#160;is set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Oruka&#8217;s
Business-License Agreements</i>&#8221; beginning on page 228 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Paragon Option Agreements&#160;is not complete and is subject to and qualified in its entirety by reference
to the complete text of the Paragon Option Agreements, copies of which are attached hereto as Exhibits 10.21 and 10.22 and incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2.01 Completion of Acquisition or Disposition of Assets.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosure set forth in the &#8220;<i>Introductory Note</i>&#8221; above, including with respect to the Merger, is incorporated into
this Item 2.01 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the proposals included in the Proxy Statement/Prospectus were approved by ARCA stockholders at a special meeting of stockholders held
on August 22, 2024 (the &#8220;<b>Special Meeting</b>&#8221;) other than the proposal to adjourn the Special Meeting, which was not presented
to the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Merger, on the Closing Date (prior to the Reverse Stock Split (as defined below)):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
                                            issued to the Financing Investors an aggregate of 39,873,706 shares of Oruka Common Stock
                                            and 9,664,208 Oruka pre-funded&#160;warrants for gross proceeds of approximately $275.0 million,
                                            inclusive of 4,764,032 shares issuable on conversion of the Convertible Note; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of the then-outstanding (i) 9,460,019 shares of
                                                                                                                                                      Oruka Common Stock, (ii) 20,000,000 shares of Oruka Series A Preferred Stock, (iii) 2,063,669 options exercisable for shares of
                                                                                                                                                      Oruka Common Stock, (iv) 5,345,336 Oruka employee&#160;warrants and (v) the Pre-Closing Financing Oruka Common Stock and pre-funded
                                                                                                                                                      warrants were automatically converted into the right to receive the number of Company Common Stock, Series B Preferred Stock or
                                                                                                                                                      Company warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the
                                                                                                                                                      &#8220;<b>Exchange Ratio</b>&#8221;), except for the preferred stock which was converted at a one to one ratio.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the consummation of the transactions contemplated by the Merger Agreement, and immediately following the Reverse Stock Split (as defined
below), the Company had 46,348,968 shares of Company Common Stock outstanding (assuming the exercise in full of all Company pre-funded
warrants and not including outstanding employee and director equity awards nor preferred stock), which is comprised of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,398,595
                                            shares of Company Common Stock (inclusive of issuances pursuant to the Merger Agreement and
                                            the Pre-Closing Financing);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,522,207
                                            Company pre-funded warrants, each exercisable for one share of Company Common Stock at a
                                            price of $0.001 per share; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,428,166
                                            shares of Company Common Stock underlying Company Preferred Stock.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the consummation of the Merger, the Company effected a 1-for-12 reverse stock split of the Company Common Stock (the &#8220;<b>Reverse
Stock Split</b>&#8221;), which became effective on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock
Split, post-Merger basis at the open of trading on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10 INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
2.01(f) of Form 8-K states that if the predecessor registrant was a &#8220;shell company&#8221; (as such term is defined in Rule 12b-2
under the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;)), as ARCA was immediately before the Merger,
then the registrant must disclose the information that would be required if the registrant were filing a general form for registration
of securities on Form 10. Accordingly, the Company is providing the information below that would be included in a Form 10 if the Company
were to file a Form 10. Please note that the information provided below relates to the Company as the combined company after the consummation
of the Merger, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cautionary
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and 21E of the Exchange Act, including statements regarding the anticipated benefits of the Merger and the financial condition, results
of operations, and prospects of the Company. These statements may discuss goals, intentions and expectations as to future plans, trends,
events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of the
Company, as well as assumptions made by, and information currently available to, the management of the Company. Forward-looking statements
generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words
such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221;
and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate
future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts
are forward-looking statements. Forward-looking statements in this communication include, but are not limited to, the section titled
&#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221;<i>&#160;</i>in this
Current Report on Form 8-K. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties
and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement
as a result of various factors, including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            limited operating history of the Company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to raise additional capital to finance operations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company&#8217;s product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to advance product candidates through preclinical and clinical development;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            actions with respect to the Company&#8217;s product candidates or its competitors&#8217;
                                            products and product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of the Company to manufacture its product candidates in conformity with the FDA&#8217;s
                                            requirements and to scale up manufacturing of its product candidates to commercial scale,
                                            if approved, and the rate and degree of market acceptance of such product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            outcome of preclinical testing and early clinical trials for the Company&#8217;s product
                                            candidates, including the ability of those trials to satisfy relevant governmental or regulatory
                                            requirements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company&#8217;s limited experience in designing clinical trials and lack of experience in
                                            conducting clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to identify and pivot to other programs, product candidates, or indications that
                                            may be more profitable or successful than the Company&#8217;s current product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            regarding the market and potential for the Company&#8217;s current product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            difficulty in predicting the time and cost of development of the Company&#8217;s product
                                            candidates; the substantial competition the Company faces in discovering, developing, or
                                            commercializing products;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
                                            regarding the potential tolerability, safety or efficacy for the Company&#8217;s current
                                            product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of the Company to protect its intellectual property and proprietary technologies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
                                            on third parties, contract manufacturers, and contract research organizations;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            adverse reactions to changes in business relationships resulting from the completion of the
                                            Merger; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislative,
                                            regulatory, political and economic developments and general market conditions beyond the
                                            Company&#8217;s control.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive
and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the
&#8220;<i>Risk Factors</i>&#8221; section of this Current Report on Form 8-K and other documents to be filed by the Company from time
to time with the SEC, discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings
with the SEC, and risk factors associated with companies, such as the Company, that operate in the biopharma industry. These forward-looking
statements involve a number of risks, uncertainties (some of which are beyond the Company&#8217;s control) or other assumptions that
may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein
will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements
in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements
herein. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement,
or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
and Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Oruka&#8217;s Business</i>&#8221; beginning
on page 214 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2024, Oruka entered into the Paragon Option Agreements. The information set forth in Item 1.01 of this Current Report on Form
8-K under the heading &#8220;<i>Antibody Discovery and Option Agreements</i>&#8221; is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks associated with Oruka&#8217;s business and operations are described in the Proxy Statement/Prospectus in the section entitled &#8220;<i>Risk
Factors-Risks Related to Oruka</i>&#8221; beginning on page 49 and the risks associated with the business and operations of the combined
company are described in the Proxy Statement/Prospectus in the section entitled &#8220;<i>Risk Factors-Risks Related to the Combined
Company</i>&#8221; beginning on page 80, each of which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unaudited
Financial Statements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited interim condensed consolidated financial statements of Oruka as of June 30, 2024 as well as the three months ended June 30,
2024 and for the period from February 6, 2024 (inception) to June 30, 2024 and the related notes thereto are attached hereto as Exhibit
99.3 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audited
Financial Statements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited financial statement of Oruka as of February 6, 2024 and the related notes thereto are attached hereto as Exhibit 99.2 and are
incorporated herein by reference, which includes the reissued, audited opening balance sheet, which gives effect to the Reverse Stock
Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited financial statements of ARCA as of and for the years ended December 31, 2023 and 2022 and the related notes thereto are included
in the Proxy Statement/Prospectus beginning on page F-2 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unaudited
Pro Forma Condensed Combined Financial Information </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information of ARCA and Oruka as of June 30, 2024 and for the six months ended June
30, 2024 and as of and for the year ended December 31, 2023 and the related notes thereto are attached hereto as Exhibit 99.5 and are
incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2024 as well as the three months ended June 30,
2024 and for the period from February 6, 2024 (inception) to June 30, 2024 is set forth in Exhibit 99.4 to this Current Report on Form
8-K, and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information regarding management&#8217;s discussion and analysis of the financial condition and results of operations prior to the Merger
is included in the Proxy Statement/Prospectus in the sections entitled &#8220;<i>ARCA&#8217;s Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations</i>&#8221; beginning on page 250, which are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 of this Current Report on Form 8-K under the heading &#8220;<i>Antibody Discovery and Option Agreements</i>&#8221;
is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security
Ownership of Certain Beneficial Owners and Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information known to the Company regarding beneficial ownership of shares of Company Common Stock as of August
29, 2024 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person or group of affiliated persons, who is known by the Company to be the beneficial owner
                                            of more than 5% of Company Common Stock;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of the Company&#8217;s directors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of the Company&#8217;s named executive officers; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of the Company&#8217;s current directors and executive officers as a group.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
column entitled &#8220;Percentage of Shares Outstanding Beneficially Owned&#8221; is based on a total of 29,398,595 shares of Company Common Stock outstanding as of
August 29, 2024, after giving effect to the Reverse Stock Split that was effected on September 3, 2024 and the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect
to Company Common Stock. Shares of Company Common Stock subject to options that are currently exercisable or exercisable within 60 days
of August 29, 2024 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating
the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as
otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of Company
Common Stock beneficially owned by them, subject to community property laws, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Name of Beneficial Owner</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number&#160;of <br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage <br/> of&#160;Shares <br/> Outstanding <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Fairmount Funds Management LLC<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,611,255</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Venrock Healthcare Capital Partners<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,937,064</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FMR LLC<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,573,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with RTW Investments, LP<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,543,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Named Executive Officers and Directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">852,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Arjun Agarwal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Joana Goncalves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Paul Quinlan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael R. Bristow<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Thomas A. Keuer<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">C. Jeffrey Dekker<sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron Turtle<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Samarth Kulkarni</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Harwin<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,611,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Carl Dambkowski</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Kristine Ball</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All executive officers and directors as a group (9&#160;persons)<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,548,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.18</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than 1%.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) (A) 363,614
                                                                                                                                     shares of the combined company&#8217;s common stock and (B) 3,674,333 shares of the combined company's common stock issuable upon
                                                                                                                                     conversion of 44,092 shares of preferred stock held by Fairmount Healthcare Fund II L.P. (&#8220;<b>Fairmount Fund II</b>&#8221;)
                                                                                                                                     and (ii) 2,573,308 shares of the combined company&#8217;s common stock held by Fairmount Healthcare Co-Invest III L.P.
                                                                                                                                     (&#8220;<b>Fairmount Fund III</b>&#8221;). Excludes (i) 5,297,664 shares of the combined company&#8217;s common stock issuable upon
                                                                                                                                     the exercise of the pre-funded warrants and (ii) 7,753,833 shares of the combined company&#8217;s common stock issuable upon the
                                                                                                                                     conversion of preferred stock owned by Fairmount Fund II. The pre-funded warrants are subject to a beneficial ownership limitation
                                                                                                                                     of 9.99% and the shares of preferred stock are subject to a beneficial ownership limitation of 19.99%, which such limitations
                                                                                                                                     restrict Fairmount Funds Management LLC (&#8220;<b>Fairmount</b>&#8221;) and its affiliates from exercising that portion of the
                                                                                                                                     warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or
                                                                                                                                     conversion, a number of shares of the combined company&#8217;s common stock in excess of the applicable ownership limitation. At
                                                                                                                                     such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of the combined company's common stock, the
                                                                                                                                     beneficial ownership limitation applicable to the shares of preferred stock will automatically reduce to 9.99%. Fairmount serves as
                                                                                                                                     investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to
                                                                                                                                     Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund
                                                                                                                                     III&#8217;s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power
                                                                                                                                     over the securities they hold and may not revoke that delegation on less than 61 days&#8217; notice, Fairmount Fund II and Fairmount
                                                                                                                                     Fund III disclaim beneficial ownership of the securities they hold. The general partner of Fairmount is Fairmount Funds Management
                                                                                                                                     GP LLC (&#8220;<b>Fairmount GP</b>&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed to
                                                                                                                                     have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Fairmount GP, Peter
                                                                                                                                     Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The
                                                                                                                                     address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 2,232,444 shares of the combined company&#8217;s common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;<b>VHCPEG</b>&#8221;),
(ii) 639,226 shares of the combined company&#8217;s common stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;<b>VHCP3</b>&#8221;),
and (iii) 63,950 shares of the combined company&#8217;s common stock held by VHCP Co-Investment Holdings III, LLC (&#8220;<b>VHCPCo3</b>&#8221;).
Excludes 170,720, 48,928 and 4,895 shares of the combined company&#8217;s common stock issuable upon the exercise of the pre-funded warrants
held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants are subject to a beneficial ownership limitation of 9.99%, which
such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants that would
result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of the combined company&#8217;s
common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;<b>VHCPM3</b>&#8221;) is the sole general
partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;<b>VHCPM EG</b>&#8221;) is the sole general partner
of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially
owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New
York, NY 10018.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
shares of the combined company&#8217;s common stock are held by funds and accounts managed by direct or indirect subsidiaries of FMR
LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including
Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing
49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217;
voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting
common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement,
members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR
LLC. The principal business address of each of these persons and entities is 245 Summer Street, Boston, MA 02210.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of 1,543,984 shares of the combined company&#8217;s common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;<b>RTW Master
Fund</b>&#8221;), RTW Innovation Master Fund, Ltd. (&#8220;<b>RTW Innovation Master Fund</b>&#8221;), and RTW Biotech Opportunities Operating
Ltd. (&#8220;<b>RTW Biotech</b>&#8221; and together with RTW Master Fund and RTW Innovation Fund, the &#8220;<b>RTW Funds</b>&#8221;).
RTW Investments, LP (&#8220;<b>RTW</b>&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and
the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of
such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities
held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest
therein. The principal business address of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr.
Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
852,338 shares of restricted voting common stock.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for Michael
Bristow&#8217;s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Keuer resigned as named executive officer at the Closing of the Merger and his last day of employment was September 1, 2024, which termination was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA. </span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Dekker resigned as named executive officer at the Closing of the Merger and his last day of employment was September 1, 2024, which termination was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA. </span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
85,233 shares of restricted voting common stock held by the Turtle Family Trust, for which Mr. Turtle serves as Trustee.</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
notes (1), (5) and (9) above.</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 5.02 of this Current Report on Form 8-K under the heading &#8220;<i>Appointment of Directors and Certain
Officers</i>&#8221; is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of the directors of Oruka prior to the Closing is set forth in the Proxy Statement/Prospectus in the section entitled &#8220;<i>Oruka
Director Compensation</i>&#8221; beginning on page 175 and is incorporated herein by reference. The compensation of the directors of
Oruka following the Closing is set forth in the Proxy Statement/Prospectus in the section entitled &#8220;<i>Management Following the
Merger-Director Compensation</i>&#8221; on page 279 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of the named executive officers of Oruka prior to the Closing is set forth in the Proxy Statement/Prospectus in the section
entitled &#8220;<i>Oruka Executive Compensation</i>&#8221; beginning on page 173 and is incorporated herein by reference.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of the named executive officers of ARCA prior to the Closing is set forth in the Proxy Statement/Prospectus in the section
entitled &#8220;<i>ARCA Executive Compensation</i>&#8221; beginning on page 166 and is incorporated herein by reference.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 5.02 of this Current Report on Form 8-K under the headings &#8220;<i>Stock Incentive Plan&#8221; </i>and
<i>&#8220;Departure of Directors and Certain Officers&#8221; </i>is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Management Following the Merger-Compensation
Committee</i>&#8221; beginning on page 277 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Certain Relationships and Related Party Transactions
of the Combined Company</i>&#8221; beginning on page 280 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
newly constituted board of directors of the Company (the &#8220;<b>Board</b>&#8221;) has determined that each of the directors other
than Lawrence Klein, the Company&#8217;s current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter
Harwin, Samarth Kulkarni and Cameron Turtle, each of whom is a current member of the Board, qualify as &#8220;independent directors&#8221;
as defined by the Nasdaq listing rules. In making these determinations, the Board considered the current and prior relationships that
each director has with ARCA and Oruka and all other facts and circumstances that the Board deemed relevant in determining the independence
of each director, including the interests of each director in the Merger, any relevant related party transactions and the beneficial
ownership of securities of ARCA, Oruka or the Company by each director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has also determined that each member of the Audit Committee (as defined below) and Compensation Committee (as defined below) is
independent and satisfies the relevant independence requirements for such committees under the Nasdaq listing rules and the Exchange
Act and that each member of the Compensation Committee is a &#8220;non-employee director&#8221; as defined in Rule 16b-3 promulgated
under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 5.02 of this Current Report on Form 8-K under the heading &#8220;<i>Committees of the Board of Directors</i>&#8221;
is incorporated herein by reference.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>ARCA Business-Legal Proceedings</i>&#8221;
on page 213 and in the section entitled &#8220;<i>Oruka&#8217;s Business-Legal Proceedings</i>&#8221; on page 249 is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of ARCA Common Stock were historically listed on The Nasdaq Capital Market of the Nasdaq Stock Market under the symbol &#8220;ABIO.&#8221;
On September 3, 2024, shares of Company Common Stock were listed on The Nasdaq Global Market of the Nasdaq Stock Market under the symbol
&#8220;ORKA.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Closing Date and following the completion of the Merger and after giving effect to the Reverse Stock Split effected on September
3, 2024, the Company had approximately 29,398,595 shares of Company Common Stock issued and outstanding held of record by approximately
 68 holders. The number of holders of record does not include a substantially greater number of &#8220;street name&#8221; holders
or beneficial holders whose shares of Company Common Stock are held of record by banks, brokers and other financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Market Price and Dividend Information-Dividends</i>&#8221;
on page 14 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Registrant&#8217;s Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the section of the Proxy Statement/Prospectus entitled &#8220;<i>Description of ARCA Capital Stock</i>&#8221;
beginning on page 296 and in the section entitled &#8220;<i>Comparison of Rights of Holders of ARCA Capital Stock and Oruka Capital Stock</i>&#8221;
beginning on page 301 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
of Directors and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Amended and Restated Charter (as defined below) contains provisions that eliminate, to the fullest extent permitted by law, the personal
liability of directors and officers for monetary damages for breach of fiduciary duty as a director or an officer. The Amended and Restated
Charter also provides that, to the fullest extent permitted by law, the Company may indemnify and advance expenses to its directors,
officers or employees and may maintain liability insurance on behalf of a director or an officer. The Amended and Restated Bylaws (as
defined below) provide that the Company shall indemnify and advance expenses to its directors and executive officers and may indemnify
and advance expenses to its employees or other agents, to the fullest extent permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Amended and Restated Charter and Amended and Restated Bylaws do not purport to be complete and are subject
to and qualified in their entirety by reference to the full text of the Amended and Restated Charter and Amended and Restated Bylaws,
copies of which are attached hereto as Exhibits 3.5 and 3.6, respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company obtained insurance that covers certain liabilities of its directors and officers, effective as of August 29, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 of this Current Report on Form 8-K under the heading &#8220;<i>Indemnification Agreements</i>&#8221;
is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in the sections of the Proxy Statement/Prospectus entitled &#8220;<i>The Merger Agreement-Indemnification and Insurance
for Directors and Officers</i>&#8221; beginning on page 147 and &#8220;<i>Part II, Item 20. Indemnification of Directors and Officers&#8212;Delaware</i>&#8221;
beginning on page II-1 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Information and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2.02 Results of Operations and Financial Condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unaudited interim condensed consolidated financial statements of
Oruka as of June 30, 2024 as well as the three months ended June 30, 2024 and for the period from February 6, 2024 (inception) to June
30, 2024 and the related notes thereto are attached hereto as Exhibit 99.3 and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations as of June 30, 2024 as well as the three months ended June 30, 2024 and for the period from February 6, 2024 (inception)
to June 30, 2024 is set forth in Exhibit 99.4 to this Current Report on Form 8-K, and is incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.03 Material Modification to Rights of Security Holders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARCA
convened and adjourned the Special Meeting on August 22, 2024. At the Special Meeting, ARCA&#8217;s stockholders approved, among other
matters, amendments to the amended and restated certificate of incorporation of ARCA to (i) increase the number of authorized shares
of Company Common Stock from 100,000,000 shares to 545,000,000 (the &#8220;<b>Authorized Share Increase</b>&#8221;), (ii) effect the
Reverse Stock Split and (iii) reflect Delaware law provisions regarding officer exculpation (the &#8220;<b>Officer Exculpation Proposal</b>&#8221;).
Following the Special Meeting, ARCA&#8217;s board of directors approved the Reverse Stock Split at a ratio of 12:1. On August 29, 2024,
ARCA filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the Company Preferred Stock,
effective immediately upon filing (the &#8220;<b>Certificate of Designation</b>&#8221;). Immediately thereafter on August 29, 2024, ARCA
filed a Certificate of Elimination with the Secretary of State of the State of Delaware eliminating the old Oruka Series A Preferred
Stock, effective immediately upon filing (the &#8220;<b>Certificate of Elimination</b>&#8221;). To effect the Officer Exculpation Proposal,
ARCA filed a Certificate of Amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware (the &#8220;<b>Officer Exculpation Certificate of Amendment</b>&#8221;), effective immediately upon filing,
on August 29, 2024. To effect the Authorized Share Increase, ARCA filed a Certificate of Amendment to the Company&#8217;s Amended and
Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#8220;<b>Authorized Share Increase Certificate
of Amendment</b>&#8221;), with an effective time of 4:01 p.m., Eastern Time, on August 29, 2024. To effect the Reverse Stock Split, ARCA
filed a Certificate of Amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation with the Secretary of State
of the State of Delaware (the &#8220;<b>Reverse Stock Split Certificate of Amendment</b>&#8221;), with an effective time of 12:01 a.m.,
Eastern Time, on September 3, 2024 (&#8220;<b>Reverse Stock Split Certificate of Amendment Effective Time</b>&#8221;). To effect the
Company Name Change (as defined in Item 1.01 of this Current Report on Form 8-K under the heading &#8220;<i>Introductory Note</i>&#8221;),
ARCA filed a Certificate of Amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware (the &#8220;<b>Name Change Certificate of Amendment</b>&#8221;), with an effective time of 4:03 p.m.,
Eastern Time, on August 29, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Reverse Stock Split Certificate of Amendment Effective Time, every twelve shares of Company Common Stock issued and outstanding
immediately prior to the Reverse Stock Split were automatically and without further action on the part of the Company or any holders
of such Company Common Stock, combined into one share of Company Common Stock. Immediately following the Reverse Stock Split, there were
approximately 29,398,595 shares of Company Common Stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Company Common Stock were issued as a result of the Reverse Stock Split. Instead, any stockholder who would otherwise
be entitled to a fractional share of Company Common Stock as a result of the Reverse Stock Split (after aggregating all fractions of
a share to which such stockholder would otherwise be entitled) is, in lieu thereof, entitled to receive a cash payment equal to the product
of such resulting fractional interest in one share of Company Common Stock multiplied by the closing price per share as reported by The
Nasdaq Stock Market LLC on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis
at the open of trading on September 3, 2024, at which time the Company Common Stock was represented by a new CUSIP number (687604108).
The par value per share of the Company Common Stock will remain unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Officer Exculpation Certificate of Amendment, Authorized Share Increase Certificate of Amendment, Name
Change Certificate of Amendment, Reverse Stock Split Certificate of Amendment, Certificate of Designation and Certificate of Elimination
do not purport to be complete and are subject to and qualified in their entirety by the full text of the Officer Exculpation Certificate
of Amendment, Authorized Share Increase Certificate of Amendment, Name Change Certificate of Amendment, Reverse Stock Split Certificate
of Amendment, Certificate of Designation and Certificate of Elimination, copies of which are attached hereto as Exhibits 3.1, 3.2, 3.3,
3.4, 3.7 and 3.8, respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4.01 Changes in Registrant&#8217;s Certifying Accountant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(a)</i></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dismissal
                                            of Independent Registered Public Accounting Firm</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KPMG
LLP (&#8220;<b>KPMG</b>&#8221;) served as the independent registered public accounting firm of ARCA prior to the consummation of the
Merger. On August 30, 2024, KPMG was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss
KPMG was approved by the Audit Committee of the Board (the &#8220;<b>Audit Committee</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reports of KPMG on the consolidated financial statements of the Company for the fiscal years ended December&#160;31, 2023 and 2022 did
not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting
principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">During the Company&#8217;s two most recent
fiscal years and the subsequent period from January&#160;1, 2024 to August 30, 2024, there were (i)&#160;no disagreements (as defined
in Item 304(a)(1)(iv) of Regulation&#160;S-K&#160;and the related instructions thereto) with KPMG on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction
of KPMG, would have caused it to make reference to the subject matter of the disagreement in connection with its report and (ii)&#160;no
reportable events (as described in Item 304(a)(1)(v) of Regulation&#160;S-K).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provided KPMG with a copy of the disclosures made in this Item 4.01 and requested KPMG to furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree.
A copy of KPMG&#8217;s letter to the SEC dated September 5, 2024 regarding these statements is filed as Exhibit 16.1 to this Current
Report on Form&#160;8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Appointment
                                            of New Independent Registered Public Accounting Firm</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PricewaterhouseCoopers
LLP (&#8220;<b>PwC</b>&#8221;) served as the independent registered public accounting firm of Oruka prior to the consummation of the
Merger. On August 30, 2024, the Audit Committee engaged PwC as the independent registered public accounting firm of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">During ARCA&#8217;s two most recent fiscal
years and the subsequent period from January 1, 2024 to August 30, 2024, neither  ARCA nor anyone on its behalf consulted PwC regarding:
(i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that
might be rendered on  ARCA&#8217;s financial statements, and neither a written report nor oral advice was provided to the ARCA
that PwC concluded was an important factor considered by  ARCA in reaching a decision as to any accounting, auditing or financial
reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the
related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.01 Changes in Control of the Registrant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 1.01 of this Current Report on Form 8-K under the heading &#8220;<i>Introductory Note</i>&#8221; regarding
the Merger, the information set forth in Item 2.01 of this Current Report on Form 8-K in the section entitled &#8220;<i>Security Ownership
of Certain Beneficial Owners and Management</i>&#8221; regarding the Board and executive officers following the Merger and the information
set forth in Item 5.02 of this Current Report on Form 8-K regarding the Board and executive officers following the Merger is incorporated
herein by reference<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Departure
of Directors and Certain Officers </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, Linda Grais, Anders Hove, Robert Conway, James Flynn and Jacob Ma-Weaver resigned from ARCA&#8217;s board of directors
and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating
to the Company&#8217;s operations, policies or practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="margin-top: 0pt; margin-bottom: 0pt">In addition, each of Thomas A. Keuer, ARCA&#8217;s President and Chief
Operating Officer, and C. Jeffrey Dekker, ARCA&#8217;s Chief Financial Officer, resigned as named executive officers at the Closing of
the Merger and their last day of employment was September 1, 2024 (the &#8220;<b>Separation Date</b>&#8221;), which terminations are considered
to be without &#8220;cause&#8221; related to a change in control for purposes of their employment agreements with ARCA. Each of Messrs.
Keuer and Dekker have been provided with and are expected to enter into a release with ARCA in the form attached as Exhibit A to their
respective employment agreements (the &#8220;<b>Release</b>&#8221;), pursuant to which Messrs. Keuer and Dekker will each receive (a)&#160;a
lump sum cash severance payment equivalent to 12 months of their respective annual base salary on the Separation Date, (b)&#160;a&#160;lump-sum&#160;payment
representing 12 months of health insurance premiums at a rate approved by the ARCA&#8217;s board of directors, and (c)&#160;a retention
bonus of $165,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In addition,
Mr. Dekker has entered into a consulting agreement with the Company, effective as of August 30, 2024, to provide transition services
related to the transition of ARCA&#8217;s accounting, reporting, and other financial matters through August 30, 2025, unless terminated
earlier in accordance with the agreement (the &#8220;<b>Consulting Agreement</b>&#8221;). Under the Consulting Agreement, Mr. Dekker
will receive a consulting fee of $20,000 for the initial two weeks of transition services and will receive a fee of $250 per hour for
any additional services provided thereafter, up to a total consulting fee of $27,500. The foregoing description of the Consulting Agreement
is not complete and is subject to and qualified in its entirety by reference to the complete text of the Consulting Agreement, a copy
of which is attached hereto as Exhibit 10.25 and incorporated herein by reference.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Incentive Plan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2024, ARCA&#8217;s board of directors approved the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;<b>2024 Stock
Plan</b>&#8221;), subject to stockholder approval to be effective as of the Closing Date. On August 22, 2024, ARCA&#8217;s stockholders
approved the 2024 Stock Plan at the Special Meeting (as defined below) and on August 29, 2024, the Board ratified the 2024 Stock Plan.
The purpose of the 2024 Stock Plan is to promote and closely align the interests of employees, officers, non-employee&#160;directors
and individual consultants of the Company and its stockholders by providing stock-based&#160;compensation and other performance-based
compensation. The objectives of the 2024 Stock Plan are to attract and retain the best available employees, officers, non-employee&#160;directors
and individual consultants for positions of substantial responsibility and to motivate participants to optimize the profitability and
growth of the combined company through incentives that are consistent with the combined company&#8217;s goals and that link the personal
interests of participants to those of the combined company&#8217;s stockholders. The 2024 Stock Plan allows for the grant of stock options,
stock appreciation rights (&#8220;<b>SARs</b>&#8221;), restricted stock, restricted stock units (&#8220;<b>RSUs</b>&#8221;), other stock-based&#160;awards
and incentive bonuses (collectively, &#8220;<b>Awards</b>&#8221;). No Awards were granted under the 2024 Stock Plan prior to its approval
by ARCA&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Administration</span>.
The 2024 Stock Plan is administered by the Compensation Committee of the Board or another committee designated by the Board to administer
the 2024 Stock Plan, which is referred to herein as the &#8220;Administrator.&#8221; The Administrator will have broad authority, subject
to the provisions of the 2024 Stock Plan, to administer and interpret the 2024 Stock Plan and Awards granted thereunder. All decisions
and actions of the Administrator will be final.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock
Subject to 2024 Stock Plan</span>. The initial share pool under the 2024 Stock Plan is 4,634,897 shares of Company Common Stock, subject
to certain adjustments in the event of a change in our capitalization. The shares that may be issued under the 2024 Stock Plan will be
automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount
equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants) on the preceding
December 31, unless a lower, or no, increase is determined by the Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Company Common Stock issued under the 2024 Stock Plan may be either authorized and unissued shares or previously issued shares acquired
by the Company. On termination or expiration of an Award under the 2024 Stock Plan, in whole or in part, the number of shares of Company
Common Stock subject to such Award but not issued thereunder or that are otherwise forfeited back to the Company will again become available
for grant under the 2024 Stock Plan. Additionally, shares retained or withheld in payment of any exercise price, purchase price, or tax
withholding obligation of an Award will again become available for grant under the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Eligibility</span>.
Current or prospective employees, officers, non-employee directors, and other independent service providers of the combined company and
its subsidiaries will be eligible to participate in the 2024 Stock Plan. Following the Closing, it is expected that approximately 21
employees (including four executive officers) and five non-employee directors and 16 other individual service providers of the
Company will be eligible to participate in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Types
of Awards</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. All stock options granted under the 2024 Stock Plan will be evidenced by a written agreement with the participant, which
provides, among other things, whether the option is intended to be an incentive stock option or a non-qualified stock option, the number
of shares subject to the option, the exercise price, exercisability (or vesting), the term of the option, which may not generally exceed
ten years, and other terms and conditions. Subject to the express provisions of the 2024 Stock Plan, options generally may be exercised
over such period, in installments or otherwise, as the Administrator may determine. The exercise price for any stock option granted may
not generally be less than the fair market value of the combined company common stock subject to that option on the grant date. The exercise
price may be paid in cash or such other method as determined by the Administrator, including an irrevocable commitment by a broker to
pay over such amount from a sale of the shares issuable under an option, the delivery of previously owned shares, or withholding of shares
deliverable upon exercise. The 2024 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price
of a previously awarded option or cancel and re-grant or exchange such option for cash or a new Award with a lower (or no) exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. SARs may be granted alone or in conjunction with all or part of a stock option. Upon exercising a SAR, the participant
is entitled to receive the amount by which the fair market value of the Company Common Stock at the time of exercise exceeds the exercise
price of the SAR. This amount is payable in Company Common Stock, cash, restricted stock, or a combination thereof, at the Administrator&#8217;s
discretion. The 2024 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously
awarded SAR or cancel and re-grant or exchange such SAR for cash or a new Award with a lower (or no) exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock and RSUs</i>. Awards of restricted stock consist of shares of stock that are transferred to the participant subject to restrictions
that may result in forfeiture if specified conditions are not satisfied. RSUs result in the transfer of shares of cash or stock to the
participant only after specified conditions are satisfied. The Administrator will determine the restrictions and conditions applicable
to each award of restricted stock or RSUs, which may include performance vesting conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Stock-Based Awards</i>. Other stock-based awards are Awards denominated in or payable in, valued in whole or in part by reference to,
or otherwise based on or related to, the value of Company Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
Bonuses</i>. Each incentive bonus will confer upon the participant the opportunity to earn a payment, which may be subject to vesting
or performance criteria established by the Administrator. Payment of the amount due under an incentive bonus may be made in cash or shares,
as determined by the Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Performance
Criteria</span>. The Administrator may specify certain performance criteria which must be satisfied before Awards will be granted or will
vest. The performance goals may vary from participant to participant, group to group, and period to period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Transferability</span>.
Awards generally may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a participant other
than by will or the laws of descent and distribution, and each option or SAR may be exercisable only by the participant during his or
her lifetime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Clawback</span>.
Awards will be subject to recoupment in accordance with any clawback policy adopted by the Company, including the Company&#8217;s Incentive
Compensation Clawback Policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adjustments
Upon a Change in Capitalization</span>. In the event of a change in capitalization of the Company, including any reorganization, reclassification,
combination of shares, stock split, reverse stock split, spin-off, dividend or distribution (other than quarterly cash dividends), the
share pool and outstanding Awards will be equitably adjusted by the Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Change
in Control</span>. In the event of a change in control of the Company, the Administrator may (i) provide for the assumption of outstanding
Awards, (ii) issue substitute awards, (iii) accelerate vesting or waiver any forfeiture conditions, (iv) accelerate the exercisability
of the award, (v) make any other adjustments to outstanding Awards as deemed to be appropriate or (vi) provide for the cancellation and
cash-out of outstanding Awards; however, if Awards are not assumed, continued or substituted for, then all outstanding Awards will become
fully vested and exercisable (with performance based on target or actual achievement as determined by the Administrator).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Amendment
and Termination</span>. The Board has the right to amend, alter, suspend, or terminate the 2024 Stock Plan at any time, provided certain
enumerated material amendments may not be made without stockholder approval. No amendment or alteration to the 2024 Stock Plan or an
Award or Award agreement will be made that would materially impair the rights of the holder, without such holder&#8217;s consent; however,
no consent will be required if the Administrator determines in its sole discretion and prior to the date of any change in control that
such amendment or alteration either is required or advisable in order for us, the 2024 Stock Plan, or such Award to satisfy any law or
regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard, or is not
reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately
compensated. The 2024 Stock Plan will automatically terminate as to the grant of future awards, unless earlier terminated by the Board,
on July 20, 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the 2024 Stock Plan is not complete and is subject to and qualified in its entirety by reference to the complete
text of the 2024 Stock Plan, a copy of which is attached hereto as Exhibit 10.10 and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Stock Purchase Plan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2024, ARCA&#8217;s board of directors approved the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;<b>ESPP</b>&#8221;),
subject to stockholder approval to be effective as of the Closing Date. On August 22, 2024, ARCA&#8217;s stockholders approved the ESPP
at the Special Meeting and on August 29, 2024, the Board ratified the ESPP. The purpose of the ESPP is to provide employees of the Company
and its designated subsidiaries to use payroll deductions and other additional payments, referred to as &#8220;contributions,&#8221;
to purchase shares of Company Common Stock, and thereby acquire an interest in the future of the Company. The ESPP, and the rights of
participants to make purchases thereunder, is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423
of the Internal Revenue Code of 1986, as amended (the &#8220;<b>Code</b>&#8221;); however, sub-plans that do not meet the requirements
of Section 423 of the Code may be established for the benefit of eligible employees of non-U.S. subsidiaries of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Administration</span>.
The ESPP will be administered by the Compensation Committee of the Board or another committee designated by the Board to administer,
which we refer to herein as the &#8220;ESPP Administrator.&#8221; All questions of interpretation of the ESPP are determined by the ESPP
Administrator, whose decisions are final and binding upon all participants. The ESPP Administrator may delegate, subject to applicable
law, its responsibilities under the ESPP to one or more other persons. The ESPP Administrator may adopt rules or procedures relating
to the operation and administration of the ESPP to accommodate the specific requirements of local laws and procedures, including to adopt
sub-plans for participants outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock
Subject to ESPP</span>. The initial share pool under the 2024 ESPP is 463,490 shares of Company Common Stock, subject to certain adjustments
in the event of a change in our capitalization. The shares that may be issued under the ESPP will be automatically increased on January
1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including
Company Common Stock, preferred stock and unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase
is determined by the ESPP Administrator. Shares of Company Common Stock issued under the ESPP may either be shares of authorized but
unissued Company Common Stock, Company Common Stock held as treasury shares, or Company Common Stock acquired in an open-market transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the total number of shares to be purchased by all participants on any exercise date (as defined below) exceeds the number of shares remaining
available for issuance under the ESPP, the ESPP Administrator may make a pro rata allocation of the remaining available number of shares
in as uniform a manner as possible and as the ESPP Administrator determines to be equitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Eligibility</span>.
All employees of the Company or a designated subsidiary of the Company (as defined in the ESPP) who customarily work for more than 20
hours per week and more than five months in any calendar year and satisfy the requirements set forth in the ESPP will be eligible to
participate in the ESPP. However, any employee who would own (or pursuant to Section 424(d) of the Code would be deemed to own) more
than 5% of the voting power or value of the Company Common Stock immediately after a grant under the ESPP is not eligible to participate
and no participant may purchase more than $25,000 of Company Common Stock in any one calendar year. Following the Closing, it is expected
that approximately 21 employees will be eligible to participate in the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Offering
Periods</span>. The ESPP is generally implemented by a series of &#8220;offering periods&#8221;. Unless otherwise specified by the ESPP
Administrator, the first offering period and the first purchase period will begin on the first trading day the Company Common Stock commences
trading under the symbol ORKA and end on December 8, 2024, with subsequent offering periods and purchase periods lasting for six months
and ending every June 8 or December 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Payroll
Deductions</span>. To participate in an offering period, an eligible employee must execute and submit a properly completed subscription
agreement on or before a date determined by the ESPP Administrator prior to the applicable enrollment date. Once enrolled in the ESPP,
a participant can purchase shares of our common stock with payroll deductions at the end of the applicable offering period. Once an offering
period is over, a participant is automatically enrolled in the next offering period unless the participant chooses to withdraw from the
ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
subscription agreement will request a deduction in an amount expressed as a whole percentage between 1% and 15% and all payroll deductions
will be credited to the eligible employee&#8217;s account. No interest will be paid on any amount held in the account of any eligible
employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Option
Grant</span>. On the first trading day of each offering period, each eligible employee automatically will be granted an option to acquire
shares of Company Common Stock on the exercise date. All participants granted options under the ESPP will have the same rights and privileges
consistent with the requirements set forth in Section 423 of the Code. No eligible employee will be permitted to purchase more than 5,000
shares of Company Common Stock during each purchase period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Purchase
Price</span>. The price per share at which shares are purchased under the ESPP is determined by the ESPP Administrator, but in no event
will be less than 85% of the fair market value of the Company Common Stock on the first or the last day of the offering period, whichever
is lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
of Options</span>. At the end of each offering period, unless the participant has withdrawn from the ESPP, payroll deductions are applied
automatically to purchase shares of common stock at the price described above. The number of shares purchased is determined by dividing
the payroll deductions by the applicable purchase price, rounded down to the nearest whole share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
payroll deductions accumulated in a participant&#8217;s account that are not sufficient to purchase a full share will be retained in
the participant&#8217;s account for the subsequent option period (subject to earlier withdrawal in accordance with the terms of the ESPP).
Any other amounts of payroll deductions in a participant&#8217;s account that are not used for the purchase of shares of Company Common
Stock, whether because of the participant&#8217;s withdrawal, because the amount would enable the participant to purchase more than the
maximum number of shares, or for any other reason, will be returned to the participant, without interest, as soon as administratively
practicable after such withdrawal, exercise date or other event, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cancellation
and Withdrawal</span>. Participants may cancel all (but not less than all) of their option and terminate their subscription agreement by
delivering a written notice revoking their subscription to the Company or by following an electronic or other withdrawal procedure determined
by the ESPP Administrator. Upon such termination and cancellation, the balance in the participant&#8217;s account will be returned to
the participant, without interest, as soon as administratively practicable thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Termination
of Employment or Eligibility</span>. Upon the termination of a participant&#8217;s employment with the Company (or a designated subsidiary,
as applicable) for any reason or if a participant loses eligibility to participate in the ESPP, the participant&#8217;s option will be
deemed cancelled, the balance in the participant&#8217;s account will be returned to the participant (or his or her estate or designated
beneficiary in the event of the participant&#8217;s death), without interest, as soon as administratively practicable, and the participant
will have no other rights under the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transferability.
Rights to purchase Company Common Stock under the ESPP may not be transferred by a participant and may be exercised during a participant&#8217;s
lifetime only by the participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Adjustments
Upon a Change in Capitalization</span>. In the event of any reorganizations, recapitalizations, stock splits, reverse stock splits, stock
dividends, extraordinary dividends or distributions, or similar events, the ESPP Administrator will appropriately adjust the number and
class of shares available under the ESPP and the applicable purchase price of such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Merger
or Other Corporate Transaction</span>. In the event of a merger, sale, or other similar corporate transaction involving the Company, each
outstanding option will be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the
successor corporation. If the successor corporation refuses to assume or substitute for the option, the offering period with respect
to which such option relates will be shortened by setting a new exercise date on which such offering period shall end. The new exercise
date will occur before the date of the Company&#8217;s proposed merger, sale, or other similar corporate transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Amendment
and Termination</span>. The Administrator may amend, suspend or terminate the ESPP at any time and, in the event of a termination of the
ESPP, may terminate all outstanding offering periods (and return each participant&#8217;s account balance to the participant) or allow
outstanding offering periods to expire in accordance with their terms. The ESPP will continue in effect until terminated by the Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the ESPP is not complete and is subject to and qualified in its entirety by reference to the complete text of
the ESPP, a copy of which is attached hereto as Exhibit 10.11 and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Appointment
of Directors and Certain Officers </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, the Board appointed Lawrence Klein as the Company&#8217;s President and Chief Executive Officer, Arjun Agarwal as the
Company&#8217;s Senior Vice President, Finance and Treasurer, Joana Goncalves as the Company&#8217;s Chief Medical Officer and Paul Quinlan
as General Counsel and Secretary, each to serve at the discretion of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, the Board increased its size from five to six members and appointed the following six individuals to the Board: Lawrence
Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle. Samarth Kulkarni was also appointed as Chair
of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Dambkowski and Mr. Harwin are Class I directors, whose terms will expire at the Company&#8217;s 2025 annual meeting of stockholders.
Dr. Klein and Dr. Turtle are Class II directors, whose terms will expire at the Company&#8217;s 2026 annual meeting of stockholders.
Ms. Ball and Dr. Kulkarni are Class III directors, whose terms will expire at the Company&#8217;s 2027 annual meeting of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed in the section of the Proxy Statement/Prospectus entitled &#8220;Ce<i>rtain Relationships and Related Party Transactions
of the Combined Company</i>,&#8221; beginning on page 280 and incorporated herein by reference, none of the Company&#8217;s newly appointed
officers or directors has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a)
of Regulation S-K. Other than the Merger Agreement, there are no arrangements or understandings between the Company&#8217;s officers
or directors and any other person pursuant to which such officers or directors were selected as an officer or a director. There are no
family relationships among any of the Company&#8217;s directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the newly appointed principal officer&#8217;s and director&#8217;s biographical information is set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lawrence
Klein, Ph.D.</i></b> Dr.&#160;Klein, age 42, served as Chief Executive Officer of Oruka and as a member of its board of directors from
February&#160;2024 through the Closing. Prior to joining Oruka, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC, a healthcare
and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested in and helped to grow early-stage&#160;biotechnology
companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical
company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019
to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice
President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute on several transformative
partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including
program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global
management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors
of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from
September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of Wisconsin-Madison&#160;and
his Ph.D. in biophysics from Stanford University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior
management experience in the biotechnology industry and his academic expertise and accomplishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Arjun
Agarwal.</i>&#160;</b>Mr.&#160;Agarwal, age 48, served as the Senior Vice President of Finance of Oruka from March&#160;2024 through
the Closing, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Oruka, Mr.&#160;Agarwal
served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024,
including through multiple financings and the company&#8217;s successful transition to become a publicly traded entity. Before joining
Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology
company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s finance and accounting
functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility at McKesson Corporation
(NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at
PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics
at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered
Accountants of India.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Joana
Goncalves, MBChB. </i></b>Dr.&#160;Goncalves, age 51, served as the Chief Medical Officer of Oruka from April&#160;2024 through the Closing.
Prior to joining Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics in interactions with
regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing
the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation,
a pharmaceutical company, which was later acquired by Bristol-Myers&#160;Squibb Company, from April&#160;2014 to October&#160;2018, where
she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing
medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served
as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare
company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career
at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received
her MBChB from the University of Cape Town, South Africa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paul
Quinlan. </i></b>Mr.&#160;Quinlan, age 61, served as General Counsel of Oruka since April&#160;2024 through the Closing. Prior to joining
Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a
biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s
legal affairs. From December&#160;2017 to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where
he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General
Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings,
Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to joining
TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining
Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen,
Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from
Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kristine
Ball. </i></b>Ms. Ball, age 52, served as a member of the board of directors of Oruka since May&#160;2024 through the Closing. Ms.&#160;Ball
has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April&#160;2023.
Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September&#160;2020
to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer
of Menlo Therapeutics, Inc., a Nasdaq-listed&#160;biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE),
from September&#160;2017 to March&#160;2020, where she was responsible for leading all non-R&amp;D functions, including strategic planning,
corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served
as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq-listed&#160;pharmaceutical company, which was later acquired
by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life
sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial Officer of KAI Pharmaceuticals,
Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to
that, Ms. Ball served as a senior manager in life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has previously
served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria from 2020 to
2022 and Forty Seven, Inc., a Nasdaq-listed&#160;biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018
to 2020. Ms. Ball received a B.S. from Babson College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director
of life sciences companies and her background in finance, corporate development and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Carl
Dambkowski, M.D.</i></b> Dr.&#160;Dambkowski, age 40, served as a member of the board of directors of Oruka from February&#160;2024 through
the Closing. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology
company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader for a variety
of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021 to September&#160;2022;
Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018 to June&#160;2021;
and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022, where
he served as the clinical lead starting prior to IND for BBP-398&#160;through the out licensing of the compound to Bristol-Myers&#160;Squibb
based on initial clinical data and for low-dose&#160;infigratinib in achondroplasia through initial proof-of-concept&#160;data. He was
part of the core team that brought TRUSELTIQ<sup>&#174;</sup>&#160;(infigratinib) and NULIBRY<sup>&#174;</sup>&#160;(fosdenopterin) through
regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018,
Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and
pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski co-founded&#160;Novonate,
Inc., a private medical device company focused on building life-saving&#160;devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski
has coauthored numerous peer-reviewed&#160;publications and scientific abstracts and is a named inventor on multiple published and granted
patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration
in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations
in the biotechnology industry and his academic expertise and accomplishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Peter
Harwin.</i></b> Mr.&#160;Harwin, age 38, served as a member of the board of directors of Oruka from February&#160;2024 through the Closing.
Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co-founded&#160;in April&#160;2016.
Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that
was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences,
Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc.
(Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes Mr. Harwin is qualified to serve as a member of the Board because his experience serving as a director of biotechnology
companies and as a manager of funds specializing in the area of life sciences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Samarth
Kulkarni, Ph.D. </i></b>Dr.&#160;Kulkarni, age 45, served as a member of the board of directors of Oruka from February&#160;2024 through
the Closing. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical
company, since December&#160;2017, where he has also served as a member and chair of the board of directors since June&#160;2018 and
September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017
to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp;
Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals
and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc.
(Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since September&#160;2023, Repare Therapeutics
Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology
company, since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington
and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading scientific
and business journals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive
in the biopharmaceutical industry and his academic expertise and accomplishments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cameron
Turtle, D.Phil.</i></b> Dr.&#160;Turtle, age 34, served as a member of the board of directors of Oruka from February&#160;2024 through
the Closing. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc.
(formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief
Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics,
Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs,
a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology
company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical
company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational
functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was
a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device
companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received
his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University
of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes
30 Under&#160;30, San Francisco Business Times 40 Under&#160;40, and the Biocom Life Sciences Catalyst Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing,
and shaping biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Committees
of the Board of Directors </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, Kristine Ball, Carl Dambkowski and Cameron Turtle were appointed to the Audit Committee, and Kristine Ball, an &#8220;audit
committee financial expert&#8221; within the meaning of the SEC regulations, was appointed the chair of the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, Peter Harwin, Samarth Kulkarni and Cameron Turtle were appointed to the Compensation Committee of the Board (the &#8220;<b>Compensation
Committee</b>&#8221;), and Cameron Turtle was appointed the chair of the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, Kristine Ball, Samarth Kulkarni and Peter Harwin were appointed to the Nominating and Corporate Governance Committee
of the Board (the &#8220;<b>Nominating Committee</b>&#8221;), and Peter Harwin was appointed the chair of the Nominating Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to Certificate of Incorporation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended
and Restated Certificate of Incorporation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2024, the Company filed with the Secretary of State of the State of Delaware a Second Amended and Restated Certificate of
Incorporation (as so amended and restated, the &#8220;<b>Amended and Restated Charter</b>&#8221;) that only restates and integrates and
does not further amend the provisions of the Amended and Restated Certificate of Incorporation and became effective immediately upon
such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Amended and Restated Charter does not purport to be complete and is subject to and qualified in its entirety
by reference to the full text of the Amended and Restated Charter, a copy of which is attached hereto as Exhibit 3.5 and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended
and Restated Bylaws </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, in connection with the Closing, the Board adopted an amendment and restatement of the Company&#8217;s Amended and Restated
Bylaws (as so amended and restated, the &#8220;<b>Amended and Restated Bylaws</b>&#8221;), effective as of such date, in order to, among
other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">update
                                            various provisions regarding the organization and conduct of meetings of stockholders and
                                            the authority of the meeting chair, including remove (i) the ability of stockholders to call
                                            a special meeting and (ii) the requirement to vote for directors by written ballot;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">update
                                            various provisions regarding the organization and conduct of meetings of the Board and the
                                            officers of the Company, including remove the requirement that the board consist of not less
                                            than two nor more than 10 directors;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                            a requirement that a list of stockholders entitled to vote at a stockholder meeting be made
                                            available pursuant to DGCL;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            the quorum requirement for stockholder meetings from one-third to a majority of stock outstanding;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">update
                                            the procedural and disclosure requirements for director nominations made and business proposals
                                            submitted by stockholders (other than proposals submitted pursuant to Rule 14a-8 under the
                                            Exchange Act);</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revise
                                            the time period during which notices of director nominations and business proposals for an
                                            annual meeting of stockholders shall be delivered by stockholders, such that any such notice
                                            must be received by the Company not later than the close of business on the 90th day nor
                                            earlier than the close of business on the 120th day prior to the first anniversary of the
                                            preceding year&#8217;s annual meeting;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">opt
                                            out of DGCL Section 116 regarding electronic delivery of documents or information;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clarify
                                            certain procedures and standards with respect to the right to indemnification and advancement
                                            of expenses and authorize discretionary indemnification and advancement of expenses for persons
                                            serving as directors and officers of subsidiaries;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designate
                                            the Delaware Court of Chancery, the federal district courts of the State of Delaware and
                                            federal district courts generally as the sole forum for certain types of disputes, as allowed
                                            by law;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">update
                                            provisions to align with the Company&#8217;s governance structure and remove provisions otherwise
                                            duplicative with other Company documents or the DGCL, including regarding inspector of elections,
                                            officer appointments, share certificates and contracts, loans, checks and deposits; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            va</span>rious other updates, including clarifying, ministerial and conforming changes.</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Amended and Restated Bylaws does not purport to be complete and is subject to and qualified in its entirety
by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.6 and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.05 Amendments to the Registrant&#8217;s Code of Ethics, or Waiver of a Provision of the Code of Ethics.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 29, 2024, in connection with the Closing, the Board adopted a new Code of Business Conduct and Ethics of the Company (the &#8220;<b>Code
of Conduct</b>&#8221;), effective as of such date. The Code of Conduct supersedes the existing Code of Business Conduct and Ethics, as
previously adopted by ARCA&#8217;s board of directors (the &#8220;<b>Existing Code of Conduct</b>&#8221;). The Code of Conduct applies
to all directors, officers and employees of the Company and is intended to enhance understanding of the Company&#8217;s standards of
ethical business practices and promote awareness of ethical issues that may be encountered in carrying out a director&#8217;s, officer&#8217;s
or employee&#8217;s responsibilities. Among other things, the Code of Conduct:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
                                            the Company&#8217;s policies and standards with respect to (i) conflicts of interest, gifts
                                            and corporate opportunities, (ii) fair dealing, confidential information, privacy and use
                                            of Company assets and systems, (iii) legal and regulatory compliance, insider trading and
                                            anti-corruption standards, including pursuant to the Foreign Corrupt Practices Act, (iv)
                                            the Company&#8217;s disclosure obligations and recordkeeping procedures and (v) anti-discrimination,
                                            equal employment opportunity, health and safety, and environmental matters;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
                                            the Company&#8217;s whistleblower hotline and procedures for reporting potential violations;
                                            and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
                                            the Company&#8217;s policies and procedures with respect to an</span> amendment or waiver
                                            of the Code of Conduct.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adoption of the Code of Conduct did not result in any explicit or implicit waiver of any provision of the Existing Code of Conduct. The
foregoing description of the Code of Conduct does not purport to be complete and is subject to and qualified in its entirety by reference
to the full text of the Code of Conduct, a copy of which is attached hereto as Exhibit 14.1 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.06. Change in Shell Company Status.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing Date.
The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">material provisions of the Merger Agreement are
described in the Proxy Statement/Prospectus in the section entitled &#8220;<i>The Merger Agreement</i>&#8221; beginning on page 135 and
are incorporated herein by reference<span style="background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2024, the Company issued a press release announcing the consummation of the Merger, which is included in this Current Report
on Form 8-K as Exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Financial Statements of Business Acquired</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited financial statement of Oruka as of February 6, 2024 and the related notes thereto are attached hereto as Exhibit 99.2 and are
incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited interim condensed consolidated financial statements of Oruka as of June 30, 2024 as well as for the three month period ended
June 30, 2024 and for the period from February 6, 2024 (inception) to June 30, 2024 and the related notes thereto are attached hereto
as Exhibit 99.3 and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Pro Forma Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information of the ARCA and Oruka as of June 30, 2024 and for the six months ended June
30, 2024 and for the year ended December 31, 2023 and the related notes thereto are attached hereto as Exhibit 99.5 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 3, 2024, File No. 000-22873).</a></span></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea021319301ex3-1_oruka.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, effective August 29, 2024.</a></span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-2_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment
    to Amended and Restated Certificate of Incorporation of the Company, effective August 29, 2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-3_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment
    to Amended and Restated Certificate of Incorporation of the Company, effective August 29, 2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-4_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment
    to Amended and Restated Certificate of Incorporation of the Company, effective September 3, 2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-5_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate
    of Incorporation of the Company, filed September 3, 2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-6_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws
    of the Company.</span></a></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1(b) of ARCA biopharma, Inc.&#8217;s Form&#160;S-1/A, filed on May 24, 2013, File No.&#160;333-187508).</a></span></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-8_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Certificate of
    Elimination of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, effective
    August 29, 2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><a href="ea021319301ex3-9_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Certificate of
    Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock, effective August 29,
    2024.</span></a></td></tr>
  <tr style="background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%">4.1</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Investor Rights Agreement, dated March&#160;6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto (incorporated by reference to Exhibit 4.3 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.1</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.2&#8224;</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.3&#8224;</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm">Form of Amendment to Oruka Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form 8-K filed on July 9, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.4&#8224;</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm">Form of Amended &amp; Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form 8-K filed on July 9, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.5</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.6</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.7&#8224;&#8224;</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.8&#8224;&#8224;</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting Agreement, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.9#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit 4.3 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.10*#</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex10-10_oruka.htm">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.11*#</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex10-11_oruka.htm">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.12#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated by reference to Exhibit 10.40 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.13*#</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex10-13_oruka.htm">Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.14#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
</table>
<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%">10.15#</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%">10.16*#</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="ea021319301ex10-16_oruka.htm">Form of Employee Warrant Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.17#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated by reference to Exhibit 10.43 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.18#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit 10.44 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.19#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-46_arcabio.htm">Amended and Restated Employment Offer Letter, dated February&#160;14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein (incorporated by reference to Exhibit 10.46 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.20#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-47_arcabio.htm">Employment Offer Letter, dated March&#160;11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal (incorporated by reference to Exhibit 10.47 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.21#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (incorporated by reference to Exhibit 10.48 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.22#</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (incorporated by reference to Exhibit 10.49 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.23&#8224;</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.&#8217;s Form S-4/A, filed on June 18, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.24&#8224;</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.(incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.&#8217;s Form S-4/A, filed on June 18, 2024, File No. 333-279387).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.25*&#8224;&#8224;#</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea021319301ex10-25_oruka.htm">Consulting Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>14.1*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex14-1_oruka.htm">Code of Business Conduct and Ethics of Oruka Therapeutics, Inc.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>16.1*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex16-1_oruka.htm">Letter from KPMG LLP, dated September 5, 2024. </a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>21.1*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex21-1_oruka.htm">List of Subsidiaries of Oruka Therapeutics, Inc.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.1*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex99-1_oruka.htm">Press Release, issued on September 3, 2024</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.2*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex99-2_oruka.htm">Audited Financial Statement of Oruka Therapeutics, Inc. as of February 6, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.3*</td>
    <td>&#160;</td>
    <td><a href="ea021319301ex99-3_oruka.htm">Unaudited interim condensed consolidated Financial Statements of Oruka Therapeutics, Inc. for the three months ended June 30, 2024 and the period from February 6, 2024 (inception) to June 30, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.4*</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea021319301ex99-4_oruka.htm">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the three months ended June 30, 2024 and the period from February 6, 2024 (inception) to June 30, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.5*</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea021319301ex99-5_oruka.htm">Unaudited Pro Forma Financial Statements of Oruka Therapeutics, Inc. and ARCA biopharma, Inc. as of June 30, 2024 and for the six months ended June 30, 2024, as well as for the year ended December 31, 2023.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
management contract or compensatory plan.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally
copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential
treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. Certain portions of this exhibit
(indicated by &#8220;[***]&#8221;) have been omitted because they are both (i) not material and (ii) would be competitively harmful if
publicly disclosed.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span>&#8224;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted in accordance with the rules of the Securities and Exchange
Commission.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><b>Oruka Therapeutics, Inc.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">(Registrant)</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: September 5, 2024</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">Name:</td>
    <td style="width: 31%"> Lawrence Klein</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td> President and Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZF522urA7LVrEKlJE3I42ymA7KZnx70je0rFFDIEQ3vveEyIUOS10jQyHWVnADpu2Vg6hxDMymhN6R7ZcpeBviRdtHSvjuvcHZuQZ9Mx4ECdHL3TWu7ZYpSAnQ5kM4xHIJE0mMF2L4KtnZM66QuO0qkGZCrZMLWt0il99wk49yVDz6qr2yFaTSSEayF5+QyyjGDZ0Vw/iq4WiyEQQdhOInOnWetf86dB8SZjX2Pg629P/DT4DNkqG -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ea021319301ex3-1_oruka.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 0in; text-align: left">ARCA biopharma, Inc. (the
&ldquo;<B>Corporation</B>&rdquo;), a corporation organized and existing under and by virtue of the provisions of the General Corporation
Law of the State of Delaware (the &ldquo;<B>General Corporation Law</B>&rdquo;), does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">1.&nbsp;The
current name of the Corporation is ARCA biopharma, Inc. The date of filing of the original Certificate of Incorporation of ARCA biopharma,
Inc. with the Secretary of State of the State of Delaware was March 16, 2004 under the name Nuvelo Merger Sub, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">2.&nbsp;The
Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on
March 18, 2004 (as amended, the &ldquo;<B>Certificate of Incorporation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">3.&nbsp;The
existing Certificate of Incorporation is hereby amended to add Article XIII to the Certificate of Incorporation to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&ldquo;<B>XIII.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">To the fullest extent
permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, an officer of the Corporation shall
not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as an officer.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Neither any amendment
nor repeal of this Article XIII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article
XIII, shall eliminate or reduce the effect of this Article XIII in respect of any matter occurring, or any action or proceeding accruing
or arising or that, but for this Article XIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">4.&nbsp;All
other provisions of the Certificate of Incorporation shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">5.&nbsp;The
amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of 242 of the General
Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">6.&nbsp;This
Certificate of Amendment shall become effective immediately upon the filing of this Certificate of Amendment with the Secretary of State
of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Corporation has caused this Certificate of Amendment to be executed by the undersigned authorized officer of the Corporation as of
this 29<SUP>th</SUP> day of August, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 37%"><B>/s/ </B>C. Jeffrey Dekker&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Name: C. Jeffrey Dekker</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Title: Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ea021319301ex3-2_oruka.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">ARCA biopharma, Inc., a corporation
organized and existing under the laws of the State of Delaware (the &ldquo;<B>Corporation</B>&rdquo;), certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1. The
name of the Corporation is ARCA biopharma, Inc. The Corporation&rsquo;s original Certificate of Incorporation was filed with the Secretary
of State of the State of Delaware on March 16, 2004&nbsp;under the name &ldquo;Nuvelo Merger Sub, Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2.   The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of the Corporation duly adopted resolutions proposing to amend the Certificate of
Incorporation of the Corporation (the &ldquo;<B>Amendment</B>&rdquo;), declaring the Amendment to be advisable and in the best interests
of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders
therefor, which resolution setting forth the proposed Amendment is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">The first paragraph of Article IV of
the Corporation&rsquo;s Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&ldquo;The total number of shares of
all classes of stock this Corporation shall have authority to issue is 550,000,000, consisting of 545,000,000 shares of Common Stock,
par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from
time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue
of any shares thereof.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.   This
Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation
Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">4.   This
Certificate of Amendment shall become effective on August 29, 2024 at 4:01 p.m. Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 5%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">/s/ C. Jeffrey Dekker</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. Jeffrey Dekker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>ea021319301ex3-3_oruka.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">ARCA biopharma, Inc., a corporation
organized and existing under the laws of the State of Delaware (the &ldquo;<B>Corporation</B>&rdquo;), certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1.&nbsp;The
name of the Corporation is ARCA biopharma, Inc. The Corporation&rsquo;s original Certificate of Incorporation was filed with the Secretary
of State of the State of Delaware on March 16, 2004&nbsp;under the name &ldquo;Nuvelo Merger Sub, Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2.&nbsp;The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of the Corporation duly adopted resolutions proposing to amend the Certificate of
Incorporation of the Corporation (the &ldquo;<B>Amendment</B>&rdquo;), declaring the Amendment to be advisable and in the best interests
of the Corporation and its stockholders, which resolution setting forth the proposed Amendment is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Article I of the Corporation&rsquo;s
Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&ldquo;The name of this corporation
is Oruka Therapeutics, Inc. (the &ldquo;Corporation&rdquo;).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.&nbsp;This
Certificate of Amendment shall become effective on August 29, 2024 at 4:05 p.m. Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <U STYLE="text-decoration: none">/s/ C. Jeffrey Dekker</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> C. Jeffrey Dekker </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>5
<FILENAME>ea021319301ex3-4_oruka.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE SEPTEMBER 3, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: right"><B>Exhibit 3.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>TO THE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center"><B>ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.9pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: left; text-indent: 0.5in">ARCA biopharma, Inc.,
a corporation organized and existing under the laws of the State of Delaware (the &ldquo;<B>Corporation</B>&rdquo;), certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1.<FONT STYLE="font-size: 10pt">
</FONT>The name of the Corporation is ARCA biopharma, Inc. The Corporation&rsquo;s original Certificate of Incorporation was filed with
the Secretary of State of the State of Delaware on March 16, 2004&nbsp;under the name &ldquo;Nuvelo Merger Sub, Inc.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.<FONT STYLE="font-size: 10pt">
</FONT>The Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of the Corporation duly adopted resolutions proposing to amend the Certificate
of Incorporation of the Corporation (the &ldquo;<B>Amendment</B>&rdquo;), declaring the Amendment to be advisable and in the best interests
of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders
therefor, which resolution setting forth the proposed Amendment is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Article IV of the Corporation&rsquo;s
Amended and Restated Certificate of Incorporation is hereby amended to add the following paragraph at the end of Article IV:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&ldquo;Upon the effectiveness of the
Certificate of Amendment to the Amended and Restated Certificate of Incorporation adding this paragraph (the &ldquo;<U>Effective Time</U>&rdquo;),
each six (6) to twelve (12) shares of Common Stock issued immediately prior to the Effective Time shall automatically be combined into
one (1) validly issued, fully paid and nonassessable share of Common Stock, without any further action by the Corporation or any holder
thereof, the exact ratio within the six-to-one (6:1) to twelve-to-one (12:1) range to be determined by the Board of Directors of the Corporation
prior to the Effective Time and publicly announced by the Corporation, subject to the treatment of fractional share interests as described
below (the &ldquo;<U>Reverse Stock Split</U>&rdquo;). No fractional shares of Common Stock shall be issued in connection with the Reverse
Stock Split. Each certificate that immediately prior to the Effective Time represented shares Common Stock, as applicable (the &ldquo;<U>Old
Certificates</U>&rdquo;), shall, until surrendered to the Corporation in exchange for a certificate representing such new number of shares
of Common Stock, automatically represent that number of shares of Common Stock into which the shares of Common Stock represented by the
Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">3.<FONT STYLE="font-size: 10pt">
</FONT>On August 22, 2024, the Board of Directors of the Corporation determined that each twelve (12) shares of the Corporation&rsquo;s
Common Stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), issued immediately prior to the Effective Time shall
automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock. The Corporation publicly announced
this ratio on August 22, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">4.<FONT STYLE="font-size: 10pt">
</FONT>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General
Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">5.<FONT STYLE="font-size: 10pt">
</FONT>This Certificate of Amendment shall become effective on September 3, 2024 at 12:01 a.m. Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <FONT STYLE="text-decoration: none">/s/ C. Jeffrey Dekker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 35%"> C. Jeffrey Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>6
<FILENAME>ea021319301ex3-5_oruka.htm
<DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, FILED SEPTEMBER 3, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<BR>
OF<BR>
ORUKA THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to Section 245 of the General Corporation
Law of the State of Delaware (the &ldquo;<B>DGCL</B>&rdquo;), Oruka Therapeutics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;), a corporation
organized and existing under and by virtue of the provisions of the DGCL, hereby submits the following for the purpose of amending and
restating its Certificate of Incorporation, as amended, and does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1. The current name of the Corporation is Oruka
Therapeutics, Inc. The Corporation&rsquo;s original Certificate of Incorporation was filed with the Secretary of State of the State of
Delaware on March 16, 2004 under the name Nuvelo Merger Sub, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2. The Second Amended and Restated Certificate
of Incorporation of the Corporation attached hereto as <U>Exhibit A</U>, which is incorporated herein by this reference, only restates
and integrates and does not further amend the provisions of the Amended and Restated Certificate of Incorporation of the Corporation as
theretofore amended or supplemented and there is no discrepancy between those provisions and the provisions of the Amended and Restated
Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3. This Second Amended and Restated Certificate
of Incorporation has been duly adopted by the Board of Directors of the Corporation in accordance with Section 245 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">4. This Second Amended and Restated Certificate
of Incorporation shall be effective immediately upon filing with the Secretary of State of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>IN WITNESS WHEREOF</B>, this Corporation has
caused this Second Amended and Restated Certificate of Incorporation to be signed by a duly authorized officer of this Corporation, this
3<SUP>rd</SUP> day of September, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ORUKA THERAPEUTICS, INC. </B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Lawrence Klein, Ph.D.</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Lawrence Klein, Ph.D.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECOND AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION<BR>
OF<BR>
ORUKA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The
name of this corporation is Oruka Therapeutics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
Corporation&rsquo;s registered office in the State of Delaware is the Corporation Trust Company, Corporation Trust Center, 1209 Orange
Street, City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation
Law of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
total number of shares of all classes of stock this Corporation shall have authority to issue is 550,000,000, consisting of 545,000,000
shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. The Preferred
Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or
title, prior to the issue of any shares thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
Board of Directors of the Corporation is hereby authorized to fix or alter the dividend rights, dividend rate, conversion rights, voting
rights, rights and terms of redemption (including sinking fund provisions, if any), the redemption price or prices, the liquidation preferences,
any other designations, preferences and relative, participating, optional or other special rights, and any qualifications, limitations
or restrictions thereof, of any wholly unissued series of Preferred Stock, and the number of shares constituting any such unissued series
and the designation thereof, or any of them; and to increase or decrease the number of shares of any series subsequent to the issue of
shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series
shall be so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution
originally fixing the number of shares of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">In
furtherance and not in limitation of the powers conferred by statute, the Board of Directors of the Corporation is expressly authorized
to make, alter or repeal Bylaws of the Corporation. Notwithstanding the foregoing, the Bylaws of the Corporation may be rescinded, altered,
amended or repealed in any respect by the affirmative vote of the holders of at least 66 &frac23;% of the outstanding voting stock
of the Corporation, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">VI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
Board of Directors of the Corporation shall have that number of directors set out in the Bylaws of the Corporation as adopted or as set
from time to time by a duly adopted amendment thereto by the Directors or stockholders of the Corporation. The Board of Directors shall
be divided into three classes, as nearly equal in number as possible. The initial classification of directors shall be determined in accordance
with a resolution or resolutions adopted by the Board of Directors. The term of office of the first class shall expire at the first annual
meeting of stockholders or any special meeting in lieu thereof following January&nbsp;1, 2004, the term of office of the second class
shall expire at the second annual meeting of stockholders or any special meeting in lieu thereof following January&nbsp;1, 2004 and the
term of office of the third class shall expire at the third annual meeting of stockholders or any special meeting in lieu thereof following
January&nbsp;1, 2004. At each annual meeting of stockholders or special meeting in lieu thereof following such initial classification,
directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding
annual meeting of the stockholders or special meeting in lieu thereof after their election and until their successors are duly elected
and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Newly
created directorships resulting from any increase in the authorized number of directors or any vacancies in the Board of Directors resulting
from death, resignation, retirement, disqualification, removal from office or other cause may be filled only by a majority vote of the
directors then in office even though less than a quorum, or by a sole remaining director, and not by the stockholders. In the event of
any increase or decrease in the authorized number of directors, (a)&nbsp;each director then serving as such shall nevertheless continue
as a director of the class of which he or she is a member until the expiration of his or her current term or his or her prior death, retirement,
removal or resignation and (b)&nbsp;the newly created or eliminated directorships resulting from such increase or decrease shall if reasonably
possible be apportioned by the Board of Directors among the three classes of directors so as to ensure that no one class has more than
one director more than any other class. In the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise
provided by law, may exercise the powers of the full Board of Directors until the vacancy is filled. Notwithstanding the foregoing, each
director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation or removal. No decrease
in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Elections
of directors need not be by written ballot unless otherwise provided in the Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">VIII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">No
action shall be taken by the stockholders except at a duly called annual or special meeting of stockholders. The stockholders may not
take action by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Special
meetings of the stockholders of the Corporation for any purpose or purposes may be called at any time by the Board of Directors, or as
otherwise set forth in the Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">An
affirmative vote of the holders of shares representing a majority of the outstanding Common Stock shall be required to approve (a)&nbsp;the
sale of U.S. Patent 5,202,231, or (b)&nbsp;exclusive license or assignment to a single person or entity, other than a wholly-owned subsidiary,
which license or assignment has the same effect as a sale of all rights, title and interest in U.S. Patent 5,202,231.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">IX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">To
the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, a director of
the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty
as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">To
the fullest extent permitted by law, the Corporation may indemnify and advance indemnification expenses to any person made or threatened
to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he
or she, his or her testator or intestate is or was a director, officer or employee of the Corporation or any predecessor of the Corporation,
or serves or served at any other enterprise as a director, officer or employee at the request of the Corporation or any predecessor to
the Corporation. The Corporation may, to the fullest extent permitted by law, purchase and maintain insurance on behalf of any such director
or officer against any liability which may be asserted against him or her and may enter contracts providing for the indemnification of
any such person to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Neither
any amendment nor repeal of this Article IX, nor the adoption of any provision of this Certificate of Incorporation inconsistent with
this Article IX, shall eliminate or reduce the effect of this Article IX in respect of any matter occurring, or any action or proceeding
accruing or arising or that, but for this Article IX, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
Corporation is to have perpetual existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">XI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Meetings
of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may be kept
(subject to any statutory provision) outside the State of Delaware at such place or places as may be designated from time to time by the
Board of Directors or in the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">XII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">The
Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, by an
affirmative vote of the holders of a majority of the voting rights of all classes of stock entitled to vote, provided, however, that
no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of
the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the
holders of 66 &frac23;% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of
the Certificate of Incorporation relating to: (i)&nbsp;the requirement that all stockholder action be taken only at a duly called
annual meeting or special meeting; (ii)&nbsp;the authority and power of the Board of Directors and the procedure required to amend
the Corporation&rsquo;s Bylaws; (iii)&nbsp;the percentage of the shares necessary to amend the Certificate of Incorporation;
(iv)&nbsp;the elimination of Directors&rsquo; personal liability for monetary damages arising from their negligence and gross
negligence; and (v)&nbsp;indemnification of Directors, officers and other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">XIII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">To
the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, an officer of
the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty
as an officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in; background-color: white">Neither
any amendment nor repeal of this Article XIII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with
this Article XIII, shall eliminate or reduce the effect of this Article XIII in respect of any matter occurring, or any action or proceeding
accruing or arising or that, but for this Article XIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">* * * * * * * * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>7
<FILENAME>ea021319301ex3-6_oruka.htm
<DESCRIPTION>AMENDED AND RESTATED BYLAWS OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 3.6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AMENDED AND RESTATED BYLAWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ORUKA THERAPEUTICS, INC.<BR>
(a Delaware corporation)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
I</FONT><BR>
CORPORATE OFFICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Registered Office</U>. The registered office of Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;),
shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the
&ldquo;<U>Certificate of Incorporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Other Offices</U>. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except
as otherwise required by law, at such other place or places, either within or without the State of Delaware, as the Corporation may from
time to time determine or the business of the Corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
II</FONT><BR>
MEETINGS OF STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Annual Meeting</U>. The annual meeting of stockholders, for the election of directors and for the transaction of such other
business as may properly come before the meeting, shall be held at such place, if any, either within or without the State of Delaware,
on such date, and at such time as the Board of Directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo; or the &ldquo;<U>Board</U>&rdquo;)
shall fix. The Board of Directors may postpone, reschedule or cancel any annual meeting of stockholders previously scheduled by the Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Special Meeting</U>. Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to the Certificate
of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as
a &ldquo;<U>Preferred Stock Designation</U>&rdquo;), a special meeting of the stockholders of the Corporation may be called at any time
only by the Board of Directors. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders previously
scheduled by the Board. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the
meeting by or at the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Stockholders&rsquo; Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Whenever stockholders are required or permitted to take any action at a meeting, a notice of the meeting of stockholders shall
specify the place, if any, date, and time of the meeting of stockholders, the record date for determining the stockholders entitled to
vote at the meeting (if such date is different from the record date for determining the stockholders entitled to notice of the meeting)
and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote
at such meeting. The notice shall be given not less than 10 nor more than 60 days before the date on which the meeting is to be held,
to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the
meeting, except as otherwise provided by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws.
In the case of a special meeting, the purpose or purposes for which the meeting is called also shall be set forth in the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Except as otherwise required by law, notice may be given in writing directed to a stockholder&rsquo;s mailing address as it appears
on the records of the Corporation and shall be given: (i) if mailed, when notice is deposited in the U.S. mail, postage prepaid; and (ii)
if delivered by courier service, the earlier of when the notice is received or left at such stockholder&rsquo;s address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">         </FONT>So
long as the Corporation is subject to the Securities and Exchange Commission&rsquo;s proxy rules set forth in Regulation 14A under
the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), notice shall be given in the manner
required by such rules. To the extent permitted by such rules, notice may be given by electronic transmission directed to the
stockholder&rsquo;s electronic mail address, and if so given, shall be given when directed to such stockholder&rsquo;s electronic
mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to
receiving notice by electronic mail or if such notice is prohibited by Section 232(e) of the General Corporation Law of the State of
Delaware (as the same exists or may hereafter be amended from time to time, the &ldquo;<U>DGCL</U>&rdquo;). If notice is given by
electronic mail, such notice shall comply with the applicable provisions of Sections 232(a) and 232(d) of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notice may be given by other forms of electronic transmission with the consent of a stockholder in the manner permitted by Section
232(b) of the DGCL, and shall be deemed given as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>An affidavit that notice has been given, executed by the Secretary, Assistant Secretary or any transfer agent or other agent of
the Corporation, shall be <I>prima facie</I> evidence of the facts stated in the notice in the absence of fraud. Notice shall be deemed
to have been given to all stockholders who share an address if notice is given in accordance with the &ldquo;householding&rdquo; rules
set forth in Rule 14a-3(e) under the Exchange Act and Section 233 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>When a meeting is adjourned to another time or place (including an adjournment taken to address a technical failure to convene
or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the place, if any, date and time
thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person
and vote at such adjourned meeting are: (i) announced at the meeting at which the adjournment is taken; (ii) displayed, during the time
scheduled for the meeting, on the same electronic network used to enable stockholders and proxyholders to participate in the meeting by
means of remote communication; or (iii) set forth in the notice of meeting given in accordance with Section 2.3(a); <U>provided</U>, <U>however</U>,
that if the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled
to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting,
the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with Section 7.6(a), and shall give
notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for
notice of such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Organization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Meetings of stockholders shall be presided over by the Chair of the Board of Directors, or in his or her absence, by the Chief
Executive Officer (if separate and serving as a director) or another person designated by or in the manner provided by the Board of Directors.
The Secretary, or in his or her absence, an Assistant Secretary, or in the absence of the Secretary and all Assistant Secretaries, a person
whom the chair of the meeting shall appoint, shall act as secretary of the meeting and keep a record of the proceedings thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT>The
date and time of the opening and the closing of the polls for each matter upon which the stockholders shall vote at a meeting of
stockholders shall be announced at the meeting. The Board of Directors may adopt such rules and regulations for the conduct of any
meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted
by the Board of Directors, the chair of the meeting shall have the authority to adopt and enforce such rules and regulations for the
conduct of any meeting of stockholders and the safety of those in attendance as, in the judgment of the chair of the meeting, are
necessary, appropriate or convenient for the conduct of the meeting. Rules and regulations for the conduct of meetings of
stockholders, whether adopted by the Board of Directors or by the chair of the meeting, may include, without limitation,
establishing: (i) an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and
the safety of those present; (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at
the meeting, their duly authorized and constituted proxies, qualified representatives (including rules around who qualifies as such)
and such other persons as the chair of the meeting shall permit; (iv) restrictions on entry to the meeting after the time fixed for
the commencement thereof; (v) limitations on the time allotted for consideration of each agenda item and for questions and comments
by participants; (vi) regulations for the opening and closing of the polls for balloting and matters that are to be voted on by
ballot (if any); and (vii) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to
attend the meeting. Subject to any rules and regulations adopted by the Board of Directors, the chair of the meeting may convene
and, for any or no reason, from time to time, adjourn and/or recess any meeting of stockholders pursuant to Section 2.7. The chair
of the meeting, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall declare
that a nomination or other business was not properly brought before the meeting if the facts warrant (including if a determination
is made that a nomination or other business was not made or proposed, as the case may be, in accordance with Section 2.10 of these
Bylaws), and if such chair should so declare, such nomination shall be disregarded or such other business shall not be
transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>List of Stockholders</U>. The Corporation shall prepare, no later than the 10th day before each meeting of stockholders, a complete
list of the stockholders entitled to vote at the meeting; <U>provided</U>, <U>however</U>, that if the record date for determining the
stockholders entitled to vote is less than 10 days before the date of the meeting, the list shall reflect the stockholders entitled to
vote as of the 10th day before the meeting date. Such list shall be arranged in alphabetical order and shall show the address of each
stockholder and the number of shares registered in the name of each stockholder. Nothing in this Section 2.5 shall require the Corporation
to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination
of any stockholder, for any purpose germane to the meeting for 10 days ending on the day before the meeting date: (a) on a reasonably
accessible electronic network, <U>provided</U> that the information required to gain access to such list is provided with the notice of
meeting; or (b) during ordinary business hours at the principal place of business of the Corporation. If the Corporation determines to
make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available
only to stockholders of the Corporation. Except as otherwise required by law, the stock ledger shall be the only evidence as to who are
the stockholders entitled to examine the list of stockholders required by this Section 2.5 or to vote in person or by proxy at any meeting
of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Quorum</U>. Except as otherwise required by law, the Certificate of Incorporation (including any Preferred Stock Designation)
or these Bylaws, at any meeting of stockholders, the holders of a majority of the voting power of the stock outstanding and entitled to
vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business; <U>provided</U>,
<U>however</U>, that where a separate vote by a class or series or classes or series is required, the holders of a majority of the voting
power of the stock of such class or series or classes or series outstanding and entitled to vote on that matter, present in person or
represented by proxy, shall constitute a quorum entitled to take action with respect to such matter. If a quorum is not present or represented
at any meeting of stockholders, then the chair of the meeting, or the holders of a majority of the voting power of the stock present in
person or represented by proxy at the meeting and entitled to vote thereon, shall have power to adjourn or recess the meeting from time
to time in accordance with Section 2.7, until a quorum is present or represented. Subject to applicable law, if a quorum initially is
present at any meeting of stockholders, the stockholders may continue to transact business until adjournment or recess, notwithstanding
the withdrawal of enough stockholders to leave less than a quorum, but if a quorum is not present at least initially, no business other
than adjournment or recess may be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Adjourned or Recessed Meeting</U>. Any annual or special meeting of stockholders, whether or not a quorum is present, may be
adjourned or recessed for any or no reason from time to time by the chair of the meeting, subject to any rules and regulations adopted
by the Board of Directors pursuant to Section 2.4(b). Any such meeting may be adjourned for any or no reason (and may be recessed if a
quorum is not present or represented) from time to time by the holders of a majority of the voting power of the stock present in person
or represented by proxy at the meeting and entitled to vote thereon. At any such adjourned or recessed meeting at which a quorum is present,
any business may be transacted that might have been transacted at the meeting as originally called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Voting; Proxies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Except as otherwise required by law or the Certificate of Incorporation (including any Preferred Stock Designation), each holder
of stock of the Corporation entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of such stock
held of record by such holder that has voting power upon the subject matter in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT>Except
as otherwise required by law, the Certificate of Incorporation (including any Preferred Stock Designation), these Bylaws or any law,
rule or regulation applicable to the Corporation or its securities, at each meeting of stockholders at which a quorum is present,
all corporate actions to be taken by vote of the stockholders shall be authorized by the affirmative vote of the holders of at least
a majority of the voting power of the stock present in person or represented by proxy and entitled to vote on the subject matter,
and where a separate vote by a class or series or classes or series is required, if a quorum of such class or series or classes or
series is present, such act shall be authorized by the affirmative vote of the holders of at least a majority of the voting power of
the stock of such class or series or classes or series present in person or represented by proxy and entitled to vote on the subject
matter. Voting at meetings of stockholders need not be by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Every stockholder entitled to vote for directors, or on any other matter, shall have the right to do so either in person or by
one or more persons authorized to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years
from its date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if,
and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may be made irrevocable
regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the Corporation generally.
A stockholder may revoke any proxy that is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary
a revocation of the proxy or an executed new proxy bearing a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Submission of Information Regarding Director Nominees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As to each person whom a stockholder proposes to nominate for election or reelection as a director of the Corporation pursuant
to Section 2.10, the stockholder must deliver to the Secretary at the principal executive offices of the Corporation the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a written representation and agreement, which shall be signed by the person proposed to be nominated and pursuant to which such
person shall represent and agree that such person: (A)&nbsp;<FONT STYLE="background-color: white">consents to being named as a nominee
in a proxy statement and form of proxy relating to the meeting at which directors are to be elected and to serving as a director if elected,
and currently intends to serve as a director for the full term for which such person is standing for election; (B)&nbsp;</FONT>is not
and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any
person or entity: (1)&nbsp;as to how the person, if elected as a director, will act or vote on any issue or question, except as disclosed
in such representation and agreement; or (2)&nbsp;that could limit or interfere with the person&rsquo;s ability to comply, if elected
as a director, with such person&rsquo;s fiduciary duties under applicable law; (C)&nbsp;is not and will not become a party to any agreement,
arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation,
reimbursement or indemnification in connection with service or action as a director or nominee, except as disclosed in such representation
and agreement; and (D)&nbsp;if elected as a director, will comply with all of the Corporation&rsquo;s corporate governance policies and
guidelines related to conflict of interest, confidentiality, stock ownership and trading policies and guidelines, and any other policies
and guidelines applicable to directors (which will be provided by the Corporation within five business days following a request therefor);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all fully completed and signed questionnaires prepared by the Corporation (including those questionnaires required of the Corporation&rsquo;s
directors and any other questionnaire the Corporation determines is necessary or advisable to assess whether a nominee will satisfy any
qualifications or requirements imposed by the Certificate of Incorporation or these Bylaws, any law, rule, regulation or listing standard
that may be applicable to the Corporation, and the Corporation&rsquo;s corporate governance policies and guidelines) and the background
of any other person or entity on whose behalf the nomination is being made (all of the foregoing, &ldquo;<U>Questionnaires</U>&rdquo;).
The Questionnaires will be provided by the Corporation within five business days following a request therefor; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a representation that a nominee for election or re-election as a director of the Corporation pursuant to <I>&#8206;</I>Section
2.10 will provide to the Corporation such other information as the Corporation may reasonably request, including such information reasonably
necessary for the Corporation to determine whether a nominee will satisfy any qualifications or requirements imposed by the Certificate
of Incorporation or these Bylaws, any law, rule, regulation or listing standard that may be applicable to the Corporation, or relevant
to a determination whether such person can be considered an independent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT>If
a stockholder has submitted notice of an intent to nominate a candidate for election or re-election as a director pursuant to
Section 2.10, all written and signed representations and agreements and all fully completed and signed Questionnaires described in
Section 2.9(a) above shall be provided to the Corporation at the same time as such notice, and the additional information described
in Section 2.9(a)(iii) above shall be provided to the Corporation promptly upon request by the Corporation, but in any event within
five business days after such request (or by the day prior to the day of the meeting of stockholders, if earlier). All information
provided pursuant to this Section 2.9 shall be deemed part of the stockholder&rsquo;s notice submitted pursuant to Section 2.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding the foregoing, if any information or communication submitted pursuant to this &#8206;Section 2.9 is inaccurate
or incomplete in any material respect (as determined by the Board of Directors (or any authorized committee thereof)) such information
shall be deemed not to have been provided in accordance with this &#8206;Section 2.9. Upon written request of the Secretary, the stockholder
giving notice of an intent to nominate a candidate for election shall provide, within five business days after delivery of such request
(or such longer period as may be specified in such request), (i) written verification, reasonably satisfactory to the Corporation, to
demonstrate the accuracy of any information submitted and (ii) a written affirmation of any information submitted as of an earlier date.
If such stockholder fails to provide such written verification or affirmation within such time period, the information as to which written
verification or affirmation was requested may be deemed not to have been provided in accordance with this &#8206;Section 2.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Stockholder Business and Nominations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Annual Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Nominations of persons for election to the Board of Directors and the proposal of business other than nominations to be considered
by the stockholders may be made at an annual meeting of stockholders only: (A) pursuant to the Corporation&rsquo;s notice of meeting (or
any supplement thereto); (B) by or at the direction of the Board of Directors (or any authorized committee thereof); or (C) by any stockholder
of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.10(a) is delivered to the Secretary,
who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.10(a). For the avoidance
of doubt, the foregoing clause (C) shall be the exclusive means for a stockholder to make nominations or propose other business at an
annual meeting of stockholders (other than a proposal included in the Corporation&rsquo;s proxy statement pursuant to and in compliance
with Rule 14a-8 under the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (C) of the
foregoing paragraph, the stockholder must have given timely notice thereof in writing to the Secretary and, in the case of business other
than nominations, such business must be a proper subject for stockholder action. To be timely, a stockholder&rsquo;s notice must be delivered
to the Secretary at the principal executive offices of the Corporation not later than the close of business (as defined in Section 2.10(c)(iii)
below) on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&rsquo;s
annual meeting; <U>provided</U>, <U>however</U>, that in the event that the date of the annual meeting is more than 30 days before or
more than 60 days after such anniversary date, or if no annual meeting was held or deemed to have been held in the preceding year, notice
by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting
and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the date
on which public announcement (as defined in Section 2.10(c)(iii) below) of the date of such meeting is first made by the Corporation.
In no event shall an adjournment or recess of an annual meeting, or a postponement of an annual meeting for which notice of the meeting
has already been given to stockholders or a public announcement of the meeting date has already been made, commence a new time period
(or extend any time period) for the giving of a stockholder&rsquo;s notice as described above. A stockholder&rsquo;s notice given in accordance
with this <I>&#8206;&#8206;</I>Section 2.10 must contain the names of only those nominees for whom such stockholder (or beneficial owner,
if any) intends to solicit proxies, and a stockholder shall not be entitled to make additional or substitute nominations following the
expiration of the time periods set forth in this Section 2.10(a); <U>provided</U> that, in the event a stockholder&rsquo;s notice includes
one or more substitute nominees, such stockholder must provide timely notice of such substitute nominee(s) in accordance with the provisions
of Section 2.9 and <I>&#8206;</I>this <I>&#8206;</I>Section 2.10 (including, without limitation, satisfaction of all applicable informational
requirements set forth therein). For the avoidance of doubt, the number of nominees a stockholder may nominate for election at the annual
meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate
for election at the annual meeting on behalf of the beneficial owner) shall not exceed the number of directors to be elected at such annual
meeting. Such stockholder&rsquo;s notice shall set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> as to each person whom the stockholder proposes to nominate for election or re-election as a director:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a written statement, not to exceed 500 words, in support of such person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all information relating to such person that is required to be disclosed in solicitations of proxies for elections of directors
in an election contest, or is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Exchange Act;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the information required to be submitted regarding nominees pursuant to &#8206;Section 2.9 above, including, within the time period
specified in &#8206;Section 2.9(c) above, all fully completed and signed Questionnaires described in &#8206;Section 2.9(a)(ii) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired
to be brought before the meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration
and in the event that such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment),
the reasons for conducting such business at the meeting and any substantial interest (within the meaning of Item 5 of Schedule 14A under
the Exchange Act) in such business of such stockholder and the beneficial owner (within the meaning of Section 13(d) of the Exchange Act),
if any, on whose behalf the proposal is made, and if such stockholder or beneficial owner is an entity, any related person (as defined
below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(C)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made or the other business
is proposed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the name and address of such stockholder, as they appear on the Corporation&rsquo;s books, and the name and address of such beneficial
owner;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the class or series and number of shares of stock of the Corporation that are owned of record by such stockholder and such beneficial
owner as of the date of the notice, and a representation that the stockholder will notify the Corporation in writing within five business
days after the record date for such meeting of the class or series and number of shares of stock of the Corporation owned of record by
the stockholder and such beneficial owner as of the record date for the meeting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a representation that the stockholder (or a qualified representative of the stockholder) intends to appear at the meeting to make
such nomination or propose such business; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(D)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>as to the stockholder giving the notice or, if the notice is given on behalf of a beneficial owner on whose behalf the nomination
is made or the other business is proposed, as to such beneficial owner, and if such stockholder or beneficial owner is an entity, as to
each individual who is a director, executive officer, general partner or managing member of such entity or of any other entity that has
or shares control of such entity (any such individual or entity, a &ldquo;<U>related person</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the class or series and number of shares of stock of the Corporation that are beneficially owned (as defined in Section 2.10(c)(iii)
below) by such stockholder or beneficial owner and by any related person as of the date of the notice, and a representation that the stockholder
will notify the Corporation in writing within five business days after the record date for such meeting of the class or series and number
of shares of stock of the Corporation beneficially owned by such stockholder or beneficial owner and by any related person as of the record
date for the meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT>a
description (which description shall include, in addition to all other information described in this clause (2), information
identifying all parties thereto) of (x) any plans or proposals that such stockholder, beneficial owner, if any, or related person
may have with respect to securities of the Corporation that would be required to be disclosed pursuant to Item 4 of Exchange Act
Schedule 13D and (y) any agreement, arrangement or understanding with respect to the nomination or other business between or among
such stockholder, beneficial owner, if any, or related person and any other person, including, without limitation, any agreements
that would be required to be disclosed pursuant to Item 5 or Item 6 of Exchange Act Schedule 13D (in the case of either clause (x)
or (y), regardless of whether the requirement to file a Schedule 13D is applicable), and a representation that the stockholder will
notify the Corporation in writing within five business days after the record date for such meeting of any such plans or proposals
with respect to securities of the Corporation or any such agreement, arrangement or understanding in effect as of the record date
for the meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a description (which description shall include, in addition to all other information described in this clause (3), information
identifying all parties thereto) of any instrument, agreement, arrangement or understanding (including, without limitation, any option,
warrant, forward contract, swap, contract of sale or other derivative or similar agreement or short positions, profit interests, hedging
or pledging transactions, voting rights, dividend rights and/or borrowed or loaned shares), regardless of whether it is to be settled
with shares or with cash based on the notional amount or value of outstanding shares of stock, that has been entered into as of the date
of the stockholder&rsquo;s notice by, or on behalf of, such stockholder, beneficial owner, if any, or related person, the effect or intent
of which is to mitigate loss, manage risk or benefit from changes in the share price of any class or series of the Corporation&rsquo;s
stock or the share price of any class or series of the capital stock of any principal competitor of the Corporation (as defined for the
purposes of Section 8 of the Clayton Antitrust Act of 1914) or maintain, increase or decrease the voting power of the stockholder, beneficial
owner, if any, or related person with respect to securities of the Corporation or of any principal competitor of the Corporation, and
a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such
meeting of any such instrument, agreement, arrangement or understanding in effect as of the record date for the meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>any equity interests in any principal competitor of the Corporation (as defined for the purposes of Section 8 of the Clayton Antitrust
Act of 1914) held by or on behalf of such stockholder or beneficial owner, if any, and any related person as of the date of the notice,
and a representation that the stockholder will notify the Corporation in writing within five business days after the record date for such
meeting of any such equity interests held as of the record date for the meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a representation as to whether the stockholder, beneficial owner, if any, related person or any other participant (as defined in
Item 4 of Schedule 14A under the Exchange Act) will engage in a solicitation with respect to such nomination or proposal and, if so, whether
such solicitation will be conducted as an exempt solicitation under Rule 14a-2(b) of the Exchange Act, the name of each participant in
such solicitation and the amount of the cost of solicitation that has been and will be borne, directly or indirectly, by each participant
in such solicitation and (x)&nbsp;in the case of a proposal of business other than nominations, whether such person or group intends to
deliver, a proxy statement and form of proxy to holders of at least the percentage of the Corporation&rsquo;s voting shares required under
applicable law to carry the proposal, (y)&nbsp;in the case of any solicitation that is subject to Rule 14a-19 of the Exchange Act, confirming
that such person or group will deliver, through means satisfying each of the conditions that would be applicable to the Corporation under
either Exchange Act Rule 14a-16(a) or Exchange Act Rule 14a-16(n), a proxy statement and form of proxy to holders of at least 67% of the
voting power of the Corporation&rsquo;s stock entitled to vote generally in the election of directors, and/or (z) whether such person
or group intends to otherwise solicit proxies from holders of the Corporation&rsquo;s stock in support of such proposal or nomination
(for purposes of this clause (5), the term &ldquo;<U>holders</U>&rdquo; shall include, in addition to stockholders of record, any beneficial
owners pursuant to Rule 14b-1 and Rule 14b-2 of the Exchange Act); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>a representation that promptly after soliciting the holders of the Corporation&rsquo;s stock referred to in the representation
required under clause (a)(ii)(D)(5) of this Section 2.10, and in any event no later than the 10th day before such meeting of stockholders,
such stockholder or beneficial owner will provide the Corporation with documents, which may take the form of a certified statement and
documentation from a proxy solicitor, specifically demonstrating that the necessary steps have been taken to deliver a proxy statement
and form of proxy to holders of such percentage of the Corporation&rsquo;s stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding anything in this Section 2.10(a) to the contrary, if any information or communication submitted pursuant to this
Section 2.10 is inaccurate or incomplete in any material respect (as determined by the Board of Directors (or any authorized committee
thereof)) such information shall be deemed not to have been provided in accordance with this Section 2.10. Upon written request of the
Secretary, the stockholder giving notice of an intent to nominate a candidate for election or propose other business shall provide, within
five business days after delivery of such request (or such longer period as may be specified in such request), (i) written verification,
reasonably satisfactory to the Corporation, to demonstrate the accuracy of any information submitted and (ii) a written affirmation of
any information submitted as of an earlier date. If such stockholder fails to provide such written verification or affirmation within
such period, the information as to which written verification or affirmation was requested may be deemed not to have been provided in
accordance with this Section 2.10. The obligation to update and supplement as set forth in Section 2.9, this Section&nbsp;2.10 or any
other section of these Bylaws shall not limit the Corporation&rsquo;s rights with respect to any deficiencies in any notice provided
by a stockholder, extend any applicable deadlines hereunder or under any other provision of these Bylaws or enable or be deemed to permit
a stockholder who has previously submitted notice hereunder or under any other provision of these Bylaws to amend or update any nomination
or other business proposal or to submit any new nomination or other business proposal, including by changing or adding nominees, matters,
business and or resolutions proposed to be brought before a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding anything in Section 2.10(a)(ii) above or Section 2.10(b) below to the contrary, if the record date for determining
the stockholders entitled to vote at any meeting of stockholders is different from the record date for determining the stockholders entitled
to notice of the meeting, a stockholder&rsquo;s notice required by this Section 2.10 shall set forth a representation that the stockholder
will notify the Corporation in writing within five business days after the record date for determining the stockholders entitled to vote
at the meeting, or by the opening of business on the date of the meeting (whichever is earlier), of the information required under this
Section 2.10(a), and such information when provided to the Corporation shall be current as of the record date for determining the stockholders
entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>This Section 2.10(a) shall not apply to a proposal proposed to be made by a stockholder if the stockholder has notified the Corporation
of his or her intention to present the proposal at an annual or special meeting only pursuant to and in compliance with Rule 14a-8 under
the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies
for such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding anything in this Section 2.10(a) to the contrary, in the event that the number of directors to be elected to the
Board of Directors at an annual meeting is increased and there is no public announcement by the Corporation naming all of the nominees
proposed by the Board of Directors to be elected at such meeting or specifying the size of the increased Board of Directors made by the
Corporation at least 10 days prior to the last day a stockholder may deliver a notice in accordance with Section 2.10(a)(ii) above, a
stockholder&rsquo;s notice required by this Section 2.10(a) shall also be considered timely, but only with respect to nominees for any
new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation
not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT><U>Special
Meeting</U>. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which
directors are to be elected pursuant to the Corporation&rsquo;s notice of meeting: (i) by or at the direction of the Board of
Directors (or any authorized committee thereof); or (ii) <U>provided</U> that the Board of Directors has determined that one or more
directors are to be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time the
notice provided for in this Section 2.10(b) is delivered to the Secretary, who is entitled to vote at the meeting and upon such
election and who delivers notice thereof in writing setting forth the information required by Section 2.10(a) above and provides the
additional information required by Section 2.9 above. In the event the Corporation calls a special meeting of stockholders for the
purpose of electing one or more directors to the Board of Directors, any stockholder entitled to vote in such election of directors
may nominate a person or persons (as the case may be) for election to such position(s) as specified in the Corporation&rsquo;s
notice of meeting, if the notice required by this Section 2.10(b) shall be delivered to the Secretary at the principal executive
offices of the Corporation not earlier than the close of business on the 120th day prior to such special meeting and not later than
the close of business on the later of the 90th day prior to such special meeting or the 10th day following the date on which public
announcement of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting
is first made by the Corporation. A stockholder&rsquo;s notice given in accordance with this &#8206;Section 2.10(b) must contain the
names of only those nominees for whom such stockholder (or beneficial owner, if any) intends to solicit proxies, and a stockholder
shall not be entitled to make additional or substitute nominations following the expiration of the time periods set forth in this
Section 2.10(b); <U>provided</U> that, in the event a stockholder&rsquo;s notice includes one or more substitute nominees, such
stockholder must provide timely notice of such substitute nominee(s) in accordance with the provisions of this &#8206;Section
2.10(b) (including, without limitation, satisfaction of all applicable informational requirements set forth in Section 2.9 and
Section 2.10(a) above). For the avoidance of doubt, the number of nominees a stockholder may nominate for election at the special
meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may
nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of directors to be
elected at such special meeting. In no event shall an adjournment, recess or postponement of a special meeting commence a new time
period (or extend any time period) for the giving of a stockholder&rsquo;s notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>General</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Except as otherwise required by law, only such persons who are nominated in accordance with the procedures set forth in this Section
2.10 shall be eligible to be elected at any meeting of stockholders of the Corporation to serve as directors and only such other business
shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth
in this Section 2.10. Notwithstanding any other provisions of these Bylaws, a stockholder (and any beneficial owner on whose behalf a
nomination is made or other business is proposed, and if such stockholder or beneficial owner is an entity, any related person), shall
also comply with all applicable requirements of the Exchange Act and the rules and regulations promulgated thereunder with respect to
the matters set forth in this <I>&#8206;</I>Section 2.10; <U>provided</U>, <U>however</U>, that any references in these Bylaws to the
Exchange Act or <I>&#8206;</I>the rules and regulations promulgated thereunder are not intended to and shall not limit any requirements
applicable to nominations or proposals as to any other business to be considered pursuant to this Section 2.10. The Chair of the Board
of Directors, the chair of the meeting or any other person designated by the Board of Directors shall determine whether a nomination or
any other business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures
set forth in this Section 2.10 (including whether a stockholder or beneficial owner provided all information and complied with all representations
required under Section 2.9 or this Section 2.10 or complied with the requirements of Rule 14a-19 under the Exchange Act). If any proposed
nomination or other business is not in compliance with this Section 2.10, including due to a failure to comply with the requirements of
Rule 14a-19 under the Exchange Act, then except as otherwise required by law, the chair of the meeting shall declare that such nomination
shall be disregarded or that such other business shall not be transacted, notwithstanding that votes and proxies in respect of any such
nomination or other business may have been received by the Corporation. In furtherance of and not by way of limitation of the foregoing
provisions of this Section 2.10, unless otherwise required by law, or otherwise determined by the Chair of the Board of Directors, the
chair of the meeting or any other person designated by the Board of Directors, (A) if the stockholder does not provide the information
required under Section 2.9 or this Section 2.10 to the Corporation within the time frames specified herein or (B) if the stockholder (or
a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to
present a nomination or other business, any such nomination shall be disregarded or any such other business shall not be transacted, notwithstanding
that votes and proxies in respect of any such nomination or other business may have been received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>To be considered a qualified representative of a stockholder for purposes of these Bylaws, a person must be a duly authorized officer,
manager or partner of such stockholder or authorized by a writing executed by such stockholder (or a reliable reproduction of the writing)
delivered to the Corporation prior to the making of such nomination or proposal at such meeting (and in any event not fewer than five
business days before the meeting) stating that such person is authorized to act for such stockholder as proxy at the meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">       </FONT>For
purposes of this Section 2.10, the &ldquo;<U>close of business</U>&rdquo; shall mean 6:00 p.m. local time at the principal executive
offices of the Corporation on any calendar day, whether or not the day is a business day, and a &ldquo;<U>public
announcement</U>&rdquo; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a
comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission
pursuant to Sections 13, 14 or 15(d) of the Exchange Act. For purposes of clause (a)(ii)(D)(1) of this Section 2.10, shares shall be
treated as &ldquo;<U>beneficially owned</U>&rdquo; by a person if the person beneficially owns such shares, directly or indirectly,
for purposes of Section 13(d) of the Exchange Act and Regulations 13D and 13G thereunder or has or shares pursuant to any agreement,
arrangement or understanding (whether or not in writing): (A) the right to acquire such shares (whether such right is exercisable
immediately or only after the passage of time or the fulfillment of a condition or both); (B) the right to vote such shares, alone
or in concert with others; <U>provided</U>, <U>however</U>, that a person shall not be deemed to beneficially own such shares if the
right to vote such shares arises solely from a revocable proxy or consent given to such person in response to a public proxy or
consent solicitation made pursuant to and in accordance with applicable rules and regulations promulgated under the Exchange Act;
and/or (C) investment power with respect to such shares, including the power to dispose of, or to direct the disposition of, such
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Nothing in this Section 2.10 shall be deemed to affect any rights (A) of stockholders to request inclusion of proposals in the
Corporation&rsquo;s proxy statement pursuant to Rule 14a-8 promulgated under the Exchange Act or (B) of the holders of any series of Preferred
Stock to elect directors pursuant to any applicable provisions of the Certificate of Incorporation (including any Preferred Stock Designation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white,
which shall be reserved for the exclusive use for solicitation by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Action by Written Consent</U>. Except as otherwise provided for or fixed pursuant to the Certificate of Incorporation (including
any Preferred Stock Designation), no action that is required or permitted to be taken by the stockholders of the Corporation may be effected
by consent of stockholders in lieu of a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Inspectors of Election</U>. Before any meeting of stockholders, the Corporation may, and shall if required by law, appoint one
or more inspectors of election to act at the meeting and make a written report thereof. Inspectors may be employees of the Corporation.
The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or
alternate is able to act at a meeting of stockholders, the chair of the meeting may, and shall if required by law, appoint one or more
inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath
faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Inspectors need
not be stockholders. No director or nominee for the office of director at an election shall be appointed as an inspector at such election.
Such inspectors shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence
of a quorum, and the validity of proxies and ballots;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>count and tabulate all votes and ballots; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT><U>Meetings
by Remote Communications</U>. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not
be held at any place, but may instead be held solely by means of remote communication in accordance with Section 211(a)(2) of the
DGCL. If authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of
Directors may adopt, stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote
communication: (a) participate in a meeting of stockholders; and (b) be deemed present in person and vote at a meeting of
stockholders whether such meeting is to be held at a designated place or solely by means of remote communication, <U>provided</U>
that: (i) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the
meeting by means of remote communication is a stockholder or proxyholder; (ii) the Corporation shall implement reasonable measures
to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters
submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently
with such proceedings; and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote
communication, a record of such vote or other action shall be maintained by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delivery to the Corporation</U>. Whenever this Article II requires one or more persons (including a record or beneficial owner
of stock) to deliver a document or information (other than a document authorizing another person to act for a stockholder by proxy at
a meeting of stockholders pursuant to Section 212 of the DGCL) to the Corporation or any officer, employee or agent thereof (including
any notice, request, questionnaire, revocation, representation or other document or agreement), the Corporation shall not be required
to accept delivery of such document or information unless the document or information is in writing exclusively (and not in an electronic
transmission) and delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered
mail, return receipt requested. For the avoidance of doubt, the Corporation expressly opts out of Section 116 of the DGCL with respect
to the delivery of information and documents (other than a document authorizing another person to act for a stockholder by proxy at a
meeting of stockholders pursuant to Section 212 of the DGCL) to the Corporation required by this &#8206;Article II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
III</FONT><BR>
DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Powers</U>. Except as otherwise required by the DGCL or as provided in the Certificate of Incorporation (including any Preferred
Stock Designation), the business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.
In addition to the powers and authorities these Bylaws expressly confer upon it, the Board of Directors may exercise all such powers of
the Corporation and do all such lawful acts and things as are not by law, the Certificate of Incorporation (including any Preferred Stock
Designation) or these Bylaws required to be exercised or done by the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Number, Term of Office and Election</U>. Except as otherwise provided for or fixed pursuant to the Certificate of Incorporation
(including any Preferred Stock Designation), the Board of Directors shall consist of such number of directors as shall be determined from
time to time solely by resolution of a majority of the directors then in office. The directors shall hold office in the manner provided
in the Certificate of Incorporation. At any meeting of stockholders at which directors are to be elected, directors shall be elected by
a plurality of the votes cast. Directors need not be stockholders unless so required by the Certificate of Incorporation (including any
Preferred Stock Designation) or these Bylaws, wherein other qualifications for directors may be prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Vacancies and Newly Created Directorships</U>. Subject to the rights of the holders of any outstanding series of Preferred Stock,
and unless otherwise required by law, newly created directorships resulting from any increase in the authorized number of directors and
any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other
cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office, even though less than a
quorum, or by the sole remaining director, and any director so chosen shall hold office until the next election of the class for which
such director shall have been chosen and until his or her successor shall have been duly elected and qualified. No decrease in the authorized
number of directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Resignations and Removal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Any director may resign at any time upon notice given in writing or by electronic transmission to the Board of Directors, the Chair
of the Board of Directors or the Secretary. Such resignation shall take effect upon delivery, unless the resignation specifies a later
effective date or time or an effective date or time determined upon the happening of an event or events. Unless otherwise specified therein,
the acceptance of such resignation shall not be necessary to make it effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Except for such additional directors, if any, as are elected by the holders of any series of Preferred Stock as provided for or
fixed pursuant to the Certificate of Incorporation (including any Preferred Stock Designation), any director, or the entire Board of
Directors, may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least 66
2&#8260;3% of the voting power of the stock outstanding and entitled to vote generally in the election of directors voting together as
a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regular Meetings</U>. Regular meetings of the Board of Directors shall be held at such place or places, within or without the
State of Delaware, on such date or dates and at such time or times, as shall have been established by the Board of Directors and publicized
among all directors. A notice of each regular meeting shall not be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Special Meetings</U>. Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the
Chair of the Board of Directors, the Chief Executive Officer (if separate and serving as a director) or a majority of the directors then
in office. The person or persons authorized to call special meetings of the Board of Directors may fix the place, within or without the
State of Delaware, date and time of such meetings. Notice of each such meeting shall be given to each director, if by mail, addressed
to such director at his or her residence or usual place of business, at least five days before the day on which such meeting is to be
held, or shall be sent to such director by electronic transmission, or be delivered personally or by telephone, in each case at least
24 hours prior to the time set for such meeting. A notice of special meeting need not state the purpose of such meeting, and, unless indicated
in the notice thereof, any and all business may be transacted at a special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remote Participation in Meetings</U>. Members of the Board of Directors, or of any committee thereof, may participate in a meeting
of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Quorum and Voting</U>. Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, a majority of
the total number of directors then authorized shall constitute a quorum for the transaction of business at any meeting of the Board of
Directors, and the vote of a majority of the directors present at a duly held meeting at which a quorum is present shall be the act of
the Board of Directors. The chair of the meeting or a majority of the directors present may adjourn the meeting to another time and place
whether or not a quorum is present. At any adjourned meeting at which a quorum is present, any business may be transacted that might have
been transacted at the meeting as originally called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Board of Directors Action by Written Consent Without a Meeting</U>. Unless otherwise restricted by the Certificate of Incorporation
or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or any committee thereof, may
be taken without a meeting, <U>provided</U> that all members of the Board of Directors or committee, as the case may be, consent in writing
or by electronic transmission to such action. After an action is taken, the consent or consents relating thereto shall be filed with the
minutes or proceedings of the Board of Directors or committee in the same paper or electronic form as the minutes are maintained. Any
person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action shall
be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction
is given or such provision is made and such consent shall be deemed to have been given at such effective time so long as such person is
then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Chair of the Board</U>. The Chair of the Board shall preside at meetings of stockholders in accordance with Section 2.4(a) above
and at meetings of directors and shall perform such other duties as the Board of Directors may from time to time determine. If the Chair
of the Board is not present at a meeting of the Board of Directors, the Chief Executive Officer (if separate and serving as a director)
or another director chosen by or in the manner provided by the Board of Directors shall preside.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Rules and Regulations</U>. The Board of Directors may adopt such rules and regulations not inconsistent with the provisions
of law, the Certificate of Incorporation or these Bylaws for the conduct of its meetings and management of the affairs of the Corporation
as the Board of Directors shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT><U>Fees
and Compensation of Directors</U>. Unless otherwise restricted by the Certificate of Incorporation, directors may receive such
compensation, if any, for their services on the Board of Directors and its committees, and such reimbursement of expenses, as may be
fixed or determined by resolution of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Emergency Bylaws</U>. This Section 3.13 shall be operative during any emergency condition as contemplated by Section 110 of
the DGCL (an &ldquo;<U>Emergency</U>&rdquo;), notwithstanding any different or conflicting provisions in these Bylaws, the Certificate
of Incorporation or the DGCL. In the event of any Emergency, or other similar emergency condition, the director or directors in attendance
at a meeting of the Board of Directors or a standing committee thereof shall constitute a quorum. Such director or directors in attendance
may further take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees
of the Board of Directors as they shall deem necessary and appropriate. Except as the Board of Directors may otherwise determine, during
any Emergency, the Corporation and its directors and officers, may exercise any authority and take any action or measure contemplated
by Section 110 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
IV</FONT><BR>
COMMITTEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Committees of the Board of Directors</U>. The Board of Directors may designate one or more committees, each such committee to
consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members
of any committee to replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a
member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not he, she or they constitute
a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified
member. Any such committee, to the extent permitted by law and provided in the resolution of the Board of Directors establishing such
committee, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs
of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee
shall have the power or authority in reference to the following matters: (a) approving or adopting, or recommending to the stockholders,
any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders
for approval; or (b) adopting, amending or repealing any bylaw of the Corporation. All committees of the Board of Directors shall keep
minutes of their meetings and shall report their proceedings to the Board of Directors when requested or required by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Meetings and Action of Committees</U>. Unless the Board of Directors provides otherwise by resolution, any committee of the
Board of Directors may adopt, alter and repeal such rules and regulations not inconsistent with the provisions of law, the Certificate
of Incorporation or these Bylaws for the conduct of its meetings as such committee may deem proper. A majority of the directors then serving
on a committee shall constitute a quorum for the transaction of business by the committee except as otherwise required by law, the Certificate
of Incorporation or these Bylaws, and except as otherwise provided in a resolution of the Board of Directors; <U>provided</U>, <U>however</U>,
that in no case shall a quorum be less than one-third of the directors then serving on the committee. Unless the Certificate of Incorporation,
these Bylaws or a resolution of the Board of Directors requires a greater number, the vote of a majority of the members of a committee
present at a meeting at which a quorum is present shall be the act of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
V</FONT><BR>
OFFICERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Officers</U>. The officers of the Corporation shall include a Chief Executive Officer, a Head of Finance (referred to throughout
these Bylaws as a &ldquo;Chief Financial Officer&rdquo;), and a Secretary, who shall be elected by the Board of Directors. The Corporation
may have such other officers as the Board of Directors or the Chief Executive Officer or another authorized officer may determine and
appoint from time to time. Officers shall have such authority, functions or duties as set forth in these Bylaws or as determined by the
Board of Directors or the Chief Executive Officer or another authorized officer. Each officer shall hold office until such person&rsquo;s
successor shall have been duly elected and qualified, or until such person&rsquo;s earlier death, disqualification, resignation or removal.
Any number of offices may be held by the same person. The Board of Directors may determine to leave any office vacant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.2 <U>Additional Positions and Titles</U>.
The Corporation may have assistants to officers, with such powers and duties as the Board of Directors, or the Chief Executive Officer
or another authorized officer, may from time to time determine. Any officer or employee may be assigned any additional title, with such
powers and duties, as the Board of Directors or an authorized officer may from time to time determine. Any persons appointed as assistant
officers, and any persons upon whom such titles are conferred, shall not be deemed officers of the Corporation unless appointed by the
Board of Directors or the Chief Executive Officer pursuant to &#8206;Section 5.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compensation</U>. The salaries of the officers of the Corporation shall be fixed from time to time by the Board of Directors
or by any person or persons to whom the Board of Directors has delegated such authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Removal, Resignation and Vacancies</U>. Any officer of the Corporation may be removed, with or without cause, by the Board of
Directors or an authorized officer. Any officer or assistant officer, if appointed by an officer, also may be removed by the officer authorized
to appoint such officer or assistant officer. Any officer may resign at any time upon notice given in writing or by electronic transmission
to the Corporation. Any resignation or removal shall be without prejudice to the rights, if any, of such officer under any contract to
which it is a party. Any vacancy occurring in any office of the Corporation may be filled by the Board of Directors or in accordance with
&#8206;Section 5.1 or &#8206;Section 5.2, as applicable, by the Chief Executive Officer or another authorized officer or such office may
be left vacant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Chief Executive Officer</U>. The Chief Executive Officer shall have general supervision and direction of the business and affairs
of the Corporation, shall be responsible for corporate policy and strategy, and shall report directly to the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<U>Chief Financial Officer</U>. The Chief Financial Officer shall exercise all the powers and perform the duties of the office of the
Chief Financial Officer and in general have overall supervision of the financial operations of the Corporation. The Chief Financial Officer
shall perform such other duties as the Board of Directors or the Chief Executive Officer may from time to time determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Secretary</U>. The powers and duties of the Secretary shall include acting as Secretary at all meetings of the Board of Directors,
of the committees of the Board of Directors and of the stockholders, and performing all other duties incident to the office of Secretary.
The Secretary shall perform such other duties as the Board of Directors, the Chief Executive Officer or another authorized officer may
from time to time determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authority and Duties of Officers</U>. The Chief Executive Officer, Chief Financial Officer, and the Secretary shall have such
authority, functions or duties as set forth in these Bylaws or as determined by the Board of Directors. Other officers shall have such
authority, functions or duties as set forth in these Bylaws or as determined by the Board of Directors, the Chief Executive Officer or
another officer authorized to prescribe the duties of such officer. To the extent not so set forth or determined, each such officer shall
have such authority, functions or duties as those that generally pertain to their respective offices, subject to the control of the Board
of Directors. Unless otherwise determined by the Board of Directors or otherwise provided by law or these Bylaws, contracts, evidences
of indebtedness and other instruments or documents of the Corporation may be executed, signed or endorsed: (i) by the Chief Executive
Officer; or (ii) by other officers of the Corporation, in each case only with regard to such instruments or documents that pertain to
or relate to such person&rsquo;s duties or business functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Action with Respect to Securities of Other Corporations or Entities</U>. The Chief Executive Officer, or any other person or
persons to whom the Board of Directors or the Chief Executive Officer has delegated such authority, is authorized to vote, represent,
and exercise on behalf of the Corporation all rights incident to any and all shares or other equity interests of any other corporation
or entity or corporations or entities, standing in the name of the Corporation. The authority herein granted may be exercised either by
such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by the person having such
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delegation</U>. The Board of Directors or an authorized officer may from time to time delegate the powers or duties of any officer
to any other officers or agents, notwithstanding the foregoing provisions of this &#8206;Article V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
VI</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Right to Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Each person who was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any action, suit,
arbitration, alternative dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, or any
other threatened, pending or completed proceeding, whether brought by or in the right of the Corporation or otherwise, including any and
all appeals, whether of a civil, criminal, administrative, legislative, investigative or other nature (hereinafter a &ldquo;<U>proceeding</U>&rdquo;),
by reason of the fact that he or she is or was a director or an officer of the Corporation or while a director or an officer of the Corporation
is or was serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation or of a
partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an &ldquo;<U>indemnitee</U>&rdquo;),
or by reason of anything done or not done by him or her in any such capacity, shall be indemnified and held harmless by the Corporation
to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against all expense, liability and loss
(including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes, penalties and amounts paid in settlement by or on behalf of the
indemnitee) actually and reasonably incurred by such indemnitee in connection therewith, all on the terms and conditions set forth in
these Bylaws; <U>provided</U>, <U>however</U>, that, except as otherwise required by law or provided in Section 6.4 with respect to suits
to enforce rights under this Article VI, the Corporation shall indemnify any such indemnitee in connection with a proceeding, or part
thereof, voluntarily initiated by such indemnitee (including claims and counterclaims, whether such counterclaims are asserted by: (i)
such indemnitee; or (ii) the Corporation in a proceeding initiated by such indemnitee) only if such proceeding, or part thereof, was authorized
or ratified by the Board of Directors or the Board of Directors otherwise determines that indemnification or advancement of expenses is
appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Any reference to an officer of the Corporation in this &#8206;Article VI shall be deemed to refer exclusively to the Chief Executive
Officer, Chief Financial Officer and Secretary and any officer of the Corporation (1) appointed by the Board of Directors pursuant to
&#8206;Section 5.1 or (2) designated by the Board of Directors as such for purposes of Section 16 of the Exchange Act, and any reference
to an officer of any other enterprise shall be deemed to refer exclusively to an officer appointed by the board of directors or equivalent
governing body of such other enterprise pursuant to the certificate of incorporation and bylaws (or equivalent organizational documents)
of such other enterprise. The fact that any person who is or was an employee of the Corporation or an employee of any other enterprise
has been given or has used the title of &ldquo;Vice President&rdquo; or any other title that could be construed to suggest or imply that
such person is or may be an officer of the Corporation or of such other enterprise shall not, by itself, result in such person being constituted
as, or being deemed to be, an officer of the Corporation or of such other enterprise for purposes of this &#8206;Article VI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Right to Advancement of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In addition to the right to indemnification conferred in Section 6.1, an indemnitee shall, to the fullest extent permitted by law,
also have the right to be paid by the Corporation the expenses (including attorneys&rsquo; fees) incurred in defending any proceeding
in advance of its final disposition (hereinafter an &ldquo;<U>advancement of expenses</U>&rdquo;); <U>provided</U>, <U>however</U>, that
an advancement of expenses shall be made only upon delivery to the Corporation of an undertaking (hereinafter an &ldquo;<U>undertaking</U>&rdquo;),
by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision of
a court of competent jurisdiction from which there is no further right to appeal (hereinafter a &ldquo;<U>final adjudication</U>&rdquo;)
that such indemnitee is not entitled to be indemnified for such expenses under this Article VI or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">        </FONT>Notwithstanding
the foregoing Section 6.2(a), the Corporation shall not make or continue to make advancements of expenses to an indemnitee if a
determination is reasonably made that the facts known at the time such determination is made demonstrate clearly and convincingly
that the indemnitee acted in bad faith or in a manner that the indemnitee did not reasonably believe to be in or not opposed to the
best interests of the Corporation, or, with respect to any criminal proceeding, that the indemnitee had reasonable cause to believe
his or her conduct was unlawful. Such determination shall be made: (i) by the Board of Directors by a majority vote of directors who
are not parties to such proceeding, whether or not such majority constitutes a quorum; (ii) by a committee of such directors
designated by a majority vote of such directors, whether or not such majority constitutes a quorum; or (iii) if there are no such
directors, or if such directors so direct, by independent legal counsel in a written opinion to the Board of Directors, a copy of
which shall be delivered to the indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Indemnification for Successful Defense</U>. To the extent that an indemnitee has been successful on the merits or otherwise
in defense of any proceeding (or in defense of any claim, issue or matter therein), such indemnitee shall be indemnified under this &#8206;Section
6.3 against expenses (including attorneys&rsquo; fees) actually and reasonably incurred in connection with such defense. Indemnification
under this &#8206;Section 6.3 shall not be subject to satisfaction of a standard of conduct, and the Corporation may not assert the failure
to satisfy a standard of conduct as a basis to deny indemnification or recover amounts advanced, including in a suit brought pursuant
to &#8206;Section 6.4 (notwithstanding anything to the contrary therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Right of Indemnitee to Bring Suit</U>. If a request for indemnification under Section 6.1 or Section 6.3 is not paid in full
by the Corporation within 60 days, or if a request for an advancement of expenses under Section 6.2 is not paid in full by the Corporation
within 20 days, after a written request has been received by the Secretary, the indemnitee may at any time thereafter bring suit against
the Corporation in a court of competent jurisdiction in the State of Delaware seeking an adjudication of entitlement to such indemnification
or advancement of expenses. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an
advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting
or defending such suit to the fullest extent permitted by law. In any suit brought by the indemnitee to enforce a right to indemnification
hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that the
indemnitee has not met any applicable standard of conduct for indemnification set forth in Section 145(a) or Section 145(b) of the DGCL.
Further, in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation
shall be entitled to recover such expenses upon a final adjudication that the indemnitee has not met any applicable standard of conduct
for indemnification set forth in Section 145(a) or Section 145(b) of the DGCL. Neither the failure of the Corporation (including its directors
who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination
prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has
met such applicable standard of conduct, nor an actual determination by the Corporation (including its directors who are not parties to
such action, a committee of such directors, independent legal counsel or its stockholders) that the indemnitee has not met such applicable
standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of
such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification
or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under
applicable law, this Article VI or otherwise shall be on the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Non-Exclusivity of Rights</U>. The rights to indemnification and to the advancement of expenses conferred in this Article VI
shall not be exclusive of any other right that any person may have or hereafter acquire under any law, agreement, vote of stockholders
or disinterested directors, provisions of a certificate of incorporation or bylaws, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Insurance</U>. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee
or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability
or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the
DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Indemnification of Employees and Agents of the Corporation; Service at Subsidiaries</U>. The Corporation may, to the extent
and in the manner permitted by law, and to the extent authorized from time to time, grant rights to indemnification and to the advancement
of expenses to any employee or agent of the Corporation. Any person serving as a director or officer of a subsidiary of the Corporation
shall be entitled to the rights to indemnification conferred in this &#8206;Article VI, and to the advancement of expenses, as defined
in &#8206;Section 6.2, with respect to his or her service at such subsidiary; <U>provided</U>, <U>however</U>, that the advancement of
expenses to any person who is not an indemnitee as defined in &#8206;Section 6.1(a) shall be at the discretion of the Corporation. Any
director or officer of a subsidiary is deemed to be serving such subsidiary at the request of the Corporation, and the Corporation is
deemed to be requesting such service. This &#8206;Article VI shall, to the fullest extent permitted by law, supersede any conflicting
provisions contained in the corporate governance documents of any other subsidiary of the Corporation. In addition, the Corporation may,
to the extent and in the manner permitted by law, and to the extent authorized from time to time, grant rights to indemnification and
to the advancement of expenses to individuals with respect to their service as an employee or agent of subsidiaries of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Nature of Rights</U>. The rights conferred upon indemnitees in this Article VI shall be contract rights and such rights shall
continue as to an indemnitee who has ceased to be a director or officer and shall inure to the benefit of the indemnitee&rsquo;s heirs,
executors and administrators. Any amendment, alteration or repeal of this Article VI that adversely affects any right of an indemnitee
or its successors shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any
occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Settlement of Claims</U>. Notwithstanding anything in this Article VI to the contrary, the Corporation shall not be liable to
indemnify any indemnitee under this Article VI for any amounts paid in settlement of any proceeding effected without the Corporation&rsquo;s
written consent, which consent shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subrogation</U>. In the event of payment under this Article VI, the Corporation shall be subrogated to the extent of such payment
to all of the rights of recovery of the indemnitee (excluding insurance obtained on the indemnitee&rsquo;s own behalf), and the indemnitee
shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such
documents necessary to enable the Corporation effectively to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any provision or provisions of this Article VI shall be held to be invalid, illegal or unenforceable as
applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law: (a) the validity,
legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article VI (including,
without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable,
that are not by themselves invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances
shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VI (including,
without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable,
that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent of the parties that the
Corporation provide protection to the indemnitee to the fullest extent set forth in this Article VI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
VII</FONT><BR>
CAPITAL STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certificates of Stock</U>. The shares of the Corporation shall be represented by certificates; <U>provided</U>, <U>however</U>,
that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be
uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered
to the Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name
of the Corporation by any two authorized officers of the Corporation, including, without limitation, the Chief Executive Officer, the
Chief Financial Officer, the Treasurer, the Controller, the Secretary, or an Assistant Treasurer or Assistant Secretary certifying the
number of shares owned by such holder in the Corporation. Any or all such signatures may be facsimiles or otherwise electronic signatures.
In case any officer, transfer agent or registrar who has signed or whose facsimile or otherwise electronic signature has been placed upon
a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation
with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Special Designation on Certificates</U>. If the Corporation is authorized to issue more than one class of stock or more than
one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights
shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class
or series of stock; <U>provided</U>, <U>however</U>, that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing
requirements there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or
series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations,
the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated
stock, the registered owner thereof shall be given a notice, in writing or by electronic transmission, containing the information required
to be set forth or stated on certificates pursuant to this Section 7.2 or Sections 151, 156, 202(a) or 218(a) of the DGCL or with respect
to this Section 7.2 and Section 151 of the DGCL a statement that the Corporation will furnish without charge to each stockholder who
so requests the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each
class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise
expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders
of certificates representing stock of the same class and series shall be identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Transfers of Stock</U>. Transfers of shares of stock of the Corporation shall be made only on the books of the Corporation upon
authorization by the registered holder thereof or by such holder&rsquo;s attorney thereunto authorized by a power of attorney duly executed
and filed with the Secretary or a transfer agent for such stock, and if such shares are represented by a certificate, upon surrender of
the certificate or certificates for such shares properly endorsed or accompanied by a duly executed stock transfer power and the payment
of any taxes thereon; <U>provided</U>, <U>however</U>, that the Corporation shall be entitled to recognize and enforce any lawful restriction
on transfer. Transfers may also be made in any manner authorized by the Corporation (or its authorized transfer agent) and permitted by
Section 224 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Lost Certificates</U>. The Corporation may issue a new share certificate or uncertificated shares in the place of any certificate
theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen
or destroyed certificate or the owner&rsquo;s legal representative to give the Corporation a bond (or other adequate security) sufficient
to indemnify it against any claim that may be made against it (including any expense or liability) on account of the alleged loss, theft
or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. The Board of Directors may adopt
such other provisions and restrictions with reference to lost certificates, not inconsistent with applicable law, as it shall in its discretion
deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Registered Stockholders</U>. The Corporation shall be entitled to recognize the exclusive right of a person registered on its
books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other
claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof,
except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Record Date for Determining Stockholders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjourned
meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the
record date is adopted by the Board of Directors, and which record date shall, unless otherwise required by law, not be more than 60 nor
less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date
for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such
record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date
is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders
shall be at the close of business (as defined in Section 2.10(c)(iii) above) on the day next preceding the day on which notice is given,
or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders
of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjourned meeting; <U>provided</U>, <U>however</U>,
that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting,
and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier
date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution
or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose
of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the
resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 days prior to
such action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close
of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulations</U>. To the extent permitted by applicable law, the Board of Directors may make such additional rules and regulations
as it may deem expedient concerning the issue, transfer and registration of shares of stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Waiver of Notice</U>. Whenever notice is required to be given under any provision of the DGCL or the Certificate of Incorporation
or these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled
to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting
shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at
the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business
to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, the Board of Directors or a committee of
the Board of Directors need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by
the Certificate of Incorporation or these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">Article
VIII</FONT><BR>
GENERAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Fiscal Year</U>. The fiscal year of the Corporation shall begin on the first day of January of each year and end on the last
day of December of the same year, or shall extend for such other 12 consecutive months as the Board of Directors may designate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Corporate Seal</U>. The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall
be in the charge of the Secretary. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may
be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reliance upon Books, Reports and Records</U>. Each director and each member of any committee designated by the Board of Directors
shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records
of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees,
or committees of the Board of Directors so designated, or by any other person as to matters that such director or committee member reasonably
believes are within such other person&rsquo;s professional or expert competence and who has been selected with reasonable care by or on
behalf of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subject to Law and Certificate of Incorporation</U>. All powers, duties and responsibilities provided for in these Bylaws, whether
or not explicitly so qualified, are qualified by the Certificate of Incorporation (including any Preferred Stock Designation) and applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Electronic Signatures, etc</U>. Except as otherwise required by the Certificate of Incorporation (including as otherwise required
by any Preferred Stock Designation) or these Bylaws (including, without limitation, as otherwise required by Section 2.14), any document,
including, without limitation, any consent, agreement, certificate or instrument, required by the DGCL, the Certificate of Incorporation
(including any Preferred Stock Designation) or these Bylaws to be executed by any officer, director, stockholder, employee or agent of
the Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable
law. All other contracts, agreements, certificates or instruments to be executed on behalf of the Corporation may be executed using a
facsimile or other form of electronic signature to the fullest extent permitted by applicable law. The terms &ldquo;electronic mail,&rdquo;
&ldquo;electronic mail address,&rdquo; &ldquo;electronic signature&rdquo; and &ldquo;electronic transmission&rdquo; as used herein shall
have the meanings ascribed thereto in the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
IX</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORUM
FOR ADJUDICATION OF DISPUTES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Forum</U>. Unless the Corporation, in writing, selects or consents to the selection of an alternative forum: (a) the sole and
exclusive forum for any complaint asserting any internal corporate claims (as defined below), to the fullest extent permitted by law,
and subject to applicable jurisdictional requirements, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery
does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware); and
(b) the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, to the fullest
extent permitted by law, shall be the federal district courts of the United States of America. Notwithstanding anything herein to the
contrary, and for the avoidance of doubt, this Article IX shall not apply to suits brought to enforce a duty or liability created by the
Exchange Act. For purposes of this Article IX, internal corporate claims means claims, including claims in the right of the Corporation
that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity, or as to
which the DGCL confers jurisdiction upon the Court of Chancery. Any person or entity purchasing or otherwise acquiring or holding any
interest in shares of stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article IX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Enforceability</U>. If any provision of this Article IX shall be held to be invalid, illegal or unenforceable as applied to
any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and
enforceability of such provision in any other circumstance and of the remaining provisions of this Article IX (including, without limitation,
each portion of any sentence of this Article IX containing any such provision held to be invalid, illegal or unenforceable that is not
itself held to be invalid, illegal or unenforceable), and the application of such provision to other persons or entities or circumstances
shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
X</FONT><BR>
AMENDMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Amendments</U>. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board
of Directors is expressly authorized to adopt, amend or repeal these Bylaws. Except as otherwise provided in the Certificate of Incorporation
(including the terms of any Preferred Stock Designation that provides for a greater or lesser vote) or these Bylaws, and in addition to
any other vote required by law, the affirmative vote of the holders of at least 66 2&#8260;3% of the voting power of the stock outstanding
and entitled to vote thereon, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal, or
adopt any provision inconsistent with, any provision of these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The foregoing Amended and Restated Bylaws were
adopted by the Board of Directors on August 29, 2024</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.8
<SEQUENCE>8
<FILENAME>ea021319301ex3-8_oruka.htm
<DESCRIPTION>FORM OF CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 3.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>CERTIFICATE OF ELIMINATION<BR>
OF SERIES A CONVERTIBLE PREFERRED STOCK OF<BR>
ARCA BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(Pursuant to Section 151(g)
of the General Corporation Law of the State of Delaware)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ARCA biopharma, Inc., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.   The
Amended and Restated Certificate of Incorporation (the &ldquo;<B><I>Charter</I></B>&rdquo;) of the Company, including as amended pursuant
to that certain Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &ldquo;<B><I>Series
A Certificate of Designation</I></B>&rdquo;), authorizes the issuance of 135,000 shares of preferred stock, par value $0.001 per share,
of the Company, designated as Series A Convertible Preferred Stock (the &ldquo;<B><I>Series A Preferred Stock</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.   Pursuant
to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;), the
Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;) of the Company adopted the following resolutions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><B>WHEREAS</B>, the
Board deems it advisable and in the best interests of the Company and its stockholders to effect the elimination of the Series A Convertible
Preferred Stock of the Company (&ldquo;<B><I>Series A Preferred Stock</I></B>&rdquo;) pursuant to Section 151(g) of the DGCL;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><B>WHEREAS</B>, a
total of up to 135,000 shares of Series A Preferred Stock were authorized pursuant to that certain Certificate of Designation of Preferences,
Rights and Limitations of Series A Convertible Preferred Stock (the &ldquo;<B><I>Series A Certificate of Designation</I></B>&rdquo;),
125,000 of which shares have been previously issued and were subsequently converted into Common Stock, such that no shares of Series A
Preferred Stock remain outstanding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><B>WHEREAS</B>, Article
IV of the Charter provides that the Board is authorized to increase or decrease the number of shares of any series of Preferred Stock
subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in"><B>NOW, THEREFORE, BE
IT RESOLVED</B>: That the Board hereby confirms that no shares of Series A Preferred Stock are outstanding, and none of the authorized
shares of Series A Preferred Stock will be issued subject to the Series A Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in"><B>RESOLVED FURTHER</B>:
That, pursuant to Article IV of the Charter, the Board hereby decreases the number of authorized shares of Series A Preferred Stock to
zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in"><B>RESOLVED FURTHER</B>:
That the officers of the Company are, and each of them hereby is, authorized and directed, for and on behalf of the Company and in its
name, to prepare a certificate of elimination (the &ldquo;<B><I>Series A Certificate of Elimination</I></B>&rdquo;), with the effect under
the DGCL of eliminating from the Charter all matters set forth in the Series A Certificate of Designation, and to execute and file the
Series A Certificate of Elimination with the Secretary of State of the State of Delaware, at such time as they deem appropriate, and to
take such further actions as they may deem necessary or appropriate to carry out the intent of the foregoing resolutions in accordance
with the applicable provisions of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.   Pursuant
to the provisions of Section 151(g) of the DGCL, all references to the Series A Preferred Stock in the Charter are hereby eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Certificate of Elimination to be signed on its behalf by its duly authorized officer on this 29<SUP>th</SUP> day of August,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>ARCA BIOPHARMA, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><B>/s/ </B>C. Jeffrey Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 35%"> C. Jeffrey Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.9
<SEQUENCE>9
<FILENAME>ea021319301ex3-9_oruka.htm
<DESCRIPTION>FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.9</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Arca
biopharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES,<BR>
RIGHTS AND LIMITATIONS<BR>
OF<BR>
SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 151 of the<BR>
General Corporation Law of the State of Delaware</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf
of ARCA biopharma, Inc., a Delaware corporation (the &ldquo;<B><I>Corporation</I></B>&rdquo;), that the following resolution was duly
adopted by the Board of Directors of the Corporation (the &ldquo;<B><I>Board of Directors</I></B>&rdquo;), in accordance with the provisions
of Section 151 of the General Corporation Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;), by unanimous written consent
on August 14, 2024, which resolution provides for the creation of a series of the Corporation&rsquo;s Preferred Stock, par value $0.001
per share, which is designated as &ldquo;Series B Non-Voting Convertible Preferred Stock,&rdquo; with the preferences, rights and limitations
set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>WHEREAS</B>: the Amended
and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;),
provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the
&ldquo;<B><I>Preferred Stock</I></B>&rdquo;), issuable from time to time in one or more series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>RESOLVED</B>: that,
pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the
Corporation be, and hereby is, authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of
251,504 shares of &ldquo;Series B Non-Voting Convertible Preferred Stock&rdquo; pursuant to the terms of the Agreement and Plan of Merger
and Reorganization, dated April 3, 2024, by and among the Corporation, Atlas Merger Sub Corp., a Delaware corporation and wholly owned
subsidiary of the Corporation, Atlas Merger Sub II LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and
Oruka Therapeutics, Inc. (the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), and (iii) the Board of Directors hereby fixes the designations,
powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions
thereof, of such shares of such series of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation
that are applicable to the Preferred Stock of all classes and series, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>TERMS OF SERIES B NON-VOTING
CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">1. <U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Business Day</I></B>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to&nbsp;close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Buy-In</I></B>&rdquo;
shall have the meaning set forth in <U>Section 6.4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Closing Sale
Price</I></B>&rdquo; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00
p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or
an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter
market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such
security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by
OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases,
the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Commission</I></B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Common Stock</I></B>&rdquo;
means the Corporation&rsquo;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Conversion Shares</I></B>&rdquo;
means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Non-Voting Preferred Stock in accordance
with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Exchange Act</I></B>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Holder</I></B>&rdquo;
means a holder of shares of Series B Non-Voting Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Person</I></B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Trading Day</I></B>&rdquo;
means a day on which the principal Trading Market is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&ldquo;<B><I>Trading Market</I></B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or
any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">2. <U>Designation,
Amount and Par Value</U>. The series of Preferred Stock shall be designated as the Corporation&rsquo;s Series B Non-Voting Convertible
Preferred Stock (the &ldquo;<B><I>Series B Non-Voting Preferred Stock</I></B>&rdquo;) and the number of shares so designated shall be
251,504. Each share of Series B Non-Voting Preferred Stock shall have a par value of $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">3. <U>Dividends</U>.
Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B Non-Voting Preferred Stock (on
an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the
same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock)
actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock)
are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of
Series B Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock)
on shares of the Common Stock unless it simultaneously complies with the previous sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">4. <U>Voting
Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">4.1 Except
as otherwise provided herein or as otherwise required by the DGCL, the Series B Non-Voting Preferred Stock shall have no voting rights.
However, as long as any shares of Series B Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative
vote or written waiver of the holders of a majority of the then outstanding shares of the Series B Non-Voting Preferred Stock: (i) alter
or change adversely the powers, preferences or rights given to the Series B Non-Voting Preferred Stock or alter or amend this Certificate
of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &ldquo;<B><I>Certificate
of Designation</I></B>&rdquo;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended
and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations
and relative rights of any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights,
privileges or powers of, or restrictions provided for the benefit of the Series B Non-Voting Preferred Stock, regardless of whether any
of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization,
reclassification, conversion or otherwise, (ii) issue further shares of Series B Non-Voting Preferred Stock beyond those contemplated
for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Non-Voting
Preferred Stock, (iii) at any time while at least 41,219 shares of Series B Non-Voting Preferred Stock remains issued and outstanding,
consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into
another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such
transaction do not hold at least a majority on an as-converted-to-Common Stock basis of the capital stock of the Corporation, immediately
after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval
contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series
B Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">4.2 Any
vote required or permitted under <U>Section 4.1</U> may be taken at a meeting of the Holders or through the execution of an action by
written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed
by Holders representing a majority of the outstanding shares of Series B Non-Voting Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">5. <U>Rank;
Liquidation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">5.1 The
Series B Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution
or winding up of the Corporation, whether voluntarily or involuntarily (a &ldquo;<B><I>Liquidation</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">5.2 Upon
any Liquidation, each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount
that a holder of Common Stock would receive if the Series B Non-Voting Preferred Stock were fully converted (disregarding for such purpose
any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <I>pari passu</I> with all holders of Common Stock,
plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the
Corporation shall be insufficient to pay the Holders of shares of the Series B Non-Voting Preferred Stock the amount required under the
preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common
Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid
in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly
declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">6. <U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">6.1 <U>Conversion
at Option of Holder</U>. Subject to <U>Section 6.3</U>, each share of Series B Non-Voting Preferred Stock then outstanding shall be convertible,
at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion
Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &ldquo;<B><I>Optional Conversion</I></B>&rdquo;). Holders
shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <B><U>Annex A</U></B> (a &ldquo;<B><I>Notice
of Conversion</I></B>&rdquo;), duly completed and executed. Provided the Corporation&rsquo;s transfer agent is participating in the Depository
Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the
Holder&rsquo;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&rsquo;s prime broker
with DTC through its Deposit Withdrawal Agent Commission system (a &ldquo;<B><I>DWAC Delivery</I></B>&rdquo;). The date on which an Optional
Conversion shall be deemed effective (the &ldquo;<B><I>Conversion Date</I></B>&rdquo;) shall be the Trading Day that the Notice of Conversion,
completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original
certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying
Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date
shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred
Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set
forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">6.2 <U>Conversion
Ratio</U>. The &ldquo;<B><I>Conversion Ratio</I></B>&rdquo; for each share of Series B Non-Voting Preferred Stock shall be 1,000 shares
of Common Stock issuable upon the conversion (the &ldquo;<B><I>Conversion</I></B>&rdquo;) of each share of Series B Non-Voting Preferred
Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">6.3 <U>Beneficial
Ownership Limitation</U>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share
of Series B Non-Voting Preferred Stock with respect to a Holder, and a Holder shall not have the right to convert any portion of the Series
B Non-Voting Preferred Stock pursuant to <U>Section 6.1</U>, to the extent that, after giving effect to such attempted conversion set
forth on an applicable Notice of Conversion with respect to the Series B Non-Voting Preferred Stock, such Holder (or any of such Holder&rsquo;s
affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section
13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the United States Securities and Exchange Commission
(the &ldquo;<B><I>Commission</I></B>&rdquo;), including any &ldquo;group&rdquo; of which the Holder is a member (the foregoing, &ldquo;<B><I>Attribution
Parties</I></B>&rdquo;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For
purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution
Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject
to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock
which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting Preferred Stock beneficially owned by such Holder
or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of
the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would
exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence,
for purposes of this <U>Section 6.3</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the applicable rules and regulations of the Commission, and the terms &ldquo;beneficial ownership&rdquo; and &ldquo;beneficially own&rdquo;
have the meanings ascribed to such terms therein. In addition, for purposes hereof, &ldquo;group&rdquo; has the meaning set forth in Section
13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this <U>Section 6.3</U>, in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the
most recent of the following: (A) the Corporation&rsquo;s most recent periodic or annual filing with the Commission, as the case may be,
(B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation
or the Corporation&rsquo;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the
written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to
such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including
shares of Series B Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding
shares of Common Stock was last publicly reported or confirmed to the Holder. The &ldquo;<B><I>Beneficial Ownership Limitation</I></B>&rdquo;
shall initially be 19.99% of the number of shares of Common Stock outstanding as of the applicable measurement date. The Corporation shall
be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation.
Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i) each Holder may reset the Beneficial
Ownership Limitation percentage to a higher percentage applicable to such Holder, not to exceed 19.99%, which increase will not be effective
until the sixty-first (61st) day after such written notice is delivered to the Corporation, and (ii) each Holder may reset the Beneficial
Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon
such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i) applicable to such Holder, not to exceed 19.99%,
the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this
<U>Section 6.3</U>. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, each Holder may waive
and/or change the Beneficial Ownership Limitation applicable to such Holder effective immediately upon written notice to the Corporation
and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation
(y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&rsquo;s Attribution
Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&rsquo;s
Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this <U>Section 6.3</U> shall be construed, corrected
and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common
Stock underlying the Series B Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">6.4 <U>Mechanics
of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.1 <U>Delivery
of Certificate or Electronic Issuance</U>. Upon Conversion not later than two (2)&nbsp;Trading Days after the applicable Conversion Date,
or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original
certificate(s) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice
of Conversion (the &ldquo;<B><I>Share Delivery Date</I></B>&rdquo;), the Corporation shall either: (a)&nbsp;deliver, or cause to be delivered,
to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion
of shares of Series B Non-Voting Preferred Stock, or (b)&nbsp;in the case of a DWAC Delivery (if so requested by the Holder), electronically
transfer such Conversion Shares by crediting the account of the Holder&rsquo;s prime broker with DTC through its DWAC system. If in the
case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or,
in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share
Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation
at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as
applicable, in which event the Corporation shall promptly return to such Holder any original Series B Non-Voting Preferred Stock certificate
delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct
the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B Non-Voting
Preferred Stock unsuccessfully tendered for conversion to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.2 <U>Obligation
Absolute</U>. Subject to <U>Section 6.3</U> and subject to Holder&rsquo;s right to rescind a Notice of Conversion pursuant to <U>Section
6.4.1</U>, the Corporation&rsquo;s obligation to issue and deliver the Conversion Shares upon conversion of Series B Non-Voting Preferred
Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce
the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to
enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or
any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person,
and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection
with the issuance of such Conversion Shares. Subject to <U>Section 6.3</U> and subject to Holder&rsquo;s right to rescind a Notice of
Conversion pursuant to <U>Section 6.4.1</U>, in the event a Holder shall elect to convert any or all of its Series B Non-Voting Preferred
Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder
has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining
and/or enjoining conversion of all or part of the Series B Non-Voting Preferred Stock of such Holder shall have been sought and obtained
by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion
Shares into which would be converted the Series B Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain
in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such
Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <U>Section 6.3</U> and
subject to Holder&rsquo;s right to rescind a Notice of Conversion pursuant to <U>Section 6.4.1</U>, issue Conversion Shares upon a properly
noticed conversion. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.3 <U>Buy-In
on Failure to Timely Deliver Certificates</U>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates
or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <U>Section 6.4.1</U> (other than a failure caused
by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership
Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction
or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by
such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date
(a &ldquo;<B><I>Buy-In</I></B>&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available
to or elected by such Holder) the amount by which (x) such Holder&rsquo;s total purchase price (including any brokerage commissions) for
the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder
was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such
purchase obligation was executed (including any brokerage commissions) and (B) deliver to such Holder the number of shares of Common Stock
that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section 6.4.1</U>. For example,
if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion
of shares of Series B Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving
rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall
be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the
occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations
and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Corporation&rsquo;s failure to timely deliver certificates representing shares of Common Stock upon conversion of
the shares of Series B Non-Voting Preferred Stock as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.4 <U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that at all times it will reserve and keep available out of its authorized
and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Non-Voting Preferred Stock, free
from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Non-Voting Preferred
Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of
<U>Section 7</U>) upon the conversion of all outstanding shares of Series B Non-Voting Preferred Stock. The Corporation covenants that
all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.5 <U>Fractional
Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Series B Non-Voting Preferred Stock, no certificates
or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares
of Common Stock that a Holder of Series B Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all
fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2in">6.4.6 <U>Transfer
Taxes</U>. The issuance of certificates for shares of the Common Stock upon conversion of the Series B Non-Voting Preferred Stock shall
be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery
of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer
involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of
such shares of Series B Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless
or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have
established to the satisfaction of the Corporation that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">6.5
<U>Status as Stockholder</U>. Upon each Conversion Date, (i) the shares of Series B Non-Voting Preferred Stock being converted shall be
deemed converted into shares of Common Stock and (ii) the Holder&rsquo;s rights as a holder of such converted shares of Series B Non-Voting
Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any
remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with
the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&rsquo;s
failure to convert Series B Non-Voting Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">7. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">7.1 <U>Stock
Dividends and Stock Splits</U>. If the Corporation, at any time while this Series B Non-Voting Preferred Stock is outstanding: (A) pays
a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt,
shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B Non-Voting Preferred Stock) with
respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares;
or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the
Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any
treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares
of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant
to this <U>Section 7.1</U> shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or
combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">7.2 <U>Fundamental
Transaction</U>. If, at any time while this Series B Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger
or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person (other
than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted
into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially
all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation
or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged
for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any
compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <U>Section 7.1</U>) to
which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &ldquo;<B><I>Fundamental
Transaction</I></B>&rdquo;), then, upon any subsequent conversion of this Series B Non-Voting Preferred Stock the Holders shall have the
right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such
conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property
as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental
Transaction, converted the Series B Non-Voting Preferred Stock immediately prior to such Fundamental Transaction (the &ldquo;<B><I>Alternate
Consideration</I></B>&rdquo;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration
it receives upon any conversion of this Series B Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary
to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file
a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the
foregoing provisions and evidencing the Holders&rsquo; right to convert such preferred stock into Alternate Consideration. The terms of
any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring
any such successor or surviving entity to comply with the provisions of this <U>Section 7.2</U> and insuring that this Series B Non-Voting
Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of
the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction
is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in
the Merger Agreement) shall not constitute a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">7.3 <U>Calculations</U>.
All calculations under this <U>Section 7</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this <U>Section 7</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">8. <U>Redemption</U>.
The shares of Series B Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability
of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">9. <U>Transfer</U>.
A Holder may transfer any shares of Series B Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by
such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The
Corporation shall in good faith (i) do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute
and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B Non-Voting Preferred
Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <U>Section 9</U>. The transferee of
any shares of Series B Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor
as of the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">10. <U>Series
B Non-Voting Preferred Stock Register</U>. The Corporation shall maintain at its principal executive offices (or such other office or
agency of the Corporation as it may designate by notice to the Holders in accordance with <U>Section 11</U>), a register for the Series
B Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder
in whose name the shares of Series B Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address
of each transferee of any shares of Series B Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares
of Series B Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes.
The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B
Non-Voting Preferred Stock or his, her or its legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">11. <U>Notices</U>.
Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series B Non-Voting
Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by
electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">12. <U>Book-Entry;
Certificates</U>. The Series B Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that
such Holder&rsquo;s shares of Series B Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a
stock certificate to such Holder representing such Holder&rsquo;s shares of Series B Non-Voting Preferred Stock. To the extent that any
shares of Series B Non-Voting Preferred Stock are issued in book-entry form, references herein to &ldquo;certificates&rdquo; shall instead
refer to the book-entry notation relating to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">13. <U>Lost
or Mutilated Series B Non-Voting Preferred Stock Certificate</U>. If a Holder&rsquo;s Series B Non-Voting Preferred Stock certificate
shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation
of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares
of Series B Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft
or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">14. <U>Waiver</U>.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver
by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation
on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist
upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must
be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any
right of the Holders of Series B Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series B Non-Voting Preferred
Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B Non-Voting
Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions
contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent
of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect
on any Holder shall require the consent of such Holder(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">15. <U>Severability</U>.
Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any
provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">16. <U>Status
of Converted Series B Non-Voting Preferred Stock</U>. If any shares of Series B Non-Voting Preferred Stock shall be converted or redeemed
by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition,
and shall not be reissued as a share of Series B Non-Voting Preferred Stock. Any share of Series B Non-Voting Preferred Stock so acquired
shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized
but unissued shares of preferred stock and shall no longer be designated as Series B Non-Voting Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page Intentionally Left Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, ARCA biopharma, Inc.
has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock to
be duly executed by its Chief Financial Officer on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">ARCA biopharma, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 35%"> /s/ C. Jeffrey Dekker</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> C. Jeffrey Dekker</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The undersigned Holder hereby irrevocably elects
to convert the number of shares of Series B Non-Voting Convertible Preferred Stock (&ldquo;<B><I>Series B Non-Voting Preferred Stock</I></B>&rdquo;)
indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
of ARCA biopharma, Inc., a Delaware corporation (the &ldquo;<B><I>Corporation</I></B>&rdquo;), as of the date written below. If securities
are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of
Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &ldquo;<B><I>Certificate of
Designation</I></B>&rdquo;) filed by the Corporation with the Secretary of State of the State of Delaware on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of the date hereof, the number of shares of
Common Stock beneficially owned by the undersigned Holder (together with such Holder&rsquo;s Attribution Parties), including the number
of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to this Notice of Conversion, but
excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting
Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised
or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of
its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in <U>Section 6.3</U>
of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &ldquo;group&rdquo; has
the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONVERSION CALCULATIONS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 78%"><FONT STYLE="font-size: 10pt">Date to Effect Conversion:</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 19%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Number of shares of Series B Non-Voting Preferred Stock owned prior to Conversion:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Number of shares of Series B Non-Voting Preferred Stock to be Converted:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Number of shares of Common Stock to be Issued:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Address for delivery of physical certificates:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For DWAC Delivery, please provide the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Broker No.:___________________________<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Account No.:_________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;<U> </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase">[HOLDER]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>10
<FILENAME>ea021319301ex10-10_oruka.htm
<DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>ORUKA THERAPEUTICS,
INC.<BR>
2024 STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>1.&nbsp;Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The purpose of this Oruka Therapeutics, Inc.
2024 Stock Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) is to promote and closely align the interests of employees, officers,
non-employee directors and other individual service providers of Oruka Therapeutics, Inc. and its stockholders by providing stock-based
compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the best available employees,
officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate Participants
to optimize the profitability and growth of the Company through incentives that are consistent with the Company&rsquo;s goals and that
link the personal interests of Participants to those of the Company&rsquo;s stockholders. The Plan provides for the grant of Options,
Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Other Stock-Based Awards and for Incentive Bonuses, which may
be paid in cash, Common Stock or a combination thereof, as determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>2.&nbsp;Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white">As used in
the Plan, the following terms shall have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;&ldquo;<B><I>Act</I></B>&rdquo;
means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;&ldquo;<B><I>Affiliate</I></B>&rdquo;
means any entity in which the Company has a substantial direct or indirect equity interest, as determined by the Committee from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>&ldquo;<B>Award</B></I>&rdquo;
means an Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Other Stock-Based Award or Incentive Bonus, or any
combination of these, granted to a Participant pursuant to the provisions of the Plan, any of which may be subject to performance conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written or electronic agreement or other instrument as may be approved from time to time by the Committee
and designated as such implementing the grant of each Award. An Award Agreement may be in the form of an agreement to be executed by both
the Participant and the Company (or an authorized representative of the Company) or certificates, notices or similar instruments as approved
by the Committee and designated as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(e)&nbsp;<I>&ldquo;<B>Beneficial
Owner</B></I>&rdquo; shall have the meaning set forth in Rule 13d-3 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(f)&nbsp;<I>&ldquo;<B>Board</B></I>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(g)&nbsp;<I>&ldquo;<B>Cause</B></I>&rdquo;
has the meaning set forth in the written employment, offer, services or severance agreement or letter between the Participant and the
Company or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or
no such term is defined in such agreement or plan, means a Participant&rsquo;s (i) dishonest statements or acts with respect to the Company
or any Affiliate, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business
that results in or is reasonably anticipated to result in material harm to the Company; (ii) conviction or plea of guilty or no contest
to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform in all material
respects the Participant&rsquo;s assigned duties and responsibilities; (iv) gross negligence, willful misconduct that results in or is
reasonably anticipated to result in material harm to the Company; (v) violation of any material provision of any agreement(s) between
the Participant and the Company; or (vi) material violation of any written Company policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(h)&nbsp;&ldquo;<B><I>Change
in Control</I></B>&rdquo; means, except as otherwise provided in an Award Agreement, the occurrence of any one of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(i)&nbsp;any
Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including the securities beneficially
owned by such Person or any securities acquired directly from the Company or its Affiliates) representing 50% or more of the combined
voting power of the Company&rsquo;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection
with a transaction described in&nbsp;<U>Section 2(h)(iii)(A)</U>&nbsp;below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(ii)&nbsp;the
following individuals cease for any reason to constitute a majority of the number of directors then serving: (A) individuals who, on the
Effective Date (as defined below), constitute the Board and (B)&nbsp;any new director (other than a director whose initial assumption
of office is in connection with an actual or threatened election contest, including a consent solicitation, relating to the election of
directors of the Company) whose appointment or election by the Board or nomination for election by the Company&rsquo;s stockholders was
approved or recommended by a vote of at least a majority of the directors then still in office who were either directors on the Effective
Date or whose appointment, election or nomination for election was previously so approved or recommended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(iii)&nbsp;there
is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity, other
than (A) a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior
to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving entity or any parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving
entity or any parent thereof outstanding immediately after such merger or consolidation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(iv)&nbsp;the
implementation of a plan of complete liquidation or dissolution of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(v)&nbsp;there
is consummated a sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets, other than a sale or disposition
by the Company of all or substantially all of the Company&rsquo;s assets to an entity, at least 50% of the combined voting power of the
voting securities of which is owned by stockholders of the Company in substantially the same proportions as their ownership of the Company
immediately prior to such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(i)&nbsp;&ldquo;Code&rdquo;
means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(j)&nbsp;<I>&ldquo;<B>Committee</B></I>&rdquo;
means the Compensation Committee of the Board (or any successor committee) or such other committee as designated by the Board to administer
the Plan under&nbsp;<U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(k)&nbsp;&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of the Company, $0.001 par value per share, or such other class or kind of shares or other
securities as may be applicable under&nbsp;<U>Section 16</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(l)&nbsp;<B>&ldquo;<I>Company</I></B>&rdquo;
means Oruka Therapeutics, Inc., a Delaware corporation, and except as utilized in the definition of Change in Control, any successor
corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(m)&nbsp;&ldquo;<B><I>Disability</I></B>&rdquo;
has the meaning set forth in a written employment, offer, services or severance agreement or letter between the Participant and the Company
or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term
is defined in such agreement or plan, means the inability of the Participant to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment. A determination of Disability shall be made by the Committee on the basis of
such medical evidence as the Committee deems warranted under the circumstances, and in this respect, Participants shall submit to an examination
by a physician upon request by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(n)&nbsp;&ldquo;<B><I>Dividend
Equivalent</I></B>&rdquo; means an amount payable in cash or Common Stock, as determined by the Committee, equal to the dividends that
would have been paid to the Participant if the share of Common Stock with respect to which the Dividend Equivalent relates had been owned
by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(o)&nbsp;&ldquo;<B><I>Effective
Date</I></B>&rdquo; means the date on which the Plan takes effect, as defined pursuant to&nbsp;<U>Section 4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(p)&nbsp;&ldquo;<B><I>Eligible
Person</I></B>&rdquo; any current or prospective employee, officer, non-employee director or other individual service provider of the
Company or any Subsidiary;&nbsp;<I>provided, however</I>, that Incentive Stock Options may only be granted to employees of the Company
or any of its &ldquo;subsidiary corporations&rdquo; within the meaning of Section 424 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(q)&nbsp;&ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means as of any date, the value of the Common Stock determined as follows: (i)&nbsp;if the Common Stock is
listed on any established stock exchange, system or market, its Fair Market Value shall be the closing price of a share of Common Stock
as quoted on such exchange, system or market as reported in the Wall Street Journal or such other source as the Committee deems reliable
(or, if no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and
(ii) in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by
the Committee by the reasonable application of a reasonable valuation method, taking into account factors consistent with Treas. Reg.
&sect; 409A-1(b)(5)(iv)(B) as the Committee deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(r)&nbsp;<I>&ldquo;<B>Incentive
Bonus</B></I>&rdquo; means a bonus opportunity awarded under&nbsp;<U>Section 12</U>&nbsp;pursuant to which a Participant may become entitled
to receive an amount based on satisfaction of such performance criteria established for a specified performance period as specified in
the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(s)&nbsp;&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an Option that is intended to qualify as an &ldquo;incentive stock option&rdquo; within the meaning
of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(t)&nbsp;<I>&ldquo;<B>Merger
Agreement</B></I>&rdquo; means that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a
ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(u)&nbsp;&ldquo;<B><I>Nonqualified
Stock Option</I></B>&rdquo; means an Option that is not intended to qualify as an &ldquo;incentive stock option&rdquo; within the meaning
of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(v)&nbsp;&ldquo;<B><I>Option</I></B>&rdquo;
means a right to purchase a number of shares of Common Stock at such exercise price, at such times and on such other terms and conditions
as are specified in or determined pursuant to an Award Agreement. Options granted pursuant to the Plan may be Incentive Stock Options
or Nonqualified Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(w)&nbsp;&ldquo;<B><I>Other
Stock-Based Award</I></B>&rdquo; means an Award granted to an Eligible Person under&nbsp;<U>Section 11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(x)&nbsp;&ldquo;<B><I>Outstanding
Common Stock</I></B>&rdquo; means the sum of (i) the shares of Common Stock outstanding, (ii)&nbsp;the shares of Common Stock underlying
unexercised pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&rsquo;s preferred stock, par value $0.001
(determined on an as-converted basis without regard to any limitations on such conversion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(y)&nbsp;&ldquo;<B><I>Participant</I></B>&rdquo;
means any Eligible Person to whom Awards have been granted from time to time by the Committee and any authorized transferee of such individual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(z)&nbsp;<I>&ldquo;<B>Person</B></I>&rdquo;
shall have the meaning given in Section 3(a)(9) of the Act, as modified and used in&nbsp;<U>Sections&nbsp;14(d)</U>&nbsp;and&nbsp;<U>15(d)</U>&nbsp;thereof,
except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant
to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their ownership of stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(aa)&nbsp;&ldquo;<B><I>Restricted
Stock</I></B>&rdquo; means an Award or issuance of Common Stock the grant, issuance, vesting and/or transferability of which is subject
during specified periods of time to such conditions (including continued employment or engagement or performance conditions) and terms
as the Committee deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(bb)&nbsp;&ldquo;<B><I>Restricted
Stock Unit</I></B>&rdquo; means an Award denominated in units of Common Stock under which the issuance of shares of such Common Stock
(or cash payment in lieu thereof) is subject to such conditions (including continued employment or engagement or performance conditions)
and terms as the Committee deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(cc)&nbsp;&ldquo;<B><I>Separation
from Service</I></B>&rdquo; or &ldquo;<B><I>Separates from Service</I></B>&rdquo; means a Termination of Employment that constitutes a
&ldquo;separation from service&rdquo; within the meaning of Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(dd)&nbsp;&ldquo;<B><I>Stock
Appreciation Right</I></B>&rdquo; or &ldquo;<B><I>SAR</I></B>&rdquo; means a right granted that entitles the Participant to receive, in
cash or Common Stock or a combination thereof, as determined by the Committee, value equal to the excess of (i)&nbsp;the Fair Market Value
of a specified number of shares of Common Stock at the time of exercise over (ii) the exercise price of the right, as established by the
Committee on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(ee)&nbsp;&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means any business association (including a corporation or a partnership, other than the Company) in an unbroken chain of such associations
beginning with the Company if each of the associations other than the last association in the unbroken chain owns equity interests (including
stock or partnership interests) possessing 50% or more of the total combined voting power of all classes of equity interests in one of
the other associations in such chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(ff)&nbsp;&ldquo;<B><I>Substitute
Awards</I></B>&rdquo; means Awards granted or Common Stock issued by the Company in assumption of, or in substitution or exchange for,
awards previously granted, or the right or obligation to make future awards, by a company acquired by the Company or any Subsidiary or
with which the Company or any Subsidiary combines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(gg)&nbsp;&ldquo;<B><I>Termination
of Employment</I></B>&rdquo; means ceasing to serve as an employee of the Company and its Subsidiaries or, with respect to a non-employee
director or other service provider, ceasing to serve as such for the Company and its Subsidiaries, except that with respect to all or
any Awards held by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant&rsquo;s
short-term or long-term disability or other medical leave) or employment on a less than full-time basis is considered a &ldquo;Termination
of Employment,&rdquo; (ii) the Committee may determine that a transition from employment to service with a partnership, joint venture
or corporation not meeting the requirements of a Subsidiary in which the Company or a Subsidiary is a party is not considered a &ldquo;Termination
of Employment,&rdquo; (iii) service as a member of the Board shall constitute continued service with respect to Awards granted to a Participant
while he or she served as an employee, (iv) service as an employee of the Company or a Subsidiary shall constitute continued employment
with respect to Awards granted to a Participant while he or she served as a member of the Board or other service provider, and (v) the
Committee may determine that a transition from employment with the Company or a Subsidiary to service to the Company or a Subsidiary other
than as an employee shall constitute a &ldquo;Termination of Employment&rdquo;. The Committee shall determine whether any corporate transaction,
such as a sale or spin-off of a division or Subsidiary that employs or engages a Participant, shall be deemed to result in a Termination
of Employment with the Company and its Subsidiaries for purposes of any affected Participant&rsquo;s Awards, and the Committee&rsquo;s
decision shall be final and binding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>3.&nbsp;Eligibility</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Any Eligible Person is eligible for selection
by the Committee to receive an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>4.&nbsp;Effective
Date and Termination of Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Plan became effective on the Closing
Date (as defined in the Merger Agreement) (the&nbsp;&ldquo;<B><I>Effective Date</I></B>&rdquo;). The Plan shall remain available for the
grant of Awards until July 20, 2034. Notwithstanding the foregoing, the Plan may be terminated at such earlier time as the Board may determine.
Termination of the Plan will not affect the rights and obligations of the Participants and the Company arising under Awards theretofore
granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>5.&nbsp;Shares
Subject to the Plan and to Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Aggregate
Limits</I>. The aggregate number of shares of Common Stock issuable under the Plan shall be equal to (i) 10% of the total number of shares
of Outstanding Common Stock immediately following the closing of the transactions set forth in the Merger Agreement,&nbsp;<I>plus</I>&nbsp;(ii)
any shares of Common Stock added as a result of the following sentence (collectively, the &ldquo;<B><I>Share Pool</I></B>&rdquo;). The
Share Pool will automatically increase on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034
in an amount equal to 5% of the Outstanding Common Stock on the preceding December 31;&nbsp;<I>provided, however</I>, that the Committee
may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase in the Share Pool for any
such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence. The aggregate number
of shares of Common Stock available for grant under this Plan and the number of shares of Common Stock subject to Awards outstanding at
the time of any event described in&nbsp;<U>Section 16</U>&nbsp;shall be subject to adjustment as provided in&nbsp;<U>Section 16</U>. The
shares of Common Stock issued under this Plan may be shares that are authorized and unissued or shares that were reacquired by the Company,
including shares purchased in the open market or in private transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Issuance
of Shares</I>. For purposes of&nbsp;<U>Section 5(a)</U>, the aggregate number of shares of Common Stock issued under this Plan at any
time shall equal only the number of shares of Common Stock actually issued upon exercise or settlement of an Award. Shares of Common Stock
subject to Awards that have been canceled, expired, forfeited or otherwise not issued under an Award and shares of Common Stock subject
to Awards settled in cash shall not count as shares of Common Stock issued under this Plan. The aggregate number of shares available for
issuance under this Plan at any time shall not be reduced by (i) shares subject to Awards that have been terminated, expired unexercised,
forfeited or settled in cash, (ii) shares subject to Awards that have been retained or withheld by the Company in payment or satisfaction
of the exercise price, purchase price or tax withholding obligation of an Award, or (iii) shares subject to Awards that otherwise do not
result in the issuance of shares in connection with payment or settlement thereof. In addition, shares that have been delivered (either
actually or by attestation) to the Company in payment or satisfaction of the exercise price, purchase price or tax withholding obligation
of an Award shall be available for issuance under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>Substitute
Awards</I>. Substitute Awards shall not reduce the shares of Common Stock authorized for issuance under the Plan or authorized for grant
to a Participant in any calendar year. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which
the Company or any Subsidiary combines, has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation
of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the
extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination
to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be
used for Awards under the Plan and shall not reduce the shares of Common Stock authorized for issuance under the Plan;&nbsp;<I>provided,
however</I>, that Awards using such available shares (i) shall not be made after the date awards or grants could have been made under
the terms of the pre-existing plan, absent the acquisition or combination, (ii) shall only be made to individuals who were not employees
or service providers of the Company or its Affiliates at the time of such acquisition or combination, and (iii) shall comply with the
requirements of any stock exchange or market or quotation system on which the Common Stock is traded, listed or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;<I>Tax
Code Limits</I>. The aggregate number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options
granted under this Plan shall be equal to 10,000,000, which number shall be calculated and adjusted pursuant to&nbsp;<U>Section 16</U>&nbsp;only
to the extent that such calculation or adjustment will not affect the status of any Option intended to qualify as an Incentive Stock Option
under Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(e)&nbsp;<I>Limits
on Non-Employee Director Compensation.</I>&nbsp;The aggregate dollar value of equity-based (based on the grant date Fair Market Value
of equity-based Awards) and cash compensation granted under this Plan or otherwise to any non-employee director shall not exceed $750,000
during any calendar year;&nbsp;<I>provided, however</I>, that in the calendar year in which a non-employee director first joins the Board
or during any calendar year in which a non-employee director is designated as Chairman of the Board or Lead Director, the maximum aggregate
dollar value of equity-based and cash compensation granted to the non-employee director may be up to $1,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>6.&nbsp;Administration
of the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Administrator
of the Plan</I>. The Plan shall be administered by the Committee. The Board shall fill vacancies on, and from time to time may remove
or add members to, the Committee. The Committee shall act pursuant to a majority vote or unanimous written consent. Any power of the Committee
may also be exercised by the Board, except to the extent that the grant or exercise of such authority would cause any Award or transaction
to become subject to (or lose an exemption under) the short-swing profit recovery provisions of Section 16 of the Act. To the extent that
any permitted action taken by the Board conflicts with action taken by the Committee, the Board action shall control. To the maximum extent
permissible under applicable law, the Committee (or any successor) may by resolution delegate any or all of its authority to one or more
subcommittees composed of one or more directors and/or officers of the Company, and any such subcommittee shall be treated as the Committee
for all purposes under this Plan. Notwithstanding the foregoing, if the Board or the Committee (or any successor) delegates to a subcommittee
comprised of one or more officers of the Company the authority to grant Awards, no such subcommittee shall designate any officer serving
thereon or any officer (within the meaning of Section 16 of the Act) or non-employee director of the Company as a recipient of any Awards
granted under such delegated authority. The Committee hereby delegates to and designates the Senior Vice President of Finance of the Company
(or such other officer with similar authority), and to his or her delegates or designees, the authority to assist the Committee in the
day-to-day administration of the Plan and of Awards granted under the Plan, including those powers set forth in&nbsp;<U>Section 6(b)(v)</U>&nbsp;through&nbsp;<U>(xi)</U>&nbsp;and
to execute Award Agreements or other documents entered into under this Plan on behalf of the Committee or the Company. The Committee may
further designate and delegate to one or more additional officers or employees of the Company or any Subsidiary, and/or one or more agents,
authority to assist the Committee in any or all aspects of the day-to-day administration of the Plan and/or of Awards granted under the
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Powers
of Committee</I>. Subject to the express provisions of this Plan, the Committee shall be authorized and empowered to do all things that
it determines to be necessary or appropriate in connection with the administration of this Plan, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(i)&nbsp;to
prescribe, amend and rescind rules and regulations relating to this Plan and to define terms not otherwise defined herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(ii)&nbsp;to
determine which Persons are Eligible Persons, to which of such Eligible Persons, if any, Awards shall be granted hereunder and the timing
of any such Awards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(iii)&nbsp;to
prescribe and amend the terms of the Award Agreements, to grant Awards and determine the terms and conditions thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(iv)&nbsp;to
reduce the exercise price of a previously awarded Option or Stock Appreciation Right or cancel and re-grant or exchange such Option or
Stock Appreciation Right for cash or a new Award with a lower (or no) exercise price with any such determination made by the Committee
in its sole discretion, in each case, without stockholder approval;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(v)&nbsp;to
adopt such procedures and sub-plans as are necessary or appropriate (A) to permit or facilitate participation in this Plan by Eligible
Persons who are not citizens of, or subject to taxation by, the United States or who are employed outside the United States or (B) to
allow Awards to qualify for special tax treatment in a jurisdiction other than the United States;&nbsp;<I>provided, however</I>, that
Board approval will not be necessary for immaterial modifications to this Plan or any Award Agreement that are required for compliance
with the laws of the relevant jurisdiction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(vi)&nbsp;to
establish and verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, retention,
vesting, exercisability or settlement of any Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(vii)&nbsp;to
prescribe and amend the terms of or form of any document or notice required to be delivered to the Company by Participants under this
Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(viii)&nbsp;to
determine the extent to which adjustments are required pursuant to Section 16;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(ix)&nbsp;to
interpret and construe this Plan, any rules and regulations under this Plan and the terms and conditions of any Award granted hereunder,
and to make exceptions to any such provisions if the Committee, in good faith, determines that it is appropriate to do so;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(x)&nbsp;to
approve corrections in the documentation or administration of any Award; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 24pt; background-color: white">(xi)&nbsp;to
make all other determinations deemed necessary or advisable for the administration of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Notwithstanding anything in this Plan to the
contrary, with respect to any Award that is &ldquo;deferred compensation&rdquo; under Section 409A of the Code, the Committee shall exercise
its discretion in a manner that causes such Awards to be compliant with or exempt from the requirements of Section 409A of the Code. Without
limiting the foregoing, unless expressly agreed to in writing by the Participant holding such Award, the Committee shall not take any
action with respect to any Award which constitutes (x) a modification of a stock right within the meaning of Treas. Reg. &sect; 1.409A-1(b)(5)(v)(B)
so as to constitute the grant of a new stock right, (y) an extension of a stock right, including the addition of a feature for the deferral
of compensation within the meaning of Treas. Reg. &sect; 1.409A-1 (b)(5)(v)(C), or (z) an impermissible acceleration of a payment date
or a subsequent deferral of a stock right subject to Section&nbsp;409A of the Code within the meaning of Treas. Reg. &sect; 1.409A-1(b)(5)(v)(E).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Committee may, in its sole and absolute
discretion, without amendment to the Plan but subject to the limitations otherwise set forth in&nbsp;<U>Section 20</U>, waive or amend
the operation of Plan provisions respecting exercise after Termination of Employment. The Committee or any member thereof may, in its
sole and absolute discretion, except as otherwise provided in&nbsp;<U>Section 20</U>, waive, settle or adjust any of the terms of any
Award so as to avoid unanticipated consequences or address unanticipated events (including any temporary closure of an applicable stock
exchange, disruption of communications or natural catastrophe).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>Determinations
by the Committee</I>. All decisions, determinations and interpretations by the Committee regarding the Plan, any rules and regulations
under the Plan, and the terms and conditions of, or operation of, any Award granted hereunder, shall be final and binding on all Participants,
beneficiaries, heirs, assigns or other persons holding or claiming rights under the Plan or any Award. The Committee shall consider such
factors as it deems relevant, in its sole and absolute discretion, to making such decisions, determinations and interpretations, including
the recommendations or advice of any officer or other employee of the Company and such attorneys, consultants and accountants as it may
select. Members of the Board and members of the Committee acting under the Plan shall be fully protected in relying in good faith upon
the advice of counsel and shall incur no liability except for as a result of gross negligence or willful misconduct in the performance
of their duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;<I>Subsidiary
Awards</I>. In the case of a grant of an Award to any Participant employed by a Subsidiary, such grant may, if the Committee so directs,
be implemented by the Company issuing any subject shares of Common Stock to the Subsidiary, for such lawful consideration as the Committee
may determine, upon the condition or understanding that the Subsidiary will transfer the shares of Common Stock to the Participant in
accordance with the terms of the Award specified by the Committee pursuant to the provisions of the Plan. Notwithstanding any other provision
hereof, such Award may be issued by and in the name of the Subsidiary and shall be deemed granted on such date as the Committee shall
determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>7.&nbsp;Plan
Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Terms
Set Forth in Award Agreement</I>. Awards may be granted to Eligible Persons as determined by the Committee at any time and from time to
time prior to the termination of the Plan. The terms and conditions of each Award shall be set forth in an Award Agreement in a form approved
by the Committee for such Award, subject to and incorporating by reference or otherwise the applicable terms and conditions of the Plan,
which Award Agreement may contain such terms and conditions as specified from time to time by the Committee, provided such other terms
and conditions do not conflict with the Plan. The Award Agreement for any Award (other than Restricted Stock Awards) shall include the
time or times at or within which and the consideration, if any, for which any shares of Common Stock or cash, as applicable, may be acquired
from the Company. The terms of Awards may vary among Participants, and the Plan does not impose upon the Committee any requirement to
make Awards subject to uniform terms. Accordingly, the terms of individual Award Agreements may vary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Termination
of Employment</I>. Subject to the express provisions of the Plan, the Committee shall specify before, at, or after the time of grant of
an Award the provisions governing the effect(s) upon an Award of a Participant&rsquo;s Termination of Employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>Rights
of a Stockholder</I>. A Participant shall have no rights as a stockholder with respect to shares of Common Stock covered by an Award (including
voting rights) until the date the Participant becomes the holder of record of such shares of Common Stock. No adjustment shall be made
for dividends or other rights for which the record date is prior to such date, except as provided in&nbsp;<U>Sections 10(b)</U>,&nbsp;<U>11(b)</U>&nbsp;or&nbsp;<U>16</U>&nbsp;of
this Plan or as otherwise provided by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;<I>No
Fractional Shares</I>. No fractional shares of Common Stock shall be issued pursuant to an Award or in settlement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>8.&nbsp;Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Grant,
Term and Price</I>. The grant, issuance, retention, vesting and/or settlement of any Option shall occur at such time and be subject to
such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions
based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance
conditions. The term of an Option shall in no event be greater than 10 years;&nbsp;<I>provided, however</I>, the term of an Option (other
than an Incentive Stock Option) shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such
Option is prohibited by law or the Company&rsquo;s insider trading policy from exercising the Option, which extension shall expire on
the 30<SUP>th</SUP>&nbsp;day following the date such prohibition no longer applies. The Committee will establish the price at which Common
Stock may be purchased upon exercise of an Option, which in no event will be less than the Fair Market Value of such shares on the date
of grant;&nbsp;<I>provided, however</I>, that the exercise price per share of Common Stock with respect to an Option that is granted as
a Substitute Award may be less than the Fair Market Value of the shares of Common Stock on the date such Option is granted if such exercise
price is based on a formula set forth in the terms of the options held by such optionees or in the terms of the agreement providing for
such merger or other acquisition that satisfies the requirements of (i) Section 409A of the Code, if such options held by such optionees
are not intended to qualify as &ldquo;incentive stock options&rdquo; within the meaning of Section 422 of the Code, and (ii) Section 424(a)
of the Code, if such options held by such optionees are intended to qualify as &ldquo;incentive stock options&rdquo; within the meaning
of Section 422 of the Code. The exercise price of any Option may be paid in cash to the Company or such other method as determined by
the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable
under an Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock otherwise deliverable
upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>No
Reload Grants</I>. Options shall not be granted under the Plan in consideration for, and shall not be conditioned upon the delivery of,
shares of Common Stock to the Company in payment of the exercise price and/or tax withholding obligation under any other employee stock
option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>Incentive
Stock Options</I>. Notwithstanding anything to the contrary in this&nbsp;<U>Section 8</U>, in the case of the grant of an Incentive Stock
Option, if the Participant owns stock possessing more than 10% of the combined voting power of all classes of stock of the Company, the
exercise price of such Option must be at least 110% of the Fair Market Value of the shares of Common Stock on the date of grant and the
Option must expire within a period of not more than five years from the date of grant. Notwithstanding anything in this&nbsp;<U>Section
8</U>&nbsp;to the contrary, Options designated as Incentive Stock Options shall not be eligible for treatment under the Code as Incentive
Stock Options (and will be deemed to be Nonqualified Stock Options) to the extent that either (i) the aggregate Fair Market Value of shares
of Common Stock (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant
during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order
in which they were granted, or (ii) such Options otherwise remain exercisable but are not exercised within three months (or such other
period of time provided in Section 422 of the Code) of separation of service (as determined in accordance with Section 3401(c) of the
Code and the regulations promulgated thereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;<I>No
Stockholder Rights</I>. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents
in respect of an Option or any shares of Common Stock subject to an Option until the Participant has become the holder of record of such
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>9.&nbsp;Stock
Appreciation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>General
Terms</I>. The grant, issuance, retention, vesting and/or settlement of any Stock Appreciation Right shall occur at such time and be subject
to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions
based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance
conditions. The term of a Stock Appreciation Right shall in no event be greater than 10 years;&nbsp;<I>provided, however</I>, the term
of a Stock Appreciation Right shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such
Stock Appreciation Right is prohibited by law or the Company&rsquo;s insider trading policy from exercising the Stock Appreciation Right
which extension shall expire on the 30<SUP>th</SUP>&nbsp;day following the date such prohibition no longer applies. Stock Appreciation
Rights may be granted to Participants from time to time either in tandem with or as a component of Options granted under the Plan (&ldquo;<B><I>tandem
SARs</I></B>&rdquo;) or not in conjunction with other Awards (&ldquo;<B><I>freestanding SARs</I></B>&rdquo;). Upon exercise of a tandem
SAR as to some or all of the shares covered by the grant, the related Option shall be canceled automatically to the extent of the number
of shares covered by such exercise. Conversely, if the related Option is exercised as to some or all of the shares covered by the grant,
the related tandem SAR, if any, shall be canceled automatically to the extent of the number of shares covered by the Option exercise.
Any Stock Appreciation Right granted in tandem with an Option may be granted at the same time such Option is granted or at any time thereafter
before exercise or expiration of such Option, provided that the Fair Market Value of Common Stock on the date of the SAR&rsquo;s grant
is not greater than the exercise price of the related Option. All freestanding SARs shall be granted subject to the same terms and conditions
applicable to Options as set forth in&nbsp;<U>Section 8</U>&nbsp;and all tandem SARs shall have the same exercise price as the Option
to which they relate. Subject to the provisions of&nbsp;<U>Section 8</U>&nbsp;and the immediately preceding sentence, the Committee may
impose such other conditions or restrictions on any Stock Appreciation Right as it shall deem appropriate. Stock Appreciation Rights may
be settled in Common Stock, cash, Restricted Stock or a combination thereof, as determined by the Committee and set forth in the applicable
Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>No
Stockholder Rights</I>. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents
in respect of an Award of Stock Appreciation Rights or any shares of Common Stock subject to an Award of Stock Appreciation Rights until
the Participant has become the holder of record of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>10.&nbsp;Restricted
Stock and Restricted Stock Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Vesting
and Performance Criteria</I>. The grant, issuance, vesting and/or settlement of any Award of Restricted Stock or Restricted Stock Units
shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the
Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service
requirements, and/or satisfaction of performance conditions. In addition, the Committee shall have the right to grant Restricted Stock
or Restricted Stock Unit Awards as the form of payment for grants or rights earned or due under other stockholder-approved compensation
plans or arrangements of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Dividends
and Distributions</I>. Participants in whose name Restricted Stock is granted shall be entitled to receive all dividends and other distributions
paid with respect to those shares of Common Stock, unless determined otherwise by the Committee. The Committee will determine whether
any such dividends or distributions will be automatically reinvested in additional shares of Restricted Stock and/or subject to the same
restrictions on transferability as the Restricted Stock with respect to which they were distributed or whether such dividends or distributions
will be paid in cash. Shares underlying Restricted Stock Units shall be entitled to dividends or distributions only to the extent provided
by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>11.&nbsp;Other
Stock-Based Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>General
Terms.&nbsp;</I>The Committee is authorized, subject to limitations under applicable law, to grant to Eligible Persons such other Awards
that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Common Stock,
as deemed by the Committee to be consistent with the purposes of the Plan. The Committee shall determine the terms and conditions of such
Other Stock-Based Awards. Common Stock delivered pursuant to an Other Stock-Based Award in the nature of a purchase right granted under
this&nbsp;<U>Section 11</U>&nbsp;shall be purchased for such consideration, paid for at such times, by such methods, and in such forms,
including cash, Common Stock, other Awards, or other property, as the Committee shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Dividends
and Distributions</I>. Shares underlying Other Stock-Based Awards shall be entitled to dividends or distributions only to the extent provided
by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>12.&nbsp;Incentive
Bonuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;<I>Vesting
Criteria</I>. The Committee shall establish the vesting conditions applicable to an Incentive Bonus, including any performance criteria
and level of achievement versus such criteria that may determine the amount payable under an Incentive Bonus, which may include a target,
threshold and/or maximum amount payable and any formula for determining such achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;<I>Timing
and Form of Payment</I>. The Committee shall determine the timing of payment of any Incentive Bonus. Payment of the amount due under an
Incentive Bonus may be made in cash or in Common Stock, as determined by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;<I>Discretionary
Adjustments</I>. Notwithstanding satisfaction of any performance goals, the amount paid under an Incentive Bonus on may be adjusted by
the Committee on the basis of such further considerations as the Committee shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>13.&nbsp;Performance
Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Committee may establish performance criteria
and level of achievement versus such criteria that shall determine the number of shares of Common Stock, Restricted Stock Units, Other
Stock-Based Awards or cash to be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant
to an Award (any such Award, a &ldquo;<B><I>Performance Award</I></B>&rdquo;). A Performance Award may be identified as &ldquo;Performance
Share,&rdquo; &ldquo;Performance Equity,&rdquo; &ldquo;Performance Unit&rdquo; or other such term as chosen by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>14.&nbsp;Deferral
of Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Committee may, in an Award Agreement or
otherwise, provide for the deferred delivery of Common Stock or cash upon settlement, vesting or other events with respect to Restricted
Stock Units, Other Stock-Based Awards or in payment or satisfaction of an Incentive Bonus. Notwithstanding anything herein to the contrary,
in no event will any election to defer the delivery of Common Stock or any other payment with respect to any Award be allowed if the Committee
determines, in its sole discretion, that the deferral would result in the imposition of the additional tax under Section 409A(a)(1)(B)
of the Code. No Award shall provide for deferral of compensation that does not comply with Section 409A of the Code. The Company, any
Subsidiary or Affiliate which is in existence or hereafter comes into existence, the Board and the Committee shall have no liability to
a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not
so exempt or compliant or for any action taken by the Board or the Committee in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>15.&nbsp;Conditions
and Restrictions Upon Securities Subject to Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Committee may provide that the Common
Stock issued upon exercise of an Option or Stock Appreciation Right or otherwise subject to or issued under an Award shall be subject
to such further agreements, restrictions, conditions or limitations as the Committee in its discretion may specify prior to the exercise
of such Option or Stock Appreciation Right or the grant, vesting or settlement of such Award, including conditions on vesting or transferability,
forfeiture or repurchase provisions and method of payment for the Common Stock issued upon exercise, vesting or settlement of such Award
(including the actual or constructive surrender of Common Stock already owned by the Participant) or payment of taxes arising in connection
with an Award. Without limiting the foregoing, such restrictions may address the timing and manner of any resales by the Participant or
other subsequent transfers by the Participant of any shares of Common Stock issued under an Award, including (a) restrictions under an
insider trading policy or pursuant to applicable law, (b) restrictions designed to delay and/or coordinate the timing and manner of sales
by the Participant and holders of other Company equity compensation arrangements, (c) restrictions as to the use of a specified brokerage
firm for such resales or other transfers and (d) provisions requiring Common Stock be sold on the open market or to the Company in order
to satisfy tax withholding or other obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>16.&nbsp;Adjustment
of and Changes in the Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;The
number and kind of shares of Common Stock available for issuance under this Plan (including under any Awards then outstanding), and the
number and kind of shares of Common Stock subject to the limits set forth in&nbsp;<U>Section 5</U>, shall be equitably adjusted by the
Committee to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend
or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that
affects the number or kind of shares of Outstanding Common Stock. Such adjustment may be designed to comply with Section 424 of the Code
or may be designed to treat the shares of Common Stock available under the Plan and subject to Awards as if they were all outstanding
on the record date for such event or transaction or to increase the number of such shares of Common Stock to reflect a deemed reinvestment
in shares of Common Stock of the amount distributed to the Company&rsquo;s securityholders. The terms of any outstanding Award shall also
be equitably adjusted by the Committee as to price, number or kind of shares of Common Stock subject to such Award, vesting, performance
criteria, and other terms to reflect the foregoing events, which adjustments need not be uniform as between different Awards or different
types of Awards. No fractional shares of Common Stock shall be issued or issuable pursuant to such an adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;In
the event there shall be any other change in the number or kind of outstanding shares of Common Stock, or any stock or other securities
into which such Common Stock shall have been changed, or for which it shall have been exchanged, by reason of a Change in Control, other
merger, consolidation or otherwise, then the Committee shall determine the appropriate and equitable adjustment to be effected, which
adjustments need not be uniform between different Awards or different types of Awards. In addition, in the event of such change described
in this paragraph, the Committee may accelerate the time or times at which any Award may be exercised, consistent with and as otherwise
permitted under Section 409A of the Code, and may provide for cancellation of such accelerated Awards that are not exercised within a
time prescribed by the Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;In
the event of a Change in Control, the Committee, acting in its sole discretion without the consent or approval of any Participant, may
take one or more of the following actions, which may vary among individual Participants and/or among Awards held by any individual Participant:
(i) arrange for the assumption of an outstanding Award by the successor or acquiring entity (if any) of such Change in Control (or by
its parents, if any), which assumption will be binding on all selected Participants; provided that the exercise price and the number and
nature of shares issuable upon exercise of any such Option or Stock Appreciation Right, or any Award that is subject to Section 409A of
the Code, will be adjusted appropriately pursuant to Section 424(a) of the Code; (ii) provide for the issuance of substitute awards by
the successor or acquiring entity (if any) of such Change in Control (or by its parents, if any) that will substantially preserve the
otherwise applicable terms of the outstanding Award as determined by the Committee in its sole discretion; (iii) accelerate vesting or
waive any forfeiture conditions; (iv)&nbsp;accelerate the time of exercisability of an Award so that such Award may be exercised in full
or in part for a limited period of time on or before a date specified by the Committee, after which specified date all unexercised Awards
and all rights of Participants thereunder shall terminate; or (v) make such other adjustments to Awards then outstanding as the Committee
deems appropriate to reflect such Change in Control. Notwithstanding anything herein to the contrary, in the event of a Change in Control
in which the acquiring or surviving company in the transaction does not assume or continue outstanding Awards or issue substitute awards
upon the Change in Control, unless determined otherwise by the Committee, immediately prior to the Change in Control, all Awards that
are not assumed, continued or substituted for shall be treated as follows effective immediately prior to the Change in Control: (A) in
the case of an Option or Stock Appreciation Right, the Participant shall have the ability to exercise such Option or Stock Appreciation
Right, including any portion of the Option or Stock Appreciation Right not previously exercisable, (B) in the case of any Award the vesting
of which is in whole or in part subject to performance criteria or an Incentive Bonus, all conditions to the grant, issuance, retention,
vesting or transferability of, or any other restrictions applicable to, such Award shall immediately lapse and the Participant shall have
the right to receive a payment based on target level achievement or actual performance through a date determined by the Committee, and
(C) in the case of outstanding Restricted Stock, Restricted Stock Units or Other Stock-Based Awards (other than those referenced in subsection
(B)), all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such Award
shall immediately lapse. In no event shall any action be taken pursuant to this&nbsp;<U>Section 16(c)</U>&nbsp;that would change the payment
or settlement date of an Award in a manner that would result in the imposition of any additional taxes or penalties pursuant to Section
409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;Notwithstanding
anything in this&nbsp;<U>Section 16</U>&nbsp;to the contrary, in the event of a Change in Control, the Committee may provide for the cancellation
and cash settlement of all outstanding Awards upon such Change in Control (including the cancellation for no consideration of any Option
or Stock Appreciation Right with an exercise price that equals or exceeds the per share consideration in such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(e)&nbsp;Notwithstanding
anything in this&nbsp;<U>Section 16</U>&nbsp;to the contrary, an adjustment to an Option or Stock Appreciation Right under this&nbsp;<U>Section
16</U>&nbsp;shall be made in a manner that will not result in the grant of a new Option or Stock Appreciation Right under Section 409A
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>17.&nbsp;Transferability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Each Award may not be sold, transferred for
value, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution,
and each Option or Stock Appreciation Right shall be exercisable only by the Participant during his or her lifetime. Notwithstanding the
foregoing, (a) outstanding Options may be exercised following the Participant&rsquo;s death by the Participant&rsquo;s beneficiaries or
as permitted by the Committee and (b) as permitted by the Committee, a Participant may transfer or assign an Award as a gift to any &ldquo;family
member&rdquo; (as such term is defined in the Registration Statement on Form S-8) (an &ldquo;<B><I>Assignee Entity</I></B>&rdquo;), provided
that such Assignee Entity shall be entitled to exercise assigned Options and Stock Appreciation Rights only during the lifetime of the
assigning Participant (or following the assigning Participant&rsquo;s death, by the Participant&rsquo;s beneficiaries or as otherwise
permitted by the Committee) and provided further that such Assignee Entity shall not further sell, pledge, transfer, assign or otherwise
alienate or hypothecate such Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>18.&nbsp;Compliance
with Laws and Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;This
Plan, the grant, issuance, vesting, exercise and settlement of Awards hereunder, and the obligation of the Company to sell, issue or deliver
shares of Common Stock under such Awards, shall be subject to all applicable foreign, federal, state and local laws, rules and regulations,
stock exchange rules and regulations, and to such approvals by any governmental or regulatory agency as may be required. The Company shall
not be required to register in a Participant&rsquo;s name or deliver Common Stock prior to the completion of any registration or qualification
of such shares under any foreign, federal, state or local law or any ruling or regulation of any government body which the Committee shall
determine to be necessary or advisable. To the extent the Company is unable to or the Committee deems it infeasible to obtain authority
from any regulatory body having jurisdiction, which authority is deemed by the Company&rsquo;s counsel to be necessary to the lawful issuance
and sale of any shares of Common Stock hereunder, the Company and its Subsidiaries shall be relieved of any liability with respect to
the failure to issue or sell such shares of Common Stock as to which such requisite authority shall not have been obtained. No Option
shall be exercisable and no Common Stock shall be issued and/or transferable under any other Award unless a registration statement with
respect to the Common Stock underlying such Option is effective and current or the Company has determined, in its sole and absolute discretion,
that such registration is unnecessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;In
the event an Award is granted to or held by a Participant who is employed or providing services outside the United States, the Committee
may, in its sole discretion, modify the provisions of the Plan or of such Award as they pertain to such individual to comply with applicable
foreign law or to recognize differences in local law, currency or tax policy. The Committee may also impose conditions on the grant, issuance,
exercise, vesting, settlement or retention of Awards in order to comply with such foreign law and/or to minimize the Company&rsquo;s obligations
with respect to tax equalization for Participants employed outside their home country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>19.&nbsp;Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">To the extent required by applicable federal,
state, local or foreign law, the Committee may, and/or a Participant shall, make arrangements satisfactory to the Company for the satisfaction
of any withholding tax obligations that arise with respect to any Award or the issuance or sale of any shares of Common Stock. The Company
shall not be required to recognize any Participant rights under an Award, to issue shares of Common Stock or to recognize the disposition
of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Committee, these obligations
may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of a Participant,
the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under such Award or any
other Award held by the Participant, or by the Participant tendering to the Company cash or, if allowed by the Committee, shares of Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>20.&nbsp;Amendment
of the Plan or Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Board may amend, alter, suspend or terminate
this Plan, and the Committee may amend or alter any Award Agreement or other document evidencing an Award made under this Plan; however,
except as provided pursuant to the provisions of&nbsp;<U>Section 16</U>, no such amendment shall, without the approval of the stockholders
of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(a)&nbsp;increase
the maximum number of shares of Common Stock for which Awards may be granted under this Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(b)&nbsp;extend
the term of this Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(c)&nbsp;change
the class of Persons eligible to be Participants; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt; background-color: white">(d)&nbsp;otherwise
amend the Plan in any manner requiring stockholder approval by law or the rules of any stock exchange or market or quotation system on
which the Common Stock is traded, listed or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">No amendment or alteration to the Plan or
an Award or Award Agreement shall be made which would materially impair the rights of the holder of an Award without such holder&rsquo;s
consent;&nbsp;<I>provided</I>,&nbsp;<I>however</I>, that no such consent shall be required if the Committee determines in its sole discretion
and prior to the date of any Change in Control that such amendment or alteration either (i) is required or advisable in order for the
Company, the Plan or the Award to satisfy any law or regulation or to meet the requirements of, or avoid adverse financial accounting
consequences under, any accounting standard, or (ii) is not reasonably likely to significantly diminish the benefits provided under such
Award, or that any such diminishment has been adequately compensated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>21.&nbsp;No
Liability of Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company, any Subsidiary or Affiliate which
is in existence or hereafter comes into existence, the Board, the Committee and any delegate thereof shall not be liable to a Participant
or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from
any regulatory body having jurisdiction the authority deemed by the Company&rsquo;s counsel to be necessary to the lawful issuance and
sale of any shares of Common Stock hereunder; and (b) any tax consequence expected, but not realized, by any Participant or other person
due to the receipt, vesting, exercise or settlement of any Award granted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>22.&nbsp;Non-Exclusivity
of Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Neither the adoption of this Plan by the Board
nor the submission of this Plan to the stockholders of the Company for approval shall be construed as creating any limitations on the
power of the Board or the Committee to adopt such other incentive arrangements as either may deem desirable, including the granting of
equity awards otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific
cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>23.&nbsp;Governing
Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Plan and any agreements or other documents
hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference
in this Plan or in the agreement or other document evidencing any Awards to a provision of law or to a rule or regulation shall be deemed
to include any successor law, rule or regulation of similar effect or applicability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>24.&nbsp;No
Right to Employment, Reelection or Continued Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Nothing in this Plan or an Award Agreement
shall interfere with or limit in any way the right of the Company, its Subsidiaries and/or its Affiliates to terminate any Participant&rsquo;s
employment, service on the Board or service at any time or for any reason not prohibited by law, nor shall this Plan or an Award itself
confer upon any Participant any right to continue his or her employment or service for any specified period of time. Neither an Award
nor any benefits arising under this Plan shall constitute an employment contract with the Company, any Subsidiary and/or its Affiliates.
Subject to&nbsp;<U>Sections 4</U>&nbsp;and&nbsp;<U>20</U>, this Plan and the benefits hereunder may be terminated at any time in the sole
and exclusive discretion of the Board without giving rise to any liability on the part of the Company, its Subsidiaries and/or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>25.&nbsp;Specified
Employee Delay</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">To the extent any payment under this Plan
is considered deferred compensation subject to the restrictions contained in Section 409A of the Code, such payment may not be made to
a specified employee (as determined in accordance with a uniform policy adopted by the Company with respect to all arrangements subject
to Section 409A of the Code) upon Separation from Service before the date that is six months after the specified employee&rsquo;s Separation
from Service (or, if earlier, the specified employee&rsquo;s death). Any payment that would otherwise be made during this period of delay
shall be accumulated and paid on the sixth month plus one day following the specified employee&rsquo;s Separation from Service (or, if
earlier, as soon as administratively practicable after the specified employee&rsquo;s death).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>26.&nbsp;No
Liability of Committee Members</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">No member of the Committee shall be personally
liable by reason of any contract or other instrument executed by such member or on his or her behalf in his or her capacity as a member
of the Committee nor for any mistake of judgment made in good faith, and the Company shall indemnify and hold harmless each member of
the Committee and each other employee, officer or director of the Company to whom any duty or power relating to the administration or
interpretation of the Plan may be allocated or delegated, against any cost or expense (including counsel fees) or liability (including
any sum paid in settlement of a claim) arising out of any act or omission to act in connection with the Plan, unless arising out of such
Person&rsquo;s own fraud or willful bad faith;&nbsp;<I>provided, however</I>, that approval of the Board shall be required for the payment
of any amount in settlement of a claim against any such Person. The foregoing right of indemnification shall not be exclusive of any other
rights of indemnification to which such Persons may be entitled under the Company&rsquo;s Certificate of Incorporation and Bylaws (as
each may be amended from time to time), as a matter of law, pursuant to any individual agreement or otherwise, or any power that the Company
may have to indemnify them or hold them harmless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>27.&nbsp;Severability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If any provision of the Plan or any Award
is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Person or Award, or would disqualify
the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform
to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering
the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the
Plan and any such Award shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>28.&nbsp;Unfunded
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Plan is intended to be an unfunded plan.
Participants are and shall at all times be general creditors of the Company with respect to their Awards. If the Committee or the Company
chooses to set aside funds in a trust or otherwise for the payment of Awards under the Plan, such funds shall at all times be subject
to the claims of the creditors of the Company in the event of its bankruptcy or insolvency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>29.&nbsp;Clawback/Recoupment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Awards granted under this Plan will be subject
to recoupment in accordance with any clawback policy that the Company adopts or is required to adopt pursuant to the listing standards
of any national securities exchange or association on which the Company&rsquo;s securities are listed or as is otherwise required by the
Rule 10D-1 under the Exchange Act or other applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment
provisions in an Award Agreement as the Committee determines necessary or appropriate, including a reacquisition right in respect of previously
acquired shares of Common Stock or other cash or property upon the occurrence of misconduct. No recovery of compensation under such a
clawback policy will be an event giving rise to a right to resign for &ldquo;good reason&rdquo; or be deemed a &ldquo;constructive termination&rdquo;
(or any similar term) as such terms are used in any agreement between any Participant and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>30.&nbsp;Beneficiary
Designation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Participants may designate beneficiaries with
respect to Awards under the Plan in accordance with the procedures determined by the Committee. In the absence of a beneficiary designation,
a Participant&rsquo;s estate will be the deemed beneficiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; background-color: white"><B>31.&nbsp;Interpretation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Headings are given to the Sections and subsections
of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction
or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate,
the plural shall include the singular and the singular shall include the plural. The use herein of the word &ldquo;including&rdquo; following
any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters
set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &ldquo;without
limitation&rdquo;, &ldquo;but not limited to&rdquo;, or words of similar import) is used with reference thereto, but rather shall be deemed
to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or
matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document as amended,
supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white">14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>11
<FILENAME>ea021319301ex10-11_oruka.htm
<DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>ORUKA THERAPEUTICS,
INC.<BR>
2024 EMPLOYEE STOCK PURCHASE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Purpose</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The purpose of this Oruka Therapeutics, Inc.
2024 Employee Stock Purchase Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;) is to provide employees of the Company and its Designated Subsidiaries
with an opportunity to purchase Common Stock through accumulated Contributions. The Company&rsquo;s intention is to have the Plan qualify
as an &ldquo;employee stock purchase plan&rdquo; under Section 423 of the Code. The provisions of the Plan, accordingly, will be construed
to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Definitions.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As used in the Plan, the following terms shall
have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) &ldquo;<B><I>Administrator</I></B>&rdquo;
means the Compensation Committee of the Board (or any successor committee), or such other committee as designated by the Board to administer
the Plan under&nbsp;<U>Section 14</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) &ldquo;<B><I>Applicable
Laws</I></B>&rdquo; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S.
federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and
the applicable laws of any foreign country or jurisdiction where options are, or will be, granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) &ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(d) &ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(e) &ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of the Company, $0.001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(f) &ldquo;<B><I>Company</I></B>&rdquo;
means Oruka Therapeutics, Inc., a Delaware corporation, and any successor corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(g) &ldquo;<B><I>Compensation</I></B>&rdquo;
means an Eligible Employee&rsquo;s base salary or base hourly rate of pay before deduction for any salary deferral contributions made
by the Eligible Employee to any tax-qualified or nonqualified deferred compensation plan, but excluding commissions, overtime, incentive
compensation, bonuses and other forms of compensation. The Administrator, in its discretion, may, on a uniform and nondiscriminatory basis,
establish a different definition of Compensation for an Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(h) &ldquo;<B><I>Contributions</I></B>&rdquo;
means the payroll deductions and any other additional payments that the Administrator may permit to be made by a Participant to fund the
exercise of options granted pursuant to the Plan, subject to Section 423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(i) &ldquo;<B><I>Designated
Subsidiary</I></B>&rdquo; means any Subsidiary that has been designated by the Administrator from time to time in its sole discretion
as eligible to participate in the Plan. As of the date of adoption of the Plan, the Designated Subsidiaries consist exclusively of: Oruka
Therapeutics Operating Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(j) &ldquo;<B><I>Effective
Date</I></B>&rdquo; means the Closing Date (as defined in that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by
and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(k) &ldquo;<B><I>Eligible
Employee</I></B>&rdquo; means any person, including an officer, who is customarily employed by the Company or a Designated Subsidiary
(i) for more than 20 hours per week and (ii) for more than five months in any calendar year. For purposes of the Plan, the employment
relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company.
Where the period of leave exceeds 90 days and the individual&rsquo;s right to reemployment is not guaranteed either by statute or by contract,
the employment relationship shall be deemed to have terminated on the 91<SUP>st</SUP>&nbsp;day of such leave. &ldquo;Eligible Employee&rdquo;
shall not include any person who is a citizen or resident of a foreign jurisdiction if granting them an option under the Plan would violate
the law of such jurisdiction, or if compliance with the laws of the jurisdiction would cause the Plan to violate Section 423 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(l) &ldquo;<B><I>Employer</I></B>&rdquo;
means the Company and each Designated Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(m) &ldquo;<B><I>Enrollment
Date</I></B>&rdquo; means the first Trading Day of each Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(n) &ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(o) &ldquo;<B><I>Exercise
Date</I></B>&rdquo; means the last Trading Day of each Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(p) &ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means as of any date, the value of the Common Stock determined as follows: (i) if the Common Stock is listed
on any established stock exchange, system or market, its Fair Market Value shall be the closing price for the Common Stock as quoted on
such exchange, system or market as reported in the Wall Street Journal or such other source as the Administrator deems reliable (or, if
no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and (ii) in
the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(q) &ldquo;<B><I>Merger
Agreement</I></B>&rdquo; means that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a
ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(r) &ldquo;<B><I>New
Exercise Date</I></B>&rdquo; means a new Exercise Date if the Administrator shortens any Offering Period then in progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(s) &ldquo;<B><I>Offering</I></B>&rdquo;
means an offer under the Plan of an option that may be exercised during an Offering Period as further described in&nbsp;<U>Section 4</U>.
For purposes of the Plan, the Administrator may designate separate Offerings under the Plan (the terms of which need not be identical)
in which Eligible Employees of one or more Employers will participate, even if the dates of the applicable Offering Periods of each such
Offering are identical and the provisions of the Plan will separately apply to each Offering. To the extent permitted by Treasury Regulation
Section 1.423-2(a)(1), the terms of each Offering need not be identical;&nbsp;<I>provided, however</I>, that the terms of the Plan and
an Offering together satisfy Treasury Regulation Sections 1.423-2(a)(2) and (a)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(t)  &ldquo;<B><I>Offering
Periods</I></B>&rdquo; means the periods established by the Administrator (not to exceed 27 months) during which an option granted pursuant
to the Plan may be exercised. The duration and timing of Offering Periods may be changed pursuant to&nbsp;<U>Sections 4</U>,&nbsp;<U>18,</U>&nbsp;and&nbsp;<U>19</U>.
The first Offering Period shall commence on the Effective Date and end on the next December 9 or June 8 that follows the Effective Date,
and subsequent Offering Periods shall be each six-month period commencing the day after the prior Offering Period ends and ending on each
December 9 and June&nbsp;8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(u) &ldquo;<B><I>Outstanding
Common Stock</I></B>&rdquo; means the sum of (i) the shares of Common Stock outstanding, (ii) the shares of Common Stock underlying unexercised
pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&rsquo;s preferred stock, par value $0.001 (determined
on an as-converted basis without regard to any limitations on such conversion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(v) &ldquo;<B><I>Parent</I></B>&rdquo;
means a &ldquo;parent corporation,&rdquo; whether now or hereafter existing, as defined in Section 424(e) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(w) &ldquo;<B><I>Participant</I></B>&rdquo;
means an Eligible Employee who elects to participate in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(x) &ldquo;<B><I>Purchase
Period</I></B>&rdquo; means the period during an Offering Period during which shares of Common Stock may be purchased on a Participant&rsquo;s
behalf in accordance with the terms of the Plan. Unless the Administrator determines otherwise, during the first Offering Period, the
Purchase Period will begin on the first date of such Offering Period and end on the last day of such Offering Period, and subsequent Purchase
Periods shall be each six-month period commencing thereafter. Unless the Administrator determines otherwise, each Purchase Period following
the first Purchase Period will be a six-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(y) &ldquo;<B><I>Purchase
Price</I></B>&rdquo; means an amount equal to 85% of the Fair Market Value of a share of Common Stock on the Enrollment Date or on the
Exercise Date, whichever is lower;&nbsp;<I>provided, however</I>, that the Purchase Price may be determined for subsequent Offering Periods
by the Administrator subject to compliance with Section 423 of the Code (or any other Applicable Law) or pursuant to&nbsp;<U>Section 18</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(z) &ldquo;<B><I>Subsidiary</I></B>&rdquo;
means a &ldquo;subsidiary corporation,&rdquo; whether now or hereafter existing, as defined in Section 424(f) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(z) &ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the national stock exchange upon which the Common Stock is listed is open for trading or, if the
Common Stock is not listed on a national stock exchange, a business day as determined by the Administrator in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(aa) &ldquo;<B><I>Treasury
Regulations</I></B>&rdquo; means the Treasury regulations of the Code. Reference to a specific Treasury Regulation or Section of the Code
shall include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of
any future legislation or regulation amending, supplementing or superseding such Section or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Eligibility.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) <I>Offering
Periods</I>. Any Eligible Employee on a given Enrollment Date will be eligible to participate in the Plan if he or she was employed by
the Company for at least 30 calendar days immediately preceding the Enrollment Date, subject to the requirements of&nbsp;<U>Section 5</U>;&nbsp;<I>provided,
however</I>, that an Eligible Employee who commences employment with the Company or a Designated Subsidiary following such 30-day period
will be eligible to participate in the Plan at the beginning of the next Purchase Period to occur that is at least 30 calendar days following
the commencement of his or her employment with the Company or a Designated Subsidiary. Eligible Employees who do not elect to participate
in the Plan on a given Enrollment Date may elect to participate in the Plan at the beginning of any subsequent Purchase Period, as determined
by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) <I>Non-U.S.
Employees</I>. Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or
residents of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation
in the Plan or an Offering if the participation of such employees is prohibited under the laws of the applicable jurisdiction or if complying
with the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code. In addition, as provided
in&nbsp;<U>Section 14</U>, the Administrator may establish one or more sub-plans of the Plan (which may, but are not required to, comply
with the requirements of Section 423 of the Code) to provide benefits to employees of Designated Subsidiaries located outside the United
States in a manner that complies with local law. Any such sub-plan will be a component of the Plan and will not be a separate plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) <I>Limitations</I>.
Any provisions of the Plan to the contrary notwithstanding, no Eligible Employee will be granted an option under the Plan (i) to the extent
that, immediately after the grant, such Eligible Employee (or any other person whose stock would be attributed to such Eligible Employee
pursuant to Section 424(d) of the Code) would own capital stock of the Company or any Parent or Subsidiary of the Company and/or hold
outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of the capital
stock of the Company or of any Parent or Subsidiary of the Company, or (ii) to the extent that his or her rights to purchase stock under
all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent or Subsidiary of the Company accrues
at a rate that exceeds $25,000 worth of stock (determined at the Fair Market Value of the stock at the time such option is granted) for
each calendar year in which such option is outstanding at any time, as determined in accordance with Section 423 of the Code and the regulations
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Offering Periods</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Plan will be implemented by consecutive
Offering Periods with new Offering Periods commencing at such times as determined by the Administrator. The Administrator will have the
power to change the duration of Offering Periods (including the commencement dates thereof) without stockholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Participation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">An Eligible Employee may participate in the
Plan by (i) submitting to the Company&rsquo;s Finance department (or its delegate), on or before a date determined by the Administrator
prior to an applicable Enrollment Date, a properly completed subscription agreement authorizing Contributions in the form provided by
the Administrator for such purpose, or (ii) following an electronic or other enrollment procedure determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Contributions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) At
the time a Participant enrolls in the Plan pursuant to&nbsp;<U>Section 5</U>, such Participant will elect to have payroll deductions made
on each pay day or other Contributions (to the extent permitted by the Administrator) made during the Offering Period (or portion thereof)
in an amount equal to at least 1% but not exceeding 15% of the Compensation (or such other percentage of Compensation as determined by
the Administrator in its sole discretion, prior to the commencement of an applicable Offering Period), that the Participant receives on
each pay day during the Offering Period;&nbsp;<I>provided, however</I>, that should a pay day occur on an Exercise Date, a Participant
will have any payroll deductions made on such day applied to his or her notional account under the subsequent Purchase Period or Offering
Period. The minimum permissible projected Contribution by any Participant for an Offering Period shall be $500. The maximum permissible
Contribution by any Participant for all Offering Periods during any calendar year shall be $25,000. The Administrator, in its sole discretion
and to the extent permitted by Section 423 of the Code, may permit all Participants in a specified Offering to contribute amounts to the
Plan through payment by cash, check, or other means set forth in the subscription agreement prior to each Exercise Date of each Purchase
Period. A Participant&rsquo;s subscription agreement will remain in effect for successive Offering Periods unless terminated as provided
in&nbsp;<U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) Payroll
deductions for a Participant will commence on the first pay day following the Enrollment Date (or such later date on which a Participant
enrolls in the Plan pursuant to&nbsp;<U>Section 5</U>) and will end on the last pay day prior to the Exercise Date of such Purchase Period
to which such authorization is applicable, unless sooner terminated by the Participant as provided in&nbsp;<U>Section 10</U>;&nbsp;<I>provided,
however</I>, that with respect to the first Offering Period, payroll deduction for a Participant will not commence until such time as
determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) All
Contributions made for a Participant will be credited to his or her notional account under the Plan and payroll deductions will be made
in whole percentages only. Except to the extent permitted by the Administrator pursuant to&nbsp;<U>Section 6(a)</U>, a Participant may
not make any additional payments into such notional account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(d) A
Participant may discontinue his or her participation in the Plan as provided in&nbsp;<U>Section 10</U>. Participants shall not be permitted
to increase or to otherwise decrease their rates of Contributions during a Purchase Period unless otherwise determined by the Administrator
in its sole discretion;&nbsp;<I>provided, however</I>, that Participants shall be permitted to increase or decrease their rates of Contributions
effective as of the beginning of each Purchase Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(e) Notwithstanding
the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code, a Participant&rsquo;s Contributions may be decreased
to 0% at any time during a Purchase Period. Subject to Section 423(b)(8) of the Code, Contributions will recommence at the rate originally
elected by the Participant effective as of the beginning of the first Purchase Period scheduled to end in the following calendar year,
unless terminated by the Participant as provided in&nbsp;<U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(f) At
the time the option under the Plan is exercised, in whole or in part, or at the time some or all of the Common Stock issued under the
Plan is disposed of (or any other time that a taxable event related to the Plan occurs), the Participant must make adequate provision
for the Company&rsquo;s or Employer&rsquo;s federal, state, local, or any other tax liability payable to any authority including taxes
imposed by jurisdictions outside of the United States, national insurance, social security, or other tax withholding obligations, if any,
that arise upon the exercise of the option or the disposition of the Common Stock (or any other time that a taxable event related to the
Plan occurs). At any time, the Company or the Employer may, but will not be obligated to, withhold from the Participant&rsquo;s compensation
the amount necessary for the Company or the Employer to meet applicable withholding obligations, including any withholding required to
make available to the Company or the Employer any tax deductions or benefits attributable to sale or early disposition of Common Stock
by the Eligible Employee. In addition, the Company or the Employer may, but will not be obligated to, withhold from the proceeds of the
sale of Common Stock or any other method of withholding the Company or the Employer deems appropriate to the extent permitted by Treasury
Regulation Section 1.423-2(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Grant of Option</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On the Enrollment Date of each Offering Period,
each Eligible Employee participating in such Offering Period (or any Purchase Period within such Offering Period) will be granted an option
to purchase on each Exercise Date during such Offering Period (at the applicable Purchase Price) up to a number of shares of Common Stock
determined by dividing (i) such Eligible Employee&rsquo;s Contributions accumulated prior to such Exercise Date and retained in the Eligible
Employee&rsquo;s notional account as of the Exercise Date by (ii) the applicable Purchase Price;&nbsp;<I>provided, however</I>, that in
no event will an Eligible Employee be permitted to purchase during each Purchase Period more than 5,000 shares of Common Stock (subject
to any adjustment pursuant to&nbsp;<U>Section 18</U>);&nbsp;<I>provided, further</I>, that such purchase will be subject to the limitations
set forth in&nbsp;<U>Sections 3(c)</U>&nbsp;and&nbsp;<U>13</U>. The Eligible Employee may accept the grant of such option by electing
to participate in the Plan in accordance with the requirements of&nbsp;<U>Section 5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Administrator may, for future Offering
Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that an Eligible Employee may
purchase during each Purchase Period of an Offering Period. Exercise of the option will occur as provided in&nbsp;<U>Section 8</U>, unless
the Participant has withdrawn pursuant to&nbsp;<U>Section 10</U>. The option will expire on the last day of the Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Exercise of Option</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) Unless
a Participant withdraws from the Plan as provided in&nbsp;<U>Section 10</U>, such Participant&rsquo;s option for the purchase of shares
of Common Stock will be exercised automatically on the Exercise Date, and the maximum number of full shares subject to the option will
be purchased for such Participant at the applicable Purchase Price with the accumulated Contributions from his or her notional account.
No fractional shares of Common Stock will be purchased; unless determined by the Administrator, any Contributions accumulated in a Participant&rsquo;s
notional account that are not sufficient to purchase a full share will be retained in the Participant&rsquo;s notional account for the
subsequent Purchase Period or Offering Period, subject to earlier withdrawal by the Participant as provided in&nbsp;<U>Section 10</U>.
Any other funds left over in a Participant&rsquo;s notional account after the Exercise Date will be returned to the Participant (without
interest thereon, except as otherwise required under local laws, as further set forth in&nbsp;<U>Section 12</U>). During a Participant&rsquo;s
lifetime, a Participant&rsquo;s option to purchase shares hereunder is exercisable only by him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) If
the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which options are to
be exercised may exceed (i) the number of shares of Common Stock that were available for sale under the Plan on the Enrollment Date of
the applicable Offering Period, or (ii) the number of shares of Common Stock available for sale under the Plan on such Exercise Date,
the Administrator may in its sole discretion (x) provide that the Company will make a pro rata allocation of the shares of Common Stock
available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it
will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise
Date, and continue all Offering Periods then in effect, or (y) provide that the Company will make a pro rata allocation of the shares
available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it
will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise
Date, and terminate any or all Offering Periods then in effect pursuant to&nbsp;<U>Section 19</U>. The Company may make a pro rata allocation
of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any
authorization of additional shares for issuance under the Plan by the Company&rsquo;s stockholders subsequent to such Enrollment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Delivery</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As soon as reasonably practicable after each
Exercise Date on which a purchase of shares of Common Stock occurs, the Company will arrange the delivery to each Participant of the shares
purchased upon exercise of his or her option in a form determined by the Administrator (in its sole discretion) and pursuant to rules
established by the Administrator. The Company may permit or require that shares be deposited directly with a broker designated by the
Company or to a designated agent of the Company, and the Company may utilize electronic or automated methods of share transfer. The Company
may require that shares be retained with such broker or agent for a designated period of time and/or may establish other procedures to
permit tracking of disqualifying dispositions of such shares. No Participant will have any voting, dividend, or other stockholder rights
with respect to shares of Common Stock subject to any option granted under the Plan until such shares have been purchased and delivered
to the Participant as provided in this&nbsp;<U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B>Withdrawal</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A Participant may withdraw all, but not less
than all, the Contributions credited to his or her notional account and not yet used to exercise his or her option under the Plan at any
time by (a) submitting to the Company&rsquo;s Finance department (or its delegate) a written notice of withdrawal in the form determined
by the Administrator for such purpose, or (b) following an electronic or other withdrawal procedure determined by the Administrator. All
the Participant&rsquo;s Contributions credited to his or her notional account will be paid to such Participant as soon as reasonably practicable
after receipt of notice of withdrawal and such Participant&rsquo;s option for the Offering Period will be automatically terminated, and
no further Contributions for the purchase of shares will be made for such Offering Period. If a Participant withdraws from an Offering
Period, Contributions will not resume at the beginning of the succeeding Offering Period, unless the Participant re-enrolls in the Plan
in accordance with the provisions of&nbsp;<U>Section 5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B>Termination of Employment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Upon a Participant&rsquo;s ceasing to be an
Eligible Employee, for any reason, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to
such Participant&rsquo;s notional account during the Offering Period but not yet used to purchase shares of Common Stock under the Plan
will be returned to such Participant or, in the case of his or her death, to the person or persons entitled thereto under&nbsp;<U>Section
15</U>, and such Participant&rsquo;s option will be automatically terminated. In no event may a Participant be granted an option under
the Plan following his or her termination of employment unless such Participant subsequently becomes an Eligible Employee again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><B>Interest</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">No interest will accrue on the Contributions
of a Participant in the Plan, except as may be required by Applicable Law, as determined by the Company, and if so required by the laws
of a particular jurisdiction, shall apply to all Participants in the relevant Offering except to the extent otherwise permitted by Treasury
Regulation Section 1.423-2(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>13.</B></TD><TD STYLE="text-align: justify"><B>Stock</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) Subject
to adjustment upon changes in capitalization of the Company as provided in&nbsp;<U>Section 18</U>&nbsp;hereof, the maximum number of shares
of Common Stock that will be made available for sale under the Plan shall be equal to (i) a number equal to the lesser of (x) 1,000,000
or (y) 1% of the total number of shares of Outstanding Common Stock immediately following the closing of the transactions set forth in
the Merger Agreement,&nbsp;<I>plus</I>&nbsp;(ii) any shares of Common Stock added as a result of the following sentence (collectively,
the &ldquo;<B><I>Share Pool</I></B>&rdquo;). The Share Pool will automatically increase on January 1 of each year beginning in 2025 and
ending with a final increase on January 1, 2034 in an amount equal to 1% of the Outstanding Common Stock on the preceding December 31;&nbsp;<I>provided,
however</I>, that the Committee may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase
in the Share Pool for any such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) Until
the shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), a Participant will only have the rights of an unsecured creditor with respect to such shares, and no right to vote or receive
dividends or any other rights as a stockholder will exist with respect to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) Shares
of Common Stock to be delivered to a Participant under the Plan will be registered in the name of the Participant or in the name of the
Participant and his or her spouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>14.</B></TD><TD STYLE="text-align: justify"><B>Administration</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Plan shall be administered by the Administrator.
The Board shall fill vacancies on, and from time to time may remove or add members to, the Administrator. Any power of the Administrator
may also be exercised by the Board. The Administrator will have full and exclusive discretionary authority to construe, interpret, and
apply the terms of the Plan, to designate separate Offerings under the Plan, to determine eligibility, to adjudicate all disputed claims
filed under the Plan, and to establish such procedures that it deems necessary for the administration of the Plan (including, without
limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees
who are foreign nationals or employed outside the United States, the terms of which sub-plans may take precedence over other provisions
of this Plan, with the exception of&nbsp;<U>Section 13(a)</U>, but unless otherwise superseded by the terms of such sub-plan, the provisions
of this Plan shall govern the operation of such sub-plan). Unless otherwise determined by the Administrator, the employees eligible to
participate in each sub-plan will participate in a separate Offering. Without limiting the generality of the foregoing, the Administrator
is specifically authorized to adopt rules and procedures regarding eligibility to participate, the definition of Compensation, handling
of Contributions, making of Contributions to the Plan (including, without limitation, in forms other than payroll deductions), establishment
of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination
of beneficiary designation requirements, withholding procedures, and handling of stock certificates that vary with applicable local requirements.
The Administrator also is authorized to determine that, to the extent permitted by Treasury Regulation Section 1.423-2(f), the terms of
an option granted under the Plan or an Offering to citizens or residents of a non-U.S. jurisdiction will be less favorable than the terms
of options granted under the Plan or the same Offering to employees resident solely in the United States. The Administrator hereby delegates
to and designates the Senior Vice President of Finance of the Company (or such other officer with similar authority), and to his or her
delegates or designates, the authority to assist the Administrator in the day-to-day administration of the Plan. The Administrator may
also delegate some or all of its responsibilities to one or more other persons (which may include Company personnel) and, to the extent
there has been any such delegation, any reference in the Plan to the Administrator shall include the delegate of the Administrator. Every
finding, decision, and determination made by the Administrator will, to the full extent permitted by Applicable Laws, be final and binding
upon all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>15.</B></TD><TD STYLE="text-align: justify"><B>Designation of Beneficiary</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) If
permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any shares of Common Stock and
cash, if any, from the Participant&rsquo;s notional account under the Plan in the event of such Participant&rsquo;s death subsequent to
an Exercise Date on which the option is exercised but prior to delivery to such Participant of such shares and cash. In addition, if permitted
by the Administrator, a Participant may file a designation of a beneficiary who is to receive any cash from the Participant&rsquo;s notional
account under the Plan in the event of such Participant&rsquo;s death prior to exercise of the option. If a Participant is married and
the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) Such
designation of beneficiary may be changed by the Participant at any time by notice in a form determined by the Administrator. In the event
of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such
Participant&rsquo;s death, the Company will deliver such shares and/or cash to the executor or administrator of the estate of the Participant,
or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver
such shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent, or
relative is known to the Company, then to such other person as the Company may designate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) All
beneficiary designations will be in such form and manner as the Administrator may designate from time to time. Notwithstanding&nbsp;<U>Sections
15(a)</U>&nbsp;and&nbsp;<U>15(b)</U>, the Company and/or the Administrator may decide not to permit such designations by Participants
in non-U.S. jurisdictions to the extent permitted by Treasury Regulation Section 1.423-2(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>16.</B></TD><TD STYLE="text-align: justify"><B>Transferability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Neither Contributions credited to a Participant&rsquo;s
notional account nor any rights with regard to the exercise of an option or to receive shares of Common Stock under the Plan may be assigned,
transferred, pledged, or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in&nbsp;<U>Section
15</U>) by the Participant. Any such attempt at assignment, transfer, pledge, or other disposition will be without effect, except that
the Company may treat such act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>17.</B></TD><TD STYLE="text-align: justify"><B>Use of Funds</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company may use all Contributions received
or held by it under the Plan for any corporate purpose, and the Company will not be obligated to segregate such Contributions except under
Offerings in which applicable local law requires that Contributions to the Plan by Participants be segregated from the Company&rsquo;s
general corporate funds and/or deposited with an independent third party for Participants in non-U.S. jurisdictions. Until shares of Common
Stock are issued, Participants will only have the rights of an unsecured creditor with respect to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>Adjustments, Dissolution, Liquidation, Merger or Other Corporate
Transaction</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) <I>Adjustments</I>.
In the event that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property),
recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase,
or exchange of Common Stock or other securities of the Company, or other change in the corporate structure of the Company affecting the
Common Stock occurs, the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to
be made available under the Plan, will, in such manner as it may deem equitable, adjust the number and class of Common Stock that may
be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan
that has not yet been exercised, and the numerical limits of&nbsp;<U>Sections 7</U>&nbsp;and&nbsp;<U>13</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) <I>Dissolution
or Liquidation</I>. In the event of the proposed dissolution or liquidation of the Company, any Offering Period then in progress will
be shortened by setting a New Exercise Date, and will terminate immediately prior to the consummation of such proposed dissolution or
liquidation, unless provided otherwise by the Administrator. The New Exercise Date will be before the date of the Company&rsquo;s proposed
dissolution or liquidation. The Administrator will notify each Participant in writing or electronically, prior to the New Exercise Date,
that the Exercise Date for the Participant&rsquo;s option has been changed to the New Exercise Date and that the Participant&rsquo;s option
will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period
as provided in&nbsp;<U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) <I>Merger
or Other Corporate Transaction</I>. In the event of a merger, sale, or other similar corporate transaction involving the Company, each
outstanding option will be assumed or an equivalent option substituted by the successor corporation or a Parent or Subsidiary of the successor
corporation. If the successor corporation refuses to assume or substitute for the option, the Offering Period with respect to which such
option relates will be shortened by setting a New Exercise Date on which such Offering Period shall end. The New Exercise Date will occur
before the date of the Company&rsquo;s proposed merger, sale, or other similar corporate transaction. The Administrator will notify each
Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&rsquo;s option has
been changed to the New Exercise Date and that the Participant&rsquo;s option will be exercised automatically on the New Exercise Date,
unless prior to such date the Participant has withdrawn from the Offering Period as provided in&nbsp;<U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>19.</B></TD><TD STYLE="text-align: justify"><B>Amendment or Termination</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) The
Administrator, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason.
If the Plan is terminated, the Administrator, in its discretion, may elect to terminate all outstanding Offering Periods either immediately
or upon completion of the purchase of shares of Common Stock on the next Exercise Date (which may be sooner than originally scheduled,
if determined by the Administrator in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms
(and subject to any adjustment pursuant to&nbsp;<U>Section 18</U>). If the Offering Periods are terminated prior to expiration, all amounts
then credited to Participants&rsquo; notional accounts that have not been used to purchase shares of Common Stock will be returned to
the Participants (without interest thereon, except as otherwise required under local laws, as further set forth in&nbsp;<U>Section 12</U>)
as soon as administratively practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) Without
stockholder consent and without limiting&nbsp;<U>Section 19(a)</U>, the Administrator will be entitled to change the Offering Periods
or Purchase Periods, designate separate Offerings, limit the frequency and/or number of changes in the amount withheld during an Offering
Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding
in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&rsquo;s processing of properly
completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure
that amounts applied toward the purchase of Common Stock for each Participant properly correspond with Contribution amounts, and establish
such other limitations or procedures as the Administrator determines in its sole discretion advisable that are consistent with the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(c) In
the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences,
the Administrator may, in its discretion and, to the extent necessary or desirable, modify, amend, or terminate the Plan to reduce or
eliminate such accounting consequence including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">(i) amending
the Plan to conform with the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic
718 (or any successor thereto), including with respect to an Offering Period underway at the time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">(ii) altering
the Purchase Price for any Offering Period or Purchase Period including an Offering Period or Purchase Period underway at the time of
the change in Purchase Price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">(iii) shortening
any Offering Period or Purchase Period by setting a New Exercise Date, including an Offering Period or Purchase Period underway at the
time of the Administrator action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">(iv) reducing
the maximum percentage of Compensation a Participant may elect to set aside as Contributions; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: .25in; background-color: white">(v) reducing
the maximum number of shares of Common Stock a Participant may purchase during any Offering Period or Purchase Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Such modifications or amendments will not
require stockholder approval or the consent of any Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>20.</B></TD><TD STYLE="text-align: justify"><B>Notices</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All notices or other communications by a Participant
to the Company under or in connection with the Plan will be deemed to have been duly given when received in the form and manner specified
by the Company at the location, or by the person, designated by the Company for the receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>21.</B></TD><TD STYLE="text-align: justify"><B>Conditions Upon Issuance of Shares</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(a) Shares
of Common Stock will not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such
shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including the Securities Act of 1933,
as amended, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which
the shares may then be listed, and will be further subject to the approval of counsel for the Company with respect to such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25in; background-color: white">(b) As
a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time
of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such
shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions
of Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>22.</B></TD><TD STYLE="text-align: justify"><B>Term of Plan</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Plan will become effective upon the earlier
to occur of its adoption by the Board or its approval by the stockholders of the Company. It will continue in effect until terminated
pursuant to&nbsp;<U>Section 19</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>23.</B></TD><TD STYLE="text-align: justify"><B>Stockholder Approval</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Plan will be subject to approval by the
stockholders of the Company within 12 months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained
in the manner and to the degree required under Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>24.</B></TD><TD STYLE="text-align: justify"><B>Governing Law</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Plan and any agreements or other documents
hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference
in this Plan or in any agreements or other documents hereunder to a provision of law or to a rule or regulation shall be deemed to include
any successor law, rule, or regulation of similar effect or applicability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>25.</B></TD><TD STYLE="text-align: justify"><B>Severability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If any provision of the Plan is or becomes
or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction or as to any Participant, such invalidity, illegality,
or unenforceability shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as to such jurisdiction
or Participant as if the invalid, illegal, or unenforceable provision had not been included.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-indent: -.25in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>26.</B></TD><TD STYLE="text-align: justify"><B>Interpretation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Headings are given to the Sections and subsections
of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction
or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate,
the plural shall include the singular and the singular shall include the plural. The use herein of the word &ldquo;including&rdquo; following
any general statement, term, or matter shall not be construed to limit such statement, term, or matter to the specific items or matters
set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &ldquo;without
limitation&rdquo;, &ldquo;but not limited to&rdquo;, or words of similar import) is used with reference thereto, but rather shall be deemed
to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term,
or matter. References herein to any agreement, instrument, or other document means such agreement, instrument, or other document as amended,
supplemented, and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>12
<FILENAME>ea021319301ex10-13_oruka.htm
<DESCRIPTION>SECOND AMENDMENT TO AMENDED AND RESTATED ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN, EFFECTIVE AS OF MAY 7, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDMENT TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ORUKA
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AMENDED
AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>2024
EQUITY INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), maintains the Oruka Therapeutics, Inc. Amended and
Restated 2024 Equity Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
pursuant to Section 10(d) of the Plan, the Board may amend the Plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B></FONT>, pursuant to its authority under Section 10(d) of the Plan, the Board hereby amends the Plan as follows, effective
as of May 7, 2024 (the &ldquo;<B>Amendment Effective Date</B>&rdquo;):</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify">Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Number
of Shares</U></FONT>. Subject to adjustment under Section &lrm;8 hereof, Awards may be made under the Plan covering up to 2,063,699 shares
of common stock of the Company (the &ldquo;<B>Common Stock</B>&rdquo;), all of which may be granted as Incentive Stock Options (as hereinafter
defined). If any Award expires, lapses, or is terminated, surrendered or canceled without having been fully exercised or is forfeited
in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below
the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued
or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the grant of Awards
under the Plan. Further, shares of Common Stock delivered (whether by actual delivery or attestation) or tendered to the Company by a
Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation
(including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall again
be available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the foregoing provisions shall be
subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized
but unissued shares, shares purchased on the open market, or treasury shares. At no time while there is any Option (as defined below)
outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total
number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any
stock bonus or similar plan or agreement of the Company exceed the applicable percentage as calculated in accordance with the conditions
and exclusions of Section 260.140.45 of the California Code of Regulations (the &ldquo;<B>California Regulations</B>&rdquo;), based on
the shares of the Company which are outstanding at the time the calculation is made.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left">This Second Amendment shall be governed by and interpreted in accordance with the laws of the State of
Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction
other than such state.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in
the Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the undersigned has executed this Second Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024
Equity Incentive Plan, effective as of the Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORUKA THERAPEUTICS, INC. </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Signature page to second</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">amendment to the</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">oruka therapeutics, inc.</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Amended and restated</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2024 equity incentive plan</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>13
<FILENAME>ea021319301ex10-16_oruka.htm
<DESCRIPTION>FORM OF EMPLOYEE WARRANT AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.16</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Employee Warrant Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employee Warrant Purchaser: &nbsp;<U>         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U>Purchase Date: &nbsp;<U>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U>Aggregate Purchase Price: &nbsp;$<U>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U>Number of Employee Warrant Shares: &nbsp;<U>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
</U>Exercise Price Per Employee Warrant Share: $<I><U>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF EMPLOYEE WARRANT AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS EMPLOYEE WARRANT AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;),
dated as of the purchase date set forth above (the &ldquo;<B>Purchase Date</B>&rdquo;), is made by and between Oruka Therapeutics, Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and the individual set forth above, who is an employee of or service provider
to the Company (the &ldquo;<B>Employee Warrant Purchaser</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[WHEREAS, the Company and the Employee Warrant
Purchaser are parties to that certain [Offer Letter] dated as of [&nbsp;&nbsp;], 2024 (the &ldquo;<B>Employment Agreement</B>&rdquo;);]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, [in accordance with the terms of the Employment
Agreement], the Company wishes to afford the Employee Warrant Purchaser the opportunity to purchase shares of its common stock, par value
$0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), pursuant to the terms and conditions of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Warrant (as defined below) being purchased
pursuant to this Agreement is not being granted as an award pursuant to the Amended and Restated Oruka Therapeutics, Inc. 2024 Equity
Incentive Plan, as amended by the First Amendment dated May 7, 2024 (as may be amended from time to time, the &ldquo;<B>Current Plan</B>&rdquo;),
but shall be subject to terms and conditions substantially identical to the terms and conditions set forth in the Current Plan as if the
Warrant were a [nonstatutory] stock option award granted under the Current Plan; provided, that following the closing pursuant to the
Agreement and Plan of Merger and Reorganization by and among the Company, Atlas Merger Sub Corp, a Delaware corporation, Atlas Merger
Sub II, LLC, a Delaware limited liability company and ARCA biopharma, Inc., the Warrant shall instead be subject to the terms and conditions
substantially identical to the terms and conditions set forth in the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (as may be amended
from time to time, the &ldquo;<B>New Plan</B>&rdquo;) as if the Warrant were a [nonqualified] stock option award granted under the New
Plan and, in each case, as if the Warrant were a stock option that is not intended to qualify as an &ldquo;incentive stock option&rdquo;
within the meaning of Section 422 of the Code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, unless provided otherwise herein, the
terms and conditions of the Current Plan or the New Plan, as applicable, that are applicable to an award of stock options granted under
the Current Plan or the New Plan, as applicable, are incorporated herein by this reference and made a part of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, any capitalized terms used herein but
not otherwise defined shall have the meaning set forth in the Current Plan or the New Plan, as applicable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Board has determined that it would
be in the best interests of the Company and its stockholders to sell this Warrant to the Employee Warrant Purchaser [as an incentive for
increased efforts during his or her employment with the Company], and has approved the sale of this Warrant on the Purchase Date and has
advised the Company thereof and instructed the undersigned officer to sell said Warrant to the Employee Warrant Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the mutual
covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE I<BR>
WARRANT SALE AND PURCHASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1. <U>Purchase
and Sale of Warrant</U>. For good and valuable consideration, effective as of the Purchase Date, the Company sold to the Employee Warrant
Purchaser and the Employee Warrant Purchaser purchased from the Company a Warrant to purchase the number of shares of Common Stock set
forth above upon the terms and conditions set forth in this Agreement (this &ldquo;<B>Warrant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2. <U>Exercise
Price</U>. Subject to <U>Section 2.1</U>, the exercise price of the shares of Common Stock covered by this Warrant shall be the price
per share set forth above without commission or other charge (which was the Fair Market Value per share of the Common Stock on the Purchase
Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II<BR>
ADJUSTMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1. <U>Adjustments
to Warrant</U>. In the event of a merger, reorganization, consolidation, recapitalization, dividend or distribution (whether in cash,
shares or other property), stock split, reverse stock split, spin-off or similar transaction or other change in corporate structure affecting
the Common Stock or the value thereof, such adjustments and other substitutions shall be made to this Warrant as the Board, in its sole
discretion, deems equitable or appropriate, including adjustments in the number, class, kind and exercise price of securities subject
to this Warrant (including, if the Board deems appropriate, the substitution of similar options to purchase the shares of another company,
as the Board may determine to be appropriate in its sole discretion). Any of the foregoing adjustments may provide for the elimination
of any fractional share. For purposes of this Agreement, &ldquo;<B>Board</B>&rdquo; means, as applicable, the Board and any Committee
(as such terms are defined in the Current Plan and the New Plan, as applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE III<BR>
PERIOD OF EXERCISABILITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1. <U>Exercisability
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)  So
long as the Employee Warrant Purchaser continues to be employed by the Company or any of its subsidiaries, this Warrant shall become exercisable
pursuant to the following schedule: (1) one-quarter (1/4) of the shares subject to the Warrant shall vest on the first (1<SUP>st</SUP>)
anniversary of the Vesting Commencement Date; and (2) three-quarters (3/4) of the shares subject to the Warrant shall vest in 36 equal
installments (rounded down to the nearest whole share except for the last installment on which the remaining unvested portion shall vest)
on each one-month (1-month) anniversary thereafter over the subsequent 36-month period (each anniversary, a &ldquo;<B>Vesting Date</B>&rdquo;).
If the Employee Warrant Purchaser ceases to be an employee or service provider prior to the vesting of all or any portion of this Warrant,
then the unvested portion of this Warrant shall terminate and not be exercisable and the vested portion of the Warrant, if any, shall
remain exercisable until the earlier of (i) three (3) months following the Employee Warrant Purchaser&rsquo;s termination and (ii) the
Expiration Date (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Termination</U>.
[Except as set forth in the Employment Agreement with respect to equity-based awards subject to time-based vesting, upon][Upon] Employee
Warrant Purchaser&rsquo;s termination prior to a Vesting Date for any reason, then the unvested portion of this Warrant shall terminate
and shall not be exercisable and the vested portion of this Warrant, if any, shall continue to be exercisable until the earlier of (1)
three (3) months following the employee&rsquo;s termination and (2) the Expiration Date; provided, however, that in the event Employee
Warrant Purchaser&rsquo;s termination is for Cause (as defined in the Employment Agreement), the entire Warrant, whether vested or unvested,
shall terminate and shall not be exercisable. Notwithstanding the foregoing, if Employee Warrant Purchaser is terminated due to death
or disability, the vested portion of this Warrant, if any, shall continue to be exercisable until the earlier of (i) 12 months following
such termination and (ii) the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2. <U>Change
of Control</U>. Except as otherwise provided herein, upon a Reorganization Event (as defined in the Current Plan) or a Change in Control
(as defined in the New Plan), this Warrant shall be treated in accordance with the terms of Section 8 of the Current Plan or Section 16
of the New Plan, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3. <U>Expiration
Date</U>. This Warrant shall expire, and shall be unexercisable after, the tenth (10<SUP>th</SUP>) anniversary of the Purchase Date (the
&ldquo;<B>Expiration Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV<BR>
EXERCISE OF WARRANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1. <U>Person
Eligible to Exercise</U>. During the lifetime of the Employee Warrant Purchaser, only the Employee Warrant Purchaser may exercise this
Warrant or any portion thereof. After the death or disability of the Employee Warrant Purchaser, any exercisable portion of this Warrant
may be exercised by his or her personal representative or by any person empowered to do so under the Employee Warrant Purchaser&rsquo;s
will or under the then applicable laws of descent and distribution until the earlier of (1) 12 months following the death or disability
of the Employee Warrant Purchaser and (2) the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2. <U>Partial
Exercise</U>. Any exercisable portion of this Warrant or the entire Warrant, if then wholly exercisable, may be exercised in whole or
in part at any time (subject to any Company trading window limitations) prior to the time when this Warrant becomes unexercisable pursuant
to the terms of this Agreement; provided, however, that any partial exercise shall be for whole shares of Common Stock only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.3. <U>Manner
of Exercise</U>. The exercise price for shares of Common Stock to be acquired upon exercise of this Warrant shall be paid in full in any
manner permitted by the Current Plan or the New Plan, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4. <U>Conditions
to Issuance of Stock</U>. The Company shall not be required to issue or deliver any Common Stock purchased upon the exercise of this Warrant
or portion thereof prior to fulfillment of all of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The
obtaining of approval or other clearance from any state or federal governmental agency or stock exchange that the Board shall, in its
reasonable and good faith discretion, determine to be necessary or advisable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) The
receipt by the Company of such assurance of compliance with federal and state securities laws as it may deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.5. <U>Rights
as Stockholder</U>. Employee Warrant Purchaser shall not be, nor have any of the rights or privileges of, a stockholder of the Company
in respect of any shares purchasable upon the exercise of this Warrant or any portion thereof unless and until a certificate or certificates
representing such shares shall have been issued by the Company to the Employee Warrant Purchaser or a book entry representing such shares
has been made and such shares have been deposited with the appropriate registered book-entry custodian. The Company shall not be liable
to the Employee Warrant Purchaser for damages relating to any delay in issuing shares or a stock certificate to Employee Warrant Purchaser,
any loss of a certificate, or any mistakes or errors in the issuance of shares or a certificate to Employee Warrant Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.6. <U>Withholding</U>.
To the extent applicable, the Company shall have the right to withhold from Employee Warrant Purchaser&rsquo;s compensation or to require
Employee Warrant Purchaser to remit sufficient funds to satisfy applicable withholding tax obligations upon the exercise of this Warrant.
Subject to any applicable limitations in the Current Plan or the New Plan, as applicable, and approval of the Board, Employee Warrant
Purchaser may, in order to fulfill the withholding obligation, make payment to the Company in any manner permitted under Section 9(e)
of the Current Plan or Section 19 of the New Plan, as applicable. The Company shall not withhold from the exercise of this Warrant more
shares than are necessary to meet the established tax withholding requirements of federal, state and local obligations and pay the exercise
price of this Warrant. The Company shall be authorized to take any such action as may be necessary, in the opinion of the Company&rsquo;s
counsel, to satisfy the Company&rsquo;s obligations for payment of such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V<BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1. <U>Warrant
Not Transferable</U>. Neither this Warrant nor any interest or right therein or part thereof shall be liable for the debts, contracts
or engagements of the Employee Warrant Purchaser or his or her successors in interest or shall be subject to disposition by transfer,
alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by
operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any
attempted disposition thereof shall be null and void and of no effect; provided, however, that this <U>Section 5.1</U> shall not prevent
transfers by will or by the applicable laws of descent and distribution, or transfers to which the Board has given prior written consent
subject to the conditions set forth in Section 9(a) of the Current Plan or Section 17 of the New Plan, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.2. <U>Notices</U>.
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and
any notice to be given to the Employee Warrant Purchaser shall be addressed to him or her at the address stated in the Company&rsquo;s
records. By a notice given pursuant to this <U>Section 5.2</U>, either party may hereafter designate a different address for notices to
be given to the party. Any notice, which is required to be given to the Employee Warrant Purchaser, shall, if the Employee Warrant Purchaser
is then deceased, be given to the Employee Warrant Purchaser&rsquo;s personal representative if such representative has previously informed
the Company of his or her status and address by written notice under this <U>Section 5.2</U>. Any notice shall have been deemed duly given
when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch
post office regularly maintained by the United States Postal Service or when delivered personally to the Secretary or Employee Warrant
Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.3. <U>Amendment</U>.
The Board may amend or modify the terms of this Agreement at any time subject to any applicable restrictions in the Current Plan or the
New Plan, as applicable, and further provided that no amendment or modification of this Agreement shall in any manner materially and adversely
affect Employee Warrant Purchaser&rsquo;s rights hereunder without Employee Warrant Purchaser&rsquo;s consent, except as permitted under
the applicable provisions of the Current Plan or the New Plan, as applicable, or to bring this Warrant into compliance with the requirements
of Code Section 409A or to qualify for an exemption under Code Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.4. <U>Governing
Law</U>. The laws of the State of Delaware shall govern the interpretation, validity and performance of the terms of this Agreement regardless
of the law that might be applied under principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.5 <U>No
Guarantee of Employment</U>. Nothing in this Agreement or the Current Plan or the New Plan, as applicable, shall confer upon the Employee
Warrant Purchaser any right to continue in the employment of the Company or its subsidiaries or shall interfere with or restrict in any
way the rights of the Company and its subsidiaries, which are hereby expressly reserved, to terminate the employment of the Employee Warrant
Purchaser at any time for any reason whatsoever, with or without Cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.6 <U>Board
Authority; The Plans</U>. By accepting any benefit under this Agreement, Employee Warrant Purchaser and any person claiming under or through
Employee Warrant Purchaser shall be conclusively deemed to have indicated his, her or its acceptance and ratification of, and consent
to, terms and conditions that are substantially identical to the terms and conditions applicable to similar awards granted under the Current
Plan or the New Plan, as applicable, and this Agreement and any action taken with respect to this award by the Board or the Company, in
any case in accordance with the terms and conditions of this award. This Agreement is subject to terms, provisions and conditions substantially
identical to those of the Current Plan or the New Plan, as applicable, that are applicable to similar awards granted under the Current
Plan or the New Plan, as applicable, which are incorporated herein by reference, and to such rules, policies and regulations as may from
time to time be adopted by the Board. The Board will have the power to interpret the Current Plan or the New Plan, as applicable, as applicable
to this award and this Agreement and to adopt such rules for the administration, interpretation and application of the Current Plan or
the New Plan, as applicable, to this award as are consistent therewith and to interpret or revoke any such rules. All actions taken and
all interpretations and determinations made by the Board in good faith will be final and binding upon Employee Warrant Purchaser, the
Company and all other interested persons. No member of the Board will be personally liable for any action, determination or interpretation
made in good faith with respect to the Plan or this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.7 <U>Clawback
Policy</U>. This Agreement, the Warrant and any economic benefits recognized by the Employee Warrant Purchaser in connection with the
Warrant are subject to the Company&rsquo;s Incentive Compensation Clawback Policy as provided from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement to be effective as of the Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: left">ORUKA THERAPEUTICS, INC.:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left"> Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"></TD>
    <TD STYLE="text-align: left; width: 5%">Title:</TD>
    <TD STYLE="text-align: left; width: 31%">Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Employee
Warrant Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed this
Agreement to be effective as of the Purchase Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">EMPLOYEE WARRANT PURCHASER:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to Employee Warrant Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>14
<FILENAME>ea021319301ex10-25_oruka.htm
<DESCRIPTION>CONSULTING AGREEMENT, EFFECTIVE AS OF AUGUST 30, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND JEFF DEKKER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.25</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-indent: 0.5in; text-align: left">Certain identified information marked with [***] has been excluded
from this exhibit because it is not material and is of the type that the registrant treats as private and confidential.</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Consulting
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>This
Consulting Agreement</B></FONT> (the &ldquo;<U>Agreement</U>&rdquo;) is effective as August 30, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;),
by and between <B>Oruka Therapeutics, Inc.</B>, a Delaware corporation, with a principal place of business at 855 Oak Grove Avenue, Suite
100, Menlo Park, California 94025 (&ldquo;<U>Oruka</U>&rdquo;), and <B>C. Jeff Dekker</B>, an individual with a mailing address of [***] (&ldquo;<U>Consultant</U>&rdquo;). Oruka and the Consultant shall each be referred to herein individually
as &ldquo;<U>Party</U>&rdquo; or collectively, as &ldquo;<U>Parties</U>&rdquo; to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Recitals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
Consultant has knowledge in accounting and financial matters related to Arca Biopharma, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
Oruka has need of Consultant&rsquo;s expertise with regard to such accounting and financial matters; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
Oruka and Consultant desire to enter into this Agreement in order to set out the terms and conditions under which Oruka may engage Consultant
to provide services to Oruka as further described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now
Therefore</B></FONT>, in consideration of the promises and undertakings set forth herein, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">1.&nbsp;<U>Services
and Payment</U>. Consultant agrees to provide the services described in one or more Schedules appended hereto (the &ldquo;<U>Services</U>&rdquo;),
the form of which is set forth in the attached Exhibit A. As the only consideration due Consultant for such Services actually rendered,
Oruka will provide Consultant with the consideration described in the Scope of Services, attached hereto as <U>Schedule A</U>. From time
to time, the Parties may agree to enter into other written Scopes of Services pursuant to the terms of this Agreement and each Scope of
Services shall be sequentially referenced in successive Schedules (such as Schedule B, Schedule C, and so on) to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">2.&nbsp;<U>Performance</U>.
Consultant will provide all time, resources and attention required for the performance of the Services. Consultant represents that s/he
has the requisite expertise, ability and legal right to provide the Services. The manner and means used by the Consultant to perform the
Services desired by Oruka are in the sole discretion and control of the Consultant. Consultant agrees to perform the Services in a prompt,
efficient, skillful, and professional manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left">The Services will be provided solely and personally by Consultant. Consultant may not subcontract any
of the Services under this Agreement to any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left">Consultant represents that it has the requisite expertise, ability, and legal right to provide the Services
and will perform the Services diligently and with due care. Consultant will abide by all applicable laws, rules, and regulations applicable
to it in the performance of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left">Consultant shall keep Oruka reasonably informed about the status of the Services and will provide status
updates as often as the Parties desire. Consultant agrees to participate in activities including meetings and/or conference calls if required
that may be held on a regular basis to evaluate, review or discuss the progress made on the performance of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left">Consultant shall not disclose to Oruka any confidential or proprietary information that belongs to any
third party unless Consultant first obtains the consent of such third party and enters into a separate written agreement with Oruka covering
that disclosure. Consultant shall not represent to Oruka as being unrestricted any designs, plans, models, samples, or other writings
or products that Consultant knows are covered by valid patent, copyright, or other form of intellectual property protection belonging
to a third party and shall promptly notify Oruka prior to providing Services if that is not the case. Failure by Consultant to notify
Oruka as set forth above shall be considered a material breach of this Agreement and Oruka shall not be obligated to pay that portion
of the Fee associated with the Service(s) or deliverable(s).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: left">If so required, Consultant shall notify Consultant&rsquo;s institution and/or other applicable authorities
or organizations of the financial relationship being established by this Agreement prior to providing the Services. If required by local
laws or institution policy, Consultant shall obtain authorization from his/her employer or institution in the signature block at the end
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.&nbsp;<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left"><U>Service Fees</U>. In return for Services actually rendered, Oruka will pay Consultant at the rate set
out in the relevant <U>Schedule</U> (the &ldquo;<U>Fee</U>&rdquo;). The total fees for Services shall not exceed the amount set out in
the <U>Schedule</U> without an amendment to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left"><U>Reimbursement for Expenses</U>. Certain expenses may be identified on <U>the relevant</U> Schedule
as reimbursable by Oruka. If and only if the <U>Schedule</U> provides for the reimbursement of such expenses, Consultant may obtain reimbursement
of such expenses by submitting expense reports with receipts or such other contemporaneous written documentation as may be required under
Oruka&rsquo;s policies or under the terms of this Agreement. Oruka is not under any obligation to reimburse expenses that are not properly
documented, in the sole discretion of Oruka. All other expenses incurred by Consultant in connection with providing the Services under
this Agreement will be the sole responsibility of Consultant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left"><U>Invoicing</U>. Consultant shall invoice Oruka in accordance with the invoice schedule in the <U>Schedule</U>.
Invoices shall be submitted to ap@orukatx.com. Each invoice shall reference the relevant Schedule, describe in reasonable detail the Services
related thereto and the expenses incurred in accordance with the terms of this Agreement. Oruka shall pay each undisputed invoice within
thirty (30) days after receipt by Oruka of an invoice and all required supporting documentation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left"><U>Taxes</U>. Consultant hereby acknowledges that Oruka will report as compensation all payments to Consultant
hereunder. Consultant will pay all required taxes on Consultant&rsquo;s income from Oruka under this Agreement. Consultant will provide
Oruka with Consultant&rsquo;s taxpayer identification number or social security number, as applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: left"><U>No Benefits</U>. During the Term, Oruka shall not be obligated, under any circumstances, to pay for,
or keep in effect, any hospitalization, health, life or other insurance for the benefit of Consultant, to pay any employment or similar
taxes, to make any tax withholdings or to provide any benefits that Oruka provides to its employees. All payroll and employment taxes,
insurance and benefits shall be the sole responsibility of Consultant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.&nbsp;<U>Confidential
Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left"><U>Definition</U>. For purposes of this Agreement, &ldquo;<U>Confidential Information</U>&rdquo; means
information not generally known or available outside Oruka and information entrusted to Oruka in confidence by third parties. Confidential
Information includes, but is not limited to, all information and data in whatever form disclosed to Consultant by or on behalf of Oruka
or its Affiliates, including, without limitation, information concerning Oruka&rsquo;s business, financial condition, operations, inventions,
know-how, procedures, products, marketing plans, developmental or experimental work, clinical or other programs, and plans for research
and development. Confidential Information also includes (i) any work product, deliverables or Services provided by Consultant to Oruka
pursuant to this Agreement, and (ii) the existence and terms of this Agreement. Consultant acknowledges the confidential and secret character
of the Confidential Information and agrees that the Confidential Information is the sole, exclusive and valuable property of Oruka.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left">Confidential Information does not include information that Consultant can demonstrate by competent evidence
(i) was in the public domain at the time of its receipt from or on behalf of Oruka or thereafter enters into the public domain through
no fault of the Consultant, (ii) was already in Consultant&rsquo;s rightful possession prior to receipt from or on behalf of Oruka, as
evidenced by Consultant&rsquo;s written records, and under no obligation of confidentiality to Oruka, or (iii) was rightfully communicated
to Consultant by a third party not bound by any obligation of confidentiality.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left">At all times during the Term of this Agreement and for five (5) years following the termination or expiration
of this Agreement, Consultant shall not, directly or indirectly: (i) reproduce any of the Confidential Information except as necessary
to perform the Services without the applicable prior written consent of Oruka, (ii) use the Confidential Information except in the performance
of the Services, (iii) disclose, divulge, reveal, report, publish, or transfer to any third party for any purpose whatsoever, any Confidential
Information, and (iv) keep in confidence all Confidential Information. Consultant will exercise all reasonable precautions to physically
protect the confidentiality of the Confidential Information. Consultant shall, promptly upon request, whether during or after Term, return
to Oruka or destroy any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof)
in Consultant&rsquo;s possession or under Consultant&rsquo;s control, and upon request shall certify to Oruka the return or destruction
of all such Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left">Consultant agrees and acknowledges that, in the event of any breach of this Agreement by Consultant, Oruka
may be irreparably and immediately harmed and may not be made whole by monetary damages. Accordingly, it is agreed that, in addition to
any other remedy to which it may be entitled in law or in equity, Oruka shall be entitled to seek an injunction or injunctions in a court
of competent jurisdiction to prevent breaches or threatened breaches of this Agreement and/or to seek to compel specific performance of
this Agreement. Nothing herein shall be construed as prohibiting Oruka from pursuing any other remedies available to it for such breach
or threatened breach, including the recovery of damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: left">Consultant shall, promptly upon request, whether during or after the Term, return to Oruka or destroy
any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof) in Consultant&rsquo;s
possession or under Consultant&rsquo;s control, and upon request shall certify to Oruka the return or destruction of all such Confidential
Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: left">If Consultant is required by a governmental authority or by valid order of a court of competent jurisdiction
to disclose any of Oruka&rsquo;s Confidential Information, Consultant will give Oruka prompt advance written notice thereof (if legally
permitted) and Consultant will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Consultant will
cooperate reasonably with Oruka in any efforts to seek a protective order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: left">The Consultant shall immediately notify Oruka upon discovery of any loss or unauthorized disclosure of
the Confidential Information and will work with Oruka to help Oruka regain possession of the Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.&nbsp;<U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left">Nothing in this Agreement will affect a Party&rsquo;s rights to its Background Intellectual Property nor
imply a grant of any license to a Party&rsquo;s Background Intellectual Property unless expressly set forth herein. Except as expressly
provided in this Agreement, no right, title or interest in or to any Oruka product or any trademark or any other intellectual property
right of Oruka is granted, whether express or implied, by Oruka to Consultant. &ldquo;<U>Background Intellectual Property</U>&rdquo; means
all intellectual property owned or licensed by the respective Parties as of the Effective Date (and during the term of this Agreement)
and/or any intellectual property conceived, reduced to practice, used or developed by either Party outside the scope of this Agreement,
and any improvements or enhancements thereof, and that is under the control of either Party and that is reasonably necessary, relevant
or otherwise useful for performing the Services under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left">Consultant hereby agrees that any know-how, data, results, invention, discovery, improvement, documentation
or design or other intellectual property which Consultant develops as a result of performing the Services (collectively, &ldquo;<U>Oruka
Intellectual Property</U>&rdquo;) are &ldquo;works for hire,&rdquo; and furthermore, Consultant hereby assigns to Oruka any right, title,
and interest Consultant may have in any Oruka Intellectual Property. Upon the request of Oruka, Consultant shall provide Oruka with all
documentation relating to any Oruka Intellectual Property, and execute and deliver to Oruka such further assignments, documents, and other
instruments, as may be necessary to assign Oruka Intellectual Property to Oruka and to assist Oruka in applying for, obtaining and enforcing
patents or other rights in the United States and in any foreign country with respect to any Oruka Intellectual Property. Oruka will bear
the cost of preparation of all patent or other applications and assignments, and the cost of obtaining and enforcing all patents and other
rights to Oruka Intellectual Property. Consultant will inform Oruka immediately upon becoming aware of any Oruka Intellectual Property
that arises in the course of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left">Upon the written request of Oruka, Consultant shall make any assignment provided for in this Section 5
directly to, or for the benefit of, Oruka or Oruka&rsquo;s designee, including Consultant&rsquo;s performance of any related obligations
hereunder. If Oruka is unable, for any reason, to secure Consultant&rsquo;s signature on any document needed in connection with the actions
described in Section 5(B), Consultant hereby irrevocably designates and appoints Oruka and its duly authorized officers and agents as
Consultant&rsquo;s agent and attorney-in-fact to act for and in Consultant&rsquo;s behalf to execute, deliver and file any and all documents
with the same legal force and effect as if executed by Consultant. Consultant acknowledges that this appointment is coupled with an interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left">Consultant represents and warrants that all of its employees, agents, or subcontractors, or any of their
respective agents who will perform or contribute to the Services have assigned any intellectual property rights in Oruka Intellectual
Property to Consultant and have entered into written agreements with obligations no less stringent that those contained herein, including
obligations for non-use and non-disclosure of Confidential Information. Consultant shall be liable to Oruka for the actions of its employees,
agents, third parties or subcontractors or their respective agents for any of its obligations it delegates pursuant to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">Consultant agrees not to publish any Oruka Intellectual Property without the prior written consent of
Oruka.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: left">The Parties acknowledge that as part of Consultant&rsquo;s Background Intellectual Property, Consultant
may possess intellectual property relevant to Consultant&rsquo;s business generally, and not developed specifically for Oruka or as a
direct result of performing the Services. In consideration of the mutual obligations contained herein, Consultant hereby grants Oruka
a perpetual, worldwide, transferrable, fully paid-up, non-exclusive license to its Background Intellectual Property to the extent it is
used in the Services, and solely for the purposes of receiving or enjoying the benefits of the Services or deliverables, or of using the
end products of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">6.&nbsp;<U>Term;
Termination</U>. This Agreement is effective as of the Effective Date and will continue in full force for one (1) year (&ldquo;Term&rdquo;)
unless terminated as provided in this Section 6. The terms of the Agreement will remain in effect after its termination or expiration
with respect to a Schedule of Services that is still active between the Parties, but only through the completion of the Services or termination
of the Schedule of Services&nbsp;in&nbsp;accordance&nbsp;with&nbsp;this&nbsp;Section&nbsp;6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left"><U>Termination of the Agreement</U>. Either Party may terminate this Agreement or Schedule of Services
at any time without cause upon thirty (30) days&rsquo; prior written notice to the other Party. Oruka may also delay or suspend the Services
under a Scope of Service at any time for any reason by giving Consultant written notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left"><U>Termination for Breach</U>. Either Party may terminate this Agreement or a Schedule of Services by
written notice to the other Party, if the other Party is in breach of its material obligations, representations or warranties set forth
in this Agreement. In the case of termination due to Consultant&rsquo;s material breach, Oruka shall not be liable to pay for the Services
related to the breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify"><U>Termination for Cause</U>. Either Party may terminate this Agreement or a Schedule of Services upon
written notice if the other Party: (a) becomes insolvent; (b) becomes the subject of a petition in bankruptcy which is not withdrawn or
dismissed within sixty (60) days thereafter; or (c) makes an assignment for the benefit of creditors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left"><U>Obligations following Termination</U>. Upon the termination of this Agreement, the Parties shall work
together to arrange for an orderly wind-down of the Agreement. Consultant shall use all reasonable efforts to conclude or transfer the
Services in accordance with Oruka&rsquo;s instructions. Upon termination of this Agreement, Consultant shall: (a) be entitled only to
the Fee due and documented reimbursable expenses; and (b) immediately return the prorated share of any fees Oruka paid in advance under
any Scope of Service. If necessary, the Parties shall agree to in good faith a separate agreement setting forth a wind-down plan, including
tasks to be undertaken and costs associated with those tasks for the close-out of the Services and Consultant shall be paid for those
fees agreed to in that wind-down plan only and not the Fee set forth herein as an addition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: left"><U>Survival</U>. Any termination of this Agreement or a Scope of Service shall not relieve either Party
of its obligations or liability for breaches or defaults of this Agreement or the Scope of Service incurred prior to or in connection
with termination. All rights and obligations of the Parties arising prior to the termination of this Agreement or a Scope of Service,
all provisions of this Agreement either allocating responsibility or liability between the Parties, and all rights and obligations of
the Parties which by their terms are to be performed or complied with subsequent to or survive the termination of this Agreement, including
but not limited to, the Parties&rsquo; rights and obligations under Sections 3.E, 4, 5, 6.D, 6.E, 9, 11, 12, 13, 14.C &ndash; 14.J shall
survive the termination of this Agreement and any Scopes of Service and continue in effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.&nbsp;<U>Debarment
or Exclusion Clause</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left">Consultant hereby certifies that Consultant (i) has never been debarred under the Generic Drug Enforcement
Act of 1992, 21 U.S.C. &sect;&nbsp;&sect;&nbsp;335a(a) or (b) or debarred or sanctioned by any state or federal agency and (ii) is not
currently excluded or otherwise ineligible from participating in any federal or state health care program. In the event that during the
term of this Agreement Consultant (i) becomes debarred, (ii) becomes excluded or otherwise ineligible from participating in any federal
or state health care program, or (iii) receives notice of an action or threat of an action with respect to any such debarment, sanction,
or exclusion, Consultant agrees to immediately notify Oruka. Consultant also agrees that in the event that Consultant becomes debarred
or excluded Consultant shall immediately cease all activities relating to this Agreement and Oruka shall have the right to terminate this
Agreement immediately.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left">Consultant hereby certifies that it has not and will not use in any capacity the services of any individual,
corporation, partnership or association which (i) has been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. &sect;&nbsp;&sect;&nbsp;335a(a)
or (b), (ii) has been debarred or sanctioned by any state or federal agency, or (iii) is excluded or otherwise ineligible from participating
in any federal or state health care program. In the event that Consultant becomes aware of the debarment, sanction, or exclusion, or threatened
debarment, sanction, or exclusion of any individual, corporation, partnership or association providing services to Consultant which directly
or indirectly relate to the Services, Consultant shall notify Oruka immediately. Upon the receipt of such notice by Oruka, or if Oruka
otherwise becomes aware of such debarment, sanction, exclusion or threatened debarment, sanction, or exclusion, Oruka shall have the right
to terminate this Agreement immediately.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left">It is the intent of the Parties that this Agreement and the performance of the Parties&rsquo; duties hereunder
shall not violate the anti-kickback and related provisions of the Social Security Act, 42 U.S.C. &sect;&nbsp;1320a-7b(b) (the &ldquo;<U>Anti-Kickback
Statute</U>&rdquo;). The Parties represent that they have no intention to violate the prohibitions set forth in the Anti-Kickback Statute
in connection with this Agreement. Consultant represents and warrants that Consultant will not attempt to and will not improperly or illegally
influence, directly or indirectly individuals licensed to prescribe, and governmental agencies and their employees, by means including,
but not limited to, offering inducements through monetary payments or other gifts of value designed to influence decisions relating to
the marketing, approval, sale or purchase of Oruka&rsquo;s products. The Parties agree that for the Fee for Services contracted hereunder
is a fair market value compensation rate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left">In performing Services, Consultant will perform all obligations in compliance with all relevant anti-corruption
laws of the United States including the Foreign Corrupt Practice Act (&ldquo;<U>FCPA</U>&rdquo;), and of other countries, states, provinces
or municipalities where Services are to be performed and Studies conducted. Neither Consultant, nor any of Consultant&rsquo;s Affiliates
shall make any payment or provide any other thing of any value to any government official, political party, official of a political party,
candidate for political office, an employee of a state-owned or state-controlled entity, or any other person in order to either influence
or induce such person to perform or forbear to perform acts, wherein such performance or forbearance would constitute a violation of anti-corruption
laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">8.&nbsp;<U>Independent
Contractor</U>. Nothing in this Agreement shall be construed to create an employment relationship between Consultant and Oruka. Except
as specifically set forth herein, neither Party shall have nor exercise any control or direction over the methods by which the other Party
performs work or obligations under this Agreement. Consultant shall be an independent contractor and shall have no authority to enter
into contracts on behalf of Oruka, bind Oruka to any third parties or act as an agent on behalf of Oruka in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.&nbsp;<U>Publicity,
Use of Name, and Disclosures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left">Consultant shall not use the name of Oruka, Oruka&rsquo;s Affiliates, or any of Oruka&rsquo;s or Oruka&rsquo;s
Affiliate&rsquo;s trademarks, whether registered or not, in any marketing-related communications to third parties, including its website,
advertising or customer lists.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left">Consultant&rsquo;s relationship with Oruka is confidential information subject to the terms of Section
4, with the exception that Consultant hereby grants to Oruka an option, at no additional expense, to disclose confidentially, to display
in Oruka website, or to issue a public announcement regarding the existence of this Agreement including the appointment of Consultant
by Oruka and/or the collaboration hereunder during the Term, at a time decided by Oruka.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left">Consultant agrees to the disclosure by Oruka of Consultant&rsquo;s name, all funds payable to Consultant
or an entity by or in which any Consultant receiving payments is employed, has tenure, or has an ownership interest, and such other information
as may be required or appropriate, as follows: (i) as and if required by any laws or regulations applicable to the Services rendered to
Oruka, and/or (ii) as may be required by other applicable government authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">10.&nbsp;<U>No
Conflicts</U>. Consultant represents and warrants that s/he does not have any relationship with third parties, including competitors of
Oruka, which would place them in conflict of interest in the performance of the Services, or which would prevent them from carrying out
the terms of this Agreement. Consultant agrees to advise Oruka of any such relationships that arise during the Term of this Agreement.
Oruka will then have the option to terminate this Agreement immediately without further liability to Consultant other than the payment
of Services performed to the date of termination. Consultant further represents and warrants that Consultant&rsquo;s performance of the
Services and all other obligations under this Agreement does not and will not breach any written or oral agreement Consultant has entered
into, or will enter into, with any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">11.&nbsp;<U>Indemnification</U>.
Consultant expressly agrees that s/he is liable for (i) the Services provided hereunder, including any claim that the related intellectual
property rights or the exercise of any rights infringes on, constitutes a misappropriation of the subject matter of, or otherwise violates
any patent, copyright, trade secret or trademark of any third party or breaches any third party&rsquo;s contractual rights, (ii) any breach
or alleged breach by Consultant of any representation, warranty, certification, covenant, obligation or other agreement set forth in this
Agreement or (iii) Consultant&rsquo;s negligence or willful misconduct under this Agreement.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">12.&nbsp;<U>Limitation
of Liability</U>. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL, INDIRECT,
EXEMPLARY, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, WARRANTY, TORT (EXCLUDING GROSS NEGLIGENCE OR WILLFUL MISCONDUCT),
LOST PROFITS OR SAVING, LOSS OF INCOME, LOSS OF PRODUCTION, PUNITIVE DAMAGES, INJURY TO REPUTATION, LOSS OF CUSTOMERS OR BUSINESS, OR
OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE; PROVIDED, THAT, THE ABOVE LIMITATION OF LIABILITY
SHALL NOT APPLY TO BREACHES TO (I) THE NON-USE AND NON-DISCLOSURE OBLIGATIONS SET FORTH IN SECTION 4 AND (II) THE RIGHT AND OBLIGATIONS
RELATED TO INTELLECTUAL PROPERTY IN SECTION 5 OR FOR CLAIMS AS A RESULT OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. MOREOVER, NOTHING IN
THIS SECTION IS INTENDED TO LIMIT OR RESTRICT IN THE INDEMNIFICATION RIGHTS OR OBLIGATIONS IN SECTION 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.&nbsp;<U>General
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: left"><U>Affiliates</U>. &ldquo;<U>Affiliate</U>&rdquo; means, with respect to a Party, any entity, that controls,
is controlled by, or is under common control with, such Party. For purposes of this definition, &ldquo;<U>control</U>&rdquo; will refer
to: (a) the possession, directly or indirectly, of the power to direct the management of an entity, whether through ownership of voting
securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities
or other ownership interest of an entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: left"><U>Non-exclusivity</U>. Oruka does not grant exclusivity to Consultant for any of the Services. Oruka
is free to obtain the services of any third party to perform any or all of the Services. Consultant shall be free to provide consulting
services to any third party and/or be employed by any third party, so long as such provision of consulting services or employment does
not impede Consultant&rsquo;s provision of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: left"><U>Governing Law; Venue</U>. This Agreement will be governed by the laws of the State of California, without
giving effect to the principles of conflict of laws. With respect to any disputes arising out of or related to this Agreement, the Parties
consent to the exclusive jurisdiction of, and venue in, the state courts in San Mateo County in the State of California (or in the event
of exclusive federal jurisdiction, the United States District Courts, Northern District of California).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: left"><U>Waiver</U>. The failure or delay of either Party to enforce its rights under this Agreement at any
time for any period will not be construed as a waiver of such rights; nor shall any single or partial waiver thereof preclude any other
or further exercise of any right hereunder. No waivers to this Agreement will be effective unless in writing and signed by the Party against
which waiver is to be enforced.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: left"><U>Entire Agreement; Amendments</U>. This Agreement sets forth the entire agreement and understanding
between the Parties relating to its subject matter and supersedes all prior discussions and agreements (whether oral or written) between
the Parties with respect thereto. No amendments to this Agreement will be effective unless in writing and executed by both Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: left"><U>Severability</U>. If any provision of this Agreement is held invalid by any law, rule, order or regulation
of any government or by the final determination of any court of competent jurisdiction, such invalidity shall not affect the enforceability
of the enforceability and validity of the remainder of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: left"><U>Successors and Assigns</U>. Consultant may not assign, transfer or subcontract any obligations under
this Agreement without the written consent of Oruka. Any attempt to do so will be void. Oruka may assign its rights and obligations under
this Agreement in whole or part. This Agreement will be binding upon Consultant&rsquo;s heirs, executors, administrators and other legal
representatives, and Consultant&rsquo;s successors and permitted assigns, and will be binding on and for the benefit of Oruka and its
successors and assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">H.</TD><TD STYLE="text-align: left"><U>Remedies</U>. Consultant acknowledges and agrees that violation of this Agreement may cause Oruka irreparable
harm and that Oruka will therefore be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining
orders, preliminary injunctions and permanent injunctions without the necessity of posting a bond or other security, in addition to any
other rights or remedies that Oruka may have for a breach of this Agreement. If any Party brings any suit, action, counterclaim or other
proceeding to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to recover a reasonable allowance
for attorneys&rsquo; fees and litigation expenses in addition to court costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">I.</TD><TD STYLE="text-align: left"><U>Notices</U>. All notices under this Agreement must be in writing and shall be deemed given when delivered
personally and confirmed by signature, or when received after being sent by nationally recognized courier service, or when received when
sent by prepaid certified mail, to the address of the Party to be noticed as set forth herein or such other address as such Party last
provided to the other Party by written notice.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; width: 47%; padding-right: 0pt; padding-left: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to Consultant:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left">Jeffrey Dekker<BR>
    [***]</P></TD>
    <TD STYLE="text-indent: 0pt; width: 44%; padding-right: 0pt; padding-left: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to Oruka:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: left">Oruka Therapeutics, Inc.<BR>
    855 Oak Grove Ave., Suite 100<BR>
    Menlo Park, CA 94025<BR>
    Attention: General Counsel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">J.</TD><TD STYLE="text-align: left"><U>Not Construed Against Drafter</U>. The Parties acknowledge that they have read this Agreement, have
had the opportunity to review it with an attorney of their respective choice, and have agreed to all its terms. Under these circumstances,
the Parties agree that the rule of construction that a contract be construed against the drafter shall not be applied in interpreting
this Agreement and that in the event of any ambiguity in any of the terms or conditions of this Amendment, such ambiguity shall not be
construed for or against any Party hereto on the basis that such Party did or did not author same.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">K.</TD><TD STYLE="text-align: left"><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be
deemed to be an original, and all of which together shall be deemed to be one and the same agreement. A facsimile, PDF or other electronic
signature of a Party shall be binding as an original.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">L.</TD><TD STYLE="text-align: left"><U>Authority</U>. By signing this Agreement, each Party represents that it is duly authorized to execute,
enter into delivery and perform its obligations under this Agreement and that this Agreement is enforceable against it in accordance with
its terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties have entered
into this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Oruka Therapeutics, Inc</B></FONT><B>.</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>C. <FONT STYLE="font-variant: small-caps">Jeff Dekker</FONT></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Arjun Agarwal</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ C. Jeff Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Arjun Agarwal</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>C. Jeff Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>SVP Finance</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Consultant</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 10</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Schedule A (the &ldquo;<U>Scope
of Services</U>&rdquo;) is effective as of August 30, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;) by and between Oruka Therapeutics,
Inc. (&ldquo;<U>Oruka</U>&rdquo;) and C. Jeff Dekker (&ldquo;<U>Consultant</U>&rdquo;) pursuant to that certain Consulting Agreement between
the Parties dated August 30, 2024 (together with any amendments thereto, the &ldquo;<U>Agreement</U>&rdquo;). The terms and conditions
of the Agreement shall apply to the Parties&rsquo; conduct hereunder. Capitalized terms not otherwise defined in this Scope of Services
will have the same meaning as set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal contacts</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Oruka</B>: Arjun Agarwal/ arjun.agarwal@orukatx.com
/ (408) 505 3949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consultant</B>: C. Jeff Dekker / [***]
/ [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Services</B>. Consultants shall provide the following Services for Oruka upon request including by
not limited to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 33.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Finalize accounting and reporting for ARCA biopharma through the merger date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 33.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Ensure transition of ARCA documents, finances and other items to Oruka.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 33.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Advise or answer questions as needed related to ARCA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0pt"><B>Compensation</B>.
In consideration of the Services to be performed hereunder, Oruka will pay Consultant twenty thousand US Dollars ($20,000.00) for up to
forty (40) hours per week over an anticipated engagement of two (2) weeks duration. Additional services after the initial two week duration
will be invoiced at $250 per hour. The maximum compensation payable under this Agreement shall not exceed twenty-seven thousand five hundred
US Dollars ($27,500.00), without a written amendment to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: left"><B>Payments and Invoices</B>. Consultant shall be paid based on the terms of this <U>Schedule A</U>, unless
otherwise notified in writing by Oruka. Consultant will invoice Oruka monthly for any expenses and invoices shall be paid by Oruka in
accordance with the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD STYLE="text-align: left"><B>Expenses</B>. Oruka will also reimburse Consultant for all out-of-pocket expenses actually incurred
by Consultant in rendering services under this Agreement so long as such expenses, in Oruka&rsquo;s opinion, are reasonable and necessary
and have been pre-approved in writing by Oruka. Such expenses will include reasonable and necessary economy travel, business-class hotel
lodging and meals. Consultant shall provide Oruka with a written expense report, complete with receipts or other reasonable documentation,
for all such expenses requested for reimbursement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties have entered
into this Scope of Services as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Oruka Therapeutics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>C. <FONT STYLE="font-variant: small-caps">Jeff Dekker</FONT></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Arjun Agarwal</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ C. Jeff Dekker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Arjun Agarwal</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>SVP Finance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 10</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>15
<FILENAME>ea021319301ex14-1_oruka.htm
<DESCRIPTION>CODE OF BUSINESS CONDUCT AND ETHICS OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
14.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex14-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><U>Code
of Business Conduct and Ethics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(August
29, 2024)</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">INTRODUCTION</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Code of Business Conduct and Ethics (this &ldquo;<U>Code</U>&rdquo;) provides a general statement of the expectations of Oruka Therapeutics,
Inc. (the &ldquo;<U>Company</U>&rdquo;) regarding the ethical standards to which each director<B>,</B> officer and employee should adhere
while acting on behalf of the Company. You are expected to read and become familiar with the ethical standards described in this Code
and will be required, from time to time, to affirm your agreement to adhere to such standards by signing the Compliance Certificate that
appears at the end of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are proud of what the Company has accomplished to date, and your commitment to continued excellence is crucial as the Company changes
and grows. We expect all individuals associated with the Company to conduct themselves with the highest degree of honesty and integrity
at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Code should be read in conjunction with our other policies and procedures, copies of which are available from Human Resources. This Code
is not a substitute for those other documents. Instead, this Code should be viewed as a general statement of the guiding principles that
should help you keep our core values in mind as you conduct business on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
consider any violation of this Code to be a serious breach of our trust, and any violation may result in disciplinary action up to and
including termination, as well as potential civil or criminal penalties, depending on the nature of the violation and applicable law.
Similarly, if you are aware of someone&rsquo;s violation of this Code, you have a duty to report the violation in accordance with the
procedures detailed below. We depend on your commitment to protect our culture and values and will view your reporting of violations
in that context.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
this Code covers multiple scenarios and activities, it does not address every situation that could arise. Therefore, if you are faced
with an issue that you feel may not be covered specifically by this Code and are making a decision to act, please keep the following
in mind:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consider
                                            whether your actions would conform to the intent of the Code.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consider
                                            whether your actions could create even a perception of impropriety.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Make
                                            sure you have all of the relevant facts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consider
                                            discussing the matter with your supervisor, as applicable, or reporting the matter anonymously
                                            as described below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consider
                                            seeking help. It is always better to seek assistance before you act, rather than making a
                                            preventable mistake.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you encounter a situation where you have a question about the law, the Code or any Company policy or are unsure of the best course of
action, you should always seek guidance. Except as otherwise specifically noted in the Code, when you have a specific question, please
contact your supervisor, Human Resources or the General Counsel (the &ldquo;<U>GC</U>&rdquo;).<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">II.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">REPORTING
                                            VIOLATIONS</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you know or reasonably believe that there has been a violation of this Code or any illegal behavior, you must report such violation or
illegal behavior to your supervisor, Human Resources or the GC. Additionally, employees, consultants and others may report any violations
of this Code or any other illegal behavior anonymously through the Company&rsquo;s whistleblower hotline. There are two methods of logging
complaints anonymously:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Website</U>:
https://www.whistleblowerservices.com/Oruka</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Phone</U>:
1 (833) 257-4240</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Such
complaints will be directed to the GC. However, if the complaint involves the GC, or otherwise gives rise to a conflict of interest,
such complaints will be directed to the Company&rsquo;s Audit Committee and/or outside counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Failure
to report a known or suspected violation of this Code is itself a violation and may result in disciplinary action up to and including
termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
director, officer or employee who obtains information about a Code violation or illegal act has the responsibility to report the matter
immediately to one of the above individuals. <B>The Company will not discharge, demote, suspend, threaten, harass or in any manner discriminate
or tolerate discrimination or retaliation against any director, officer or employee for reporting, in good faith, a potential violation,
and any supervisor intimidating or imposing sanctions on any such person for reporting a matter in good faith will be disciplined. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nothing
in this Code is intended, or should be understood, to preclude employees from exercising their rights under the National Labor Relations
Act.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
any time when the Company does not have a General Counsel, the duties and responsibilities of the General Counsel under this Code shall
be fulfilled by the Chief Financial Officer (&ldquo;<U>CFO</U>&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">III.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">PERSONAL RESPONSIBILITY
                                            AND INTEGRITY</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>A.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fair
                                            Dealing</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
are expected to be honest, ethical and fair and should deal fairly with customers, vendors, suppliers, business partners, service providers,
competitors and employees. You should not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information,
misrepresentation of material facts or any other unfair-dealing practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>B.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Confidential
                                            Information and Privacy </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company holds many types of confidential information that must be carefully safeguarded. Protecting this information is essential to
maintaining our relationships with our suppliers, customers and other business partners. In addition, Company information, which includes
confidential information and third-party information the Company has a duty to keep confidential (such as patient and employee health
information), should not be used other than for its intended use, and documents including such information should be disposed of properly
and should not be copied or removed from the work area, except as required for job performance. Confidential information should not be
disclosed to outsiders without specific approval by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidential
information includes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                            marked &ldquo;Confidential,&rdquo; &ldquo;Private,&rdquo; &ldquo;For Internal Use Only&rdquo;
                                            or with a similar legend;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">technical
                                            or scientific information relating to current and future product candidates, services or
                                            research;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">business
                                            or marketing plans, strategies, forecasts or projections;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">budgets,
                                            earnings and other internal financial data;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">personnel
                                            information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">business
                                            contracts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">training
                                            materials and methods;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">other
                                            non-public information that, if disclosed, might be of use to the Company&rsquo;s competitors
                                            or harmful to the Company or its business partners; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">other
                                            non-public information that, if disclosed, would violate federal or state securities laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regardless
of whether information is specifically marked as confidential, it is each employee&rsquo;s responsibility to keep confidential information
in confidence (except as otherwise required, if at all, by applicable law). You must not use, reveal or divulge any such information
unless it is necessary for you to do so in the performance of your duties (or except as otherwise required, if at all, by applicable
law). Generally, access to confidential information should be granted, provided or given on a &ldquo;need-to-know&rdquo; basis and must
be authorized by your manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>C.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Use
                                            of Company Systems</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
data and other information you use, send, receive and store on the Company&rsquo;s telecommunications equipment (including email, voicemail
and the internet) are business records owned by the Company. <B><I>Therefore, subject to applicable laws and regulations, the Company
has the right to access, read, monitor, inspect, review and disclose the contents of, postings to and downloads from all of the Company&rsquo;s
information systems</I></B>. In addition, your use of the Company&rsquo;s systems and equipment reflects on the Company as a whole, and
at no time may you use the Company systems or equipment to view, access, store, share or send illegal, derogatory, harassing or inappropriate
information, including obscene, racist or sexually explicit information, or engage in any activity that violates the intellectual property
rights of others. We strongly encourage all directors, officers and employees to avoid references to the Company on social networking
sites or other Internet based communications sites.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>D.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Conflicts
                                            of Interest</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors,
officers and employees should avoid activities that create or give the appearance of a conflict of interest between their personal interests
and the Company&rsquo;s interests. A conflict of interest exists when a personal interest or activity of a director, officer or employee
could influence or interfere with that person&rsquo;s performance of duties, responsibilities or commitments to the Company. A conflict
of interest also exists when a director, officer or employee (or member of his or her family) receives an improper personal benefit as
a result of his or her position at the Company. Below are some examples of situations that could result in a conflict of interest:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                            a consultant to, or a director, officer or employee of, or otherwise operate, an outside
                                            business that is a significant competitor, supplier or customer of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">be
                                            a consultant to, or a director, officer or employee of, or otherwise operate, an outside
                                            business if the demands of the outside business would materially interfere with the director&rsquo;s,
                                            officer&rsquo;s or employee&rsquo;s responsibilities to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">take
                                            personal advantage or obtain personal gain from an opportunity learned of or discovered during
                                            the course and scope of your employment when that opportunity or discovery could be of benefit
                                            or interest to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">have
                                            significant financial interest, including direct stock ownership, in any outside business
                                            that does or seeks to do a material amount of business with the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">seek
                                            or accept any personal loan or services from any such outside business, except from financial
                                            institutions or service providers offering similar loans or services to third parties under
                                            similar terms in the ordinary course of their respective businesses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">accept
                                            any personal loan or guarantee of obligations from the Company, except to the extent such
                                            arrangements are legally permissible; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">conduct
                                            business on behalf of the Company with immediate family members, which include spouses, children,
                                            parents, siblings and persons sharing the same home whether or not legal relatives.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Whether
or not a conflict of interest exists or will exist can be unclear. Persons other than directors and executive officers who have questions
about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with their supervisor,
as applicable, or the GC. Directors and executive officers must consult and seek prior approval of potential conflicts of interest exclusively
from the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
avoidance of doubt, a director affiliated with an investment firm shall not be presumed to have a conflict of interest due to such investment
firm or the director acting on its behalf conducting activities in the ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>E.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Proper
                                            Use of Company Assets</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors,
officers and employees <FONT STYLE="background-color: white">are entrusted with numerous Company assets and have a responsibility to
protect them. </FONT>The Company&rsquo;s assets shall be used for their intended business purposes. Personal use of the Company&rsquo;s
funds or property, including charging personal expenses as business expenses, inappropriate reporting or overstatement of business or
travel expenses and inappropriate usage of Company equipment or the personal use of supplies or facilities without advance approval from
an appropriate officer of the Company shall be considered a breach of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>F.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
                                            Opportunities</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
owe a duty to the Company to advance its interests when the opportunity to do so arises and are prohibited from taking for yourself opportunities
that are discovered through the use of Company property, information or position. You may not use Company property, information or position
for personal gain. In addition, you may not compete with the Company. If you become aware of any actual or potential business opportunity
that relates to the Company, you may not take advantage of the opportunity or share the opportunity with anyone outside the Company without
first receiving the approval of the GC&rsquo;s office or the Board of Directors, as applicable. Notwithstanding the foregoing, the duties
of directors and officers with respect to corporate opportunities are subject to the terms of the Company&rsquo;s certificate of incorporation,
as it may be amended or restated from time to time.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">IV.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL REQUIREMENTS</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>A.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regulatory
                                            Compliance</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
participants in the heavily regulated biotechnology industry, adherence to regulatory compliance principles and procedures is among our
highest priorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have a goal of developing product candidate programs of the highest quality possible. We also are sensitive to the special considerations
involved in conducting clinical research. Therefore, we have developed policies and procedures designed to ensure that this research
is conducted effectively and legally. This means that our clinical research procedures must abide by applicable regulatory requirements
and be conducted with respect for the research participants involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>B.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Gifts</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is against Company policy for a director, officer or employee of the Company to offer anything of value to an existing or potential clinical
investigator, Institutional Review Board, patient or other party that would inappropriately influence the design, conduct, enrollment
or outcome of clinical studies. Similarly, it is against Company policy for a director, officer or employee to offer anything of value
to an existing or potential customer that would inappropriately influence that consumer to select a Company product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are similar concerns involving potential conflicts of interest in other external business relationships. Generally, giving or receiving
gifts, meals or entertainment involving our external business relationships should meet all of the following criteria:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            do not violate applicable law or fail to comply with Company policy;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            do not constitute a bribe, kickback or other improper payment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            have a valid business purpose;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            are appropriate as to time, place and value (modest; not lavish or extravagant);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            are infrequent; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">they
                                            do not influence or appear to influence the behavior of the recipient.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gifts
of cash or marketable securities may not be given or accepted regardless of amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>C.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dealing
                                            with Government Officials</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
dealings with government officials, including, but not limited to, lobbying, political contributions to candidates and meeting with government
agencies, shall be in accordance with all applicable national, state and local laws and regulations in each country in which the Company
conducts business (and shall comply with the Foreign Corrupt Practices Act (the &ldquo;<U>FCPA</U>&rdquo;), as set forth below) and the
Company&rsquo;s International Trade Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
director, officer or employee shall offer or promise a payment or reward of any kind, directly or indirectly, to any federal, state,
local or foreign government official (i) for or because of an official act performed or to be performed by that official; or (ii) in
order to secure preferential treatment for the Company or its employees. No director, officer or employee shall offer or promise any
federal, state, local or foreign government official gifts, entertainment, gratuities, meals, lodging, travel or similar items that are
designed to influence such officials. Further, because of the potential for misunderstanding, no director, officer or employee of the
Company may confer gifts, special favors, gratuities or benefits to such an official even if there is no matter pending before that official.
The Company also strictly prohibits any director, officer or employee from making any payment or providing a thing of value if the person
knows, or reasonably believes or suspects that any portion of the payment or thing of value will be offered, given or promised, directly
or indirectly, to any government official.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is our policy to cooperate fully with all legal and reasonable government investigations. Accordingly, the Company directors, officers
and employees shall comply with any and all lawful requests from government investigators and, consistent with preserving the Company&rsquo;s
legal rights, shall cooperate in lawful government inquiries. No director, officer or employee shall make a false or misleading written
or oral statement to a government official with regard to any matter involving a government inquiry into the Company matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employees
shall contact the GC when presented with any such government request or inquiry prior to responding to such inquiry. Employees with questions
about contacts with government officials should seek guidance from senior management. Officers and directors should contact the GC prior
to responding to any such inquiries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>D.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Foreign
                                            Corrupt Practices Act</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
employees must comply with the FCPA, which sets forth requirements for the Company&rsquo;s relationships with non-U.S. government representatives,
which in many countries include individuals who would not be deemed government representatives in the United States (e.g., medical professionals
and employees of educational institutions). It is important to note that these limitations apply with respect to a government representative
at any level and not only with respect to senior or policy-making roles. As a U.S.-based company, the Company is required to adhere to
all standards set forth in the FCPA regardless of the nationality or overseas location of the individual acting on behalf of the Company,
whether an employee, officer or third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FCPA requires that relations between U.S. businesses and foreign government representatives conform to the standards that exist in the
United States, even if a different business ethic is prevalent in the other country. Accordingly, no employee or third-party person or
enterprise acting on behalf of the Company, directly or indirectly, may offer a gift, payment or bribe, or anything else of value, whether
directly or indirectly, to any foreign official, foreign political party or party official, or candidate for foreign political office,
for the purpose of influencing an official act or decision or seeking influence with a foreign government in order to obtain, retain
or direct business to the Company or to any person or to otherwise secure an improper advantage. In short, such activity cannot be used
to improve the business environment for the Company in any way. Thus, even if such payment is customary and generally thought to be legal
in the host country, it is forbidden by the FCPA and violates U.S. law, unless it is a reasonable and bona fide expenditure, such as
entertainment or travel and lodging expenses, that is directly related to (a) the promotion, demonstration or explanation of products
or services or (b) the execution or performance of a contract with a foreign government or government agency, and the payment was not
made for an improper purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
is the case under U.S. law, even inexpensive gifts to government or political party officials, such as tickets to sporting events, may
constitute a violation of the FCPA. If questions arise with respect to expenses to be incurred on behalf of foreign officials, consult
with the GC before the Company pays or agrees to pay such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Some
&ldquo;expediting&rdquo; payments are authorized under the FCPA. Such payments must be directly related to non-discretionary conduct
by lower level bureaucrats and unrelated to efforts by a company to obtain significant concessions, permits or approvals. Examples include
processing of visas and work orders, mail delivery or loading and unloading of cargo. Such payments do not include payments of any kind
relating to terms of continuing or new business agreements. Consult with the GC prior to making or authorizing any proposed expediting
payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
violation of the FCPA can result in criminal and civil charges against the Company, its officers, its managers and the individuals involved
in the violation, regardless of the person&rsquo;s nationality or location.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>E.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Inside
                                            Information</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
at the Company, you may also come into contact with another form of information that requires special handling and discretion. Inside
information is material, non-public information about the Company or another company that, if made public, would be reasonably expected
to affect the price of a company&rsquo;s securities or investment decisions regarding the purchase or sale of such securities. Employees
must never use inside information to obtain any type of personal advantage and should not disclose inside information to any third parties
without the prior approval of senior management. For further discussion on Company policy with respect to inside information, please
review our Insider Trading Policy and Guidelines for Public Disclosures and Communications with the Investment Community.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>F.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company
                                            Disclosure Obligations</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s business affairs are also subject to certain internal and external disclosure obligations and recordkeeping procedures.
As a public company, we are committed to abiding by our disclosure obligations in a full, fair, accurate, timely and understandable manner.
Only with reliable records and clear disclosure procedures can we make informed and responsible business decisions. When disclosing information
to the public, it is Company policy to provide consistent and accurate information. To maintain consistency and accuracy, specific Company
spokespersons are designated to respond to questions from the public. Only these individuals are authorized to release information to
the public at appropriate times. All inquiries from the media or investors should be forwarded immediately to the GC, CFO or Chief Executive
Officer (&ldquo;<U>CEO</U>&rdquo;). All press releases, speeches, publications or other official Company disclosures must be approved
in advance in accordance with our Guidelines for Public Disclosures and Communications with the Investment Community.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
internal control procedures are further regulated by the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;). The
Sarbanes-Oxley Act was a U.S. legislative response to events at public companies involving pervasive breakdowns in corporate ethics and
internal controls over financial reporting. It was designed to rebuild confidence in the capital markets by ensuring that public companies
are operated in a transparent and honest manner. Ensuring proper and effective internal controls is among the Company&rsquo;s highest
priorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
take seriously the reliance our investors place on us to provide accurate and timely information about our business. In support of our
disclosure obligations, it is Company policy to always:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">comply
                                            with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maintain
                                            a system of internal accounting and disclosure controls and procedures designed to provide
                                            management with reasonable assurances that transactions are properly recorded and that material
                                            information is made known to management;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">maintain
                                            books and records that accurately and fairly reflect transactions; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">prohibit
                                            establishment of material undisclosed or unrecorded funds or assets.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>G.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Environmental
                                            Matters</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is committed to operating its business in a manner that protects the environment as much as possible and is further committed
to compliance with all applicable environmental laws, regulations and industry best practices, such as those that affect hazardous waste
disposal, emissions and water purity. You are expected to be aware of environmental issues and to maintain compliance with all internal
environmental policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>H.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prohibition
                                            Against Discrimination; Equal Opportunity Employment</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is committed to maintaining the highest integrity in our work environment. Our employees must comply with all applicable employment
laws and our policies addressing workplace conduct. We base hiring, promotions and performance management decisions on qualifications
and job performance. The Company&rsquo;s policy is to treat each employee and job applicant without regard to gender, sex, race, color,
age, religion, national origin, sexual orientation, ancestry, veteran status or any other category protected by law. Employees must refrain
from acts that are intended to cause, or that do cause, unlawful employment discrimination. The Company also accommodates qualified disabled
employees and applicants consistent with applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company prohibits harassment in the workplace, including, but not limited to, sexual harassment. Consistent with this policy, we will
not tolerate harassment by any of our employees, customers or other third parties. Harassment includes verbal or physical conduct that
threatens, offends or belittles any individual because of his or her gender, sex, race, color, age, religion, national origin, sexual
orientation, ancestry, veteran status or any other category protected by law. Retaliation against an employee for alleging a complaint
of harassment or discrimination or for participating in an investigation relating to such a complaint will also not be tolerated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 52.75pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>I.</B></FONT></TD><TD STYLE="padding-right: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Health
                                            and Safety</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is committed to providing a safe and healthy work environment for its employees and all other individuals working on behalf of
the Company. The Company also recognizes that the responsibilities for a safe and healthy work environment are shared with you. The Company
will continue to establish and implement appropriate health and safety policies that managers and their employees are expected to uphold
at all times. Employees are expected to conduct their work in a safe manner in compliance with all the Company policies and to report
all safety or health concerns to your manager or Human Resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Part
of our providing a safe and healthy environment is the prohibition of (1) the possession or consumption of illegal drugs on Company premises,
and (2) consumption of recreational cannabis or alcohol on Company premises (except when alcohol is authorized for special Company-sponsored
events). Individuals who consume alcohol at such events do so at their own risk. In addition, you are expected to avoid excessive consumption
of alcohol at any Company-sponsored event and will be asked to leave an event at which you are violating this requirement, and you are
expected to be sober while conducting official business on behalf of the Company. You also may be subject to other disciplinary measures.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">V.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMENDMENTS
                                            AND WAIVERS OF THIS CODE</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Code applies to all Company employees, officers and directors. Please contact the GC if you believe that a waiver under a provision of
this Code is warranted. There shall be no substantive amendment or waiver of any provision of this Code except by a vote of the Board
of Directors or the Audit Committee of the Board of Directors, which will ascertain whether an amendment or waiver is appropriate and
ensure that any amendment or waiver is accompanied by appropriate controls designed to protect the Company. In the case of non-officer
employees or consultants of the Company, waivers may also be approved by the CEO. Any such waiver of a provision of this Code shall be
evaluated to determine whether timely public disclosure of such waiver is required under the rules and regulations of the Securities
and Exchange Commission or applicable exchange listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-indent: 34.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 0; text-indent: 34.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company reserves the right to amend any provision of this Code at any time, subject to the requirements for approval set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Code is not an employment contract. By issuing this Code, the Company has not created any contractual rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>16
<FILENAME>ea021319301ex16-1_oruka.htm
<DESCRIPTION>LETTER FROM KPMG LLP, DATED SEPTEMBER 5, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 16.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We were previously principal accountants for ARCA biopharma, Inc. and,
under the date of February&nbsp;1, 2024, we reported on the financial statements of ARCA biopharma, Inc. as of and for the years ended
December&nbsp;31, 2023 and 2022. On August&nbsp;30, 2024, we were dismissed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We have read ARCA biopharma, Inc. statements included under Item 4.01
of its Form 8-K dated September&nbsp;5, 2024, and we agree with such statements, except that we are not in a position to agree or disagree
with the Company&rsquo;s statement regarding the Audit Committee approving our dismissal, or any statements under Item 4.01 (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P></TD>
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ KPMG LLP</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>17
<FILENAME>ea021319301ex21-1_oruka.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SUBSIDIARIES OF ORUKA
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 49%">
    <P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Legal Name</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Organization</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka Therapeutics Operating Company, LLC</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center; font-size: 10pt">Oruka Therapeutics Australia Pty Ltd</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font-size: 10pt">Australia</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>18
<FILENAME>ea021319301ex99-1_oruka.htm
<DESCRIPTION>PRESS RELEASE, ISSUED ON SEPTEMBER 3, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Oruka Therapeutics Announces Closing of Merger
with ARCA biopharma and Previously Announced Private Placement of $275 Million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Oruka is advancing a pipeline of potentially
best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Company on track to advance co-lead programs,
ORKA-001 and ORKA-002, into the clinic and show initial pharmacokinetic data for <BR>
ORKA-001 next year</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Samarth Kulkarni, PhD, appointed Chairman of
Oruka&rsquo;s Board of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Shares to trade on Nasdaq under the ticker symbol
&ldquo;ORKA&rdquo; commencing today, September 3, 2024</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MENLO PARK, Calif. -- (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.
(&ldquo;Oruka&rdquo;) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment
of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma,
Inc. The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq
Global Market today, September 3, 2024, under the ticker symbol &ldquo;ORKA&rdquo;. In addition, Oruka announced the appointment of Samarth
Kulkarni, PhD, current Chairman and CEO of CRISPR Therapeutics, as Chairman of Oruka&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrent with the merger, Oruka completed a previously announced
$275 million private placement with a syndicate of new and existing investors including Fairmount, Venrock Healthcare Capital Partners,
RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi-Asset Investing, Avidity
Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, along with multiple large investment management
firms. Following the merger, private placement, and reverse stock split, there are approximately 46.3 million shares of the combined company&rsquo;s
common stock and common stock equivalents outstanding, including shares of common stock underlying pre-funded warrants and Series B non-voting
convertible preferred stock, and excluding employee and director equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We have made tremendous progress since our founding in February
of this year. We have assembled a top-tier team that has executed effectively to both close this transaction and advance our co-lead programs
toward human trials,&rdquo; said Lawrence Klein, PhD, Chief Executive Officer of Oruka. &ldquo;Our drug candidates are designed to potentially
offer both improved dosing regimens and greater clinical activity compared to the current standard of care for patients with psoriasis
and related conditions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Oruka&rsquo;s product candidates have incredible potential to
change the landscape of treatment for multiple diseases,&rdquo; commented Samarth Kulkarni, PhD. &ldquo;I am very impressed with the work
the team has completed to date and believe they are well positioned to deliver on the immense promise of their programs moving forward.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORKA-001 is a novel, subcutaneously (SQ) administered, half-life extended
monoclonal antibody targeting IL-23p19. Inhibitors of IL-23p19 have become the preferred first-line therapy for patients with moderate-to-severe
plaque psoriasis given their strong efficacy and safety profile. Currently approved therapies are dosed four to six times per year and
deliver PASI 100, or fully clear skin, for less than half of patients after four months. ORKA-001 has the potential to be dosed just once
or twice a year and is designed to achieve higher exposures than currently marketed IL-23p19 antibodies, which could lead to higher rates
of disease clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORKA-002 is a novel, SQ administered, half-life extended monoclonal
antibody targeting IL-17A/F. Dual inhibition of IL-17A and F has resulted in high PASI 100 rates in psoriasis and is ideally suited to
patients with concurrent psoriatic arthritis (PsA) or recalcitrant skin disease. IL-17A/F inhibition has also shown promising efficacy
in other diseases such as hidradenitis suppurativa (HS) and axial spondyloarthritis (axSpA). ORKA-002 is designed to provide patients
an option with substantially less frequent dosing, while offering similar levels of disease clearance compared to currently marketed agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Oruka Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics is developing novel biologics designed to set a
new standard for the treatment of chronic skin diseases. Oruka&rsquo;s mission is to offer patients suffering from chronic skin diseases
like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing
as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were
engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory
diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this press release, other than purely historical
information, may constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws, including for
purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, express or implied statements relating to Oruka&rsquo;s expectations, hopes, beliefs, intentions
or strategies regarding the future of its pipeline and business including, without limitation, Oruka&rsquo;s ability to achieve the expected
benefits or opportunities with respect to ORKA-001 and ORKA-002, including the expected timelines for first in human dosing and interim
data from such trials, the ultimate profile of products from each program and the potential of ORKA-001 and ORKA-002 to become best-in-class
drugs. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations
and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting
Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which
are beyond Oruka&rsquo;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed
or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and
factors described under the heading &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;
in Oruka&rsquo;s most recent filings with the SEC (including its S-4 Registration Statement). Should one or more of these risks or uncertainties
materialize, or should any of Oruka&rsquo;s assumptions prove incorrect, actual results may vary in material respects from those projected
in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking
statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary statements herein. Oruka does not undertake or accept any duty to
make any updates or revisions to any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Alan Lada<BR>
(650)-606-7911<BR>
alan.lada@orukatx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>19
<FILENAME>ea021319301ex99-2_oruka.htm
<DESCRIPTION>AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Opinion on the Financial Statement&nbsp;&mdash;&nbsp;Balance
Sheet</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheet of Oruka Therapeutics,
Inc. (the &ldquo;Company&rdquo;) as of February&nbsp;6, 2024, including the related notes (collectively referred to as the &ldquo;financial
statement&rdquo;). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company
as of February&nbsp;6, 2024 in conformity with accounting principles generally accepted in the United&nbsp;States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Substantial Doubt about the Company&rsquo;s Ability to Continue
as a Going Concern</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statement has been prepared assuming that
the Company will continue as a going concern. As discussed in Note&nbsp;1 to the financial statement, the Company has not generated any
revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since
inception, which raises substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these
matters are also described in Note&nbsp;1. The financial statement does not include any adjustments that might result from the outcome
of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis for Opinion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statement is the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statement based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United&nbsp;States) (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S.&nbsp;federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit of this financial statement in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&nbsp;States of America. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement,
whether due to error or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statement. We believe that our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Critical Audit Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i)&nbsp;relate
to accounts or disclosures that are material to the financial statement and (ii)&nbsp;involved our especially challenging, subjective,
or complex judgments. We determined there are no critical audit matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;13, 2024, except for the effects of the reverse stock split
discussed in Note 1 to the financial statement, as to which the date is September 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
BALANCE SHEET<BR>
(In thousands, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February&nbsp;6, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Subscription receivable</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Commitments and contingencies (Note&nbsp;5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Series&nbsp;A convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February&nbsp;6, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Common stock, $0.0001 par value, 65,000,000 shares authorized, 466,387 issued and outstanding as of February&nbsp;6, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total stockholders&rsquo; equity</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
this financial statement.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO FINANCIAL STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. Nature of the Business and
Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Background and Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Oruka Therapeutics, Inc. (&ldquo;Oruka&rdquo; or
the &ldquo;Company&rdquo;) was established and incorporated under the laws of the state of Delaware on February&nbsp;6, 2024. Oruka was
founded by Paragon Therapeutics, Inc. (&ldquo;Paragon&rdquo;). The Company currently operates as a virtual company, and thus, does not
maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of
inflammatory skin diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company&rsquo;s potential products will require
approval from the U.S.&nbsp;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales.
There can be no assurance that the Company&rsquo;s potential products will receive all the required approvals. In addition, there can
be no assurance that the Company&rsquo;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United&nbsp;States of America (&ldquo;U.S.&nbsp;GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February&nbsp;6, 2024, the Company had no cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&rsquo;s development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company&rsquo;s business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO FINANCIAL STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&nbsp;2024, the Company received $3.0&nbsp;million
in proceeds from the sale of Series&nbsp;A convertible preferred stock and $25.0&nbsp;million in proceeds from the sale of an unsecured
convertible promissory note, both of which were related party transactions (see Note&nbsp;7 <I>Subsequent Events</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">ARCA biopharma, Inc., a Delaware corporation (&ldquo;ARCA&rdquo;),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the &ldquo;Merger Agreement&rdquo;) on April&nbsp;3,
2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation (&ldquo;First Merger Sub&rdquo;), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &ldquo;First Merger&rdquo;), and Oruka will merge
with and into Atlas Merger Sub&nbsp;II, LLC, a Delaware limited liability company (&ldquo;Second Merger Sub&rdquo; and together with First
Merger Sub, &ldquo;Merger Subs&rdquo;), with Second Merger Sub being the surviving entity of the merger (the &ldquo;Second Merger&rdquo;
and, together with the First Merger, the &ldquo;Merger&rdquo;). In connection with the Merger, Second Merger Sub will change its corporate
name to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA will change its name to &ldquo;Oruka Therapeutics, Inc.&rdquo;
ARCA following the Merger is referred to herein as the &ldquo;combined company.&rdquo; The combined company will be led by Oruka&rsquo;s
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Concurrent with the execution of the Merger Agreement, the Company
entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement
financing (the &ldquo;Private Placement&rdquo;) shares and pre-funded warrants of the Company&rsquo;s common stock at an estimated purchase
price of $62.62 ($5.55 prior to impact of reverse stock split) per share of common stock and estimated purchase price (prior to the impact
of the reverse stock split) of $62.61 ($5.54 prior to the impact of the reverse stock split) per warrant for gross proceeds of approximately
$275.0&nbsp;million, which will precede the closing of the Merger Agreement. Shares of the Company&rsquo;s common stock and pre-funded
warrants to purchase shares of the Company&rsquo;s common stock issued pursuant to the Private Placement will be converted into the right
to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock, respectively, in accordance with the exchange
ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&rsquo;s
pipeline, business development activities, working capital, and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $0.4 million or Oruka could be required to pay ARCA a termination fee of $0.4 million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company&rsquo;s financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve&nbsp;months from the date the financial statement is available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the Merger Agreement discussed above, the Company
effected a one-for-twelve reverse stock split of the Company&rsquo;s issued and outstanding shares of common stock on September 3, 2024
without any change in the par value per share. Unless otherwise stated, all information related to the Company&rsquo;s common stock, common
stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively adjusted to give
effect for the one-for-twelve reverse stock split for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. Summary of Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subscription receivable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of February&nbsp;6, 2024, the Company has the
authority to issue a total of 65,000,000 shares of common stock at a par value of $0.0001. As of February&nbsp;6, 2024, 466,387 shares
of common stock were issued and outstanding for a nominal consideration, which was received in March&nbsp;2024, prior to the date the
financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock
held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled
to receive dividends, if any, as declared by the Company&rsquo;s Board of Directors. Upon dissolution, liquidation or winding up of the
Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall
be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of
shares held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO FINANCIAL STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company issued 466,387 shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&ldquo;Paruka&rdquo;), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC (&ldquo;Oruka Advisors&rdquo;), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February&nbsp;6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common
stock holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February&nbsp;6, 2024, there were no material proceedings to which the Company was
a party, nor did the Company have knowledge of any proceedings threatened against it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On February&nbsp;6, 2024, the Company&rsquo;s Board of Directors approved
the 2024 Equity Incentive Plan (the &ldquo;2024 Plan&rdquo;), under which the Company may grant stock options, restricted stock awards,
restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The Company reserved
31,076 shares of its common stock for issuance under the 2024 Plan. As of February&nbsp;6, 2024, no awards had been issued under the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 24pt">The Company evaluated all events subsequent to February&nbsp;6, 2024,
through May 13, 2024, the date on which the financial statement was available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock-Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In February&nbsp;2024, the Company&rsquo;s Board
of Directors authorized and granted 172,780 restricted stock awards at a price of $0.0001 per share to employees of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company&rsquo;s Board of Directors
authorized and granted 149,163 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;5, 2024, the Company&rsquo;s Board
of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the
2024 Plan from 31,076 to 72,742.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;22, 2024, the Company granted options
for the purchase of an aggregate 58,221 shares of common stock, at an exercise price of $34.80 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company&rsquo;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
72,742 to 171,969.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company granted options for
the purchase of an aggregate 113,748 shares of common stock, at an exercise price of $46.68 per share.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Antibody Discovery and Option Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;6, 2024, the Company entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&nbsp;28, 2024,
whereby the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&rsquo;s
right, title and interest in and to the intellectual property (&ldquo;ORKA-001&rdquo;) resulting from the applicable research program
to develop, manufacture and commercialize products directed at the selected target (&ldquo;IL-23&rdquo;), with the exception of pursuing
ORKA-001 for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a
one-time, non-refundable research initiation fee of $0.8&nbsp;million was due to Paragon. This amount was recognized as a research and
development expense during the period ended March&nbsp;31, 2024, and paid to Paragon in April&nbsp;2024. The Company is also responsible
for 50% of the development costs incurred prior to March&nbsp;31, 2024, provided that the Company receives rights to at least one selected
IL-23 antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL-23
antibody and has not paid or accrued the $5.9&nbsp;million of development costs incurred prior to March&nbsp;31, 2024. The Company will
be responsible for 50% of the ORKA-001 development costs incurred from and after March&nbsp;31, 2024, through the completion of the IL-23
selection process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO FINANCIAL STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;6, 2024, the Company also entered
into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&nbsp;28,
2024, whereby the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&rsquo;s
right, title and interest in and to the intellectual property (&ldquo;ORKA-002&rdquo;) resulting from the applicable research program
to develop, manufacture and commercialize products directed at the selected target (&ldquo;IL-17&rdquo;). The Company was also required
to reimburse Paragon $3.3&nbsp;million for development costs related to ORKA-002 incurred by Paragon through December&nbsp;31, 2023 and
certain other development costs related to ORKA-002 incurred by Paragon between January&nbsp;1, 2024 and March&nbsp;6, 2024. This amount
was recognized as a research and development expenses during the period from February&nbsp;6 (inception) to March&nbsp;31, 2024 and accounts
payable as of March&nbsp;31, 2024. The Company paid $3.3&nbsp;million to Paragon in April&nbsp;2024. The Company is also responsible for
the development costs incurred by Paragon from January&nbsp;1, 2024 to March&nbsp;31, 2024 of $0.9&nbsp;million, which was recognized
as a research and development expense in the period from February&nbsp;6 (inception) to March&nbsp;31, 2024. The Company will be required
to pay Paragon $0.8&nbsp;million for the research initiation fee related to ORKA-002 within 30&nbsp;days following finalization of the
ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of the date of issuance of the Company&rsquo;s
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0&nbsp;million
upon the achievement of certain clinical development milestones, up to $10.0&nbsp;million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December&nbsp;31, 2024 and December&nbsp;31, 2025, the Company will grant Paruka warrants to purchase
a number of shares equal to 1.00% of the then outstanding shares of the Company&rsquo;s common stock as of the date of the grant on a
fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series&nbsp;A Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;6, 2024, the Company issued 20,000,000
shares of Series&nbsp;A convertible preferred stock to Fairmount Healthcare Fund&nbsp;II, L.P. (&ldquo;Fairmount&rdquo;), a related party
of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0&nbsp;million. The Company incurred less than $0.1&nbsp;million
of issuance costs in connection with this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The holders of Series&nbsp;A convertible preferred
stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder
of outstanding shares of Series&nbsp;A convertible preferred stock is entitled to the number of votes equal to the number of shares of
common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders
entitled to vote on such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Each share of Series&nbsp;A convertible preferred stock is convertible
at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of
Series&nbsp;A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio
then in effect upon either (i)&nbsp;the closing of a firm-commitment underwritten public offering of the Company&rsquo;s common stock
at a price of at least $12.00 per share resulting in at least $50.0&nbsp;million of gross proceeds to the Company, or (ii)&nbsp;the vote
or written consent of the holders of a majority of the Preferred Stock, voting as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO FINANCIAL STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The conversion ratio of Series&nbsp;A convertible
preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original
Issue Price is $0.15 per share for Series&nbsp;A convertible preferred stock (in each case subject to appropriate adjustment in the event
of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&rsquo;s
certificate of incorporation, as amended and restated). The Conversion Price is $1.80 per share for Series&nbsp;A convertible preferred
stock and each outstanding share of Series&nbsp;A Preferred Stock was convertible into common stock at a 0.0833 conversion ratio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series&nbsp;A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on
each outstanding share of Series&nbsp;A convertible preferred stock in an amount at least equal to (i)&nbsp;in the case of a dividend
being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted
basis or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend
rate on Series&nbsp;A convertible preferred stock calculated based on the respective Original Issue Price of Series&nbsp;A convertible
preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series&nbsp;A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available
for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&nbsp;A convertible preferred
stock are entitled to an amount equal to the greater of (i)&nbsp;the applicable Original Issue Price per share of Series&nbsp;A convertible
preferred stock, plus any declared but unpaid dividends thereon, or (ii)&nbsp;the amount per share that would have been payable had all
shares of Series&nbsp;A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution,
winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution
to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&nbsp;A convertible
preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective
amounts which would otherwise be payable if it were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Unless the holders of a majority in voting power
of the then outstanding shares of Series&nbsp;A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include
a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all
of the Company&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Series&nbsp;A convertible preferred stock does not
have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Convertible Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March&nbsp;6, 2024, the Company entered into
a Series A Preferred Stock and Convertible Note Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Fairmount, whereby the
Company issued a convertible note (the &ldquo;Convertible Note&rdquo;), with an initial principal amount of $25.0 million, that can be
converted into Series&nbsp;A preferred stock (or a Series&nbsp;of preferred shares that is identical in respect to the shares of preferred
shares issued in its next equity financing) or shares of the Company&rsquo;s common stock in exchange for proceeds of $25.0&nbsp;million.
The Convertible Note will automatically convert into shares of the Company&rsquo;s common stock upon the closing of a corporate transaction,
including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible
Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&nbsp;31, 2025.
Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right
to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million
of initial principal amount of the Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Oak Grove Lease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On April&nbsp;12, 2024, the Company entered into
a lease agreement with Oak Grove LP (&ldquo;Oak Grove Lease&rdquo;) for office space located in Menlo Park, California. The lease commencement
date is June&nbsp;15, 2024 with an initial term of 39.5&nbsp;months. The total lease payment is expected to be $1.4&nbsp;million over
the initial lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8. Events subsequent to the reissuance of the financial
statement (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through September 5, 2024, the date the financial statement was available to be
reissued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">7</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0in; margin-bottom: 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>20
<FILENAME>ea021319301ex99-3_oruka.htm
<DESCRIPTION>UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit <FONT STYLE="text-transform: uppercase">99.3</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Oruka Therapeutics,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Unaudited Interim
Condensed Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO UNAUDITED INTERIM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">&nbsp;</TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Financial
    Statements: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; vertical-align: top; font-size: 10pt"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">Condensed Consolidated Balance Sheets</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; vertical-align: top; font-size: 10pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Operations and Comprehensive Loss</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; vertical-align: top; font-size: 10pt"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&rsquo; Deficit</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; vertical-align: top; font-size: 10pt"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Condensed Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Notes to Unaudited Interim Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font-size: 10pt; text-align: center">5<FONT STYLE="font-size: 10pt">&nbsp;-&nbsp;23</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ORUKA THERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS<BR>
(UNAUDITED)<BR>
(In thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February&nbsp;6,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 0.125in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">15,121</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,358</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,178</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&rsquo; DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Operating lease liability, current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Common stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Related party accounts payable and other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Long term liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accrued interest payable, related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Operating lease liability, non-current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Note payable to related party, noncurrent</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,982</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies (Note&nbsp;12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Series&nbsp;A convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of June&nbsp;30, 2024 and February&nbsp;6, 2024; 20,000,000 and no&nbsp;shares issued and outstanding as of June 30, 2024 and February&nbsp;6, 2024, respectively; liquidation preference of $3,000 and $0 as of June 30, 2024 and February&nbsp;6, 2024, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Common stock, $0.0001 par value; 65,000,000 shares authorized, 788,330
and 466,387 shares issued and outstanding as of June 30, 2024 and February 6, 2024, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(29,320</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total liabilities, convertible preferred stock and stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,178</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>ORUKA THERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS<BR>
(UNAUDITED)<BR>
(In thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR> June 30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period&nbsp;from <BR> February&nbsp;6,<BR> 2024 <BR> (Inception)&nbsp;to<BR> June 30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">18,673</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,866</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,820</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,490</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,493</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,356</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,493</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,356</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(22,243</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(29,320</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(47.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(62.87</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Weighted-average common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">466,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">466,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $15,457 for the three months ended June 30, 2024 and $20,430 for
                                            the period February 6, 2024 (inception) to June 30, 2024</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $342 for the three months ended June 30, 2024 and $1,268 for the
                                            period February 6, 2024 (inception) to June 30, 2024</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $750 for the three months ended June 30, 2024 and $964 for the period
                                            February 6, 2024 (inception) to June 30, 2024</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_003"></A>ORUKA
THERAPEUTICS, INC.<BR>
CONDENSED&nbsp;CONSOLIDATED STATEMENT&nbsp;OF&nbsp;CONVERTIBLE PREFERRED&nbsp;STOCK&nbsp;AND&nbsp;STOCKHOLDERS&rsquo;&nbsp;DEFICIT<BR>
(UNAUDITED)<BR>
(In thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Convertible Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional Paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balances as of February&nbsp;6, 2024 (inception)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">466,387</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of Series&nbsp;A convertible preferred stock, net of issuance costs of $69</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,077</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,077</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><B>Balances as of March&nbsp;31, 2024</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,077</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,059</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balances as of June&nbsp;30, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,931</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-left: Black 1.5pt solid; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">788,330</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(29,320</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(28,981</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes issuance of
                                            321,943 restricted stock awards (see Note 8)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>ORUKA THERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS<BR>
(UNAUDITED)<BR>
(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period&nbsp;from<BR> February&nbsp;6,<BR> 2024<BR> (Inception)<BR> to June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(29,320</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash lease expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,721</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,022</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left">Related party accounts payable and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,437</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Accrued interest payable, related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">961</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,201</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from issuance of Series&nbsp;A convertible preferred stock, net of issuance costs paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,931</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Payment of deferred offering costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,121</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Cash at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,121</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental disclosure of non-cash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease liability arising from obtaining operating right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred offering costs in accounts payable and accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>ORUKA THERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<BR>
(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>1. Nature
of the Business and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Background and Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc. (&ldquo;Oruka&rdquo; or the &ldquo;Company&rdquo;) was established and incorporated under the laws of the state of
Delaware on February&nbsp;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&ldquo;Paragon&rdquo;). </FONT>The Company is based
in Menlo Park, California. <FONT STYLE="font-family: Times New Roman, Times, Serif">Oruka was formed to develop biologics to optimize
the treatment of inflammatory skin diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is subject to risks and uncertainties
common to early stage companies in biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials,
obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key
personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology,
compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional
capital to fund operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s potential products require
approval from the U.S.&nbsp;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales.
There can be no assurance that the Company&rsquo;s potential products will receive all the required approvals. In addition, there can
be no assurance that the Company&rsquo;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying unaudited interim condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&nbsp;States
of America (&ldquo;U.S.&nbsp;GAAP&rdquo;) and pursuant to the rules and regulations of the U.S.&nbsp;Securities and Exchange Commission
(&ldquo;SEC&rdquo;) regarding interim financial information. Accordingly, they do not include all of the information and notes required
by U.S.&nbsp;GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal
and recurring adjustments the Company believes are necessary to fairly state the Company&rsquo;s financial position and the results of
its operations and cash flows. The results for the three months ended June 30, 2024 and period from February 6, 2024 (inception) to June
30, 2024 are not necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The accompanying
condensed consolidated financial statements include accounts of the Company and its wholly owned subsidiary, Oruka Therapeutics Australia
PTY LTD (&ldquo;Oruka Australia&rdquo;). For the three months ended June 30, 2024 and the period from February 6, 2024 (inception) to
June 30, 2024, Oruka Australia has not had any financial transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Going Concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying condensed consolidated financial
statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization
of assets and satisfaction of liabilities in the normal course of business. As of June 30, 2024, the Company had $15.1 million in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since inception, the Company has devoted substantially
all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning,
raising capital, and providing general and administrative support for these operations. Current and future programs will require significant
research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts
require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&rsquo;s development efforts
are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains
regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related
to developing its internal commercialization capability to support product sales, marketing, and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a result, the Company will need substantial
additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory
approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company
can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the Company is unable to obtain additional
funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of
its planned operations, which may have a material adverse effect on the Company&rsquo;s business, financial condition, results of operations
and ability to operate as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has not generated any revenue from
product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.
The Company has incurred a net loss of $22.2 million for the three months ended June 30, 2024 and $29.3&nbsp;million during the period
from February&nbsp;6, 2024 (inception) to June 30, 2024. As of June 30, 2024, the Company had an accumulated deficit of $29.3&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, the Company received $3.0&nbsp;million
in gross proceeds from the issuance of Series&nbsp;A convertible preferred stock (&ldquo;Series A Preferred Stock&rdquo;) and $25.0&nbsp;million
in gross proceeds from the issuance of a convertible note, both of which were related party transactions (see Note&nbsp;14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ARCA biopharma, Inc., a Delaware corporation
(&ldquo;ARCA&rdquo;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &ldquo;Merger Agreement&rdquo;)
on April&nbsp;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth
in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&ldquo;First Merger Sub&rdquo;), will merge with and into Oruka,
with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &ldquo;First Merger&rdquo;),
and Oruka will merge with and into Atlas Merger Sub&nbsp;II, LLC, a Delaware limited liability company (&ldquo;Second Merger Sub&rdquo;
and together with First Merger Sub, &ldquo;Merger Subs&rdquo;), with Second Merger Sub being the surviving entity of the merger (the
&ldquo;Second Merger&rdquo; and, together with the First Merger, the &ldquo;Merger&rdquo;). In connection with the Merger, Second Merger
Sub will change its corporate name to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA will change its name to &ldquo;Oruka
Therapeutics, Inc.&rdquo; ARCA following the Merger is referred to herein as the &ldquo;combined company.&rdquo; The combined company
will be led by Oruka&rsquo;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory
skin diseases. See Note 15 for subsequent events related to the closing of this transaction on August 29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Concurrent with the execution of the Merger Agreement, the Company
entered into a subscription agreement with certain investors (the &ldquo;Subscription Agreement&rdquo;) pursuant to which the Company
agreed to issue and sell to investors in a private placement financing (the &ldquo;Private Placement&rdquo;) shares of the Company&rsquo;s
common stock and pre-funded warrants to purchase shares of the Company&rsquo;s common stock at an estimated purchase price of $66.62 ($5.55
prior to the effect of the reverse stock split) per share of common stock and an estimated purchase price of $66.61 ($5.54 prior to the
effect of the reverse stock split) per warrant for gross proceeds of approximately $275.0&nbsp;million, inclusive of $25.0&nbsp;million
proceeds received as of June 30, 2024 from the issuance of the Company&rsquo;s convertible note, which will precede the closing of the
Merger. Shares of the Company&rsquo;s common stock and warrants to purchase shares of the Company&rsquo;s common stock issued pursuant
to the Private Placement will be converted into the right to receive shares of ARCA common stock and warrants to purchase shares of ARCA
common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds
from the Private Placement are expected to advance the Company&rsquo;s pipeline, as well as for general corporate purposes, which may
include capital expenditure, working capital and general and administrative expenses. See Note 15 for subsequent events related to the
closing of this transaction on August 29, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expects that its research and development and general and
administrative costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and
clinical trials and manufacturing for its existing product candidates and any future product candidates to support commercialization and
providing general and administrative support for its operations, including the costs associated with operating as a public company. The
Company expects that its existing cash of $15.1 million as of June 30, 2024, together with the proceeds from the Merger and Private Placement,
will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date these condensed
consolidated financial statements were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Following the consummation of the Merger, the Company effected a one-for-twelve
reverse stock split of the Company&rsquo;s common stock (the &ldquo;Reverse Stock Split&rdquo;), which became effective on September 3,
2024. All information related to the Company&rsquo;s common stock, common stock warrants, restricted stock awards, and stock options,
as well as the per share amounts, have been retroactively adjusted to give effect for the one-for-twelve reverse stock split for all periods
presented, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>2. Summary
of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of the Company&rsquo;s condensed
consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates, assumptions, and judgments
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the
condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates
and assumptions reflected within these condensed consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
may differ materially from those estimates or assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Concentrations of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that potentially expose
the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial
institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its
deposits of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is dependent on third-party organizations
to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs,
ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements
for all products. The Company&rsquo;s research and development programs could be adversely affected by a significant interruption in
the supply of the necessary materials. A significant amount of the Company&rsquo;s research and development activities are performed
under its agreements with Paragon (see Note&nbsp;10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Deferred Offering Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company capitalizes certain legal, professional,
accounting, and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until
such financings are consummated. After the consummation of equity financing, these costs are recorded as a reduction of the proceeds
from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&rsquo; deficit as a reduction
of additional paid-in capital generated as a result of the offering. Should the in-process equity financing (see Note&nbsp;1) be abandoned,
the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive
loss. As of June 30, 2024, deferred offering costs of $2.3 million were recorded as Other assets in the condensed consolidated balance
sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Debt Issuance Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Debt issuance costs incurred in connection with
the Company&rsquo;s convertible note (see Note&nbsp;5) are recorded as a reduction of the carrying value of the notes payable liability
on the Company&rsquo;s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subscription receivable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company accounts for any notes received in
exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial
statement is available to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair Value Measurements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain assets and liabilities are carried at
fair value under U.S.&nbsp;GAAP.&nbsp;Fair value is defined as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs
and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed
in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered
unobservable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level&nbsp;1 &mdash;&nbsp;Quoted
                                            prices in active markets that are identical assets or liabilities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level&nbsp;2&nbsp;&mdash;&nbsp;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level&nbsp;3&nbsp;&mdash;&nbsp;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The carrying values of the Company&rsquo;s prepaid
expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values
due to their relatively short maturity period. The Company accounts for its convertible note at amortized cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Classification of Convertible Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has classified the convertible preferred
stock outside of stockholders&rsquo; deficit on the Company&rsquo;s condensed consolidated balance sheet because the holders of such
stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the
control of the Company and would require the redemption of the then-outstanding convertible preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s Series&nbsp;A Preferred Stock
is not redeemable, except in the event of deemed liquidation (see Note 6). Because the occurrence of a deemed liquidation event is not
currently probable, the carrying values of the convertible preferred stock are not being accreted to their redemption values. Subsequent
adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Note&nbsp;Payable to Related Party</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company accounts for its convertible note
at amortized cost. The Company considers if optional conversion features are required to be bifurcated and separately accounted for as
a derivative. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible
note (see&nbsp;Note&nbsp;5) and are accounted as interest expense in other expenses within the condensed consolidated statements of operations
and comprehensive loss using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Contract Costs Accruals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company records the costs associated with research studies and
manufacturing development as incurred. These costs are a significant component of the Company&rsquo;s research and development expenses,
with a substantial portion of the Company&rsquo;s ongoing research and development activities conducted by third-party service providers,
including contract research organizations (&ldquo;CROs&rdquo;) and contract manufacturing organizations (&ldquo;CMOs&rdquo;), and the
Company&rsquo;s related-party Paragon (see Note&nbsp;10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &ldquo;Option Agreements&rdquo;) between Paragon, Paruka Holding
LLC (&ldquo;Paruka&rdquo;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company and agreements with
CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are
provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established
with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the
proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress
or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each
reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded
as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material
changes to the Company&rsquo;s accruals could materially affect the Company&rsquo;s results of operations. As of June 30, 2024, the Company
has not experienced any material deviations between accrued and actual research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the lease commencement date, when control
of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance
lease and recognizes a right-of-use (&ldquo;ROU&rdquo;) asset and a current and non-current lease liability, as applicable, in the balance
sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably
certain that the Company will exercise its option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the lease commencement date, operating lease
liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining
lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the
risk-free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is
recognized on a straight-line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset
recognized on a straight-line basis over the lease term and interest expense recognized on the finance lease liability. In addition,
certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs.
As of June 30, 2024, the Company has one operating lease and no finance leases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases  as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Segment Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company operates and manages its business
as a single segment for the purposes of assessing performance and making operating decisions. The Company&rsquo;s chief executive officer,
who is the chief operating decision maker (the &ldquo;CODM&rdquo;), reviews the Company&rsquo;s financial information on an aggregated
basis for purposes of evaluating financial performance and allocating resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development costs are expensed as
incurred. Research and development costs include salaries and bonuses, stock-based compensation, employee benefits, and external costs
of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information
technology costs, and facility-related costs, including rent, maintenance, utilities and depreciation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Nonrefundable advance payments for goods or services
to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed
consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when
it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one-time
cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, professional fees, as well as
allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities and
depreciation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Commitments and Contingencies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is subject to contingent liabilities,
such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies
when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the
range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue
for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range
of reasonably possible losses. As of June 30, 2024, no liabilities were recorded for loss contingencies (see Note&nbsp;12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company measures all stock-based awards granted
to employees, directors, and non-employees in the form of stock options to purchase shares of its common stock, based on the fair value
of the awards on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards
(&ldquo;RSAs&rdquo;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company&rsquo;s
common stock at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company grants stock options and restricted
stock awards that are subject to either service or performance-based vesting conditions. Compensation expense for awards to employees
and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which
is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service-based vesting
conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally
over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the
probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the
performance-based vesting condition will be achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has issued stock options and RSAs
with service-based vesting conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company classifies stock-based compensation
expense in its condensed consolidated statement of operations and comprehensive loss in the same manner in which the award recipient&rsquo;s
payroll costs are classified or in which the award recipient&rsquo;s service payments are classified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Loss per Share Attributable to Common Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company applies the two-class method when
computing net loss per share attributable to the Company&rsquo;s common stockholders as the Company has issued shares that meet the definition
of participating securities. The&nbsp;two-class&nbsp;method determines net loss per share for each class of common and participating
securities according to dividends declared or accumulated and participation rights in undistributed earnings. The&nbsp;two-class&nbsp;method
requires loss available to common stockholders for the period to be allocated between common and participating securities based upon
their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers
its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible
preferred stock would be entitled to receive dividends on a basis consistent with the Company&rsquo;s common stockholders. There is no
allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation
to share in the losses of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Basic net loss per share attributable to common stockholders is computed
by dividing the net loss attributable to the Company&rsquo;s common stockholders by the weighted average number of common shares outstanding
for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed
by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive
securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted
average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation,
the Company&rsquo;s outstanding convertible preferred stock, stock options to purchase common stock and unvested RSAs are considered potential
dilutive common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company generated a net loss for the period
presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities
would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company accounts for income taxes using the
asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences
of events that have been recognized in the financial statements or in the Company&rsquo;s tax returns. Deferred tax assets and liabilities
are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax
rates in effect for the&nbsp;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future
taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all
or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense.
The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent
and feasible tax planning strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company accounts for uncertainty in income
taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit
to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination
by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine
the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may be recognized
is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes
includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related
net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of June
30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recently Issued Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
November&nbsp;2023, the FASB issued ASU No.&nbsp;2023-07, <I>Segment Reporting</I> (<I>Topic&nbsp;280</I>) (&ldquo;ASU&nbsp;2023-07&rdquo;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&rsquo;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&rsquo;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&nbsp;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&nbsp;2023-07 are effective for fiscal&nbsp;years beginning after December&nbsp;15,
2023, and interim periods within fiscal&nbsp;years beginning after December&nbsp;15, 2024. Early adoption is permitted. The Company is
currently evaluating the impact of this standard on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December&nbsp;2023, the FASB issued ASU&nbsp;2023-09,
<I>Income Taxes (Topic&nbsp;740): Improvements to Income Tax Disclosures</I>. This ASU expands disclosures in an entity&rsquo;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&nbsp;and foreign jurisdictions. This update is effective
beginning with the Company&rsquo;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard
on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>3. Prepaid
Expenses and Other Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prepaid expenses and other current assets consisted
of the following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
    2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Prepaid research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">275</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,700</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. Accrued Expenses and Other Current Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued expenses and other current liabilities
consisted of the following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,<BR>
    2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Accrued employee compensation and benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">403</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued professional and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accrued research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">853</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. Note&nbsp;Payable with Related Party</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, the Company entered into
a Series A Preferred Stock and Convertible Note Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Fairmount Healthcare Fund&nbsp;II,
L.P. (&ldquo;Fairmount&rdquo;), whereby the Company issued a convertible note (the &ldquo;Convertible Note&rdquo;), with an initial principal
amount of $25.0 million, that can be converted into Series&nbsp;A Preferred Stock (or a Series&nbsp;of preferred shares that is identical
in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&rsquo;s common stock in exchange
for aggregate proceeds of $25.0&nbsp;million. The Convertible Note will automatically convert into shares of the Company&rsquo;s common
stock upon the closing of a corporate transaction, including the Private Placement, and is otherwise due and payable at the request of
the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled
to mature on December&nbsp;31, 2025 (the &ldquo;Maturity Date&rdquo;). Prepayment is not permitted without prior written consent of Fairmount.
Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal
amount equal to $30.0 million, in addition to the $25.0 million of initial principal amount of the Convertible Note. The principal payment
along with the accrued interest on the Convertible Note is due in full on the Maturity Date. As of June 30, 2024, the Company had outstanding
borrowings of $25.0&nbsp;million from Fairmount under its Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the reverse recapitalization
transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus
any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon the Company&rsquo;s fully-diluted
capitalization immediately prior to the reverse recapitalization transaction (see Note 15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company assessed all terms and features of
the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the
Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption
feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion
options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition
of a derivative under ASC&nbsp;815, <I>Derivatives and Hedging</I>, and as a result, did not require separate accounting as a derivative
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company paid debt issuance costs of less
than $0.1&nbsp;million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value
of Convertible Note on the condensed consolidated balance sheet and are being amortized as interest expense over the term of the Convertible
Note using the effective interest method. For the three months ended June 30, 2024 and the period from February&nbsp;6, 2024 (inception)
to June 30, 2024, the Company recognized interest expense related to the Convertible Note of $0.8 million and $1.0 million, respectively,
which includes non-cash interest expense related to the amortization of debt issuance costs of less than $0.1 million for the three months
ended June 30, 2024 and the period from February 6, 2024 (inception) to June 30, 2024. For the three months ended June 30, 2024 and the
period from February&nbsp;6, 2024 (inception) to June 30, 2024, the weighted average effective interest rate of the Convertible Note
was approximately 12.0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>6. Convertible
Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, the Company issued and sold
an aggregate of 20,000,000 shares of Series&nbsp;A Preferred Stock to Fairmount, at a purchase price of $0.15 per share, for gross proceeds
of $3.0&nbsp;million. The Company incurred less than $0.1&nbsp;million of issuance costs in connection with this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Upon the issuance of the Series&nbsp;A Preferred
Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that
such features did not require the Company to separately account for these features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, convertible preferred stock
consisted of the following (in thousands, except share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&nbsp;Stock<BR> Authorized</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&nbsp;Stock<BR> Issued and<BR> Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying<BR> Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Liquidation<BR> Preference</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&nbsp;Stock<BR> Issuable Upon<BR> Conversion</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Series&nbsp;A Preferred Stock</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">20,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">20,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,931</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,666,666</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,931</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,666,666</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The holders of the Series A Preferred Stock have
the following rights and preferences:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The holders of Series&nbsp;A Preferred Stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of
outstanding shares of Series&nbsp;A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock
into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled
to vote on such matter. A majority vote of the holders of Series&nbsp;A Preferred Stock is required to liquidate or dissolve the Company,
amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares
that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the holders of shares of Series&nbsp;A
Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series
of voting stock (including Series&nbsp;A convertible preferred stock), exclusively and voting together as a single class, are entitled
to elect the balance of the total number of directors of the Company. The Company controls the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conversion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each share of Series&nbsp;A Preferred Stock is convertible at the option
of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&nbsp;A
Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either
(i)&nbsp;the closing of a firm commitment underwritten public offering of the Company&rsquo;s common stock at a price of at least $12.00
per share resulting in at least $50.0&nbsp;million of gross proceeds to the Company, net of the underwriting discount and commissions,
or (ii)&nbsp;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single
class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The conversion ratio of Series&nbsp;A Preferred Stock is determined
by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.15 per
share for Series&nbsp;A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend,
combination or other similar recapitalization and other adjustments as set forth in the Company&rsquo;s certificate of incorporation,
as amended and restated). The Conversion Price is $1.80 per share for Series&nbsp;A convertible preferred stock. As of June 30, 2024,
each outstanding share of Series&nbsp;A Preferred Stock was convertible into common stock at a 0.0833 conversion ratio.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company may not declare, pay or set aside
any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock)
unless the holders of the Series&nbsp;A Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series&nbsp;A Preferred Stock in an amount at least equal to (i)&nbsp;in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)&nbsp;in
the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&nbsp;A
Preferred Stock calculated based on the respective original issue price of Series&nbsp;A Preferred Stock. For the three months ended
June 30, 2024 and the period from February&nbsp;6, 2024 (inception) through June 30, 2024, no cash dividends had been declared or paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders
of shares of Series&nbsp;A Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available
for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&nbsp;A Preferred Stock
are entitled to an amount equal to the greater of (i)&nbsp;the applicable original issue price per share of Series&nbsp;A Preferred Stock,
plus any declared but unpaid dividends thereon, or (ii)&nbsp;the amount per share that would have been payable had all shares of Series&nbsp;A
Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation
Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient
to pay the full amount to which they are entitled, then the holders of shares of Series&nbsp;A Preferred Stock will share ratably in
any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable
if it were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless the holders of a majority in voting power
of the then outstanding shares of Series&nbsp;A Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or
consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving
or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&rsquo;s
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Redemption</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Series&nbsp;A Preferred Stock does not have redemption
rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>7. Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, the Board of Directors authorized up to 65,000,000
shares of common stock at a $0.0001 par value. As of June 30, 2024, 466,387 shares of common stock were issued and outstanding and 321,943
shares of RSAs were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company&rsquo;s common stock
and RSAs are subject to and qualified by the rights, powers and preferences of the holders of Series&nbsp;A Preferred Stock set forth
above. Each share of common stock entitles the holder to one vote, together with the holders of Series&nbsp;A Preferred Stock, on all
matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by
the Company&rsquo;s Board of Directors, subject to the preferential dividend rights of Series&nbsp;A Preferred Stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, there are 1,666,666 shares of common stock reserved
for issuance for the potential conversion of shares of Series&nbsp;A preferred stock into common stock, and 171,969 shares of common stock
reserved for issuance for the exercise of outstanding stock options for common stock under the Company&rsquo;s 2024 Equity Incentive Plan
(the &ldquo;2024 Plan&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>8. Stock-Based
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2024 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The 2024 Plan was adopted by the Company&rsquo;s Board of Directors
on February&nbsp;6, 2024. The 2024 Plan provides for the Company to grant stock options, restricted stock awards, restricted stock units,
and other stock-based awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board
of Directors, or at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and
other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted
under the 2024 Plan generally vest over four&nbsp;years, subject to the participant&rsquo;s continued service, and expire after ten&nbsp;years,
although stock options have been granted with vesting terms less than four&nbsp;years. Upon adoption, the 2024 Plan authorized 31,076
shares of common stock reserved for issuance under the plan. On March&nbsp;5, 2024, the 2024 Plan was amended to increase the number of
shares of common stock reserved for issuance by 41,666 shares. On May 7, 2024, the 2024 Plan was further amended to increase the number
of shares of common stock reserved for issuance by 99,227 shares. As of June 30, 2024, the total number of shares of common stock reserved
for issuance under the 2024 Plan was 171,969, with no shares reserved of common stock available for future grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Option Valuation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The fair value of each stock option grant is
estimated on the grant date using the Black-Scholes option-pricing model. The Company is a private company and lacks company-specific
historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility
of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding
the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&rsquo;s
stock options has been determined utilizing the &ldquo;simplified&rdquo; method for awards that qualify as &ldquo;plain-vanilla&rdquo;
stock options. The risk-free interest rate is determined by reference to the U.S.&nbsp;Treasury yield curve in effect at the time of
grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the
fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the weighted-average assumptions or
range of assumptions used in calculating the fair value of the awards for the three months ended June 30, 2024 and for the period February&nbsp;6,
2024 (inception) to June 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three&nbsp;Months<BR>
Ended <BR>
June 30,<BR>
 2024</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Period from<BR>
 February&nbsp;6, 2024<BR>
 (Inception) to <BR>
June 30,<BR>
 2024</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Expected volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.6</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">101.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term (in&nbsp;years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2 - 4.5</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the stock option
activity for the period of February&nbsp;6, 2024 (inception) through June 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Stock Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR> Average<BR> Exercise<BR> Price Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term (in Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<BR> Intrinsic<BR> Value (in Thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance as of February&nbsp;6, 2024 (inception)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right">&mdash;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">&mdash;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right">&mdash;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">&mdash;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-indent: -10pt; padding-left: 0.25in">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">171,969</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">42.66</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Balance as of June 30, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">171,969</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">42.66</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.8</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">3,195</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Vested and expected to vest, June 30, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">171,969</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">42.66</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.8</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">3,195</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Exercisable, June 30, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The weighted average grant-date fair value per
share of stock options granted during the period from February&nbsp;6, 2024 (inception) to June 30, 2024 was $34.71 per share. The aggregate
intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of
the Company&rsquo;s common stock for those stock options that had an exercise price lower than the fair value of the Company&rsquo;s common
stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Stock Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2024 and March&nbsp;2024, the Company
issued 321,943 shares of Restricted Stock Awards (RSAs) to certain employees, directors, and consultants at a price of $0.0001 per share,
the par value of the common stock. Such RSAs have service-based vesting conditions only and vest over a four-year period, during which
time all unvested shares are subject to forfeiture in the event the holder&rsquo;s service with the Company voluntarily or involuntarily
terminates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the RSAs activity
for the period from February&nbsp;6, 2024 (inception) through June 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> RSAs</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR> Average<BR> Grant Date<BR> Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Unvested balance as of February&nbsp;6, 2024 (inception)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Granted</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">321,943</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Unvested balance as of June 30, 2024</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">321,943</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Paruka Warrant Obligation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, the Company entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paruka will be entitled to grants of warrants
to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&rsquo;s stock, on a fully diluted basis, on December&nbsp;31,
2024 and December&nbsp;31, 2025, at the fair market value determined by the Board of Directors of the Company (the &ldquo;Paruka Warrant
Obligation&rdquo;). The grant dates for the issuance of warrants are expected to be December&nbsp;31, 2024 and December&nbsp;31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period
for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
As of June 30, 2024, the pro-rated estimated fair value of warrants to be granted on December&nbsp;31, 2024 was $1.1 million. For the
three months ended June 30, 2024 and the period February&nbsp;6, 2024 (inception) to June 30, 2024, $0.3 million and $0.4 million, was
recognized as stock-based compensation expense related to the Paruka Warrant Obligation, respectively. The warrants expected to be granted
to Paruka are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting
period, with changes in fair value recorded in the statement of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the classification
of the Company&rsquo;s stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss
(in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#8239;Months Ended<BR> June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<BR> February&nbsp;6,<BR>
2024<BR> (Inception) to<BR> June 30,<BR>
 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">468</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;538</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">215</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">683</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">768</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, total unrecognized compensation
cost related to the unvested stock options was $5.6 million, which is expected to be recognized over a weighted average period of approximately
3.7 years. As of June 30, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1 million, which is
expected to be recognized over a weighted average period of 3.7 years. As of June 30, 2024, the unrecognized compensation cost related
to the Paruka Warrant Obligation was $0.7 million, which is expected to be recognized over a weighted average period of 0.5&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the award types
of the Company&rsquo;s stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss
(in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&nbsp;Months Ended <BR> June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<BR> February&nbsp;6, 2024<BR> (Inception) to<BR> June 30,<BR>
 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Paruka warrant obligation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;430</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Stock options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">321</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">338</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">683</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">768</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>9. Income
Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No provision for income taxes was recorded for
the three months ended June 30, 2024 and the period of February&nbsp;6, 2024 (inception) through June 30, 2024. Deferred tax assets generated
from the Company&rsquo;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the
benefit will be realized due to the Company&rsquo;s cumulative losses generated to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>10. Paragon
Option Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, the Company entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements includes two selected
targets, IL-23 (ORKA-001) and IL-17 A/F (ORKA-002). Under the Option Agreements, the Company has the exclusive options to, on a research
program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon&rsquo;s right, title and interest in
and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies
and products directed to the selected targets (each, an &ldquo;Option&rdquo;), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. If the Company exercises its options, it will be required to make non-refundable milestone payments to
Paragon of up to $12.0&nbsp;million under each respective agreement upon the achievement of certain clinical development milestones,
up to $10.0&nbsp;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty
payments in the low-to-mid single-digits beginning on the first commercial sale. From time to time, the Company can choose to add additional
targets to the collaboration by mutual agreement with Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the Option Agreements,
the parties initiated certain research programs that generally focus on a particular target (each, a &ldquo;Research Program&rdquo;).
Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target.
For each Research Program, the parties will establish a research plan that sets forth the activities that will be conducted, and the
associated research budget (each, a &ldquo;Research Plan&rdquo;). The Company and Paragon will agree on initial Research Plans that outline
the services that will be performed commencing at the inception of the arrangement related to ORKA-001 and ORKA-002. The Company&rsquo;s
exclusive Option with respect to each Research Program is exercisable at its sole discretion at any time during the period beginning
on the initiation of activities under the associated Research Program and ending a specified number of&nbsp;days following (i) with respect
to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan
activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the
&ldquo;Option Period&rdquo;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless terminated earlier, the Option Agreements
shall continue in force on a Research Program-by-Research Program basis until the earlier of: (i)&nbsp;the end of the Option Period for
such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&nbsp;the expiration of the 30-day period after
Oruka exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and
the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the &ldquo;Term&rdquo;).
Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically
expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon
30&nbsp;days&rsquo; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such
termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated
Research Program. Each party has the right to terminate the Option Agreements or any Research Program upon (i)&nbsp;30&nbsp;days&rsquo;
prior written notice of the other party&rsquo;s material breach that remains uncured for the 30-day period and (ii)&nbsp;the other party&rsquo;s
bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&nbsp;million related to the ORKA-001 program. This
amount was recognized as a research and development expense during the period from February&nbsp;6 (inception) to March 31, 2024 and
paid to Paragon in April&nbsp;2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection
process of its development candidate for IL-23 antibody for ORKA-001 program. The Company is responsible for 50% of the development costs
incurred through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody
in June 2024. Oruka&rsquo;s share of development costs incurred through March 31, 2024 is $5.9 million, which was recorded as a research
and development expense during the quarter ended June 30, 2024. Oruka is also responsible for the development costs incurred from April
1, 2024 to June 30, 2024 of $6.5 million, which was recognized as a research and development expense in the three months ended June 30,
2024. An amount of $12.4 million is included in related party accounts payable and other current liabilities as of June 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company was also required to reimburse Paragon $3.3&nbsp;million for development costs related to ORKA-002 incurred by Paragon through
December&nbsp;31, 2023 and certain other development costs incurred by Paragon between January&nbsp;1, 2024 and March&nbsp;6, 2024 as
stipulated by the Option Agreements. This  amount was recognized as a research and development expense during the period from February&nbsp;6
(inception) to March 31, 2024. The Company paid $3.3&nbsp;million to Paragon in April&nbsp;2024. The Company is also responsible for
the development costs incurred by Paragon from January&nbsp;1, 2024 to March 31, 2024 of $0.9 million. This was recognized as a research
and development expense in the period from February&nbsp;6 (inception) to March 31, 2024. The development costs from April 1, 2024 to
June 30, 2024 of $1.9&nbsp;million, was recognized as a research and development expense in the three months ended June 30, 2024. The
Company recognized an amount of $0.8&nbsp;million payable to Paragon for the research initiation fee related to ORKA-002 following the
finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the three months ended June 30,
2024. The Company will be responsible for ORKA-002 development costs incurred after June 30, 2024, through the completion of the IL-17
selection process. An amount of $2.7 million is included in related party accounts payable and other current liabilities as of June 30,
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, the Paragon Agreement provides for
an annual equity grant of warrants to Paruka to purchase 1.00% of the then outstanding shares of the Company&rsquo;s common stock, on
a fully diluted basis, on December&nbsp;31, 2024 and December&nbsp;31, 2025, during the term of the Paragon Agreement, at the fair market
value determined by the Board of Directors of the Company. The warrants are liability-classified and after the initial recognition, the
liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement
of operations and comprehensive loss (see Note&nbsp;8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company expenses the service fees as the
associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development
expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company concluded that the rights obtained
under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in-process research and development
assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the
fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable
assets. The research initiation fee represents a one-time cost on a research program-by research program basis for accessing research
services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part
of research and development costs immediately. Amounts paid as reimbursements of on-going development cost, monthly development cost
fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of
the Option Agreement that is associated with services being rendered under the related Research Programs is recognized as research and
development expense when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the three months ended June 30, 2024 and
the period from February&nbsp;6, 2024 (inception) to June 30, 2024 the Company recognized $15.4 million and $20.4 million of expenses,
respectively in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research
and development expense fees following the finalization of a Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>11. Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2024, the Company entered into an operating
lease agreement for the Company&rsquo;s headquarters in Menlo Park, California, which commenced on June 15, 2024 with an initial term
of 39.5 months. The Company leases office space under this noncancelable operating lease agreement. Lease liabilities are based on the
net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments,
the Company used its incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily
determinable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, the Company had $1.0 million
of operating lease right-of-use assets, operating lease liability, current of $0.1 million, and operating lease liability, noncurrent
of $0.9 million on its condensed consolidated balance sheets. As of June 30, 2024, the operating lease arrangement had a remaining lease
term of 39.0 months and a discount rate of 17.95%. For the three months ended June 30, 2024 and the period February 6, 2024 (inception)
to June 30, 2024, the Company recorded operating and variable lease expense of less than $0.1 million in general and administrative expenses
in its condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table presents the Company&rsquo;s
supplemental cash flow information related to leases (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: 0pt; padding-left: 0.125in">Operating cash flow from operating leases</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2024, the total remaining operating
lease payments included in the measurement of lease liabilities was as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: -10pt; padding-left: 10pt">2024 (remaining)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">105</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">494</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">2027</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">380</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Total payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,348</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(362</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">986</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>12. Commitments
and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>401(k)&nbsp;Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company maintains a defined-contribution
plan under Section&nbsp;401(k)&nbsp;of the Internal Revenue Code of 1986 (the &ldquo;401(k)&nbsp;Plan&rdquo;). The 401(k)&nbsp;Plan covers
all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation
on a pre-tax basis. Matching contributions to the 401(k)&nbsp;Plan may be made at the discretion of management. For the three months
ended June 30, 2024 and the period from February&nbsp;6, 2024 (inception) to June 30, 2024, the Company has not recorded any expense
related to 401(k)&nbsp;match contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Indemnification Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the ordinary course of business, the Company
may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain
matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims
made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive
officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of
their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required
to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs
as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect
on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in
its condensed consolidated financial statements as of June 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Legal Proceedings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, the Company may become involved
in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability
for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant
judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings
are expensed as incurred. As of June 30, 2024, the Company was not a party to any material legal proceedings or claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>13. Net Loss
per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Basic and diluted net loss per share attributable
to common stockholders was calculated as follows (in thousands, except share and per share amounts):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&nbsp;Months<BR>
 Ended<BR> June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<BR> February&nbsp;6, 2024<BR> (Inception) to<BR> June 30,<BR>
 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Net loss</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(22,243</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(29,320</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Weighted-average common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">466,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">466,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to common stockholders, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(47.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(62.87</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the computation of basic net loss per share
attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted
common stock as such shares are not considered outstanding for accounting purposes until vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s potential dilutive securities
have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore,
the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to
common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable
to common stockholders for the period presented because including them would have had an anti-dilutive effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&nbsp;Months<BR> Ended <BR> June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<BR> February&nbsp;6, 2024<BR> (Inception) to<BR> June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Convertible preferred stock (as converted to common stock)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,666,666</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,666,666</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Unvested restricted stock awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321,943</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Stock options to purchase common stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">171,969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">171,969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,160,578</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,160,578</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>14. Related
Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Paragon and Paruka each currently beneficially
own more than 5% of the Company&rsquo;s capital stock through its common stock holdings. For the three months ended June 30, 2024 and
the period from February&nbsp;6, 2024 (inception) to June 30, 2024, the Company recognized $15.4 and $20.4 million, respectively, of
expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and
development expense fees following the finalization of a Research Plan on its condensed consolidated statement of operations and comprehensive
loss. As of June 30, 2024, the Company had $15.4 million in amounts due to related parties pertaining to services provided by Paragon
and Paruka under the Option Agreements including legal fees related to patent, and reimbursements of recruiting and start-up fees on
its condensed consolidated balance sheet. In addition, under the terms of the Option Agreements, Paruka will be entitled to grants of
warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&rsquo;s common stock, on a fully diluted
basis, as of the date of the grants (see Note&nbsp;8). If the Company exercises its options, it will be required to make non-refundable
milestone payments to Paragon of up to $12.0&nbsp;million under each respective agreement upon the achievement of certain clinical development
milestones, up to $10.0&nbsp;million under each respective agreement upon the achievement of certain regulatory milestones, as well as
tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Fairmount Funds Management LLC (&ldquo;Fairmount
Funds Management&rdquo;) beneficially owns more than 5% of the Company&rsquo;s capital, currently has one representative appointed to
the Company&rsquo;s Board of Directors, and beneficially owns more than 5% of Paragon. In March&nbsp;2024, the Company issued and sold
an aggregate of 20,000,000 shares of Series&nbsp;A Preferred Stock to Fairmount, an affiliated fund of Fairmount Funds Management, at
a purchase price of $0.15 per share, for gross proceeds of $3.0&nbsp;million (see Note&nbsp;5). In March&nbsp;2024, Fairmount entered
into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $25.0&nbsp;million (see
Note&nbsp;5). As of June 30, 2024, the Company had $1.0 million in accrued interest payable, related party related to the Company&rsquo;s
outstanding borrowings of $25.0&nbsp;million under the Purchase Agreement with Fairmount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a summary of related party accounts
payable and other current liabilities (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Paragon reimbursable Option Agreement fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">15,318</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Paragon reimbursable recruiting and start-up fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">119</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,437</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a summary of related party noncurrent
liabilities (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accrued interest payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">961</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Note payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,982</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,943</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>15. Subsequent
Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has evaluated events and transactions occurring subsequent to June 30, 2024 through September 5, 2024, the date at which the
condensed consolidated financial statements were issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employee Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July 3, 2024, the Private Placement agreement
was amended and restated, among other things, for warrants to be issued to certain Oruka&rsquo;s employees, directors and service providers
(the &ldquo;employee warrants&rdquo;), immediately prior to the closing of the Merger. Pursuant to this amendment, in July and August
2024, the Company agreed to issue 445,438 employee warrants at an exercise price of $53.28 per warrant.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reverse Recapitalization and Pre-Closing&nbsp;Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 29, 2024 (the &ldquo;Effective Time&rdquo;), Oruka completed
its merger with ARCA in accordance with terms of the Merger Agreement, pursuant to which, among other matters, Oruka merged with and into
Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. Second Merger Sub changed its corporate name
to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA changed its name to &ldquo;Oruka Therapeutics, Inc.&rdquo; ARCA following
the Merger is referred to herein as the &ldquo;combined company.&rdquo; The combined company is led by Oruka&rsquo;s management team and
remains focused on developing biologics to optimize the treatment of inflammatory skin diseases. Immediately prior to the completion of
the Merger on August 29, 2024, and in order to provide Oruka with additional capital for its development programs, Oruka issued and sold,
and certain new and current investors purchased, 3,322,793 shares of common stock of Oruka and 805,350 Oruka&nbsp;pre-funded&nbsp;warrants,
exercisable for 805,350 shares of Oruka common stock, at an estimated purchase price of $66.62 ($5.55 prior to the impact of the reverse
stock split) per share or an estimated purchase price of $66.61 ($5.54 prior to the impact of the reverse stock split) per warrant, for
the aggregate amount of $275.0&nbsp;million which includes $25.0&nbsp;million of proceeds previously received from the issuance of the
Convertible Note and accrued interest on such note and will precede the closing of the Merger. These pre-funded warrants were recorded
as a component of stockholders&rsquo; deficit within additional paid-in capital and have no expiration date. As part of the pre-closing
financing, immediately prior to the completion of the Merger, the Convertible Note with the related party was converted into 397,002 shares
of common stock based on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the
conversion price of $66.62 ($5.55 prior to the impact of the reverse stock split) per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &ldquo;Exchange Ratio&rdquo;),
 immediately prior to the Effective Time, (i) each share of Oruka common stock outstanding, including outstanding and unvested Oruka
restricted stock and shares of Oruka common stock issued in connection with the Subscription Agreement,  were converted into the right
to receive shares of ARCA common stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii)
each share of Oruka Series A convertible preferred stock was converted into the right to receive ARCA Series B convertible preferred
stock, (iii) each option or warrant to purchase Oruka common stock was converted into the right to receive an option or warrant to purchase
ARCA common stock, which were subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre-funded
warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement was converted into the right to
receive a pre-funded warrant to purchase shares of ARCA common stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Exchange Ratio is calculated as 6.8569
shares of ARCA common stock for each fully-diluted share of Oruka common stock. Under the Exchange Ratio formula, the former Oruka
stockholders immediately before the effective time, including those purchasing shares and pre-funded warrants in the Oruka
pre-closing financing, own approximately 97.6% of the outstanding common stock of the combined company on a fully-diluted basis, and
the stockholders of ARCA immediately before the effective time are estimated to own approximately 2.4% of the outstanding common
stock of the combined company on a fully-diluted basis. Oruka stockholders received on, a post reverse stock split basis,
approximately 25,533,880 shares in connection with the Merger, including (i) 939,350 shares of ARCA common stock, stock options and
warrants subject to vesting terms, based on the number of shares of Oruka common stock outstanding immediately prior to the Merger,
including Oruka Restricted Stock, (ii) 805,350 shares of, and pre-funded warrants related to, Oruka common stock issued to investors
participating in the Subscription Agreement, and (iii) 20,000,000 shares of Oruka Series A convertible preferred stock outstanding
as of June 30, 2024, which were exchanged into 20,000,000 shares of Oruka Series B convertible preferred stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with the Merger discussed above,
the Company effected a one-for-twelve reverse stock split of the Company&rsquo;s issued and outstanding shares of common stock on September
3, 2024 without any change in the par value per share. All information related to the Company&rsquo;s common stock, common stock warrants,
restricted stock awards, and stock options, as well as the per share amounts, have been retroactively adjusted to give effect for the
one-for-twelve reverse stock split for all periods presented. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>






















<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>21
<FILENAME>ea021319301ex99-4_oruka.htm
<DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit <FONT STYLE="text-transform: uppercase">99.4</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ORUKA&rsquo;S
MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>On August 29, 2024, First Merger Sub merged
with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &ldquo;<B>First
Merger</B>&rdquo;), and Oruka merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the merger
(the &ldquo;<B>Second Merger</B>&rdquo; and, together with the First Merger, the &ldquo;<B>Merger</B>&rdquo;), whereby the bylaws of the
Company, dated August 29, 2024, were amended and restated in the form attached hereto as Exhibit 3.3. In connection with the completion
of the Merger, Second Merger Sub changed its corporate name to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA changed
its name to &ldquo;Oruka Therapeutics, Inc.&rdquo;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>You should read the following discussion and
analysis of Oruka&rsquo;s financial condition and results of operations together with the section titled &ldquo;Oruka&rsquo;s financial
statements and the related notes&rdquo; included as Exhibit 99.3 and Exhibit 99.2 of the Company&rsquo;s Current Report on Form&nbsp;8-K&nbsp;filed
with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on September 5, 2024 (the &ldquo;Current Report on Form&nbsp;8-K&rdquo;)&nbsp;of
which this Exhibit 99.4 is a part. This discussion contains forward-looking statements that involve risks and uncertainties, such as statements
regarding Oruka&rsquo;s plans, objectives, expectations, intentions and projections. Oruka&rsquo;s actual results could differ materially
from those described in or implied by these forward-looking statements.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Oruka is a biotechnology company focused on developing
novel monoclonal antibody therapeutics for psoriasis (&ldquo;PsO&rdquo;) and other inflammatory and immunology (&ldquo;I&amp;I&rdquo;)
indications. Oruka&rsquo;s name is derived from <I>or</I>, for &ldquo;skin,&rdquo; and <I>arukah</I>, for &ldquo;restoration&rdquo;&mdash;&nbsp;reflects
Oruka&rsquo;s mission to deliver therapies for chronic skin diseases that provide patients the greatest possible freedom from their condition.
Oruka&rsquo;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will
enable it to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly intending to
reduce technical and biological risk. Oruka&rsquo;s programs aim to treat and potentially modify disease by targeting mechanisms with
proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells. Oruka&rsquo;s
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (&ldquo;IL-23p19&rdquo;) for the treatment of PsO. Oruka&rsquo;s
co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (&ldquo;IL-17A/F&rdquo;) for the treatment of PsO,
psoriatic arthritis (&ldquo;PsA&rdquo;), and other conditions. These programs each bind their respective targets at high affinity and
incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused
strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&nbsp;I&amp;I markets with
continued unmet need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka Therapeutics, Inc. was established and incorporated
under the laws of the state of Delaware on February&nbsp;6, 2024. Oruka Therapeutics, Inc. was founded by Paragon and has since assembled
a management team with significant experience in clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">ORKA-001 is a high affinity, extended half-life
monoclonal antibody (&ldquo;mAb&rdquo;) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in
the proliferation and development of Th17 cells, which are the primary drivers of several autoimmune and inflammatory disorders, including
PsO.&nbsp;IL-23 is composed of two subunits: a p40 subunit that is shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation
IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit
have shown improved efficacy and safety when applied by other companies. Based on preclinical evidence, Oruka believes that ORKA-001 could
achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety
profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension technology, a specific three amino acid change
in the Fc domain to modify the pH-dependent binding to the neonatal Fc receptor (&ldquo;FcRn&rdquo;). As a result, it has a pharmacokinetic
profile designed to support a subcutaneous (&ldquo;SQ&rdquo;) injection as infrequently as once or twice a year. In addition, emerging
evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the
development of PsA.&nbsp;Oruka believes that the expected characteristics of ORKA-001 increase its potential to deliver these disease-modifying
benefits. Oruka plans to initiate a Phase&nbsp;1 trial of ORKA-001 in the first half of 2025 that will have the potential to not only
generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">ORKA-002 is a high affinity, extended half-life
mAb designed to target IL-17A/F.&nbsp;IL-17 inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA,
and has also shown efficacy in other&nbsp;I&amp;I indications, such as HS and axSpA.&nbsp;More recently, the importance of inhibiting
the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab)
has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes,
or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient
dosing intervals. Oruka plans to initiate Phase&nbsp;1 trials of ORKA-002 in the second half of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka views ORKA-002 and ORKA-001 as highly complementary.
Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high
efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an
IL-17 inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors are often
used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL-23 inhibitor. Together,
ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well
as the opportunity to address additional&nbsp;I&amp;I indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka has a third mAb program, ORKA-003, designed
to target an undisclosed pathway. Oruka&rsquo;s strategy as a company is to remain highly focused on&nbsp;I&amp;I diseases, and specifically
on inflammatory dermatology conditions. Oruka&rsquo;s third program provides the potential for indication expansion beyond PsO and creates
combination opportunities with Oruka&rsquo;s more advanced programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since Oruka&rsquo;s inception in February&nbsp;2024,
it has devoted substantially all of its resources to raising capital, organizing and staffing the company, business and scientific planning,
conducting discovery and research activities, establishing arrangements with third parties for the manufacture of Oruka&rsquo;s programs
and component materials, and providing general and administrative support for these operations. Oruka does not have any programs approved
for sale and has not generated any revenue from product sales. To date, Oruka has funded its operations primarily with proceeds from the
issuance of its Series&nbsp;A convertible preferred stock to a related party, the issuance of the Convertible Note to a related party
and the proceeds from the Merger and Oruka&rsquo;s Pre-closing financing (as defined in &ldquo;<I>Recent developments&rdquo; </I>below).
Through June&nbsp;30, 2024, Oruka received gross proceeds of $3.0&nbsp;million from the issuance of its Series&nbsp;A convertible preferred
stock and gross proceeds of $25.0&nbsp;million from the issuance of the Convertible Note. Under the Series A Preferred Stock and Convertible
Note Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) pursuant to which the Convertible Note was sold, Oruka can sell up to an
additional $30.0&nbsp;million in convertible notes. Oruka intends to sell an additional $30.0&nbsp;million in convertible notes but there
is currently no expectation as to when that will occur.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka has incurred operating losses since its inception.
Oruka&rsquo;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development
and eventual commercialization of any programs Oruka may develop. Oruka generated net losses of $22.2 million for the three months ended
June 30, 2024 and $29.3 million for the period from February&nbsp;6, 2024 (inception) to June&nbsp;30, 2024. As of June&nbsp;30, 2024,
Oruka had an accumulated deficit of $29.3 million. Oruka expects to continue to incur significantly increased expenses for the foreseeable
future if and as it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">continues its research
                                            and development and discovery-related development of its programs, ORKA-001, ORKA-002, and
                                            ORKA-003;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">submits for and receives
                                            allowance to proceed with its investigational new drug applications, or INDs, for certain
                                            of its programs in order to commence future clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">successfully completes
                                            future preclinical studies for its pipeline;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">seeks and identifies
                                            additional research programs and product candidates and initiates discovery-related activities
                                            and preclinical studies for those programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">hires additional
                                            research and development and clinical personnel;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">experiences any delays,
                                            challenges, or other issues associated with the pre-clinical and clinical development of
                                            its programs, including with respect to its regulatory strategies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">seeks marketing approvals
                                            for any programs for which it successfully completes clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">develops, maintains
                                            and enhances a sustainable, scalable, reproducible and transferable manufacturing process
                                            for the programs it may develop;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">ultimately establishes
                                            a sales, marketing and distribution infrastructure to commercialize any programs for which
                                            it may obtain marketing approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">adds operational,
                                            financial and management information systems and personnel, including personnel to support
                                            its product development;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">seeks timely and
                                            successful completion of preclinical studies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">pursues effective
                                            investigational new drug applications or comparable foreign applications that allow commencement
                                            of its planned clinical trials or future clinical trials for any programs it may develop;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">initiates enrollment
                                            and successful completion of clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">pursues positive
                                            results from its future clinical trials that support a finding of safety and effectiveness,
                                            and an acceptable risk-benefit profile in the intended populations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">seeks marketing approvals
                                            from applicable regulatory authorities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">maintains, expands,
                                            enforces, defends and protects its intellectual property portfolio and other intellectual
                                            property protection or regulatory exclusivity for any products it may develop;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">seeks maintenance
                                            of a continued acceptable safety, tolerability and efficacy profile of any programs it may
                                            develop following approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">further acquires
                                            or in-licenses product candidates or programs, intellectual property and technologies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">establishes and maintains
                                            any future collaborations, including making royalty, milestone or other payments thereunder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">maintains a continued
                                            acceptable safety profile of its products following approval; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">incurs additional
                                            costs of operating as a public company, including audit, legal, regulatory and tax related
                                            services associated with maintaining compliance with an exchange listing and SEC requirements,
                                            director and officer insurance premium and investor relation cost.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Any changes in the outcome of any of these variables
with respect to the development of programs that Oruka may identify could mean a significant change in the costs and timing associated
with the development of such programs. For example, if the FDA or another regulatory authority were to require Oruka to conduct clinical
trials beyond those that Oruka currently anticipates will be required for the completion of clinical development of a program, or if
Oruka&rsquo;s experiences significant delays in its clinical trials due to patient enrollment or other reasons, Oruka would be required
to expend significant additional financial resources and time on the completion of clinical development. Oruka may never obtain regulatory
approval for any of its programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka will not generate revenue from product sales
unless and until it successfully initiates and completes clinical development and obtains regulatory approval for any product candidates.
If Oruka obtains regulatory approval for any of its programs and do not enter into a commercialization partnership, Oruka expects to
incur significant expenses related to developing Oruka&rsquo;s commercialization capability to support product sales, manufacturing,
marketing, and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As a result, Oruka will need substantial additional
funding to support its continued operations and growth strategy. Until such a time as Oruka can generate significant revenue from product
sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including
collaborations with other companies or other strategic transactions. Oruka may be unable to raise additional funds or enter into such
other agreements on favorable terms, or at all. If Oruka fails to raise capital or enter into such agreements as, and when, needed, Oruka
may have to significantly delay, scale back or discontinue the development and commercialization of one or more of Oruka&rsquo;s programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Because of the numerous risks associated with product
development, Oruka is unable to accurately predict the timing or amount of increased expenses or when or if Oruka will be able to achieve
or maintain profitability. Even if Oruka is able to generate product sales, it may not become profitable. If Oruka fails to become profitable
or are unable to sustain profitability on a continuing basis, then Oruka may be unable to continue Oruka&rsquo;s operations at planned
levels and be forced to reduce or terminate its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Oruka believes that its existing cash of $15.1
million as of June 30, 2024, together with the proceeds from the Merger and Oruka&rsquo;s&nbsp;Pre-closing&nbsp;financing (as defined
in &ldquo;<I>&mdash;&nbsp;Recent Developments</I>&rdquo; below), will be sufficient to fund its operating expenses and capital expenditure
requirements for at least 12 months from the date Oruka&rsquo;s condensed consolidated financial statements for the period ended June
30, 2024 were issued. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital
resources sooner than Oruka expects. See &ldquo;<I>&mdash;&nbsp;Liquidity and Capital Resources</I>&rdquo; and &ldquo;<I>Risk Factors&nbsp;&mdash;&nbsp;Risks
Related to Oruka&rsquo;s Financial Condition and Capital Requirements</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B><I>The Merger, Pre-Closing Financing, and Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 3, 2024, Oruka entered into a Merger
Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the
Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the Merger. On August 29, 2024, Oruka completed its merger with ARCA in accordance with terms of the Merger Agreement,
pursuant to which, among other matters, Oruka merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity
of the Second Merger. Second Merger Sub changed its corporate name to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA
changed its name to &ldquo;Oruka Therapeutics, Inc.&rdquo; ARCA following the Merger is referred to herein as the &ldquo;combined company.&rdquo;
The combined company is led by Oruka&rsquo;s management team and remains focused on developing biologics to optimize the treatment of
inflammatory skin diseases. Immediately prior to the completion of the Merger, and in order to provide Oruka with additional capital for
its development programs, Oruka issued and sold, and certain new and current investors purchased, 3,322,793 shares of common stock of
Oruka and 805,350 Oruka&nbsp;pre-funded&nbsp;warrants, exercisable for 805,250 shares of Oruka common stock, at an estimated purchase
price of $66.62 ($5.55 prior to the impact of the reverse stock split) per share or an estimated purchase price of $66.61 ($5.54 prior
to the impact of the reverse stock split) per warrant, for the aggregate amount of $275.0&nbsp;million, which includes $25.0&nbsp;million
of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note and the related conversion
into 397,002 shares of Oruka common stock (the &ldquo;Oruka&rsquo;s&nbsp;Pre-closing&nbsp;financing&rdquo;), and will precede the closing
of the Merger.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with an exchange ratio
determined in accordance with the terms of the Merger Agreement (the &ldquo;Exchange Ratio&rdquo;) (together with the Oruka
pre-closing financing as defined below, the &ldquo;Transactions&rdquo;), immediately prior to the Effective Time, (i) each share of
Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued in
connection with the Subscription Agreement (both defined in Note 1 to its financial statement included as Exhibit 99.2 and condensed
consolidated financial statements included as Exhibit 99.3 of the Company&rsquo;s Current Report on Form 8-K of which this Exhibit
99.4 is a part), were converted into the right to receive shares of the ARCA&nbsp; common stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Oruka Series A convertible preferred stock was
converted into the right to receive ARCA Series B convertible preferred stock, (iii) each option or warrant to purchase Oruka common
stock was converted into the right to receive an option or warrant to purchase ARCA common stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, and (iv) each pre-funded warrant to purchase shares of Oruka common
stock issued in connection with the Subscription Agreement was converted into the right to receive a pre-funded warrant to purchase
shares of the Company common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">On August 29, 2024, the Company&rsquo;s Board of Directors approved
an amended and restated certificate of incorporation of the Company effecting a one-for-twelve reverse stock split of the Company&rsquo;s
issued and outstanding shares of common stock. This was approved by the stockholders on August 29, 2024 and the split was effected on
September 3, 2024 without any change in the par value per share. The Company commenced trading on a post Reverse Stock Split, post-Merger
basis at the open of trading on September 3, 2024. All information related to the Company&rsquo;s common stock, common stock warrants,
restricted stock awards, and stock options, as well as the per share amounts, have been retroactively adjusted to give effect for the
one-for-twelve reverse stock split for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Impact of Risk Factors on Oruka&rsquo;s Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Uncertainty in the global economy presents significant
risks to Oruka&rsquo;s business. Oruka is subject to continuing risks and uncertainties in connection with the current macroeconomic environment,
including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, including the ongoing conflicts between
Russia and Ukraine and Israel and Gaza and the responses thereto, and supply chain disruptions. While Oruka is closely monitoring the
impact of the current macroeconomic conditions on all aspects of Oruka&rsquo;s business, including the impacts on its participants in
future clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the impact on its business remains
highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are
outside Oruka&rsquo;s control and could exist for an extended period of time. Oruka will continue to evaluate the nature and extent of
the potential impacts to Oruka&rsquo;s business, results of operations, liquidity and capital resources.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Components of Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">To date, Oruka has not generated revenue from any
sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If Oruka&rsquo;s
development efforts for its product candidates are successful and result in regulatory approval, Oruka may generate revenue in the future
from product sales or payments from future collaboration or license agreements that Oruka may enter into with third parties, or any combination
thereof. Oruka cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product
candidates. Oruka may never succeed in obtaining regulatory approval for any of its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Research and Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Research and development expenses consist primarily
of costs incurred in connection with the development and research of Oruka&rsquo;s programs. These expenses include costs of funding
research performed by third parties, including Paragon, that conduct research and development activities on Oruka&rsquo;s behalf, expenses
incurred in connection with continuing Oruka&rsquo;s current research programs and discovery-phase development of any programs Oruka
may identify, including under future agreements with third parties, such as consultants and contractors, personnel related expenses,
including salaries, bonuses, benefits, equity-based compensation expense, and allocated human resource costs, information technology
costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for Oruka&rsquo;s leased office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka expenses research and development costs as
incurred. For the three months ended June 30, 2024 and period from February&nbsp;6, 2024 (inception) to June&nbsp;30, 2024 Oruka recognized
$15.4 million and $20.4&nbsp;million of expenses, respectively, in connection with services provided by Paragon and Paruka under the
Option Agreements, including nonrefundable research and development expense fees associated with each Research Plan on its condensed
consolidated statement of operations and comprehensive loss. See &ldquo;&mdash;<I>&nbsp;Contractual Obligations and Commitments</I>&rdquo;
below for further details on Oruka&rsquo;s research plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka&rsquo;s primary focus since inception has
been the identification and development of its pipeline programs. Oruka&rsquo;s research and development expenses primarily consist of
external costs, such as fees paid to Paragon under the Paragon Option Agreements. Oruka separately tracks the amount of costs incurred
under the Paragon Option Agreements with Paragon between ORKA-001 and ORKA-002. See &ldquo;&mdash;&nbsp;<I>Contractual Obligations and
Commitments</I>&rdquo; below for further details on the Paragon Option Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>General and Administrative</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">General and administrative expenses consist primarily
of personnel related expenses, including salaries, bonuses, benefits, and equity-based compensation, for individuals in Oruka&rsquo;s
executive, finance, operations, human resources, business development and other administrative functions. Other significant general and
administrative expenses include legal fees relating to corporate matters, professional fees for accounting, auditing, tax, information
technology, insurance, recruiting costs, and allocated human resource costs, information technology costs, and facility-related costs,
including rent, utilities, maintenance, and depreciation for Oruka&rsquo;s leased office space. In April&nbsp;2024, Oruka entered into
a lease agreement with Oak Grove LP (&ldquo;Oak Grove Lease&rdquo;) for office space located in Menlo Park, California. The Oak Grove
Lease began on June&nbsp;15, 2024 with an initial term of 39.5&nbsp;months. Oruka&rsquo;s lease payment is expected to be $1.4&nbsp;million
over the initial lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka expects that its general and administrative
expenses will increase substantially for the foreseeable future as Oruka increases its headcount to support the expected growth. Oruka
also expects to incur increased expenses associated with a reverse merger public transaction and becoming a public company, including
increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements,
additional director and officer insurance costs, and investor and public relations costs. Oruka also expects to incur additional intellectual
property-related expenses as Oruka files patent applications to protect innovations arising from its research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Interest expense of $0.8 million and $1.0&nbsp;million
incurred for the three months ended June 30, 2024 and period from February&nbsp;6, 2024 (inception) to June&nbsp;30, 2024, respectively,
relates to the Convertible Note issued to Fairmount Healthcare Fund&nbsp;II, L.P. (&ldquo;Fairmount Fund II&rdquo;) in March&nbsp;2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">No provision for income taxes was recorded for
the three months ended June 30, 2024 and period of February&nbsp;6, 2024 (inception) through June&nbsp;30, 2024. Deferred tax assets
generated from Oruka&rsquo;s net operating losses have been fully reserved as Oruka believes it is not more likely than not that the
benefit will be realized due to its cumulative losses generated to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations for the Three Months Ended June 30, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s statement
of operations and comprehensive loss for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three&nbsp;Months
                                            Ended&nbsp;<BR> June&nbsp;30, <BR> 2024</P></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">18,673</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,820</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating
    expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,493</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,493</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(750</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(750</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,243</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $15,457 for the
                                            three months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $342 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $750 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s research
and development expenses incurred for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Three
    Months Ended&nbsp;<BR>
    June&nbsp;30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">External research and development costs by selected target:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">14,428</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,685</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other research and development costs:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,344</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">216</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; padding-bottom: 4pt">Total research and
    development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,673</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $12,412 for the
                                            three months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $2,683 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $362 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Research and development expenses were $18.7&nbsp;million
for the three months ended June 30, 2024 and consisted primarily of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$12.4&nbsp;million
                                            of research and development expense due to Paragon for services rendered under the Paragon
                                            Option Agreement for ORKA-001, including $5.9 million of research and development expense
                                            due to Paragon incurred through March 31, 2024 upon completion of IL-23 selection process;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$2.0 million of
                                            research and development expense due to an increase in chemistry, manufacturing, and development
                                            costs for ORKA-001, including $0.3 million of toxicology testing for ORKA-001 with a third-party
                                            contract research organization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$2.7&nbsp;million
                                            of research and development expense due to Paragon for services rendered under the Paragon
                                            Option Agreement for ORKA-002;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$1.3 million of
                                            personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related
                                            costs, including stock-based compensation expense of $0.5 million; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$0.2 million of
                                            allocated human resource costs, information technology costs, and facility-related costs,
                                            including rent, maintenance, utilities, and depreciation for Oruka&rsquo;s leased office
                                            space.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s total
general and administrative expenses for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Three
    Months Ended&nbsp;<BR>
    June 30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,374</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,185</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees related to patent<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">234</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<SUP>(3)
    </SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Total general and
    administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,820</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $26 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $223 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $93 for the three
                                            months ended June 30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">General and administrative expenses were $2.8&nbsp;million
for the three months ended June 30, 2024 and consisted primarily of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$1.4&nbsp;million
                                            of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related
                                            costs, including stock-based compensation of $0.2&nbsp;million;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$1.2&nbsp;million
                                            of professional and consulting fees associated with accounting, audit, and legal fees due
                                            to an increase in Oruka&rsquo;s business activity and as Oruka began preparation to become
                                            a public company; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$0.2&nbsp;million
                                            of legal fees due to Paragon associated with patent related activities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations for the Period of February 6, 2024 (Inception)
to June 30, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s statement
of operations and comprehensive loss for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Period&nbsp;from
    <BR> February&nbsp;6, <BR> 2024<BR>
(Inception)&nbsp;to<BR>
June&nbsp;30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,866</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,490</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Total
    operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,356</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Loss
    from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(28,356</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Other expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Total
    other expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net
    loss and comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(29,320</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $20,430 for the
                                            period February&nbsp;6, 2024 (Inception) to June&nbsp;30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $1,268 for the period
                                            February&nbsp;6, 2024 (Inception) to June&nbsp;30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $964 for the period
                                            February&nbsp;6, 2024 (Inception) to June&nbsp;30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s research
and development expenses incurred for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Period&nbsp;from <BR> February&nbsp;6, <BR> 2024<BR>
(Inception)&nbsp;<BR> to<BR>
June&nbsp;30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">External research and development costs by selected target:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">15,178</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,840</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other research and development costs:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related (including stock-based compensation)<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,608</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">240</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; padding-bottom: 4pt">Total research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,866</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $13,162 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $6,838 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $430 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Research and development expenses were $23.9&nbsp;million
for the period from February&nbsp;6, 2024 (inception) to June 30, 2024 and consisted primarily of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$13.2&nbsp;million
                                            of research and development expense due to Paragon for services rendered under the Paragon
                                            Option Agreement for ORKA-001, including $5.9 million of research and development expense
                                            due to Paragon incurred through March 31, 2024 upon completion of IL-23 selection process;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$2.0 million of
                                            research and development expense on chemistry, manufacturing, and development costs for ORKA-001,
                                            including $0.3 million in toxicology testing for ORKA-001 with a third-party contract research
                                            organization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$6.8&nbsp;million
                                            of research and development expense due to Paragon for services rendered under the Paragon
                                            Option Agreement for ORKA-002;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$1.6&nbsp;million
                                            of personnel-related costs related to recruiting costs, salaries, benefits, and other compensation-related
                                            costs, including stock-based compensation expense of $0.5 million; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$0.2 million of
                                            allocated human resource costs, information technology costs, and facility-related costs,
                                            including rent, maintenance, utilities, and depreciation for Oruka&rsquo;s leased office
                                            space.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s total
general and administrative expenses for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Period&nbsp;from <BR> February&nbsp;6, <BR> 2024<BR>
(Inception)&nbsp;<BR> to<BR>
June 30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related (including stock-based compensation)<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,155</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,629</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees related to patent<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">490</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">216</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Total general and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,490</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes related party amount of $609 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes related party amount of $479 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes related party amount of $180 for the period February&nbsp;6,
2024 (Inception) to June 30, 2024</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">General and administrative expenses were $4.5&nbsp;million
for the period from February&nbsp;6, 2024 (inception) to June 30, 2024 and consisted primarily of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$2.2&nbsp;million
                                            of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related
                                            costs, including stock-based compensation of $0.2&nbsp;million and $0.6 million of personnel-related
                                            costs are amounts due to Paragon related to recruiting costs for hiring Oruka&rsquo;s executive
                                            team, legal, and finance and accounting functions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$1.6&nbsp;million
                                            of professional and consulting fees associated with accounting, audit, and legal fees as
                                            Oruka began preparation to become a public company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$0.5&nbsp;million
                                            of legal fees due to Paragon associated with patent related activities; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$0.2&nbsp;million
                                            of other business expenses due to Paragon.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Since Oruka&rsquo;s inception, Oruka has incurred
significant operating losses. Oruka expects to incur significant expenses and operating losses for the foreseeable future as Oruka commences
the pre-clinical and clinical development of its programs and continues its early-stage research activities. Oruka has not yet commercialized
any products and Oruka does not expect to generate revenue from sales of products for several&nbsp;years, if at all. As of June 30, 2024,
Oruka had funded its operations primarily with proceeds from the sale of its Series&nbsp;A convertible preferred stock and the issuance
of the Convertible Note. In March&nbsp;2024, Oruka received $3.0&nbsp;million in gross proceeds from the issuance of Series&nbsp;A convertible
preferred stock and $25.0&nbsp;million in gross proceeds from the issuance of the Convertible Note, both of which were related party
transactions. As of June&nbsp;30, 2024, Oruka had cash of $15.1&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The following table summarizes Oruka&rsquo;s cash
flows for the period presented (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Period&nbsp;from <BR> February&nbsp;6, <BR> 2024<BR>
(Inception)&nbsp;to<BR>
June 30, <BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,201</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,322</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Net increase in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,121</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From February&nbsp;6, 2024 (inception) to June&nbsp;30,
2024, net cash used in operating activities was $11.2 million, which was primarily attributable to a net loss of $29.3 million, offset
by non-cash charges of $0.8 million and net cash provided by changes in operating activities of $17.3 million. Non-cash charges consisted
of a $0.8 million increase in stock-based compensation expense. Net cash provided by changes in our operating activities primarily consisted
of a $2.0 million increase in accounts payable, $0.6 million increase in accrued expenses and other current liabilities, $15.4 million
increase in related parties accounts payable and other current liabilities, $1.0 million increase in accrued interest, related party,
partially offset by a $1.7 million increase in prepaid expenses and other current assets. The increase in amounts due to related parties,
accounts payable, and accrued expenses and other current liabilities was primarily due to an increase in Oruka&rsquo;s business activity,
as well as vendor invoicing and payments. The increase in accrued interest, related party was primarily due to an additional quarter
of interest associated with Oruka&rsquo;s outstanding convertible note. The increase in prepaid expenses and other current assets was
primarily due to prepaid research and development expenses with Oruka&rsquo;s contract research organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">From February&nbsp;6, 2024 (inception) to June&nbsp;30,
2024, net cash provided by financing activities was $26.3 million, consisting of $2.9&nbsp;million of net proceeds from the issuance
of Oruka&rsquo;s Series&nbsp;A convertible preferred&nbsp;stock and $25.0&nbsp;million of net proceeds from the issuance of the Convertible
Note, partially offset by $1.6 million of payments in deferred offering costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><B><I>Funding Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">To date, Oruka has not generated any revenue from
product sales. Oruka has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing
and staffing, business planning, raising capital, and providing general and administrative support for these operations. Current and
future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory
approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure.
Even if Oruka&rsquo;s development efforts are successful, it is uncertain when, if ever, Oruka will realize significant revenue from
product sales. If Oruka obtains regulatory approval for any of its product candidates and start to generate revenue, Oruka expects to
incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka believes that its existing cash of $15.1&nbsp;million as of June 30, 2024,  together with the proceeds from the Merger and Oruka&rsquo;s&nbsp;Pre-closing&nbsp;financing,
will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these
financial statements. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available
capital resources sooner than Oruka expects. Oruka expects that it will require additional funding to advance its potential product candidates
through development, regulatory approval and commercialization if any of its product candidates are approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Until such time, if ever, as Oruka can generate
substantial product revenue, Oruka expects to finance its cash needs through a combination of equity offerings and debt financings. To
the extent that Oruka raises additional capital through the sale of equity or convertible debt securities, ownership interest may be
materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights
as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit Oruka&rsquo;s
ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Oruka is
unable to raise additional funds, it may be required to delay, reduce or eliminate some or all of its planned operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations and Commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Paragon Option Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">In March&nbsp;2024, Oruka entered into the Paragon
Option Agreements. Under the terms of the Paragon Option Agreements, Paragon identifies, evaluates and develops antibodies directed against
certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL-23 (&ldquo;ORKA-001&rdquo;)
and IL-17A/F (&ldquo;ORKA-002&rdquo;). Under each of the Paragon Option Agreements, Oruka has the exclusive option to, on a research
program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon&rsquo;s right, title and interest in
and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies
and potential products directed to the selected targets. If Oruka exercises its options, Oruka will be required to make non-refundable
milestone payments to Paragon of up to $12.0&nbsp;million under each respective agreement upon the achievement of certain clinical development
milestones, up to $10.0&nbsp;million under each respective agreement upon the achievement of certain regulatory milestones, as well as
tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale. From time to time, Oruka can choose to
add additional targets to the collaboration by mutual agreement with Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Pursuant to the terms of the Paragon Option Agreements,
the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing
antibodies directed to the respective target. For each Research Program, the parties established a Research Plan that sets forth the
activities that will be conducted, and the associated research budget. Oruka and Paragon will agree on initial Research Plans that outline
the services that will be performed commencing at inception of the arrangement related to IL-17 and IL-23. Oruka&rsquo;s exclusive option
with respect to each Research Program is exercisable at Oruka&rsquo;s sole discretion at any time during the period beginning on the
initiation of activities under the associated Research Program and ending a specified number of&nbsp;days following the delivery of the
data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option
pursuant to the Paragon Option Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Pursuant to the Paragon Option Agreements, on a
research program-by-research program basis following the finalization of the Research Plan for each respective research program, Oruka
was required to pay Paragon a nonrefundable fee in cash of $0.8&nbsp;million related to the research initiation fee for ORKA-001. This
amount was recognized as a research and development expense during the period from February&nbsp;6 (inception) to June 30, 2024, and
paid to Paragon in April&nbsp;2024. In June 2024, pursuant to the Option Agreements with Paragon, Oruka completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. Oruka is responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process, provided that Oruka receives rights to at least one selected IL-23 antibody. Oruka&rsquo;s
share of development costs incurred through March 31, 2024 is $5.9 million, which was recorded as a research and development expense.
Oruka is expected to pay 50% of the development costs incurred through selection which totaled $12.4 million which was recorded as research
and development in the three months ended June 30, 2024 and is expected to be paid in September 2024 to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka was also required to reimburse Paragon $3.3&nbsp;million
for development costs related to ORKA-002 incurred by Paragon through December&nbsp;31, 2023 and certain other development costs incurred
between January&nbsp;1, 2024 and March&nbsp;6, 2024. This amount was recognized as a research and development expense during the period
from February 6 (inception) to June 30, 2024. Oruka paid $3.3&nbsp;million to Paragon in April&nbsp;2024. Oruka is also responsible for
the development costs of $1.9 million and $2.8 million, respectively, which was recognized as a research and development expense in for
the three months ended June 30, 2024 and the period from February&nbsp;6 (inception) to June 30, 2024, respectively. Oruka incurred $0.8&nbsp;million
for the research initiation fee related to ORKA-002 during the three months ended June 30, 2024 following the finalization of the ORKA-002
Research Plan. Oruka will also be responsible for ORKA-002 development costs incurred after June 30, 2024, through the completion of
the IL-17 selection process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Furthermore, the Paragon Option Agreements provide
for an annual equity grant of warrants to purchase 1.00% of the then outstanding shares of Oruka common stock, on a fully diluted basis,
on each of December&nbsp;31, 2024 and December&nbsp;31, 2025, during the term of the Paragon Option Agreements, at the fair market value
determined by Oruka&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka expenses the service fees as the associated
costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in
the accompanying statement of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Note&nbsp;Payable with Related Party</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March&nbsp;2024, Oruka entered into the Purchase
Agreement with Fairmount Fund&nbsp;II, whereby Oruka issued a convertible note, with an initial principal amount of $25.0 million that
can be converted into Series&nbsp;A Preferred Stock (or a Series&nbsp;of preferred shares that is identical in respect to the shares of
preferred shares issued in its next equity financing) or shares of Oruka&rsquo;s common stock in exchange for aggregate proceeds of $25.0&nbsp;million.
The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&nbsp;31,
2025 (the &ldquo;Maturity Date&rdquo;). Prepayment is not permitted without prior written consent of Fairmount Fund II. Pursuant to the
Purchase Agreement, Oruka has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0
million, in addition to the $25.0 million of initial principal amount of the Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Immediately prior to the completion of the Merger,
the Convertible Note was converted into 497,287 shares of common stock based on the aggregate principal amount of $25.0 million, plus
any unpaid accrued interest of $1.5 million divided by the conversion price of $66.62 ($5.55 prior to the impact of the reverse stock
split) per share, in connection with the pre-Merger financing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As of June 30, 2024, the aggregate principal amount
of outstanding borrowings under the Convertible Note was $25.0&nbsp;million and Oruka has the right to issue and sell up to an additional
$30.0&nbsp;million in convertible notes under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Significant Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka&rsquo;s management&rsquo;s discussion and
analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance
with U.S. GAAP.&nbsp;The preparation of these condensed consolidated financial statements requires Oruka to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the
financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Oruka&rsquo;s estimates
are based on its historical experience and on various other factors that Oruka believes are reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While Oruka&rsquo;s significant accounting
policies are described in more detail in Note&nbsp;2 to its financial statement included as Exhibit 99.2 and condensed consolidated
financial statements included as Exhibit 99.3 of Oruka&rsquo;s Current Report on Form&nbsp;8-K&nbsp;of which this Exhibit 99.4 is a
part, Oruka believes the following accounting policies used in the preparation of its financial statements require the most
significant judgments and estimates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accrued Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As part of the process of preparing Oruka&rsquo;s
financial statements, Oruka is required to estimate its accrued research and development expenses. This process involves estimating the
level of service performed and the associated cost incurred for the services when Oruka has not yet been invoiced or otherwise notified
of actual costs. The majority of Oruka&rsquo;s service providers invoice the company in arrears for services performed, on a pre-determined
schedule or when contractual milestones are met; however, some require advance payments. Oruka makes estimates of its accrued expenses
as of each balance sheet date in the financial statements based on facts and circumstances known to Oruka at that time. At each period
end, Oruka corroborates the accuracy of these estimates with the service providers and makes adjustments, if necessary. Estimated accrued
research and development expenses include those related to fees paid to vendors in connection with discovery development activities and
any research organizations in connection with studies and testing. Although Oruka does not expect its estimates to be materially different
from amounts actually incurred, Oruka&rsquo;s understanding of the status and timing of services performed relative to the actual status
and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka measures stock-based awards granted to employees,
directors, and non-employees in the form of stock options to purchase shares of Oruka common stock, based on their fair value on the
date of the grant using the Black-Scholes model. Oruka measures restricted common stock awards using the difference, if any, between
the purchase price per share of the award and the fair value of Oruka common stock at the date of grant. Compensation expense for those
awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees.
Compensation expense for awards to non-employee with service-based vesting conditions is recognized in the same manner as if Oruka had
paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Oruka uses the straight-line
method to recognize the expense of awards with service-based vesting conditions. Oruka accounts for forfeitures as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Black-Scholes model uses inputs that are determined
by the Board on the date of grant and assumptions Oruka makes for the volatility of stock-based awards, the expected term of stock-based
awards, the risk-free interest rate for a period that approximates the expected term of Oruka&rsquo;s stock-based awards and its expected
dividend yield. Oruka has historically been a private company and lacks company-specific historical and implied volatility information
of Oruka&rsquo;s stock. Therefore, Oruka estimates its expected stock volatility based on the historical volatility of a representative
group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term
of Oruka&rsquo;s stock options has been determined utilizing the &ldquo;simplified&rdquo; method for awards that qualify as &ldquo;plain-vanilla&rdquo;
stock options. The risk-free interest rate is determined by reference to the U.S.&nbsp;Treasury yield curve for time periods approximately
equal to the remaining contractual term of the options on the date of measurement. Oruka has estimated a 0% dividend yield based on the
expected dividend yield and the fact that Oruka has never paid, and does not expect to pay, any cash dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><I>Determination of Fair Value of Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As there had been no public market for Oruka&rsquo;s
stock-based awards from February&nbsp;6, 2024 (inception) to June 30, 2024, the estimated fair value of stock-based awards has been determined
by Oruka&rsquo;s board of directors as of the date of grant, with input from management, and with consideration of additional objective
and subjective factors that it believed were relevant. In addition, Oruka&rsquo;s board of directors considered various objective and
subjective factors to determine the fair value of its share-based awards as of each grant date, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the prices at
                                            which Oruka sold shares of Series&nbsp;A convertible preferred stock and preferences of the
                                            Series&nbsp;A convertible preferred stock relative to Oruka&rsquo;s stock-based awards at
                                            the time of each grant;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the progress of
                                            Oruka&rsquo;s research and development programs, including the status of discovery-phase
                                            studies for its product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Oruka&rsquo;s
                                            stage of development and business strategy;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">external market
                                            conditions affecting the biotechnology industry and trends within the biotechnology industry;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Oruka&rsquo;s
                                            financial position, including cash on hand, and Oruka&rsquo;s historical and forecasted performance
                                            and operating results;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the lack of an
                                            active public market for Oruka common stock and its Series&nbsp;A convertible preferred stock
                                            at the grant dates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the likelihood
                                            of achieving a liquidity event, such as the proposed reverse recapitalization transaction,
                                            or sale of Oruka in light of prevailing market conditions; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the analysis of
                                            reverse recapitalization transactions and market performance of similar companies in the
                                            biotechnology industry.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka&rsquo;s common stock valuations were prepared
using a hybrid method, including an option pricing method (&ldquo;OPM&rdquo;). The OPM treats common stock and preferred stock as call
options on the total equity value&nbsp;of a company, with exercise prices based on the value thresholds at which the allocation among
the various holders of a company&rsquo;s securities changes. Under this method, the common stock has value only if the funds available
for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event,
such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&ldquo;PWERM&rdquo;), where
the equity value in one or more of the scenarios is calculated using an OPM.&nbsp;The PWERM is a scenario-based methodology that estimates
the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value
is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available
as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation
date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock.
A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The assumptions underlying these valuations represented
management&rsquo;s best estimate, which involved inherent uncertainties and the application of management&rsquo;s judgment. As a result,
if Oruka had used significantly different assumptions or estimates, the fair value of Oruka&rsquo;s incentive shares and its stock-based
compensation expense could have been materially different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Once a public trading market for Oruka common stock
has been established in connection with the completion of this Merger, it is no longer necessary for Oruka&rsquo;s board of directors
to estimate the fair value of its stock-based awards in connection with its accounting for granted stock-based awards or other such awards
Oruka may grant, as the fair value of Oruka&rsquo;s common stock and share-based awards is determined based on the quoted market price
of Oruka&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A description of recently issued accounting pronouncements
that may potentially impact Oruka&rsquo;s financial position, results of operations or cash flows is disclosed in Note&nbsp;2 to Oruka&rsquo;s
condensed consolidated financial statements as of June 30, 2024 included in Exhibit 99.3 of this Current Report on Form 8-K of which this
Exhibit 99.4 is a part.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">As of June 30, 2024, Oruka did not have any off-balance
sheet arrangements, as defined in the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Quantitative and Qualitative Disclosures about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Interest Rate Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The Convertible Note bears interest until December&nbsp;2025
at a fixed rate per annum equal 12%. An immediate 10% change in the prime rate would not have a material impact on Oruka&rsquo;s debt-related
obligations, financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inflation Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Oruka&rsquo;s results of operations and financial
condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise
nature of the estimates required, Oruka believes the effects of inflation, if any, on Oruka&rsquo;s results of operations and financial
condition have been immaterial. Oruka cannot assure you its business will not be affected in the future by inflation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>22
<FILENAME>ea021319301ex99-5_oruka.htm
<DESCRIPTION>UNAUDITED PRO FORMA FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. AND ARCA BIOPHARMA, INC. AS OF JUNE 30, 2024 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024, AS WELL AS FOR THE YEAR ENDED DECEMBER 31, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit <FONT STYLE="text-transform: uppercase">99.5</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Defined
terms included below shall have the same meaning as terms defined and included in the Company&rsquo;s definitive proxy statement/prospectus
filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on July 22, 2024.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&nbsp;3, 2024, Oruka entered into a Merger Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction
or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the Merger. On August 29, 2024, (the &ldquo;Closing Date&rdquo;
or the &ldquo;Effective Time&rdquo;), Oruka completed its merger with ARCA in accordance with terms of the Merger Agreement, pursuant
to which, among other matters, Oruka merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the
Second Merger. Second Merger Sub changed its corporate name to &ldquo;Oruka Therapeutics Operating Company, LLC&rdquo; and ARCA changed
its name to &ldquo;Oruka Therapeutics, Inc.&rdquo; ARCA following the Merger is referred to herein as the &ldquo;combined company.&rdquo;
The combined company is led by Oruka&rsquo;s management team and remains focused on developing biologics to optimize the treatment of
inflammatory skin diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &ldquo;Exchange Ratio&rdquo;)
(together with the Oruka pre-closing financing, the &ldquo;Transactions&rdquo;), immediately prior to the Effective Time, (i) each share
of Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued
in connection with the Subscription Agreement (both defined in Note&nbsp;1 of the accompanying notes), were converted into the right
to receive shares of ARCA common stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii)
each share of Oruka Series A convertible preferred stock was converted into the right to receive ARCA Series B convertible preferred
stock, (iii) each option or warrant to purchase Oruka common stock was converted into the right to receive an option or warrant to purchase
ARCA common stock, which were subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre-funded
warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement was converted into the right to
receive a pre-funded warrant to purchase shares of ARCA common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Exchange Ratio is calculated as 6.8569
shares of ARCA common stock for each fully-diluted share of Oruka common stock on the Closing Date. Under the Exchange Ratio
formula, the former Oruka stockholders immediately before the effective time, including those purchasing shares and pre-funded
warrants in the Oruka pre-closing financing, own approximately 97.6% of the outstanding common stock of the combined company on a
fully-diluted basis, and the stockholders of ARCA immediately before the effective time are estimated to own approximately 2.4% of
the outstanding common stock of the combined company on a fully-diluted basis and which give effect to, (a)&nbsp;ARCA&rsquo;s net
cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&nbsp;million, (b)&nbsp;Oruka closing on
approximately $275.0&nbsp;million, which includes $25.0&nbsp;million of proceeds previously received from the issuance of the
Convertible Note and accrued interest on such note, in the Oruka pre-closing financing described in the accompanying notes below,
(c)&nbsp;a valuation for ARCA equal to its net cash as of the business&nbsp;day immediately prior to the closing date of the Merger,
plus $6.0&nbsp;million, and (d)&nbsp;a valuation for Oruka equal to $175.0&nbsp;million, in each case as further described in the
Merger Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following unaudited pro forma condensed combined
financial information gives effect to the Merger, which is accounted for as a reverse recapitalization under United&nbsp;States Generally
Accepted Accounting Principles, or U.S.&nbsp;GAAP.&nbsp;For further details related to the accounting for the Merger, please see Notes
1 and&nbsp;3 below. Following the consummation of the Merger, the Company effected a one-for-twelve reverse stock split of the Company&rsquo;s
common stock, which became effective on September 3, 2024. All information related to the Company&rsquo;s common stock, common stock warrants,
restricted stock awards, and stock options, as well as the per share amounts, have been retroactively adjusted to give effect for the
one-for-twelve reverse stock split for all periods presented, unless stated otherwise.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined balance sheet combines the historical balance sheets of ARCA and Oruka as of June 30, 2024 and
depicts the accounting of the transactions prepared pursuant to the rules and regulations of Article&nbsp;11 of SEC Regulation&nbsp;S-X,
as amended (&ldquo;pro forma balance sheet transaction accounting adjustments&rdquo;). The unaudited pro forma condensed combined statements
of operations for the six&nbsp;months ended June 30, 2024 for ARCA, the period from February&nbsp;6, 2024 (inception) to June 30, 2024
for Oruka, and the year ended December&nbsp;31, 2023 for ARCA combine the historical results of ARCA and Oruka for those periods and
depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&nbsp;1, 2023 (&ldquo;pro
forma statements of operations transaction accounting adjustments&rdquo;). Collectively, pro forma balance sheet transaction accounting
adjustments and pro forma statements of operations transaction accounting adjustments are referred to as &ldquo;transaction accounting
adjustments&rdquo; or &ldquo;pro forma adjustments&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction
with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the historical unaudited condensed consolidated financial statements of Oruka as of June 30, 2024 and for the period from February&nbsp;6, 2024 (inception) to June 30, 2024, as well as the three months ended June 30, 2024, and the related notes included in Exhibit 99.3 of this Current Report on Form 8-K of which this Exhibit 99.5 is a part;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the historical audited financial statement of Oruka as of February
    6, 2024, and the related notes included in Exhibit 99.2 of this Current Report on Form 8-K of which this Exhibit 99.5 is a part;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
historical unaudited condensed consolidated financial statements of ARCA as of and for the six&nbsp;months ended June 30, 2024, and the
related notes included in its Quarterly Report on Form 10-Q filed with the SEC on August 1, 2024;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
historical audited consolidated financial statements of ARCA for the year ended December&nbsp;31, 2023, and the related notes included
in its Annual Report on Form 10-K filed with the SEC on February 1, 2024;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
section titled &ldquo;<I>ARCA&rsquo;s Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo;
and other financial information relating to ARCA in its Quarterly Report on Form 10-Q filed with the SEC on August 1, 2024; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the section titled &ldquo;<I>Oruka&rsquo;s Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation</I>,&rdquo; and other financial information relating to Oruka included in Exhibit 99.4 of this Current Report on Form 8-K of which this Exhibit 99.5 is a part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described
in the accompanying notes. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions,
regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies.
The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of
operations in the future periods or the result that actually would have been realized had ARCA and Oruka been a combined organization
during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected
in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited
to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED BALANCE SHEET<BR>
AS OF JUNE 30, 2024<BR>
</B>(In thousands, except share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">5(A)</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">5(B)</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ARCA Biopharma, Inc.</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Oruka Therapeutics, Inc.</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction Accounting Adjustments</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Notes</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Combined</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 45%; text-align: left">Cash and cash equivalents</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">33,283</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">15,121</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(1,509</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center">5(a)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">251,668</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">249,039</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(17,685</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(d)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(3,016</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(e)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(465</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(h)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(23,400</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(i)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">300</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(j)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">537</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,700</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(502</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">5(f)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,735</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Total current assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">33,820</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">16,821</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">202,762</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">253,403</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease right-of-use assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">999</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(8</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(g)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">999</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">4</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(4</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(g)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other assets</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,358</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,315</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">5(d)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total assets</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">33,844</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">20,178</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">200,435</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">254,457</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Liabilities, Convertible Preferred Stock and Stockholders&rsquo; Equity (Deficit)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accounts payable</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">571</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2,579</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">3,150</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accrued expenses and other current liabilities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">700</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">853</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(18</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">944</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(567</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(e)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(24</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(g)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Related party accounts payable and other current liabilities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">15,437</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">15,437</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Operating lease liabilities, current</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">61</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">61</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Common stock warrant liability</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">430</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">430</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Total current liabilities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,271</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">19,360</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(609</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">20,022</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in; text-align: left">Operating lease liabilities - net of current portion</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">925</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">925</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; text-align: left">Accrued expenses and other current liabilities</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">961</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(961</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Notes payable to related parties, noncurrent</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,982</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,982</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">5(c)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,271</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,228</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,552</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,947</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; text-align: left">Oruka Series A convertible preferred stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,931</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(2,931</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(b)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity (deficit)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Oruka Series B convertible preferred stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,931</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(b)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,931</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">ARCA common stock, $0.001 par value</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">14</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(14</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(k)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Oruka common stock, $0.0001 par value</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">4</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Additional paid-in capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">225,987</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">338</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">25,961</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">259,894</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">249,035</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(20,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(d)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">171</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(h)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(23,400</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(i)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(198,198</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(k)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accumulated deficit</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(193,428</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(29,320</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,509</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(a)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(29,320</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(2,449</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(e)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(502</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(f)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">12</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(g)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(636</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(h)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">300</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5(j)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">198,212</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">5(k)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; equity (deficit)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32,573</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,981</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">226,987</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230,579</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total liabilities, convertible preferred stock and stockholders&rsquo; equity (deficit)</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">33,844</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">20,178</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">200,435</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">254,457</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the unaudited pro forma condensed combined financial information.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<BR>
FOR THE SIX MONTHS ENDED JUNE 30, 2024<BR>
</B>(In thousands, except share and per share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">6(A)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">6(B)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ARCA Biopharma, Inc.</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Oruka Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction Accounting Adjustments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Combined</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 40%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">295</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,866</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center">6(f)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">24,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,309</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,490</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,715</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">6(f)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,514</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,604</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,356</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income (loss) from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,604</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,356</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,354</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">6(e)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,687</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(29,320</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,390</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(35,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,687</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(35,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,504,011</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,712,988</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">6(h)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the unaudited pro forma condensed combined financial information.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<BR>
FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023<BR>
</B>(In thousands, except share and per share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Historical</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">6(C)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">6(D)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ARCA Biopharma, Inc.</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Oruka Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transaction Accounting Adjustments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center"></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma Combined</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 40%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,013</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,277</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center">6(f)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,430</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">6(f)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,296</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,342</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,638</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Income (loss) from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,296</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,342</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,638</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Gain on sale of assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">6(g)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,257</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,042</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(12,381</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt"></TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD></TD>
    <TD STYLE="text-align: center"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(12,381</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt"></TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,415,877</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,705,644</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">6(h)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes to the unaudited pro forma condensed combined financial information.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Description of the Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&nbsp;3, 2024, ARCA, Oruka, First Merger Sub, and Second Merger Sub entered into the Merger Agreement to which the First Merger
Sub merges with and into Oruka, with Oruka becoming a wholly owned subsidiary of ARCA.&nbsp;On August 29, 2024, Oruka completed its merger
with ARCA in accordance with terms of the Merger Agreement, pursuant to which, among other matters, Oruka merged with and into the Second
Merger Sub, with the Second Merger Sub being the surviving entity. Subsequent to the Second Merger, Second Merger Sub remained a wholly
owned subsidiary of ARCA and ARCA changed its name to &ldquo;Oruka Therapeutics, Inc.&rdquo; Subject to the terms and conditions of the
Merger Agreement, at closing of the Merger (the &ldquo;Closing&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of, and pre-funded warrant related to, Oruka common stock, including (i)&nbsp;outstanding and unvested Oruka Restricted Stock (defined below) was converted into the right to receive a number of shares of, and pre-funded warrants related to, ARCA common stock, based on the Exchange Ratio;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of Oruka Series A convertible preferred stock at closing was exchanged into Oruka Series B convertible preferred stock, which are each convertible into 83.33 shares of ARCA common stock multipled by the Exchange Ratio divided by 1,000; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding and unexercised option or warrant to purchase shares of Oruka common stock (&ldquo;Oruka options&rdquo; or &ldquo;Oruka warrants&rdquo;, respectively) immediately prior to Closing was assumed by ARCA and was converted into an option or warrant to purchase shares of ARCA common stock which continues to vest pursuant to the original terms with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Oruka restricted stock outstanding and unvested immediately prior to Closing (&ldquo;Oruka Restricted Stock&rdquo;) that was assumed
by ARCA in the Merger remained unvested to the same extent and is subject to the same repurchase option, risk of forfeiture or other
condition under any applicable restricted stock purchase agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the Merger Agreement, the board
of directors of ARCA took actions to accelerate the vesting of certain outstanding options to purchase ARCA common stock held by a current
employee, director or consultant of ARCA as of the closing of the Merger. The acceleration of vesting of ARCA&rsquo;s options occurred
either upon a change of control as defined, pursuant to the terms of the original awards, or a modification of the awards as a result
of the Merger.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Immediately following the Merger, ARCA
stockholders owned approximately 2.4% of the outstanding capital stock of the combined company on a fully diluted basis, former
Oruka stockholders owned approximately 41.6% of the outstanding capital stock of the combined company on a fully diluted basis, and
investors participating in the Subscription Agreement (defined below) owned approximately 56.0% of the outstanding capital stock of
the combined company on a fully diluted basis. Oruka stockholders received approximately 49,373,591 shares on a fully diluted basis
in connection with the Merger, including (i) 9,639,079 shares of ARCA common stock, stock options and warrants, based on the number
of shares of Oruka common stock outstanding immediately prior to the Merger, including Oruka Restricted Stock, of which 6,441,104 of
stock options, warrants and restricted stock remains subject to vesting terms (ii) 22,784,139 shares of Oruka common stock, and
5,522,207 pre-funded warrants related to, Oruka common stock issued to investors participating in the Subscription Agreement
(defined below), and (iii) 11,428,166 shares of Oruka convertible preferred stock outstanding as of June 30, 2024, which were
exchanged into shares of Oruka Series B convertible preferred stock. These amounts were subject to certain inputs, which include,
but are not limited to, (a)&nbsp;ARCA&rsquo;s net cash balance (as defined in the Merger Agreement) as of the Closing being
approximately $5.0&nbsp;million, (b)&nbsp;Oruka raising approximately $275.0&nbsp;million in the Oruka pre-closing financing
described in Exhibit 99.2 of this Current Report on Form 8-K, (c)&nbsp;a valuation for ARCA equal to its net cash as of the
business&nbsp;day immediately prior to the closing date of the Merger, plus $6.0&nbsp;million, and (d)&nbsp;a valuation for Oruka
equal to $175.0&nbsp;million, in each case as further described in the Merger Agreement. The following table summarizes the pro
forma number of shares of common stock of the combined company outstanding following the consummation of the Transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Pro&nbsp;Forma <BR> (ARCA&nbsp;Net&nbsp;Cash<BR> at&nbsp;Closing&nbsp;of&nbsp;$5.0&nbsp;Million)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Equity Capitalization Summary (fully diluted basis) Upon Consummation of the Merger</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of<BR> Shares&nbsp;Owned</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">%<BR> Ownership</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Oruka stockholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,067,245</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">41.6</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">ARCA stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,208,928</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors participating in the Subscription Agreement<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,306,346</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">56.0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Total common stock of the combined company</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50,582,519</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Includes 5,522,207 pre-funded warrants related to the Subscription Agreement.</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreements for ARCA employees include entitlement to change in control payments for certain executives, and severance and
retention bonus payments for certain non-executives, the aggregate of which was treated as pre-merger compensation expense of ARCA and
was reflected as an increase to accrued expenses of ARCA, which were assumed by the combined company at Closing. Prior to the Closing,
ARCA also (i)&nbsp;discontinued its research and development activities, (ii)&nbsp;sold its assets held for sale, and (iii)&nbsp;terminated
and/or expired its operating leases. Additionally, ARCA&rsquo;s current Directors&nbsp;&amp; Officers (&ldquo;D&amp;O&rdquo;) policy
was fully utilized at Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Private
Financing Transaction&nbsp;&mdash;&nbsp;Subscription Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Concurrently with the execution of the Merger Agreement,
certain parties entered into a subscription agreement with Oruka to purchase, prior to the consummation of the Merger, approximately 3,322,793
shares of Oruka common stock and 805,350 pre-funded warrants, at a purchase price of $66.62 per share and $66.61 per warrant, for an aggregate
purchase price of approximately $275.0&nbsp;million, which includes $25.0&nbsp;million proceeds received as of June 30, 2024 from the
issuance of a convertible note and accrued interest. At the close of the Merger based on the Exchange Ratio, the Oruka common shares and
pre-funded warrants subscribed for were converted into the right to receive 22,784,139 shares of common stock and 5,522,207 pre-funded
warrants. The subscription agreement was subsequently amended and restated on July 3, 2024 (the &ldquo;Subscription Agreement&rdquo;)
to provide for, among other things, the issuance of warrants to certain of Oruka&rsquo;s employees, directors and service providers. The
purchase price of the common stock and pre-funded warrants was reduced to the amounts above due to the issuance of employee stock options
since the original Subscription Agreement signing. Shares of Oruka common stock and pre-funded warrants to purchase shares of Oruka common
stock issued pursuant to the Subscription Agreement were converted into shares of ARCA common stock and pre-funded warrants to purchase
shares of ARCA common stock at Closing per the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information has been prepared in accordance with Article&nbsp;11 of SEC Regulation&nbsp;S-X,
as amended. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented
to provide relevant information necessary for an understanding of the combined company upon consummation of the Merger. The unaudited
pro forma condensed combined statement of operations data for the six&nbsp;months ended June 30, 2024 and the unaudited pro forma condensed
combined statement of operations data for the year ended December&nbsp;31, 2023, give effect to the Merger as if it had been consummated
on January&nbsp;1, 2023. The unaudited pro forma condensed combined balance sheet as of June 30, 2024 gives effect to the Merger and
combines the historical balance sheets of ARCA and Oruka as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The unaudited pro forma condensed combined financial
information is based on the assumptions and adjustments that are described in the accompanying notes. Following the consummation of the
Merger, the Company effected a one-for-twelve reverse stock split of the Company&rsquo;s common stock, which became effective on September
3, 2024. All information related to the Company&rsquo;s common stock, common stock warrants, restricted stock awards, and stock options,
as well as the per share amounts, have been retroactively adjusted to give effect for the one-for-twelve reverse stock split for all periods
presented, unless stated otherwise.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Accounting for the Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma condensed combined financial information gives effect to the Merger, which was accounted for under U.S.&nbsp;GAAP
as an in-substance reverse recapitalization of ARCA by Oruka, as the transaction is, in essence, the issuance of equity for ARCA&rsquo;s
net assets, which primarily consist of cash and other nominal non-operating assets and liabilities. Under this method of accounting,
Oruka was considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that,
immediately following the Merger:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
stockholders own a substantial majority of the voting rights in the combined company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka&rsquo;s
largest stockholder retains the largest interest in the combined company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
designated the initial members of the board of directors of the combined company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka&rsquo;s
executive management team became the management of the combined company; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined company was renamed &ldquo;Oruka Therapeutics, Inc.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of Oruka being the accounting acquirer, Oruka&rsquo;s assets and liabilities were recorded at their pre-combination carrying
amounts. ARCA&rsquo;s assets and liabilities were measured and recognized at their fair values as of the effective time, which approximate
the carrying value of the acquired cash and other non-operating assets, with no goodwill or other intangible assets recorded. Any difference
between the consideration transferred and the fair value of the net assets of ARCA following the determination of the actual consideration
transferred for ARCA was reflected as an adjustment to additional paid-in capital. For periods prior to Closing, the historical financial
statements of Oruka became the historical financial statements of the combined company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Shares of ARCA Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Oruka Stockholders upon Closing of the Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
Closing, all outstanding shares of Oruka common stock, on a fully-diluted basis, were exchanged for shares of ARCA common stock based
on the Exchange Ratio of 6.8569 determined in accordance with the terms of the Merger Agreement and subsequently adjusted for giving
effect to the one-for-twelve reverse stock split of Oruka common stock that occurred on September 3, 2024. The number of shares of ARCA
common stock that ARCA issued to Oruka&rsquo;s stockholders based on ARCA&rsquo;s net cash at Closing of $5.0&nbsp;million is determined
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Oruka common stock outstanding as of June 30, 2024<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,405,528</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of Oruka common stock issued upon conversion of Oruka convertible preferred&nbsp;stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,428,166</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of Oruka common stock issued upon exercise of Oruka stock options and warrants<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,233,551</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares of Oruka common stock issued in connection with the Subscription Agreement, see Note&nbsp;5(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,784,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Shares of Oruka common stock issued upon exercise of Oruka pre-funded warrants issued in connection with the Subscription Agreement,&nbsp;see Note&nbsp;5(c)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,522,207</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Fully diluted shares issued to Oruka stockholders and Investors participating in Subscription Agreement adjusted for one-for-twelve reverse stock split of combined company common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">49,373,591</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
shares of Oruka common stock outstanding as of June 30, 2024, including 2,207,553 shares of unvested Oruka Restricted Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Represents the outstanding options as of June 30, 2024 to acquire Oruka
common stock and warrants issued in July 2024 and August 2024 to acquire Oruka common stock. Such stock options and warrants became exercisable
for shares of ARCA common stock following the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be differences because for purposes of the pro forma presentation as the reverse stock split was already reflected in the re-casted
historical financials, however, the actual sequence of the events was the merger preceded the reverse split which results in some immaterial
rounding differences on the share numbers. The Pro Forma presentation reflects share calculations based on the actual order of events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
forma notes:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(A)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the unaudited condensed consolidated balance sheet of ARCA as of June 30, 2024.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(B)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the unaudited condensed consolidated balance sheet of Oruka as of June 30, 2024.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
forma Balance Sheet Transaction Accounting Adjustments:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect preliminary
                                                                                                                                                                    incremental compensation expense of $1.5&nbsp;million related to severance, retention bonuses and change in control payments
                                                                                                                                                                    resulting from pre-existing employment agreements or from approval from ARCA&rsquo;s board of directors that were incurred upon
                                                                                                                                                                    closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $1.5&nbsp;million for the severance and
                                                                                                                                                                    retention bonuses payments made subsequent to June 30, 2024 and an increase to accumulated deficit of $1.5&nbsp;million.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the exchange of all outstanding shares of Oruka Series&nbsp;A convertible preferred stock, with a carrying amount of $2.9&nbsp;million,
into ARCA Series&nbsp;B convertible preferred stock at the closing of the Merger, with the terms of ARCA Series B convertible preferred
stock resulting in classification within stockholders&rsquo; equity.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(c)</FONT></TD><TD STYLE="text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">To reflect the issuance of 22,784,139 shares of Oruka common stock and
5,522,207 pre-funded warrants, pursuant to the Subscription Agreement entered into concurrently with the execution of the Merger Agreement,
for an aggregate purchase price of $275.0 million, which includes $25.0 million proceeds received as of June 30, 2024 from the issuance
of the convertible note. The aggregate proceeds are net less than $0.1 million of debt issuance costs and include accrued interest of
$1.0 million as of June 30, 2024 adjusted through accumulated deficit (see Note 6(e)), for net proceeds prior to transaction costs of
$249.0 million. The proceeds received in connection with the Subscription Agreement are recorded net of transaction costs deemed to be
direct and incremental costs of the equity financing in the amount of approximately $20.0 million (see Note 5(d)) for net proceeds from
the Subscription Agreement post-transaction costs of $229.0 million. The issuance of shares in connection with the Subscription Agreement
are recorded as the issuance of Oruka common stock at par value, with the remaining amount recorded to additional paid-in-capital.</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment
to additional paid-in-capital upon close of the Merger is determined as follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Aggregate purchase price of the Subscription Agreement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">275,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net proceeds previously received from issuance of convertible note as of June 30, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,982</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Debt issuance costs recorded as part of issuance of convertible note as of June 30, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accrued interest payable as part of issuance of convertible note as of June 30, 2024, see <BR> Note&nbsp;6(e)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(961</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net proceeds received prior to direct and incremental transaction costs from the Subscription Agreement upon close of the Merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">249,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Issuance of Oruka common stock and pre-funded warrants at par value upon close of the Merger</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Additional paid-in capital related to the issuance of Oruka common stock and pre-funded <BR> warrants upon close of the Merger (excluding Oruka common stock issued in connection with conversion of convertible note)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">249,035</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(d)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect transaction costs of $17.7&nbsp;million, not yet reflected in the historical financial statements, that were incurred by Oruka
in connection with the Merger, and $2.3&nbsp;million reflected in the historical financial statements as deferred offering costs, such
as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined
balance sheet. As the Merger was accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets,
primarily cash, of ARCA, these direct and incremental costs are treated as a reduction of the net proceeds received within additional
paid-in capital.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(e)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect transaction costs of $2.4&nbsp;million, not yet reflected in the historical financial statements and $0.6&nbsp;million reflected
in the historical financial statements, which were incurred by ARCA in connection with the Merger, such as advisory, legal and auditor
fees and including the estimated $0.4 million cost of a D&amp;O tail policy, as a reduction in cash of $3.0 million, a reduction in accrued
expenses of $0.6 million, and a reduction in accumulated deficit of $2.4 million in the unaudited pro forma condensed combined balance
sheet.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(f)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
derecognize $0.5&nbsp;million of ARCA&rsquo;s prepaid expenses consisting of $0.1&nbsp;million of prepaid expenses related to software
that were not utilized and $0.4&nbsp;million of prepaid insurance primarily related to the current ARCA&rsquo;s D&amp;O policy that were
fully utilized at Closing.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(g)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the derecognition of ARCA&rsquo;s operating leases that expired prior to the closing of the Merger and the derecognition of property
and equipment that was fully depreciated prior to the closing of the Merger. The operating lease right-of-use assets and property and
equipment of less than $0.1&nbsp;million were derecognized.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(h)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the one-time stock compensation expense of $0.6&nbsp;million in general and administrative expense related to the acceleration
of stock options pursuant to pre-existing grant agreements, which provide for such acceleration upon a change in control provision, which
was triggered by the Merger, as well as a modification to accelerate vesting of in-the-money stock options, and to reflect the one-time
cash payment of $0.4&nbsp;million to settle in-the-money stock options per terms of the Merger Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(i)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect a one-time dividend of $23.4&nbsp;million declared and paid on the shares of ARCA common stock outstanding prior to the Merger.
The dividend was treated as a decrease in additional paid-in capital in the unaudited pro forma condensed combined balance sheet.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(j)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect a one-time gain on sale assets for $0.3 million for the disposition of ARCA remaining assets to ARCA&rsquo;s former CEO.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5(k)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect the recapitalization of Oruka and the derecognition of the
accumulated deficit of ARCA which is reversed to additional paid-in capital.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derecognition of accumulated deficit of ARCA of $198.5&nbsp;million is determined as follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: -10pt; padding-left: 10pt">Accumulated deficit of ARCA as of June 30, 2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">193,428</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Compensation expense related to ARCA severance, retention bonuses and change in control payments, see Note&nbsp;5(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Preliminary estimated transaction costs of ARCA, see Note&nbsp;5(e)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Derecognition of ARCA prepaid software expenses and prepaid insurance, see Note&nbsp;5(f)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Derecognition of ARCA operating leases, see Note&nbsp;5(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Pre-Merger stock-based compensation expense for ARCA&rsquo;s accelerated awards, see Note&nbsp;5(h)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Disposition of ARCA remaining assets, see Note 5(j)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(300</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total adjustment to derecognize the accumulated deficit of ARCA</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">198,212</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
forma notes:</I></B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(A)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the unaudited condensed consolidated statement of operations and comprehensive loss of ARCA for the six&nbsp;months ended June 30,
2024.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(B)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the unaudited condensed consolidated statement of operations and comprehensive loss of Oruka for the period February&nbsp;6, 2024
(inception) to June 30, 2024.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(C)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the audited consolidated statement of operations and comprehensive loss of ARCA for the year ended December&nbsp;31, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(D)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derived
from the unaudited condensed consolidated statement of operations and comprehensive loss of Oruka for the year ended December&nbsp;31,
2023.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka
and ARCA did not record any provision or benefit for income taxes during the six&nbsp;months ended June 30, 2024 because each company
expects to incur a pre-tax loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly,
no pro forma adjustments have an impact on associated income tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro
forma Statements of Operations Transaction Accounting Adjustments:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect preliminary estimated incremental compensation expense related to severance, retention bonuses and change in control payments
recorded in general and administrative expenses of $1.5&nbsp;million, resulting from pre-existing employment agreements or from approval
from ARCA&rsquo;s board of directors that were incurred upon Closing assuming that the adjustment described in Note&nbsp;5(a)&nbsp;was
made on January&nbsp;1, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the derecognition of ARCA&rsquo;s prepaid expenses of $0.1&nbsp;million related to software that was not be utilized, and prepaid
insurance of $0.4&nbsp;million primarily related to the current ARCA D&amp;O policy that was fully utilized at Closing, assuming the
adjustment made in Note&nbsp;5(f)&nbsp;was made on January&nbsp;1, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(c)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the derecognition of ARCA&rsquo;s operating leases that expired prior to the closing of the Merger and the derecognition of property
and equipment that was fully depreciated prior to the closing of the Merger. The operating lease right-of-use assets and property and
equipment of less than $0.1&nbsp;million will be derecognized, assuming the adjustment made in Note&nbsp;5(g)&nbsp;was made on January&nbsp;1,
2023.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(d)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect the one-time stock compensation expense of $0.6&nbsp;million in general and administrative expense related to the acceleration
of stock options pursuant to pre-existing grant agreements which provide for such acceleration upon a change in control provision, which
were triggered by the Merger, as well as a modification to accelerate vesting of in-the-money stock options, assuming the adjustment
made in Note&nbsp;5(h)&nbsp;was made on January&nbsp;1, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(e)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect Oruka&rsquo;s interest expense related to its convertible note that is recorded in its historical financial statements, to be
derecognized in the unaudited pro forma condensed combined statement of operations for the six&nbsp;months ended June 30, 2024 assuming
that the adjustment described in Note&nbsp;5(c)&nbsp;was made on January&nbsp;1, 2023.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(f)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect stock compensation expenses of $3.4&nbsp;million and $1.7 million for the year ended December 31, 2023 and the six months ended
June 30, 2024, respectively, in general and administrative expense and reflect stock compensation expenses of $1.3 million and $0.6 million
for the year ended December 31, 2023 and the six months ended June 30, 2024, respectively in research and development, related to warrants
issued to certain employees, directors and service providers pursuant to the Subscription Agreement as amended and restated, assuming
the adjustment was made on January 1, 2023. These warrants vest over 4 years from the date of issuance.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(g)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
reflect a one-time gain on sale assets for $0.3 million for the disposition of ARCA remaining assets to ARCA&rsquo;s former CEO.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6(h)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the six&nbsp;months ended June 30, 2024 and the year ended December 31, 2023. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods, after giving effect to the one-for-twelve reverse stock split. Pro forma weighted average shares outstanding includes the pre-funded warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. The pro forma weighted average shares have been calculated as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Arial, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, <BR> 2023</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Basic and <BR> Diluted</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Basic and <BR> Diluted</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">Historical weighted average number of ARCA common shares outstanding</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,208,667</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,201,323</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of ARCA common stock issued to Oruka stockholders upon close of Merger and giving effect of one-to-twelve reverse stock split, assuming consummation of the Merger as of January&nbsp;1, 2023<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">31,504,321</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">31,504,321</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Pro forma combined weighted average number of common shares <BR> outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,712,988</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,705,644</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the shares of ARCA common stock issued to Oruka stockholders at Closing, excluding (i)&nbsp;the outstanding and unvested Oruka Restricted Stock, Oruka stock options, and Oruka warrants at Closing that were converted to the right to receive 2,207,553 shares of the Combined Company&rsquo;s common stock, 1,179,193 stock options, and 3,054,358 warrants, respectively and (ii)&nbsp;the outstanding Oruka convertible preferred stock that were exchanged for 11,428,166 shares of Oruka Series B convertible preferred stock. The 2,207,553 shares of Oruka common stock, 1,179,193 stock options, and 3,054,358 warrants are subject to the same vesting conditions.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">Please see below selected financial data presenting
selected share and per share data reflecting the effect of the reverse stock split on all periods previously reported. The selected financial
data is derived from the consolidated financial statements included in the ARCA Annual Report on Form&nbsp;10-K filed with the SEC on
February&nbsp;1, 2024 and consolidated financial statements included in the ARCA Quarterly Reports on Form&nbsp;10-Q filed with the SEC
on April&nbsp;25, 2024 and August&nbsp;1, 2024, as adjusted to reflect the reverse stock split for all periods presented. The results
for interim periods are not necessarily indicative of the results that may be expected for the entire year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AS REPORTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(in thousands, except per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Years Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2022</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,339</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(9,926</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.37</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,415,877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,501,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<BR> March 31,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,009</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,346</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,501,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,501,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<BR> June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,678</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,480</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.10</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,506,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,507,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Six Months Ended<BR> June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,687</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,826</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,504,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,507,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,410,143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AS ADJUSTED FOR ONE-FOR-TWELVE REVERSE STOCK SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(in thousands, except per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Years Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2022</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,339</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(9,926</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.37</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,201,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; padding-left: 0.125in">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<BR> March 31,</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; padding-left: 0.125in">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,009</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,346</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,428</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<BR> June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,678</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,480</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.10</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Six Months Ended<BR> June 30,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2024</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2023</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net loss applicable to common shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,687</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,826</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.20</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding, basic and
    diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common shares outstanding at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,208,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">15</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex14-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex14-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M 2$# 2(  A$! Q$!_\0
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MI<7 P/,DB!)QTSZ_C6JJJBA5 50,  8 %+10VWN"26J"BBBD,**** "BBB@
MHHHH ****  @'K2  = !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>orka-20240829.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaiLyaPtyJ1xqYkxuG91fYkq3ykhySk1ZiiAnj5WIe8D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ORKA="http://arcabio.com/20240829" elementFormDefault="qualified" targetNamespace="http://arcabio.com/20240829">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://arcabio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240829_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240829_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240829_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>orka-20240829_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://arcabio.com/role/Cover" xlink:href="orka-20240829.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://arcabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>orka-20240829_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US">Former Address [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>orka-20240829_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://arcabio.com/role/Cover" xlink:href="orka-20240829.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://arcabio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140253322173664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 29,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oruka Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">855 Oak Grove Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">606-7910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORKA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA biopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10170 Church Ranch Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westminster<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MO0%^7TMIWD[LQFBQKSW^%U!+ P04    " !+BB59GZ ;\+$"  #B#   #0
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M?P%02P$"% ,4    " !+BB59!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $N*)5FPE*D'[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( $N*)5F97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 2XHE68WPW+0H!0  XQ8  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( $N*)5F?H!OPL0(  .(,   -              "  6P-  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ 2XHE69>*NQS     $P(   L
M ( !2!   %]R96QS+RYR96QS4$L! A0#%     @ 2XHE6:K$(A8S 0  (@(
M  \              ( !,1$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $N*)5DD'INBK0   /@!   :              "  9$2  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $N*)5EED'F2&0$  ,\#   3
M              "  783  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  , 4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0213193-8k_orukathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcabio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0213193-8k_orukathera.htm">ea0213193-8k_orukathera.htm</File>
    <File>orka-20240829.xsd</File>
    <File>orka-20240829_def.xml</File>
    <File>orka-20240829_lab.xml</File>
    <File>orka-20240829_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>36
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0213193-8k_orukathera.htm": {
   "nsprefix": "ORKA",
   "nsuri": "http://arcabio.com/20240829",
   "dts": {
    "inline": {
     "local": [
      "ea0213193-8k_orukathera.htm"
     ]
    },
    "schema": {
     "local": [
      "orka-20240829.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "orka-20240829_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "orka-20240829_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orka-20240829_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 64,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://arcabio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0213193-8k_orukathera.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0213193-8k_orukathera.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r14",
      "r15"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r16"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcabio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>37
<FILENAME>0001213900-24-076184-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-076184-xbrl.zip
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MV!QL#':L038R,2X-!+_WSI/+&\?9VQCVU3BURRGO%+\>^9D^\4!4CEO-"5_
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M5(7E"E@E<,R_BC#%S9K%X_#6HH'!!K"Z22[U#CFRPR-7]LUB0'G+,&M6S##
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MN-[P2%D*ELMOD+R Y%ZR,N?PG6GJ+[Z(=(QZ(6\:#W[M,K1!0(M-]=-H$;1
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MB+.J1T(QRH"FT1L-&$E RKWE-!:\420OIFPCPO!N'<0P"H 3: ]0I#'&SC?
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M-[2+M?SG:&F(SW]ZMOF,?L\PK5W^OO0>K :7MU40\U1-0R&/8S]2BB:\^.S
ML=J(R]$QUB&,GST_:/WJ00]O?V=WO]3=_&&[I[,!R%WBCXQAU$U8Z@&W=F5#
MA/CVL-MR_=EE5K%4B&X]R+:IMB(&V;HR>-9;[DAB;?*<U.->=59L+2>V$FQ+
M(@5YF&L=U74[]7O@]DVHT&'\WP+C34$._#_>L,N 8)NT?6]K9]/;[%M5LY="
MAJ?[4R<ALIO58)/:"I7[%BW.(U<]B ;>YLX0Z,J^]%YDI63Z4F;Z-W4JE^ON
MMC?<@O^'.\HW!WIF<BU$A5ARAY?U:H2Z1>E;8M\-^5W1D]%;9)&^I9=7>S,A
M_-"T\6KNK"3AZU6M3D&2KNBIJ'V8) 6LP2$*#FU![V2E8Q)G%) #R&XAT)*"
M4"M"1QU<O_:FF_\8+:R<.%%V%<M2):I94Z4_FZ5L&9@B!1%[IV!44BP/K_?]
M<?E5TCO>JL(53IL6UEH-3(6U-1<2:^_[<(.RYJB6BW;(VM0/W*T=(,U[WO[.
MW@W]Z$HUN]:HZ9V:6Q<:P3I:!?-X9/6Z?KFASB52CQ8!8[.RQU?\0=88Y_ [
MI 98Y0J[\09H3TBK"* #'4/JW S:+/7YF'0J:B>PWFF"P;XWW-_SMO>WEV(;
M-V#26DEI4RF0V>W:V"ZSCE8Y:OWE]\< .JQ9%:S9]K8' V^PN;L4L-:YA98+
M/0Y3JZI#I8YPC9B&PL]2B]#M-:O];3O;2(<TCXHT_;ZW-=CS^CL[#\EJJ+)H
M=&WU1FCO;??= /4JR7<WJP)VBP^==Z3:P?JF16Q+"UG[M;*447;N-10K:$H1
M&HDQ-K4H%?O7#6G=H=V0MG%6BC.-,<=(-0/&2$QWGF3Y1DE'<6@)'G\C)1V*
MO57),LE<\!F9<>H+6=V+?PS ; I'?.!@D+>?3C\X_4WW^"/^=/CY^-/'AP_Q
M>.Q]K#I1T!$W:Q/JTJ(+05.\/[5;S54'6!"' H&MPA,LPGV._;901:">J0J]
MLRF6GAV;[#+J68,]U3$G#V/]42-6?EO0TD\+X/K]P6ACX)C:TU:_$&V#.N1J
M)_W]X9;=*:9*7.SG;:JR[NDB\+A@VWQA5551!531)\#F3[//&08LR! 9(6/E
M,>.)22@=U%521 $WE*5&[X$Z.ONXT.PZ"2-N-7HN8FJ\0ZE3$^M@<UEFVQ2Y
MU76Z^]C[EHR,,(:JMJ.3#U4ZHS*)V(LDTTMEJ780B*\F4.N6HSJT:- %L=&+
M>:KGGD3"SP17OZ%AJS/*U$KIHH?=10Q623ES,U,!?:5VGBY7WZVR*Z?"KHJ8
M.@.;>L,4A#*1-FW, QUS[HH>B@,&]?/RMKJPCR<(L-_N NPIP'ZK"[#_GM%A
M='#D4XT[/[WF\F&GXMPGBHW4$^W&&^^3Y(**HJF NZP+8;U?"&N8.0MZ6^A:
M4A-Y 9&\ -W3C,LGR&C(F?!C&<*HNMD-=@]US1C#EXUD,K0E$TZS&_3?J%=L
MT:143-Y,GVH@47EQXW#.SA@0%"9A7NWCIDKU3MB>BNU658*^)[/VJ"16PHT)
M@8MZ*L>.0CNKQ0-(GR+53J]IYE^3V%, CSU/_"CSN(V@J;Z%A1#&NAP7<?=)
M@0E_[CSR<<8<KB3(/ >[_J$-32[,+2T,^7/C-NQ> AYJ9IR'*HOU5V:G*GE1
M*"9Z9P Z0,14T0;TN^K>C#YZP4%>Q4M#-Y(,=ICY 7:NE(XN2YHQ_0'\2S^,
MR&*%B9V-TY@C?=L*;XZ4_TA.(3G,/GF2J-"HB))WR$HPUL'TZ6PY 7:.G7>I
MR#X)C]AEP1P_G[?LZ"#+-JA=\6Q7P&XSAX1S. 0I1L.-ZQXI\J.K,(JJGV53
ME"%K3S9]R'=4_=3 M_K&D=\@W%2?CL(++%!2^90N^U+4)LQRBFFK?@YP_V?#
M2K@OIEX%U>>D,.,L!%KD8_<(#!C.%)Q2$ 2&]I%=(@4X+U+=>BF3QVH@MW&8
MVNW*L97 ZM0N42.MAPUQX/3/J? D>3@7T#1)]^RE]2RF8Q:"8P$-S9,496<7
MLW8S![]H'WP1<'-8.3M 9T6LJD9(T -,+LRTJM^)PB:56<998PHL?@P//F@T
MT[G-KYDXJ8*RA[$?7:/U!M5934^.% +0,Z>& 'W2!,C*8_@QU-PN/)#;6,!:
M%IX";K%&M!2-HI1_B_3HN[ RH](PN^ GBU@FLU.E0U4P'<_OO/ I1YP-L(KZ
MBI1H%Z9.(-/!"!9%>L>D_P4A-I1Q5;]0].5S?C>JN!)NI&H87[>#@4,F !X:
MY[_T4RS@0Q"4I)G%[+B9,=:[H1NG@^]\XIVCXDX3+!M#I8A,HKLT,[6[KG#L
MSB7= >W* *T_"B.,-4)&X*.URJI*(1L4LF4NYNK5FIUU4-Q!\<I <;7>G*SQ
M A ,8AD60NG M0/7U0%7B^C*HH\-$ LB0THZ&"APXRB,26FB"D?J%UD$"47D
M#KP[\'XT\$[%.>8?@"2[')1+HT-3CO[-!)ML%3F'-PO0TT'1DT\O&><FJWU9
MI;\ZMM#AS2JSA4JP$Z",5>6.D*(!7;@L,!ID< B=&O3V]:$N@K3,6J33VNH^
MF+@9W"#VG;66(ST8+6O*$ZL<'[^^9-+O1%>%, WFL9J'-$]CP#C.#^!W(7+,
MC1+S7+79X7[('<IW*+^Z*)\4.6"(ZERL);M<< LRKCF>8NZD_@HMJ9G.C&MA
MI$LMPN"&[3<D%Z%-D2@NB6='8N#G83;!\CF1N,3(HW,L_ALCP4!7!84:W45J
ML E/AZH=JJX,JE8Q39E[T?F8AA1> SPX$!F<(>)/%6,1ERG<2-;VU^\LAZM)
MC/C=,$&'+!VRK RR6!8.66";ZX_/P\LD-WTC9$5GF+@NIWF6MUH[+Y=:!(:6
MC(0[2\@+GDQ"AB>L+U&,,=)X4D2FTE<5OY4OM9,@.TQ[0DRSXXV6%)SLX"ZE
M$2'.)11.Q6'@':AWH+XJH+XL4\%PDG!<1#DU05)Q31+@<YA+-@#(*$K$LHY7
M+"H/I"R]Y%"B8H35''*.*F1;99B46T=-_#%;: +9(X5"5>0"Z><E*]?830[P
M )25LT/7#EU7G3,9=I0GD4BEI.BYF3_!4MQ8_@31W!]?W\2O[N((Z'A;ARRK
MR-O:;?\ N#EZSD(*>6UJGR-=6_,T%#FVL(;'IW$2)>=A!^0=D#^J8S@*T=NR
MG,F;XIW30'5.]R@2./4!Q"TW5YJI=D[R.]T%*DG/_3C\;Q>%UH'W(X.WEE26
MH^0!%W](A0J 0#<HI6:1#C"2K6@X6QD?F(;SK*D'VKC4I6)9CL(I7%TYGPY)
M'A5)(JPH@(!\N:1OW_@'L38*"#\ZP$T T4]FX=A6X=E_HNH92.N623MS1^(Z
MX?B >SEUB-TD45<KZ)%3:>UV3]B/&U[%,)(9ICZA,UFF]G#"$B<3C?T"P]-9
M]I59:]@)DG.,B&B6<C4Y?Y#2ET9<X2%/L:B^C^6FIS 8@BQE.<DGJ;"&'\A(
MFC^+V&HRT90VJ4M;R$9-!+I1)J[P]ZHG';.L]*XJG5&L_+-3?.PM/V8WOBFU
M0@LS=T$>LLDN#))Q,5/G-**R(*;NJK9-I;)AI2,;5IK8H;,W1Y[*S>7TP8FE
MO5/>F%=.&O.LV>N7&38[6DQ;6%FX)'/*2Z 6L?;Y^5F6C$-*7*8GN: 'S:]R
M3:V)/+XR3ET0:A6C,)E/_73FHX\)@"'5R<F5/#2GE')XF4276*/$U*AN.@=W
M+9-1':87F*%0;51GW61T5I/V'/1EE3! )SFG=B*>O&DKXX[Q@P[7Y-[)1%&N
M6@(7%84:,.H'8 %_#XL-3/&SYN1+&Y/0YL/HAKE[LB&.KSJ:4@%$D)-4;9M\
MNFA>JV&4[.&-&<,XCS^>8H*N++\B!RK5&;:RP7%2 I"%*?KE@1?F5[><PESX
M%X"3$96>T>U8Z7BO"18H!5PE6);:TL$C8=K<F$YWA]6E'^RE\+GTL P 5L[V
M,U,E"(_;M-.-_*MR31\JC)3[%P)+#;O)"*077S85)MJ<D<NTF <<=[<@4=-S
MN*G.# :C)QF8VT\;B[$)"?"E%,\8&(*5&N_54\YUSGY75N?QR^KL=&5UJ*S.
M=E=6YWM&A]&!ZA-+<B'(86B4!7[>5<ZYK[AOUSEYQ$:_KKK QJZ^CN[JV]_J
M.OH^ZOH^Q<X',M?N< %3U8*>*+3= ::UHR[77FV%&^KAV<<>GHMU(@=U(E/[
M<2JXR*J!GT, J5$27%.A#W3.LT.EMAX;HCK8>60ZC'JPH_7@COC>C_C*$B\5
MK;E,.+59FC1X4S8+-11NR#VZ52O7"DEO(-CVW6Z<TM).!>MJ0!-H58M[LF_M
MFUR@QIV1?M^R'\EC5#%01Q<#?91]NJW[E!H8+T*J8HNWO;<IVP.4S H='7I,
M.J0K/#G'AA%U!.F>IPK(\5OL%P'F3SBFB)95- PQH3OF^]+]0ATR!8ZDX8P\
M)B+.J AR3*HYT0U3&-&RA.E^CFS$^K6(A3O<E!VUK=J&%'TYQ4S,&2QBBD(Z
M&O[4\PX_#U18=W.#I20!VR/?BE%:H"EK1[7J!H(F2/9:1S)9F561?4E'L3)T
MQDWTL)8"EBW,<R"1DA3B9UCC>QJ.PMS9W^\-M=&M(YN/C."''7H_-GHKY&[
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MI??OOKJ&+61X_4[E^N5A&(><VB)(VE&T[":Y:%-SL^_2F3F+AC.'@ULD21T
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M?%%_LPLP^IX10OHGM]#6PY262NDWE>,@RGB-;!:;P!<Q9IU_@_[)1VJ49_7
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MCV%X3IRH#_7DV 0DI,(D35E6FM%DJO9#AH9SXQMEJY!=$#Z0O7))JZN)/U1
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M0]DB65^H[V+&HR3#)L-$=BH(8Z<"][5)5'2<;0-D 4:J4&M6$(-*)E"(0R$
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M98%ZIGK:89[&S/3>AE;JH>.&TXH<4&/3F'0&1 LF:J%YU=Y9#*"S@3!GE6Y
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M6>K,G"^</<:K$"1*4\_1AP,Z\[V]T[7.[@Z/:'I;$"?6A2_Q0E5\JSVLI$K
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M3=.G7LTAK0Y-&5>&X9*B#LXBNO+A[<">J,QZ#_8W%2*UR*A%QHL1&7"@2][
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M<#FY338K/[I/MKW%@B[I.$J=>"49=IP)P<8*IN%6&S @EMI<A1-@KX;:@GG
M0XX]?<P4C'4F!+F&Q4X,;X:1%5%!!6&>#+"!MHW]:9D&0OL*U6K!3E*J4Q^#
MTFA/8"%C7:[.R+ZY-^'L]2OJL4P[]H3,5K!;.1GPJ[J!=W:4I6C0RM)@1]-@
M;44_K%COKUI@A9"&(HQ[]"@-TM?"_/[X' Q':EPN,IP^Z9.YFW*YV2-'9\.>
M[?>()^;PO,&YH7/-K!XRD].C5NFC"$^@'CJ0 Z4SM^C!SIWODLU2/JX3;Y^H
MKT:[CO-SG+_UT\7Y?RJ&@(MMN&IIZ^\'NL'*[>UD[B29)PWDFH';?&!WZ8\T
M8K2O;24,!K[KBFD(Z]7_>H64.B>"R[3_2M%S&@^]6;H\9!R,<K*)(#+T@!''
MW#K5%B8+I24^(/^4+&&YK6)Y><^;=9!&Z/(;1A%:IH%DY8^S/4""^-M_O6H_
M['D87UCM% ]&_95VL]MH=W8:[<W-U2+%D]M\#5D4YO+\JT!,7]LE"0_W^3'M
M]1:%!+IS":R*9Q^3R!]X(_XI;#!Y+_[U:AQ%T_#7C8VKJZOU4 [61_[E1B\8
MC)U+&6[(X4@$&V!GBXW=YO;69G>CV6RV6KN=5GNSW6WN;'8[VQO#[=WNUO;F
M4%ZW6^OC"/;)B/1@9UU7D*:NXC-<LF8"JC=LMN19;^]- \=-'=-]SG^F!B:L
MZ/<=?SH68 (TL%W=>L/N12Z\JH8_C_O4++CL]T='#?OX>-\P%< " ;*3<43E
M+3@<F>ZI49VOQM/J.Q 2+;9D04GJ2.+9YK:$8*_DONTM_-[^X*_;L*MK[?;.
M=F<5-'U1)4ZJF>U/CD#5XN:9B9O.>NN76M"PH)&BV6YU0'8T6_*ZL];ZCX\<
MR (CUX4RJ8^D%M!+MZW,=T](*^1R-7WWPFPF'SS2GE8?:LV(58S8_D$9L8)]
MVB;[W-\JJQB1UOK@S*CV1MR!&9^: >M;<1%F[+PL9NS4S%C?C#\L,W9?%C-V
M?WQF+.1GU>SX\[#CYLMBQ\V'8<>;V,U2E33S68X=,P_#;K6Z^6Q8:NMEL=36
M([(48XII;C*8I[Z2?A[^V?XQV><9!4M:G7:GL[7;WAAN-K?AIR'P<:O/'$QA
M JRJRRJ+!PJ;6MU;ITD8 A9ZAK#TG,5][$R<2$2ZW@8_08:\8STLU*.MP7@X
M#X#84N?4R6ZQ.$=GO;727UTHU,&3GJ^U-GJ--.1Q(F8VQCK:S58GC7CPLYU.
M9ZVUL[W9W+F?N$<M3GX(<;+SLJ[CG8>YCLO% JWTT$V0A^Y9<-AS989AH](Z
M:J?13\O#NR^+AW<?G8?O?KWOP47JK7WQ%:+ (EQK<"PMHC9VYW*F=1,2RZWX
ME=,(=__QZDUWO55*NCK3\!_IXJJ?VB7(F#MHJ, 'NTT@A&:WO=G>W4#.:&ZV
MVFWDC.Y:YS\B& C0^Y@WCH#,0NP&H&@T2?7123PG\/B85[U5FL-3F7A#P(FZ
M29,($# Q2:9?3%GMKG?(%7MC4L[Y6C>GHK:ZA:0<U$[;V[N=G6VMG98SQX*4
MD>>8DI.]Z7>WG[R:+-^TFCDJ+%W%@^2+M9JMK G$M'$>$QZB 1BPV/'CEU2<
M?XFA4DS,4D8)$\)+/_-VD@?Y1$??+C_Z?@I]<XOS;R]R_G-R\E[ZJ7<>Y=23
M&V6KV=K<XAMEM]7IXHW2:JZULE>*IH!,UM?]D,-"XB!+#K_'[LS>_3FHH?L<
MJ*$]AQH0XT5,X,L2?_23B8F?B2XVG^Q2Z.2(8/^L=Q=UH$H=K*\#/NBM)SOH
M;O:@C\%.7?MC>ILS[M9G//>,MY60?PQ9W]S=;+:VR99L[72W-E"LK^%Q_T<I
M^N<2+#N1$]L<<"20H<16[,OH2DJOU):C!TZ<P5A(U]X+'+!'K^;4D"RC+MRV
MI*/[<]#2SK.@)64Y[", E4O>+\,+\93TTZ[I9S[][/[7(ZF:B[BR]-USE&NS
MG0HF341S758(HUK1.KOV6CVHUZKYRS+DE/'XHQ7:-'W^E4=,$H CYO S0D]>
M2BII?.F[V[K;[K86W]U#U;1*;?-I#$R.@(,_PRZWGU BPC%UFUF96)H#=L/I
M_1T[T2S''-Q,7 T&@H_Z^CA!&!E>'ATOF-G;RUZTW68M,6]#;9V[\72FSN5<
M(DS3 K6:MR*??%=#@TQ>^B%UGU@D5+AG\3P#9Q E"60??.S*E9QUYF^)#+^-
M05_EM;UGYOZG[J)0BB6S*-C,/$2I3HTHQ8A2[1\74:J*))X:9.B!4Q-0$&UF
M!='SRTY :541/F Q]#$?(: >K[>YD9807U7!A8<27\O(K]M#>CT/JK_?Z[:"
M[K=^N7?"+ZA2F1H.3;2)(?2G"+ 7N-G+X$6K/-M/K/)T%K""#I2/Q_X(JFE@
M'TOLP%F2]=1N)VE/B[B/S@5P6C2VW\?N=Q%XSA*"IG8;W8K8=IZ8V+I98IM+
M5T9>4KN[%%V]#ZC7E+3WA.LN0515X;2:J.82U5-ZMI&HMA:08(=IQ^$R6M,@
MYKST]#AS$96Y5'<LKIBJWKN(8;PXV6W59'>;)+[F$Y/==I;L;J PXY9LM6Y#
M7KW@6XSJO BNQ#)";;NFKMM05^N)J6MG>>JR6YNW(:S??>$)^YWOP9[!>I<@
MK9V:M&Y#6D\=]]A=BK0,-:S5O@U]G8K8M3_%CK><*V&W)J[;$-?"6<YZVA)H
M;9/V;DEZFYV=G99!>FTBO<U%0FX]+W+Z_G!&;>]\V!6FM8(_:^7H>*VUO5IF
MANZ45M^<BD",8(@BG3;P;TC"O_DN>G+N"RD7\TD7#]=E:L>IA4=KYV<FY853
MM)^$E%OW3,KMSM.0\N*4O'ALZ@>BY&K:>0P2W_PEFU5XLV:P *WG':[M# Y5
M>>I@/N:LBF5U8Z E-4H8S3Z0W[_+X$7+J"Y!7"^LRF7/I9N#@5;]Q9.>B;K;
M.;6KC,:PPVFI6''?7_(V;]UEF[>RV\RZ+7>N>W]Z\@[$XZD6NRD6FK*CUNT7
MO*WMUAVVM=W*;:L34O])+$YRAHX@/(V?DURQ?^^M]W5W-[NOI]2%."D04-V)
MX5(MX/:][!UMWV5',WCA/=5QKZ1G[3R"K>BI^L()N7.7;<]DS/VQ:$O3JE["
ME0=3TL;4[&U8;#UZZ^:E+_RPNS<?]K+*)U!!!I+X1'AB1&>:F QH&<5AB/80
M>;D]X<Y"AYDM(074A9Q(/P/F%2BP3!5PF HAIJ:#>Z*#S0>A@\UR:5#68W9!
MQB=R*2UQNDT/5,/4*>F1/*\7ZDLFAU:S>_,B]M&S02F/L/\@W 4;D@<B$FSM
MK^"&#7'SKARP9#S:TB//Q1#]O_?.CNVA/XCQP%>S7U),4KUU#E=%_J*9N97/
M[+KEE'-S2#/I7L M-YR5R5_?P!YW+F:4_IA/N&HZWJN--R6_7V]O.M[#MD_,
M@*%5R(9D[?<(+X;N)>H7C#2UGL',(@*Z3^JY]Y:\-3D^%#G^U].0XQ$H* AQ
M%UJ31,=!Q39":6C#+3+P)U-0=T7D@Y8QY>JN'X-D-:VJU=8D>]\D6]*5<[Z.
M=6\SZT;(%JA'&T"D(39LCUT88RS@!N^CI]>?.!&UJ(^#,!9<ZW0$^IF]U6RM
MB-65S56ND!G%+M<0GZ^]7T=]S0[DR DC2N9%.=V?<0IZ)+XCNIUO7\2!YX1C
M.XRG4Y<X1KCNS!KX4^4]$MY,(Z_K54BU8E+HTN7&4Y@XP-J*,-(U=^>'^Z_M
M:>!?.J!Y-.RQ?R4O,:P=C46D>M<GZYN(6?(Z<.T%O.)%H(M:42!%1,QL?O\9
M3&JWN_VUMLJJQ^$.KP=CX8$2U ..1\41EY^L-[.[8?+Q<KA.")D$_.<'"=@E
MJ$FA?MD"8X2E"\5GB%R:K__?+[_\\O_IWZW7JR7GU9<#$8=H#\F9+0*)0*1C
ML&M6;<_'#T8K')1MW,<5!WY[Y<<NOL62*G)0AW-G-BK6%[%K.Q?6-.Z[S@!^
M-P2;S?7!=/]A9%A][3ZJ##,#MX\DRNS3"NZQ;\4]P(YB,/"#H<! **J8+#*(
M?95,.I>#.' (JY."-(K_K7U_,G'(I?' _/$P=2[SJOJZ=54?5_5U?MRJOF<@
MCLM4RKNNKXP"[O4*Z;\Y/WKWH??YC[/#\TSC^Q]B^0^QY?>YOE.E7EF@7K%R
M]G?L!*D;,"=P,\H6_+FUV^DV\EK=6(3V$+$+21,:\K402$+4@VGZZ H<>1Q0
M0QVM+\?"O8!;PL*!2+-3#Z#^&GOP#@TGXFCL![!X0P%Z=ALZWVQ[GB6,\SV@
M*09ZA]BQ.KC<7\8?N\2D*V<)<:W>VPSS9VW?(A')F.\ ])Y?BYD-V07LS7ZM
MG'W1F_W5FXUP(U<#<ZLEYY37K>9"):?=A9[:A*?H*I_W4 >+7._C2Q;VXG]V
M(C>WIC?8R2 D,Y24R_VQ(R] ZH$$).?Z1\;9>AQ_^=,/=WOE[M[D*3*-*4L-
M-0O= 6M:U3(5OEO8@D5EFMXNT:3-%9H"'S5!]5]3%<PLTK)^@-OJ(2R:<QEI
M;?YZ>/W:/CJ@?_RGN;/W'Z QZ85D0^(6T6OR]^NWW_YHOK_ZWCL9_['QZ6/W
M[.O;S78[#GK;QU^"P_?N[X>=HVY[-NEMO__J76\WO\EF\/;MP='AI\[EI3R<
M'?WQ\;S5_/9I]MN?7[S>P31N?QEMC:\/3F:3\8>ML^VO@ZG<NW3.AM%OYY??
MXLO!;U_C3U]W3ZZ[A_O#WXX[G_^,M[_^-3WO>9\VOY]TKW\[^OVP.3EYVS[N
MOH^\KR=;6Y_BC\V_O[_[NA]\/3G^,VHZ[N[NU??N[NS+P?]N_1VT9V_%Y_/S
M0S%[N_D_GV:S;^\.OC:_7&TX?W?_=&:'GSX-QQ^/O(_>GS*ZV-D:[NV<?_WV
M[_;I:*N]>[IQ\+E[\.'[W^]X1S8PF1G_=QQ-W#?_!U!+ P04    " !+BB59
M S4<CYM0  !YOP$ '    &5A,#(Q,S$Y,S Q97@Q,"TQ,%]O<G5K82YH=&WM
M??MSW,:Q[N^LVO\!-Y6;(JM 6I1DQ[%T744]<J)S'%DER4F='[$++ D+"VSP
M($7_];>?,ST#8$G9<L20O%7W1%[B,9CIZ>G'UU\__=O[O__P_6+OZ=]>GKR
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MFW4:?O\WO3\KDBU_7-*LD_ZL[)(?V^%#EL!?VFQ;#'VY@L>^JE='*D%]L_J
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M._A!-Z+0H<U))KBW4-&FROELNIM"DT]N<URXQ=[):5L4H -C/9J(^"07+>[
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M:N^Q2I\@?<MBA2GHPO&52ACT.1?)R<18_E()A DDV4$(#ZBOZ:XJXV2BR/C
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MAY?*<1G8K;RJ1-0$GIVV%>@T]R&XU#B3-:.4J%9;#4O5HL;EEGZC_)8#Z;C
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M"99<!^8T*#-SPT^%?*D#[=KC753O&O[8;<'^;];KU,$G"(=LX1/,S:+&:NI
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M 54HUSFXKEOW*$?0ZHL]!'RETU$D!R+R>Y^IWXU;X5*?DF]PN$7;CS.DYB2
M#FT(#I]3T2%58LZV")54AML 73JJB""=BP$G'[;"LPBV5YJL"_06*@0<*CZC
M:E9914=KFK0#XIOQ5].4#?N5TKL56#)S&7^O0HXD']UI&O@4.U\0NRNC_N7.
M!O/+IT6](F9'.1"%YS4/RB;Y.Q=[8H[H-1P<Q0."6[=DDRJ/N#S]](9S&L3N
M"6986">NM<</7"A=%%?B948 /0]HG9MT+#W1.=>H(\RHA";]C.K[_<PERR:_
M-(F="(AC2FP%8%,7F#N5$M,L/V<;!Z8UZO=H$.?X!4IH-"JKY Q7B;['NLBZ
M4J];(C6"\@3V<,!S*W">/%UF&OQ91KFGG^$8['(.L+IDN][.)D#$OQ< $;'%
M(FR<T5<JW#>[6 ^5V[]L%6I;\AT%%&;OVCDA%KJ^\\T@\=ATNZX%D2J0FE>>
M[8MKHSIICNBOL[+"O"W"/773HP[8B?)D1*1!BI'T=V5?F%GSAZW'@O'*X$YZ
MW;AHQ*3=BQ]9-[M!AMIOV#E AFCJTE+O:68O"S=/YVPWG!KB>MT:E/98T3&[
M7-2UQB?@*,!#!4.]D55:L[,@ 1\6G%/*> G_Q#REJ3ZWEF P;MH43LKN9$CE
M6L'LX]L>S#Z^#V;?(IF> 07[?%EGF\>1UU]-Q"LNSAI22]Q:G=EJR47BKDG$
M7=^1_\]5M$R.0\E14(==%-<&YUC83B8),C9-C@6H% :V?9U\R4+C:P:<,TZE
M"E@+DC&BA/YJ@'E1>85M8216C&L>2*GH!MS/7PH'N5UQV92S:E+1REQ B/5J
M7$X8L]P1A+;JFD3:1X5UK5.6N.]%;HQR:X>W/N-KC'*MHXL_5(EEW1?J"=<D
M2&2XP8^<LC],I9WX5?8H@^^EP+V4 5&&(  E>5'Q0E&">&'+'^H>_3D/F=OE
MV&I;VW_Z LC;%X -S7/GZ:#F,3Z=>!7HG8$>267[<76 "O1$TLPUSLC&R).4
MP7!!-PE'3M1X UNM+,V[60(C*:B\#&I4<4^83:-P<_2DY]F$1CC1]AI&?. S
MJJT[Z3.J%HO@THHDC,NHG<$^5TT5*4<<.FAN15.,',6Q9X_-L!F':&8*TWP\
MO24YQ"$WL@O5D>+S<A)%;^$_NR+46JA[+=+-O2/RN8)EI&RJ\^V"BFL?ZE=N
M.SXS540XZ"B)*HM.=^24H[=E,1YMK@8.A<F_GU$MWFM!F0H6.(ZAB!.NQ?C\
MFY[U41"5TAH3Z0'B0N+0;KA%A$B5,<?"C35>H/C+A%SC_A28',]#;7)U BHJ
M=U7<U@2ZS?0LS'E%QA-^/V+A>HQ9= ,HT9KUIJ*<F;@_X=CFF!?,/83V #[&
MZ%_+LJ?=:YK50+\45"6\8N"H2Q;FHUKO)]H_FTRW5;&E]IXNA1 "X*[J5<K)
M\A3C%!QDU.77T\L6Q]B*&%(>OIU29_+=M$N_NXLNO0M_:]DQ:V)E_+Z*6M44
M(8J5'74?CB7A3LZQNIC<^9UG6%O6W_&IT2(Y3BH(-![I$JB(0[K$%-HVAD.]
M8955T][)B5,,GLV4D@YW!V#)'98%/>29:(P.]/IQ>>F<^S/-[:B)'>9]B%U!
MJ6K $^XEK'O9]05(-/(J!;D)PTQ$Q$(8B*W*3NQ5?$#Q&3.X-^)\?MV84TG/
MU$P95XV%@DD);W[&!VX(!>-99;MVDU') U:IE7!VE;)JKOH)_\NW#';OT).1
MSDW^NT8S%GM21_K$L=CK^8RHB=3]*B<Y_<A&MQ[$6HAJDB+BB\0TL#XHW\W$
MN#A;$^3D/)+]<@*<Z8/V<S-?E&2\8,%IV?FQV9R8#Q&)PT(L+TS7:NU*_+<4
ML'A&)DK[\!:RZ3N.(Q4%VR.V>:4K.#AORAP'07PO:[#8P*3*L(J#PD $6:2Y
MY4"S.*6IU!+H-0D!B\A)Q9*VDC^3D8)8_$]T&U7YH>#>.@0>P?QEW2,@!9FX
MM,6).&G&0/.^DK#7ISP+6>]K4/41-//<O;I I"0&P:@FPCF*GW.[WRZ/1EO6
M88?T'TI3H"E2>#L]&<N(G.PD1%[L_19&Y#@,INUK\J(J3J5(%DF"DR!<A)E<
MZ>QC#0^"<QN*9+)4.$7['4']\%UU4Q].!:ZND>"-TYBTFTQ2GI/M&(7AOIW7
M2+&S0^0RQ9\SN<XU8I^27'_B,8<UL]D9%0?+MQ5.D.70JQ*KN/F@0$E"#L5@
M&19[V.5&1DHU<]M^"K[3S'=I5O?%C?=>9?TFYNCCA[<]*_SP/BM\IR3_X4-W
M6->'+S^NJJ$KSPGVA(XK&(JW[[!^+28TG2-YL_51>>5TM'S\"-*3Q-"PW,!)
M,;I:6SZ;F%R,C5Q;5AOG6 A9,)?D8]BJU]IU2^?,)]YB;PL>2ZL/GFD5@,<[
M?I&E@"A=)7F0"H-7RCQP_SUP>I%FL.5R][!&C(X1[M>VV!.*6J$V\:D**G*(
MXF2ID ZB/V-?KL4"/(!3[MY;!2G!)FC!2WASK EC(HT5N!)95]Q3P\YL:FW8
M]5\$MR37ZX?LXO9MY?=N$ZH5[ G3QX'^;K$7,ZA@9@V/FBTB+;C9B-^5&'E:
M(>LEV8:N.;)6[N"_W_7BSK\H*MP18HZ/,MMXTU%R4IN6SIZ63?UQ*1')KINJ
M\#RS:-6[= ,.QR-<,HJ"1>Z\^WBVGHF2V7709%=8B(HH[S[Q!#3_04E562L8
M1KMAR>&[WYO3>_.Q\8[?*B7&2T+1<+.FMX5K;-2T%!EB;I=W#+^Z?;OX=1/4
ML;K],&Z1Y4@J<,_B/N)=V4@#!(T57V27/I(8G<7I&/XL&!+\W7GJS,*AF<?8
M5?/AQL(LG.#C%._ESFC]7>),RJRHK8"$U9+99YJS<EE*O1+MO=H!&Z;G!D9=
M5&L*K6$!&U5^QXXEO45%S9$?F?(__Q5VO#I SUX54F(=)6I*Z6C86,)[7/1-
MFQ;$O-G\3:1LA62IML/@0N65Z4D_%U^97+TCZDDE%21Q[K5+'OM"9;C=_?WA
M \[)]L&Q$@03_0$B-HR3D3Q87]'E& ^60DZQK0,"Q,":T[#V*5-:$:!(,$0>
MAR^R14Q"OTZP[_7RM%[6)CKO5-H7>ZR5P:[&T_TVABT# !:19@DA4[1;*6*I
M! W4@5#*I@/85$14'_ .X7[.M!!VGO:57 4=A"G8IM01-WCSVJC0Y=D/&0HG
M[+;,T>Y*,Q!RDZ8!8@& #VO/ @2AZ=0S]QD'K(7?%<BWRZA9A)G)^:T4@BX9
MY%@LRX_)!J;IK!/N0%(@HZ]UL4W_?*E1TA?L"T2KR-JJU *@'0^B*ML#-D]U
M[@VGDN&QDX5PA;]E9XX$ZI%B*G)@#09LJ*Z&-35[%OT%WPH335^;;"OJ]8RS
M<1E5!U_KZY.ICX>36;\>*[(;CFIG.65WJ!;FG*GN$.C)IOJU)EWFZF;HK!NG
M0[_9D?F1$,7?J5S^%J+97F-^5&%&$Q6-N"4XL(^ACL6>9&1"6G-"HHKEX[R_
MDAQ2]O\^%JM!]!;I2GUEBSO+6'3+ MZY1E5H?EQEVVQ%P1LL9^-;+7Q,AEL;
MXW0#NX7(EM?)ST-^*GJ9*5U.&]CXZXQ:8AHXGB]PQ;*,8E.7:ZX[Q.!8<I:U
M&ZJG(V8+-V-Q6W?'?2$-.V0?IG#I&K9YRRSI;8%0[HE*Y(LSP?7F _<,X>A9
M6U0<9),CRNJ#AI$,+AR060N-C$%M1E\A.EV 'YIU0^3B:88K)8O8]4QUA,=C
M84F7-"6U+HKN@%T7W2C^*LZ&=<.&M>:H W>&Z*)R<^#,:S0<E>-.9$>#E7B,
MK?JP:Y@WJSE,IS6.X=,X5<[P)5\O<H$:-QOH\Y'1!#-HRTPD88R[2),QUB+&
M,[(!/$9<*.#:LP+*)W*;C[EI"9:"M@E_ ^/I?1L,YQ^JG$HA=)@Z]9:[-@;I
MJ<^ QZG$MX?UK0K_TJ"GTF_X]BQQUO)YT?;\-'KGJQJ,F6TC0HH[X]DE!:'
M[L%S3OC-430WW,:63D3R0U#0X7\/4MGS6=^SAB+G,NB'%O*;CZ-0W#E!] +O
M)]M&D6L4<"!,Y]J8W0^7;$@)H0:@_U U<'^23I^D2M#T#G?.K65G>L4;*@A=
M6H22BW&2 X+5"@6C(]"K=87UG-PO:U H)99'5ZB2*Q+5H2YJV.^K0G%1^,0
M3<"4,2+_O%4=B(T>P48P..W,E2!4[J,1FN)Q#+[*T$PD>*)0@IP=]^T3>2$Z
M8/A!&]>@&B,]X,F0"R+@<-/(L*-!@_5?]LCM)SILUR,E[N"("]63"@Y ,VR#
MVB-<&AU75-Q4]Z*')U%F\Q],?B)RR/)*T&4AJ\)H8=3>:(M-5FJ/3<J3!>F
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M#0;Y;Y:/KY[]^.)_O\=__.W]WW_X_O\#4$L#!!0    ( $N*)5D;-=*LTS8
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M[+DM$/#GOP#?KZJAF.,<I)I<*BAAX-1T<$%3H019BPB<^M4T1'Y@9H"(6[3
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M=1]I$J. "W69^A4]51_KA<.E_+ERRO;BP8F'FU55HZMY#];TP9KO_ 0%EYQ
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M6@+3PP2!/=%(S%7\76@ JGH9U-PD;[_%\+G*I<;QI:-[6WYOX/;*59&G;]#
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M3O]F*!+Y==9#]X!<0A5A(O!K*K+U*SYY$8)%AC/T?"3XN-X^>5$_^>47EA@
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M@*8IT[D4P]CP=OVLD<-!+R63J?1LF8U,ZP Y84%N\VOCUG[F[9]$??%XHO9
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MK#!P&VDETW:^59I9L_^+,^L&R!T98\NZ+?J>L_WB,WT_^M]02P,$%     @
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MYTMXV&P\"N-7ZPA9.E'5D 7"WFP\*.UH8>J27@J:6"!G'P$7Z:%6X9IR!C.
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MI)+:;*Q((M'GRVS<:C:L4EA9!1P'8IC?[[1,I)]!!)CC+* EF:I^F$T!^ ,
MHVJ:GNA( @Z#+662E=+7@'BD&)B84%\PHBLPV< 6/QZ9!$)%ZCDJI;J"A80P
M<0&*)$MR>KB%<GDZ+XPUM4I,J0.;'K<J;C214#O!)L+;203*!70#<&SH">8W
M$PJSW.2P8$T$>,$HD#L"'!T5(0)G?TD&Y+-_ *Y%,@.I^:!C=G_S-BI3 <!O
M@DDF:VDJDMZ*M]U<+9N&XYB#UUA9%MD\CQHTA^&2S=_4O5EI(V5L6&?RO>#6
M/6I1VM+%.#C,0/FS^\04)2UW]D0;O*DQ;QB:CI(ZW7!DD_#")U@K,"\<DW@W
M&[2X>_#1+&58\\55,[R W4R33"TH$;4\QTE[\-PFI4BR!>DPNUW*@<.D*)LZ
MSQ5(""9O20Z-&T_+_,O"4H#!'TOR*YMAR-=)KAR^%%<L?2]P+N/ 7[(/A*^_
M5NZ%-QXGZ00D:)W]?W8VQ*>&I<-+T;^?PG;;J1SHX*6XE!/%M+I,D *'E62)
M?0N_^9'T^?9R7@(6@UBN.S?=JW-J0/K?SLU9M]<^[5YT^W]L GQY:N"+0>.F
M,$=VV$<PF[#5;;DC1"]I-B(L=QJ'MR)BQ,2)C@ONK@ /:#J,7+W;AH^(&-CO
MD5,$IZQ#+5.-JUL8=(#7=6$,NH=ZC5]Y]=XL&*NPB$#AMP]V($Q0NQ\+F8*<
MPL]/CG9JX4^M(%J=^ XSDB;0&%*M?OO@N'=[?9(!C_'?'8SN8XU84*;.D?\.
MK^%*T#NBF:)@%<,3JAJ([<,=> S<L%U8)K:??L[*P*\^?8Y #+-8F!.$;Q@T
M;*=)037&,)G%=H18X;@Y=H!%9A:@::"FN0,6 ,IRX8V$F^<P#;]-U41J*IT4
M,2X QL>V&,12Y:J )(FID"+M ;I"4+A]P/_9$3ZY"+_*(;(&@TZ'T,BZY[ W
M\S8@<)T W6A0;P LE9<@QE*]WH.WUVQTAP]*+B9^K=A6>N/F&^,0HB:II>J=
MF19A&)# B+:E2RWOVR)('YNL;8V&]1PQTY0QI4T/<_.*KPH.22T:S6V5X#'U
M*="HS0;SLC)0 <H;,;Z4::0YB[.MC;""C.X(XD=6:ZY83M:?TPQ9D+E-4)D=
M54#3L*#'G4]3;=*RE .?[^_9#$LZV$&?T2_I0$ZBV7C780V4"UHH%G7X<=D!
M]'AJ; /%8?>[ TK445FZ:CI@I>9+(ZDMRKB]?W>+?SOFE1TYJ[GG9%\*7^'(
M@J#@8P4EX4+\YXDYYTOYP[\I[9Z>5<7=.2;KEQZ4^H,=U-258F]-Q'(A)SL/
M;*R*N-^J-$YFF$@PG0;:SWG\7<;HC'AP)HNLJD4KA&G'Y >!!*EG*FQ:Q- 8
M1K5,Y S)G%5:QJT]<9GD*+#83A1:PKDXE[BTPBCK<H?HRIA]H9+Y&'P,Y7(,
M^&I]#9$ BW5P."<*V"UE@MY%!J[._(TP9D]-/OJ,TEB$?,]@_#2).'=7FK2R
M%\/U[-A.'4K[RWI_78=D?X'X^LF#'?*RXLQET<SLG(2HO6@3##M+H*7(P63E
M_/S*_F*;6O_O9:U$]H&#YT22%=F-#9&"IR8.LA+..7B6@?X\K14^J%J>Q1B@
MKE6L.X+!EJ$[ \=] MSYV !NL0!O5ZOHVX0KO#[YJ@9^T>K0-PV^?^?8VT3<
M'8R^3:5U$\3MR-95@?<H:AV@@C8->;8PQJ)WSET;%,_HH:+FT>2A"* %T4IT
M_U"8@,E8EZE&<U)ZYQKP-[GY/=&F^ ;')<\E*HYKG77AJ+Z.+/%OS89IG;7K
MHZC;:UV9$N%D!!!M"O@1:"NIK Q?4U?SO7D"@4TRHQH@MR9DB=<,^S#8QPY5
M#H3*MP@->DV4D9R130U5%MCFZTII9ADJ6^2"EQ'76>$5#%V!TS;"2!\95WV-
M#2>8)JBJ2GL]V;)EISI0Y))+3!F%J#)22\Q)HXY-YH%[K;AM%?MKL;D)=73;
M"UM,<8$[GU))V!%X'28S[HDG-F4[U5"<1IEQX.$MGM-'6<W5V 22.^;F'22J
M]-$NA>ND,DS7TB@XQX9@W,NTS!?:T=YLA(RM4^5X^J.@42UH//U1T/B.1?K(
M8-LW@#:QD1\/Y%<,9W^^K085?HFJF[1B\+'0Z%8I]'%O+\Z'#+!)4)/5'!9T
MA@?M#3IY7!&Z:BJ\EJGU]7O7-\+H'.T=<0SJG5L",G<S-.K<0&!.4UIVN0XY
M/UF1*L.3'$]%9P7!H5!%&&*X"K?C8]D1YYK6EK&1,A0U,%AZ*V#I4-L4NTD<
MVR8 BVK*)KA'[P']5K6D/D9FR2 W503<.75*R\CKC8D \1$+J>N0.(:G+O&)
MH<*^R$B,L%P0(_7@!S Y<4 U)6[&49],>PTYZ;)G@?ANVUHP 8Z)2I=3I#[,
MH<2HO]KK4NWIB%6@,HX]03ZP37NC3H-@FIJ89+N9ZX6[H>DU E5)K9YA2TRD
MRZR)Y1+%^3E?G^!:>0CYXZ&YW/3,J,D2HFZ(F7I&9NH&;ZO*J&FH5QY@,.FR
MY>&);ZM:B&7X%),LFX;H&BR*\<"XW.E(C<C_M.P)1)ZH=IB"\+>M(9C^(>.Z
MC(GC/.A#1FY)T&O/Z:$ <" GZ=(#/00'Q)KL_4BZ:")2JM^B@-D::'ER:X#7
M9I")GBLG/WS@@_*%@R3Y@"%,>B^63=ALX/$-FHH/UZ$(>^LI5Q*J:9+1V5R7
M*?3[O5(U@G"6&VEAVEV>-BB )R&HR@J/A$=]L<#]\*80<(1R(I'CJ8HD;<;$
M3N#"0+LT4XPVZ1H;[=%4GR.80UF>@L"2S+V(DHP[X?PW6U8$)K!=^8%G4&F:
MI*[C3WLNV5_%VO-OB"%X3H;@+4@+ZB3PQ%0 ^XG1L9PR(;5^NZJ,N#.,I/9(
MMID9C[WE&J58M-8JSJ3M2(4Q# AJ-E;=@H&/ >0$=< 31AK7.BSBD,]@P6@9
M'F,N,SRS<I\BEY]$,H"(@Z/VA^W*'IV(]W,!?NZHC/\_X^ FIY]+V.$UC;96
M'I@ ;T7@@2)0#\/1^_YNRYUB$N0#XG@NN]6NTV%$+^8 /6?-;#'AUVVUXQ)9
M2RL.OXH'"@Y+[$U5>E::^DF"$F(4&*!53"V>I>N&W4V48L"%]V0 %;(Q FM@
MOD\>(VS<IP*3&+30,E !N1,E>-N +S'X*9"QLL)FPSO.X,G.@JUB\%7DXR3E
ML\/ !^0+?4]HAJE8WC[@=M6R$I9, ;*6715F^#+E&21%G"G8A:<-"QZL; KM
MMY4-"ZR 6BK;J+*$J4J\Z?;..A<7[<O.U>U&G&)X9NH1SE1<@C[UL=M_"/(,
M.L?@[E)I"FLJNA0;IVD/NZ(N&XMNCB"2:*2Y0U1.CAD>N(:M4 WRC,Y Y-C_
MG5'8J>(1@ *G80]C(Z]* %*(LF_\M[_ 1??&0*A$,,A<C9*;[2-BB,!%&"N(
M5XD$>FI^FM)!R!:L,B@F XHBT%KA^556!=,<2&2C1G37D$ J4IE3B;LD HQI
M@@<=5W[$ Y5X?D/:I#9$'[C./XMPQ#WPD;K#-K(\E\&8/QG)- ;+-;\4@-8<
MIY8G'\")!$JA6<N\HPAB(.,/:3'-@WMS)QM!;IA$3:;4R>#M8([!,69[Z$!@
MHLT!U"$(C#D'N#P;30+FG0![QB? /&,_3:FS!*"E85.&M+#%&H.I_T:1AK!?
M.1:"$=<J6)[\'FF8U&0^9BFZ.#Z.2RNI]3@N._=7.D/INB27^L)?'O*%FV!]
MULFY'_W(N5=S[D<_<N[?L4@_,Z5*\*, ZS(3'6&%,J9/3 :.[8E76EY<MJNC
M[1((AB%XM$R%"_!X8 Z;8E<ZV)-4Y=QE'(<< B]8R,-A^N*9QWIB7:[)4IJO
MA;ECSH8V=:29*NQ1RO;$*1[#-BLR1K9^[UW%'1SR@6"#1Q!=W!/>+9NPP="#
MA!(*!T,_I*N&<K<NA!P\'=IZNKBC0@(:D4O*_%BKO C!3[.O3[J6R]D^!&*:
M#9UQ*3I4U,H-[G']>1PZ7]8BH0TZKWV,[@V=JDZ*#"]*BX%$$[RTK)8R]>$5
MWG''\8RE*_I@XQ<--ZUP+^2@3^&Y_!BF4ZE5$I9#FV\VJ!X.=BY*3!%>FD.M
M\$BF9(37G<1W*H*/!+EH\)0HE$Y8T7FB[<.;1%I>WFN;$E_P4XX&".B ]:H=
M,T."F)&N(B%L@2AO# &;]W&J1D4D<178B&[NVS @Y#:F&7JH"9FXQBDBM"1W
M9KP9<YJJ--CQ:=@6N52@4UY\>D54OQ%8X)DI5KI[)&UBJ7(ZE6[40W),DE";
MZ'29[?2[,K*EB1@,#" "?R@3 Y'1JE3,L$AS<]*:&T0)S0+@E>Y:3+MHS!7Z
MW2GE@NT]AWY&90+"D_(5AJQN=&([0B1.4'H=@V"RZV@B62GMO09K)=H(Y+;L
M&1N9U9,\;"@\BA(-LL^^KHZS>0/3_>;%FZ!?R5R9AM*(7C+&]/&&RD'IH_U?
MVV90>U$AM_EC#F8R-8U:2):YUS9$L;C&_!N5&ZG9^T+.RHJR#9#(XG"-<EC>
MW<DRR:5*3H0C[INB7>+HZ0Y(&F(3(&6W5(K>PR;*5VDG_CZ#-,0*BTL,8EQ+
M>C.A+,+ 2)7+)D+X%4,$'G%O DCF$(2&LP.XB0WAUC.&C\W&;X6DBQA5^9L4
MG%W$(PECU)#Y^V22^7ME']0Y=Y@ K_)VB>T5AS?XE(Q-W[M3"/;L1WE*HW;_
M&68W:H<ERZP,B1;B-59M3"<9X^P:1V8F?6H+ADMN5ZN<Q63\AL)L;K)2GQ
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M5\W$Z%U?>"]4[.TY1O,\$'I.QOE;_%(J=$O%K>O/ E]1=H%K#TY(XRPRP!Y
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M8:F7U\):1<+FYU$%$<&6=+#"S]U/EP1=5"GP/58*$-UJQXRL:HGG#08AFS=
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M=DL'DB$I+@T')LJ,*)KXB^7P6%]'GPBVX_B81X;=R<]<H) G;@]DG;!SD\A
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MF,HJ6]UOB.GCTUE.-B/'C^_C_4T-DQ2:/]3E/M_@RG-\I?*B0>IMFX"B6&V
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MX>L69*T7J/W%Z2_.52X.2&YK[HV8PUSPF(,8*XP2W')?A^A$FDNI6;TE 7J
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M?!KL*[ 9RXE+I_%R4%#^5$/J2I7_APY9Z+>EEY-(WW'NBI'>J S S0!L2E(
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M#WY<4*2NZ/^+%,M\O/QRI*3N<(4>7PG$9R-VDA]IX[R_^%V2S?X%D"9M\EP
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M#>PS0K\L,SMOU>Y[; +;W *+:Z&Y/?X$4$L#!!0    ( $N*)5G$T4:P*0(
M % (   ;    96$P,C$S,3DS,#%E>#(Q+3%?;W)U:V$N:'1MS59=;YLP%'VO
MU/]PA90]Y;/:'I;02'QU96,!@?/01P<<8A5L9)REZ:^?@9!U:=JL4K:5!^#:
M]UZ?<^ZU9?T6??>FEQ?ZK6/8Z@O5HR,7><Y4'S1?-3O83>NF;]]!A.X\YUI;
M<B;',!H6$A#-20DSLH&0YYAUFX$N1$30I:8"56CPUK@)Y%BDE(VA<AU.0)('
MV<,93=60H.E*3F"!X_M4\#5+>C'/N!C#9D4ET::Z.74>5G1!)5R-^B-]8"H^
MP=] $A,FB7@=R@>V*(O)?P81S<W(M5TC=)T(_!OPP_DWX_("W3JA$3ASY%I1
M%]R9U3\SSA<QM:KL5D*&Z3E@.9X7!8;ESKY<:T.MM@/#MEO[S6@V-)&KRG78
M>1&+FN B(:(:S'!1$J7H[D^K=X6.PG;E'T1(&N.LE7[!I>2YMML\.K);QSIS
MKRQPK-(QOA&XV*/Y^+FSC]@KO,/0)!R#F2FP,.I_4AQ+GM%D F?LE;HE/)+B
M#&8X)VW-U::WCU!I4%]U?A7MF-MI L=ZMB+5*^DC:9C]KI%^X\_0TZ+WECBG
MV79\2H"#K#7=KVM!RX3&DG(&? F^2#&CC[BR&P&JU1H-U"ML2_^<Z6$32%[\
M$;ES$O+%^AX#6A'56&2MX)3@%\J0E*5@\;S ;-L%S[.>TCK)I&WGU^K\'MC;
M),,;+,B_J-D1I8UU*86*PQ#(+7@R>0_J[D$=J#&HC];I&4[S9X?VH+H1-%>$
MZB;Q$U!+ P04    " !+BB595I_O08@&   ]'0  &@   &5A,#(Q,S$Y,S Q
M97@S+3%?;W)U:V$N:'1MY5EI;]M&$/TN0/]A*B!!"NCR$:>U5 .T)<<J;$F0
MV*;YN"17TM8D5UDNK;B_OC/+0Y1,*W'J(T4,6,=R9^?MS-LW0ZI[85]=GE0K
MW8N^U<-WH+^N/; O^R?=5O*.5UOIY>[IJ/<1IO;'R_YOM9D,]3'LM9<:;!'P
M"(9\!1,9L+">#-1ARI68U= 03<</M>M P-1<A,= 4]L=T/RS;C!?S'%(B?E"
MUTZZIR?]SPOA" T'S;UNZQ11CY_"G\M#S95Q^#ITHF7G>7R=]2?VX'QP9ME]
M&)V#==4?]O#?!GL$]D7_>4 8K_T>6,,>3/I3&\'T8 O98'@VFHQ'$\L>C(;/
M XOB,3FSX'0P&E]8DRNK3BB:_R<2F,5%Z'$R:#??BG#+?_)*PT4</I\A]\WF
M'2&7"Z8"AIL/W2:\T0M>K;SVO4^Q[!"!I%I*Q;20(8%]K<R%G^O P%U? JGF
M+!3_< ]8Z '_+"(MPCG$"$V9(><6;H32,0<Y _0!2R5O1(2V43;RGH=<,1\*
M+JN52[;*KD\UT\:\QWVV8HH;L+#&6K( H/TF;D]B0!=<<43D<J7%[/;XB=+]
M=QS1\F5IJN4$>!+/E. [;M\9OWO-Q+-->79CI? JA"S($U.,GHB@E"5H#%Z:
MC9GP*=6IM41A%2$EP<16N.DL-"O29;:];K5B%EX)O4B2S5W%-5.W-#?/?#D-
M5BR"*Z;<!>P=U6&_W3Y,B4?3S=:&\0WW)5QQ-<?A:>PD^WBTZ">O)L*E%'BY
M=.\7TVT%'"\G9W3"(PJD]\5$;7."HHTY1\MO2A8=ZC19OZ3)>H,KL@1:'3:/
M]"YPQ7/]#*E,1/.E\GA0S&.NKSMS)W*=2X,+6@+S/+#0R/4Y_#48#&C,9'C7
M2CA'<8:\P<Q+WY>KZ+DE\]VC:F9#RZ5QGP\X4FL9I&-E)7M-28K:DS0)V6[W
M#YMO"8;#W.NYDBAE#5?Z4AW#:B$T?PD.FL-P+QX[H= L]GT4%:S^&LVJE257
M@= D,4A!FI!KP#V%NDX$HXD1:;8A.38'BD8#=FO(S&:8#7#X6B\8B102%X=+
MQ"I:,-^O5D*IR0@111*+DW\+OF .'H&,_1NM# CT&VGI7B^DCW6$6*\@D&&B
M<1X+V)PG@PY"0BDS9="+76&NQ_J6,*^1E:C3W9#_H.09<JPBIDE,=2HPY DQ
MN(HO.;+$I)4ZD8)LU8$F4.J8)Y=9J:(U\KXRM]LMDO@MC)!IU :E!6WMJUI)
MG!D: ?=%@+T-+4/@,-_<0."S&7=U*4Y<'V=&R_0Z 0R8)@Y+EYHO%/&ZH3CM
MWLWXAWMP.?=(X9GKJA@_5"LT2^'.J->BK3-=!R?6AH8E\5G)V/<2<X.7;'D=
MEQ8T7T(4(V_S@-?S8*NMB&Y&*(]N,ZV\3UL'7J[>'J;UUB+YD(:A=^]8=C(K
MX8SB 1,41"./E"PDC;E',J3Y$5K0M\76)6?<5\60)!]#E]RG":PD"]15A_,0
M119%W# 51W$*$ETJCX48W;PMW4S8_N'^UIUFM;)5@'Z$;!SEV1 1!F S^E:>
MG82]#G=ED F<N.$@@@!U"6=C].,EM894^ MW@'?U=KWFCOL%/&/WW# \7DY>
M[N:\MNX5?VHTX%QPWSN&,781'9S_*>9(6UP6&HWT$6JW-_@S\UEL68]*6E8S
MYB#YN<K'3GTLM[!'K0!$TA<>(BAM/9+V]JOZXF03W19"*T%)C=!UP^$H<+B5
MI=G:5R OXBJ$K)B!#8^%\+4H?DG('B=%S_!D]K[^R'@?#.'#P![VIU/X<-&?
M]$?GA*1>K6QWJ"2"+HLCNJ/;>>"PS#O42',W+K3AYME(A'CH24"L%U*9!W<[
MNFA& DHXT-G^K]WI'^,3O>BVZ!V[87.*K7B.!XINZ+$#?5P9/2@YD;9U>MF'
ML_[EY71LG0V&[W^KM6OF^]CJ];+OJ?.5\/2"O+=?Y2<%FU"?+2/D:O8IZ< ;
M$08C05HSI.O:DXQ\=B];\88B[C(_RRM2O .IFZ/VJS5<N_<PXP.T/:4'DF6&
M7SKDG:2G;D1+1GH2RI5BN/2VO\1^[?+=*T._5M0"(MQ9$WY'P5?\%C7X^IJK
MPE[P9?*@J#PL$@FR;[,98F=Q#'? ?^^P;:%]PKT0?(;*%F('([ -'R6'<0M]
MR]!^ZVAM2/==X;Z_F'V'AF5E<A+[O)%I?;'D%(YU;>-"\1P7BJ-Q6U(9,[14
M9M+78IG9\/_? M&BGS^3WT/I9]-_ 5!+ P04    " !+BB599)W@=G,&   Z
M'0  &@   &5A,#(Q,S$Y,S Q97@S+3)?;W)U:V$N:'1MW5E9;]M&$'XWX/\P
M%5JC!719L0W49@3HH&,5MB1(3(.@Z,.*7(K;4%QEN;2L_/K.+$F+5BCG@.7
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MO=C^/-"_'^ :]-MG^F,H_6;Z/U!+ P04    " !+BB59G5PLEE$%  #5&
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M_4Z:&Q_J@$0JON#P52VI.GME3'Y/X,7BL1R6PT;E&='02H^:W<OIQ,GK:L2
MW2JL]4CZHUN+%NPYP#6D*Y9!GT.6\)B4Q98X1;EW,M;H(WKH"#RD 1G8*'AI
M%+$HM^N:QF3! S!AS=6R6C$!9YYDBLI'+;Z)?CD5L,4-E=Z2')W62:?=/K%
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M'L.8"6R<8CW38%'1U'SW_'[UV?RV0YFFP'&A^GUDTC4(_VBD$@W-80/* MJ
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M^LH/6Q.VRN'"\>ONEICQMK#Y0M]%I<6224**5%;BTVYY!C>IS1EP]Q:Y\6N
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M*1&S $V#MSH$%43.AR87 +]A5:QK>NR[BML]SHE#^!P->^B]//^PK$K]@RK
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MSQBP9*DQ[C*\T?0<@VDER&I1KAHZ$T$C@HA@9J/!?\.S5[D:!J80SJ+A.&?
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M\*[)\V3-;#?DL.(!SH1ABA: [R>A8X:R90GR2# ZL*AGX$:&3RW Y+BHV5B
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M&B/8NJ[)H:'N04MZ5<'Q Z>3X3SUYMK3LQ[,*^(U(9##$;08SA;GC8 %CZF
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M$5M%T@+%:@516GSSG#LE46/?66NK**A.U3#5TY5I@)J=H-&UJGJGZYK[AY*
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M(!+B?.+8%NG9P(0Y<>S99/3>'B!'6G"(V/"_#T&[,)&ZY#)4MP3D3K[!CJ@
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M8.+!PQ@SKMBG[05^T A(X?%I#)9%F5=%B>YF_1/F\U7J?0(B(!O&\OQO8"*
M,@]SJU#T= 80P'[@G[)@TI\ZSA\T2'&RH&FEPX4B@VF \R8.*-[S7>LV@D?(
MVF 1=P-K?*C'KQT$2_R&OB]OJ7\!#.)L'J5D,@[$)?G0=Y:W9HE3UAC-QIDM
M-CML8B22H_ /H";Y'0<.#*YM]E(F(!X",JE!KH/I5^#]>\51V?-?K_H(6P![
M'+<!?WD>%J/P=W4<SF-TJ_("O*_>)]E@Z3=7Y($Q/Q ?OW%9\<2-6!1WT@+U
MR"&0#(;F)%95]RCLWB,Y'7X+6J*7/I%@B0E& @OLS=#7Q5%D4.!_1@6>7+,8
M+5T2?C=>%!^4U&4JK(B!HQ/4'[\9F%U#VM9CM48!2BMTESG2N\C<B>O%F"#^
MONJ'.AZZKG+K.,%#QQB"I^OVT(,@MJ=,;!H9)G$YUK(*2SXD,Q/40#.TYB(*
M?^MC<[$=_,0<0TD&;J;X\]RB[=8YJ!V,.:-8+_;B\1[;-$ %>V6VQQQPCW\W
M" M$D*"5DE4EJL[H]I/ ]%&41N.88O 7=Z*NJ#,3;2>PU0C#DNC_C8 %[^ZB
M7QM^3BQH)#[G[:T"M'5D1+/ ^5C1IW 0,#*I]';).ZQKE,#CEFV$Q\MAU\B(
MD\'Q;75+;Q>V9%C"_# P$,:C%2/>3:.4;0V<L_A;5TURS6G E5L]@WUU85\1
MMD .YGET&R/&$X&=Z)8,T-G.\[)3,G38>./VUAJTM()4\8U?9E.6GT:5)ABE
MC4&7C<&D*\,T@I4GK.HFN @7[>EORX-@1NLXK9^\5A>$LRE>X;LE6/F:12)\
M?5\^;=Z(%.@ F,4Z^_'97F9W-_0^O%;7BSDLMY>#N31\#0K8+.*].L]P!YYX
M3FC]%'[SW9G^Y[\'ST@H,R_;WKHD\-@]!^(/[P$QU?W:9_N':"!$\Q($3<'B
MX"XN(HWI9^PH(G]SY7WO8D60CV)R0;"VRN'HAB 2;OE'C-TCI>@NNA5!GR 2
M,V03;C/G*JFJ55D ]Q\1:K!=+*59:74:BAN/QS'P&G0&;V_!U CQK!,C[D+X
M.-="9RK:&Z4YS,+?&/0K7\+_4W<"FVMFKQCTFU#HW7CS53A"IS,B%DB M8 G
M$<O#B0L3F&ZJ=;1U=@W/&5](?T"_*3P)IJ\#6*0,%<=HLM:0Y$Q<VIR),Q=N
MV7YL2Y"_;?D^W?-H :;2_ G8-(\0N>2B,A4!/7.$;=:^*+-@)4@3GVS/0CA:
M).%=6^*&[XJ&Y\<Q+)F0NQCE3P28@#^8$=1CZ+_? \WZ62I>:HJ+G-5D("ZX
MY0#6"$T\3,0T"JQ O>ZR*ADY9&<(1 BR(VN&<B! KTNB"=,DDZK>>!=[:]F-
M3B$:D#U1;G!; K%(2/6#QT E)_T2%DZDXD,F0GFQ47B!C[&SR#T$?7-6D0(]
MC#AISM<@Y%XI.3]#=O!HX/GVE@W2#>5';APIMTR6<?@4<X*I5SDCG3=B@H-H
MD=$=S@H$IX.6  HPTNGV%NZT >R+MET'>Q.B*,5TKH+8X"B2/[NZ^V#A+&"W
MYE]P,UV6S;SA\0@$4QXRB)(R4.ZF=&5*$&@($GIV&#PY?+GACN31+(P1%XF[
M.B(NY4J)[2T\P&HVPZ..8EPEL.'>+DWB'6(W!09YC1G,<D&:QBUNULX1/\64
MP7Y]AS;:4I+(+*$]+S.\R;X?7:!O+$%# H4'UMNN/<%HY QBX<VQZ\^D)QV9
M57^["X9CW52P5J6S5L&3X3#V)%SIERKV);0X$I3C2- 3D.MAP^$-MNE,"_:$
M0MW$G=Q9X7;'M[N*]&".F1-G-81,.PMD,D>':8?7DQ-&1QF0$"XQ^H3H^[B$
MW1!MA_6#.3*K,"%*,?=)ZTDPM$- ]7GNJP]V^SM"S.%0-"N3,N2'F>ODOKVU
MAJI5\RP9EXJG>J& (B' !&5#?)ZCX>&HQD]4#V4'Z8!&WT4YAFBX$@^=(L0N
ME!?T:;0?%"(S$%(7WH#Z%=(%B2*=Q(>[;^@ F6B>51.^HM&G:&AS0%,M@1%G
M6,O-Q:N=Q%%ET'WF!9HAU'36P4( ) X7"*S@-<G2>GS4>OE)N*P\+Q0;,(R>
M.ZA50(E(5RA0&PIPN^[[YPH2?SO3\SF9GI=A>O-Z>^LL!NH:B1K[@,S/YV!^
M7J/7=WVC$9CI#0J9>4BT9AQY/@\M. W;YE073E(U,=;$;KF7C4V6UEW,9%O-
M6R625BUOX1E0!O(X6;#4=C_8"7W3Q3MCWU1Y0.?]1/TTYWC#0IVY1T""ASG+
MTF@(LA5]*'R>]CRT+D'(A'R>5$70IN<8Z1=2L$\GW'4(/#%_].OC]0,K=Y@&
M,*Z21"O(*#)V@-;84,%'#.I<$K-X8U8$4XI=W(]:_ &5/%Y/W8L/M(>7!?X"
M*B^2'E\:\L!8;<0=#BTWV#P20)+5B.8SAT:=J,W"\=N/T*K)&2H/5PY$([T<
M?N>D4B(J/N#[)X'HJ4\%]E1;$YK-PD"#K\:X16*D87#!$ZOCSPB$T<MYD4;<
MLX2GB<R1!%B:F1 *.7F(+9%908*PJW*#$R/6C E> -^% _3E9-X"=!RE<4+
M*YO80<L&1<5%2M740-3-1$PDP?&5C.==PY0B>>/'^EG]:P;WI$S2>+"894:T
MO:]T;F%XF\4C2?]FXLBJ 68<=]I-Q@/'@7/0U,&F< E"1W+J.PFJ.2RT0(-
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MR[(=_^+>A3E8Y"7H\JOI<.62E"FSZ2HL6$05[^GV%MXXBD=8=*6J46!N=Z.
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M1^YD*]=<K?J7H91/H_ ND:P6^6)R-$F ,JO==7"='](>7%RUS<\>L7O+  )
M;\P9K R:T#RR%2];=1WL0=5=:BY7H):@BFIZE"71)$R\9EFWL)J'(.L/#XGQ
M<<TSX\!(%XWF1%GN&%H2[F[Q5W;CU46+EDA YF7@?5:F /E,L"%B0!7^4%+!
M^6%ZB>G&C9]KAJJ9"CD.BRGV/A8/(3.H]FYX62XS1EO&80=T\:5F2IM!TK8]
MD3IY?WP6>&!![5DA6\@$66EA@@[I>.G#H,XG1)U'67:SUT_+?/$:++E&2;CK
M->.KVK.M:PVEY!7>BW!@9"VSFN49*+<\D-,M 5/\V^I6;9JFX\S$L?:(N\Z:
M]7!H^F@'1J$.W(0PCWK![7HN2K.QPA^9=3TZQLFT""39,%\N7W(."."B$"BJ
M1Y*, ZN20+=K&.L6N=JDI\U!T.[8EL!S!@>FQGO9J+ F.<0/XE(]I4MU!KR1
M4%$_@CK*H*MU#LZY?B:GHU$Z:..Z] [P7B83J 0F&&#X)HDX.P.KT&8+_*I=
MT10/BYLM&D@?+48T275BCF'@<YQ=JQ/?D7LGB8:+X;+,;-S9!I+ZI:$W_+?F
MN-T+\$=K!G--^9C-%+PB6W/[L&<\)=+1NIWN!::@E/9[P""<,3%F6J%!*I,*
M4<];#73V 4%MC/=%%$?'P61R1Q%W]DU+Z7_#>_B,[N$O5)#=T;RD0GL[I-#5
MFD)3]9QU=5NT?0UMS+KJ$>FAN_#F7D<]0CP@CL=4C7<+E-N72_P^L^ _^:$_
M/S$6-IDEK9A?3G51[3!BW++TUWF*+9:RNV>8>DTP!M&TRCS&0J^C*<L:G7J/
M$?TU)D>E:]$G#*\@J&@V'(:L[GEAE*$@%]#>=,KOCT NQ[>"NV-0@H[.NRLT
MY?,$-6&[6)K5;&]U+H=C-+0>=^@U5\@I.NO1XZS"B0PBI[%V:[S:.7]*>EEI
M,[AQ[: V@NW *%J"U,G08,G,[?>SMFXR 35;AY,X="LU#&@G1@);\FL\K>5E
MW]%H,CTA,:F=,E4:C% +CS@K\&ML85/+WS)$;NB?;FA+E;5,P&!IJ&\SYWIH
M01M2O\2:1(0C]0^/=<D\LB!P4<Y6O!6AH:E<MEDV E+"R<MA.?TBI!9++0)E
MZU_HR1HC0((Z@=%R"1>7(291+H4%S0:ZQC'A@0+V-5&**3V34ZT644Z<ZL[A
MB+,<&>U!+,6I_J$=:&2#U\-FSIQWBMV'(3*?BYL6-DWBRB(X?P$RQD_1Y"]B
M*M!-HJ?>R,0I-X2><C"-ZMUA^7:[O;OIS*CLFB Y'"JGU@NH3\5C9CR-%\8%
M!T-Y4/AZ&@]BT[P+7KULY-*TV[7C.BMP,$)ILO CY):N]3N%9<L;8\PFT/=!
M/F.;R*][P 1*R8MC#[RJ*Q$Y;HY[+U7Y#4GQ!9,BU?5P.@BN:4=9V^GS Y\6
M89[E M;H:HOAXBBDSJ 0"Y8/Q%"OV/.>CZ]!Y]2SB]R!A"5E@TD# SD-"ML(
M%D1KTN&F!BG1GO="HY?6=CST]$ZMO5&9Z6HH%J:NKD@]X$JI%^VN16>4I4X?
M1"D^F7F-E]S*]O5MPO08'9_@LB_XK%-"%/E%2PG1.@+6W3VPQ-()51:Q$1_:
MQ8=6CX,CG(_>_O>;T[>7Q(/$&J)0Y2G!$E#4HG ]@PEB3#F]P?2'__G*,[J7
M9:\3F__G]]B\'YO_Y_?8_)^)I#6S.) T_Z.WI^?JE]/K\_[5E?KE0_^R?_$.
M<Y4"U;L\[JE!G,V!1\[" *[W<)][8G&OE-7^@[$P0_(E!^K25D"R]D.GY!6)
MCNID"S".K%WN,JR[*(@)<#R-HS&<4PI"A8P6BD#E&&_J51/,&GKR,E!/#IX\
M^^*LN;:WM0.\[AV=]=5Q_^SL8^_DY/3\_;\>'3RBOU]][!WKOV\\$>$4PPP$
MZ+R RZ+_]!H4S%$YQ5$._OZ(B/C-]:5^ >WM,$PTU?$%>*1I_?K$3!_^:#Y4
MQQ<XV_-_/7KB377O+L+#Q6&2D>P&A^>!*[T"<0ZJ#4+D'KUMHRIZ!_SK\L\R
M26?4SYJ6_J$<P O<_]:9?BX'EX&?P[A'BU=?:-!5,L>\]BF^5STN'JOC??4?
M8 ?E$7:-NKE!5^H7/<JW)$UJGWW]MUYC#FO]M1V,I?;NQW3-Z<9_ <9"_WZ*
M[*3&8O;:><Q7?]\Z*M#+^U)\OK2 ?ZCZQWU368=V??2V=W[>_R_50_WCW\%>
M.+^X/CWNJXMW()'.?^Y?7IU>G/\[K&OG^D(=]57_O_K'/UWW3]31K^KZ0U]=
M]M^?7EV#!GFB/ER<G?0O%:B6%Y?X!WB M^!:77WH7?:O<%.N^I>G\"?0^B[.
M]WZ&O3I_KW]UBJK2Q\O^N_XE#G=U?7'\G[M?T9*^!S_6H[<8+"-/(ZK(%DPH
MB3/8C/@V&U*$EF!'!44 =9IN5^+6IJKSCE>Q8"UGF5^\ )&@(\'*#*(DNW.Z
MOG< 2FJ%;H><:U8P@'4>YM+4]6\'^P<'A^@%$U=3L\*"FZ;6J A"CL V_1+#
M_"=1$M[AH$,GAM;V O-ML^*(S4^@!#L=+J)=('^B37_9W@KSR$_9DS)S7!0;
M \BZ+%/I]7YQ*"2H?\ P)*KRC6!-G9;#)<AUR4RW&Q.EE>91F>VK8UV4*1I)
MVC3"%>BOZ!)#'Z%.1_4:5.D:*&H6A2FG&@[S>.!$B'@T'4,:<E76FF&XO74_
MEF'+B7;/HW["E.#?6D_(P JOL$<6%8+'R95B]=(WI3&!A=+NP>*\;Q;6\V^
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M?P/%@:B19%7*71[B\" :#SC2)$@!%XB7&0(Q0\&6 <C4YM+UT(4D8+4E_P+
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MRYCK.?\C2OR?*?P/+/\/4$L#!!0    ( $N*)5F1NX=]/R@  ,S/   ;
M96$P,C$S,3DS,#%E>#DY+3)?;W)U:V$N:'1M[5WI<Q-)LO_N"/\/]0AFPD3(
MPC<PL$0(8P;O&NQGFWTQ'UOJDE1#JUO3AXWFKW]Y577U9<M@#GO8V $D==>1
ME969E?G+K!=OS]\=O5Q=>?'V8/ :_E;XOQ?GA^='!R]?/.:_X=?'\O.+5\>O
M_U!GYW\<'?SKP3B)\]_4YL8\5^=FIC/U7E^JTV06Q#W^HJ?.=&K&#^!%>/7$
MOI?K3_EZ$)E)_)M*S62:/U>S()T8^+CQX.6+5R\//DW-T.3JV;/^UHO'KV @
M)[4FO.=_C8?9_'GSD65'9SM?SY,Y-#AWHUD?)GF>S.0[?] C'><ZI:&>'IP<
MGYZKXS?J\/WK@Y,#^./]N3H]^/WP[/S@]."U.OGPZNAP7PWV]X\_O#\_?/_[
MZLJ;P]-W[=.ZZ9AI;+=)!-?@>:+RJ5:ODB -53)6KTVJ1WF29BJ(0W66)Z./
MTR0*-7P!OQZGQ<= G4]U&LQUD9L1M'L8C_JW.""@]8M#-\_#E[=,0&[^>&YB
MD\0*_H^S?V/B(!Z9((()![F>P;+S 'Z=A4$V?<X?7@41/*575\ZF6N=?86RW
MOKC_I]4TN- J*$*3ZY#F&HQ&R6P>Q L33]20IZ0RG%'' J^NX JK-7SYURC\
MJTB>[W,+OZ;TZ9$*B#G>Z&%:!.F"I['74UL;6SL]9>)1!/U#;]A"JJ, AQ(G
M.4QD;91$$?";N=#1 GX;ZS3%<2;8I-?AV"[0ZDKF5DAZ[P,'JJ1(5<*+VJ,7
MW1O*O:#FJ<[@[TR- Y-&"QR:"J((J :['!^%W^<PFJS>Q#S)3$[\,J9?9/ZK
M*U=,'!L?)?$X26<F7ZA+DT^)]D6<(RWF*=#%S",@PD3'0.X(" "_ZSE2QS!?
M?HAQV;A9XDSJ;C"#T8Z"6]UTU1UWF^V>%4-8 9@TT/%U4@QS%0R3(O?I^&N:
MX4IF:C T$1(+UG\_03H5FF@<J-\3)!I\.=)I?,N#O'V96M]F;<PXA7D-M8Z1
M*^<!<GV09<6,]TF0KZYX! +N 38="4D4461"%!DQ1?IJD*G09*,BRYA]WL/^
MXHEM(CD[MD3/7P8:$NQ+84CD0V+R5%]H[':<)C,8;1(6HUQE ;)N KL.6DA5
M!AMPI%EI8#/ W 5MY0P4J1D#N\*4DSDVB\..$A@G/QWK28#[7XU TJIQE%QF
MW),\G<09-$)R%_^<Y[3%+Z=F-%5I8+"9S&.QT&,Q UL]*%GJ2OJ]"^)@(G)%
MN'$.LA%G F)A@MJ1R9C!0$!@Y*@18=E @&2)"G4V2LVP0?H^BM+6Y0\3S<1F
M\:B1U"H(_RRR?$8R"IE S=!J0K%41#E3!=<+Y@;,!>,@<60R5> D\L#$^>+.
MJ>)7008S #&I1"G?!<7:M:HF$R67S8%OC?!>56M8_D(VLCS75\>@P&JO86.)
MTI]0;>%>L0K.6BUUZ=DVH&& \B!A!4EF0%^!54",J^;%,#(CD+"E6AJ;=(;\
M;C)@<'B3U!9V=D+/.E$Q*%\YOH"M0'S*1N1:4VL]4FLG^X/C5X]HQV/GJ?ZK
M,*+JAQHV0:CG&OZ(0?!1GZ**K>RR_:+&AJ[3D,P6-[H/_;,^=SC6(2I3E6D0
M0*"T85&CX))%#9D_\SG,(QA&,(8B$AD$$RXBD36R6&?N?: //'+P:30-X@F-
M9&:R#-?!MDESN\V-]S4,09!T*+B1&RPK*"L_6EFY06E622AI0UAG1RF:/=&B
M97&H'^22\K7/-7= E":9US\J)F(B%I67F@0V#00T!]I=O. T4V"C9(@2$M8Z
MR)*8&  5;DIC97UQ.=6DS+KL1Z14JC4.RIF,R M.FP+O2A,AJ!G<O&F**C*%
M]V </S2+'#NN$(WDR,CF:C+280&[DHWS#$42B3J3?<Q\BH!8\TABF:35]KB2
M6#U_)>M#P 5G:2EJ&3F#AM)79P58!N7#9#;P?/2G %J"MGHH$0,XZF<D(0T0
M15\8D#XC+<K>'E>"&8HYEA)H7X'A0B,0CFV9%HMRIB39!K;[U15]$40%&T#V
M)-8\#109V5U5RPD&:F:T(68!V K#A2IU1P_MF4L-!B+\7>LBN:"M9D\^).+$
M;.@8/$B*H8X,F'Q,Y5)8 $F11F@[>7MHZ-2W=P2[<T;(/HKZ$5!B0%-]Q_;=
M7;!$W,AYD7S+M/RWR4BW6_N13',\#T.+"?"EIPS:!9\(V!2UR&Q6Q- A*9*T
MKL<K/XOJYM;Q%P/CT:(UH<$U\XC)P3X!4"^)W1-TLO#W&[T@DV+!VWVHH1[6
MC&W=Q!=)="%ZCZP*0]H']'D4Z7A"\@".$'^R'P*$./2-A[=(?U)_%N&$['':
M&:&&SD&$L"LE93LJAI-%ZR+\T.+^<?98G8!>U9=(T&D"8F<_P2-7IHZ.3G[D
MD;]*LAR/@.] "P6C*0P\S[-;;/]=((Z<S6WKPM*?T% A*8<\I\=C]!+9'8/G
MXY0LDV3T465@7X(1VSB,JZO/X0$I5C[6XD,A_((&QQE:2+,A:,E='LV/O#36
MWYCI]((<&JWG%-HD0$HZU=.<?NB=XIKZG_5U]<;H*/Q-G8#N?0[/_U6@S0#-
MJO5U":J\>'WXWVKT@@,.FULM$8<]_&X(%K-.W7>OH@#8:+._"]UG261"&$(S
M'C+/_:F^> R]M@Q@")KZX_I0 ^?"*.<T:G]0>RUCPH'>M$N/-(^1-DR.'W$]
M.P,\QZ<?_C-0YV\/3@<G!Q_.#_?/>NKP_7[_Q:M3Z/G5X&CP?O] G;T].#CG
MK]8.T08$P0GJ)G,R(IO2V9K-QD>W:CVT#[U&G_/!JZ,#M7\ 0GSP^O7A^]__
M]6#C 7T^.QGLV\^6/9CST D?S#/@$/NOYW!Z"_,I#G+CE^?J)@% C"J>V@Y
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MM5:5=0:-9Q<:YNK(F"W?GN0A^08-U2RL\YN386(#VQW#)>XFTYP\3Q;Q40Z
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MN#A6P\U+)ICEUU8ESEJK]:?=EA+%#!,2+&9;W0:$LC5B'%CSEFJ?;/8W2G<
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M\U"7T9?!6>F300.+\%W=KZ^!SY@E<:PBGTZ9=C%A@8(\3\&%I]&G"L?J_:=
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MR?SZVOC;*^$;Z(JB+E6C";VY $Q_>1$N)]A'-R$8%/!CCLX'>T,!".ZUI%W
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M<9[EN:3PV;A0?(/I\ %[D]Y9^1+FT RM27-DACXD\ED+TFB!3)F@@24J5WH
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M-[QCQ+;(!XC'K!3*?]O=>^B(@M(H,'[N(X3W!O_&:O .TU6EBO=2J,_2._,
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M''/P%,<^SRL_CG \,)UPR,:6?@;,BJVUM_O[G?VNM_%VK[.WAQZ1 [S2+NE
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M9:"47$4H.GTX1KT\NJ^%V<)X4VL3 5U;A+5'56C-=([X<JQ-1$BY^XW4";N
M^^T=#W)MF%6B,=77^<9>)A.5@F"8A>*L8<!X8M==:D@CZ4'ZG@IS[E;6],U>
MD*94?(FVG[+/*X/^4(M*N.0FB>"\97)B#?ZR_'0ND+1%!FA[;U+1(L?W'#2M
MK5S0+]<CQR0EZ2=*B+9O3NU\OR.-=@7"D,2J[[.B:MN].ZT"Q9#O>^$0]$K(
MR5X:'O)17"L+?2Z%+05,9CR7,GB:HYH@TZFZ@<^'&$C#:[\%[-HV2$HJ=W9,
MU%:@CU8FW(9T>D@MWI;81""P-TKE2Z@)KW+O3*?'5U +T@0K'3 ,E+N>.RG9
MTJWX@.H9V7LWC5II5@[E-AX&XT?HSL:B Q8XC^2-\R,<)87Q_27PF4K/7@\9
MFCACKM*A?G&4@ U?9#H\84/$YNM#!1[D7".=BZ%2I.>V]C1=%4EV[W/#3:%+
M734CBJ!AT)XTL KA0G' '%D5Y677R[<=+[1T<@PDNK>!+/UA]$ H$%1"*.FL
M42/5 !$'N"545_//%"U>=TZ!0CA\X2B$@Y>*0GB4>_M3$*;>/^D>^5T%&#4A
M3VVU[NX3\53: O@IWZDA<:.!L8YKPG<K>['E-(4FP;.?HOC)@,#0DG8T.I/A
MD.3E&)/6:%=6NCPL-.9)!:+R0U35 &'F@0/6WT# Y9]ASL]\I^U)H?\"\QUY
MWDR@!-DNDR+3W(@ZB6G>99\;<OPY)=U<0G1=J?Q.J1ACP_00:@B&[Z+LA'#6
M6:DAA=TA:6(?BN@>0SBP&?=*Q%P.?]QSUGB(D+%A\*?%=A><6TNN,I7*_1"/
MBEPR&@CBJ'ZTB&L?[G@V^-FR\7;3W?&@./!]THO@B\R"*<P)!!MD/EAP8K0%
MY +LL5XOP@B)06 ZC[X)P0-)>S?WOJV7X@L.BQ0PTJ7=4[@XR>&PL](ID0@Q
M%F'F? J#+?:#/\\W_[M[:)J:U!*]E=-+30:\D]//G\^//WX\^_*/O[_9>D,_
M7YP?G^B?'SBFL3?++V!S]_,;?-[63Z#:VMM-P%,:<]G89\+IJR"/LP03Y;8+
MI3\WMGSYKZ/]@Z.Q;4K,BS^CM(B/[$F?(/[Q_RD2X@3Q9O@_4@[2S(*L<#Z[
M3J0EQ%UD !<?"T<;A$0<3"TKJ'N$VSGB59Z63IZZ_#\EH?IJ-,5L@L5:U=O0
M@3RX,^A-WK;W'Y)3$;UW/M,XP$U8^GV#2!+F&'1Y%*2SC:51</WZ^VJRC_D>
M&03E(,Q1F/-(3*985LT,P%'HPN]*H/HT3:Z$$_WJWOG0;(.1:QJNX>#U%*_.
M*=YI.,5_Q \5DJI$"@R6)0_D-V?1C!-+JTTYGGOG*T[BB.@T,!Q$!.>S#:5B
M'8F]U'*D7':TD +,PZ2OD P-[3*,8BB'GW3&@T,!*BHU5!I7R-K L6$7=Z2>
M/!Q4CBBVU@X)7*<"YBFWPN+=\^?12LNM\,+Q@*!8:<',?*&Y<\*4@3\,Y,QN
M$-8]Q,XF*+8NFVMCW(MK=RN1V2!W8J$8[EVFL!+#7,1[Z9F$UHDSR0H_Q&HY
M_.Y6(\S#<>0D!5,GTL#8(B750#N&?64 9RV9M9:H^OCLC@3;$4R-CBL^0!Y/
MKP.S28^"0,HFPPKZ!Q]$$5:LMC/))"K38EZ./B;9^Z7/\E\9,8,I"GE<%N:%
M*71@# R,%$^.A042A#%/DZBB"[B CR(9FD620[E]Q7 P4U-WH^)-7,L\8.JK
M,>PEJP>I,?)09G"I'+KU-5E^7#XUY+ Y@IE&>6V#&[;7)(^\_7<=[X,C5$F/
MU:GF;&F5#7X_;#9K7Q !T+A7/)!ZJLE<#..8:+29S=0.A.VR!0"DJ(VH\$,[
M1!7!=8=8SN30G2</'82)M0T#S:Z.1*+CE@(.98(BH!=@Z?2]32.>RY4+Z_=-
M\+#G"+E8724_\3X'P:I=Z"6+0(?3,F0-Y'(29F%#!!91<BEJE::!'Y9-#J3L
M*AP4:4]XR)!L@(#S*C(#T\%>#&&""%)E%A@K'<Z45ZMDJF7F=>.DEB0FZD%M
M"/O.3!M3MLX#U]=,(IJWK9R-UFEA,XT@JZ>%,1I*1IRQZ^Q%TG8C.ICR!EZ[
M$C:#.=(>/\.\^"/[S<75?71P=2=X^6)+)I:/8[2;@VC^:9FG.*LLN-F8RDH#
M-\QR\/AT>6FYE+2$0K10#,UU;3%:9;0D"E82JP= ';5L:WZHP.5N)>[R,84R
M&MT_#9!2JF[9(7<!<^CO8S9)$NLI#L5ZQ3TM,N8=)>BNX7@Z^?8U*['!F2^6
M%[CEV[]_S6IT9:;.U5E%4F@R\,=!?#X)1\#1"\_.'[[4[/R3V#AI(>!YAS<>
M,9JZ13RV&H2-ES-K(=B4601%=97T[]E*@.N??;FD0L]4)F+Z6J%@LII#<L/Z
M;/OX#V0Y^PW\60H$?OY\XC;;M$U#26]HEC=I?>GT["1SYE;=A#VV8-%!UN#2
ML.1TU^D2R5PIP\U!-X'"\SU47"X26;OY-:5*Z\NIV5%PSYQ01/4J;:6&02Y9
M6RF_8Q-+D[4(OIX2"OQHNH8T)T&M%+IC+O>R5<=E;DGLEET-[",M7Q&6=7$S
M!:G/5^5>7<YZ.+U8Y1(SNS?C(IF6$F9PE#6_'V%4'<Q>,WI]N3AEC<%H%(4.
MIPQVF[.W)Y+9V#H"N2<YODS1&R'D!N/\'OO)"$1<.B28YA12[2:_KN]Q8)Q+
M*KI0&;9#2Z5'*)-=47M/>Z/KE:\6-WU76<G ,+6H/ 2S/DA)9^/D'.CFC3?!
M(?B("C $5*WP)')"&PW01$,BGKSVY.CFB=W1 />4MI3342U;R7Z^>90FB-!R
M2 7U@2G49/B(0VKE(K0#;=.9+7=/@-U4\'ILL6)>D2-*,@CRG#)X?*#6UW2!
M8PN30*!/$1?/."6,3C5P@[%79]:>S'B\OM96.V:(O\&V"T4-:TVI@]\<"-?%
ME^.-S:7S:#X3Z>)J!1J.67@BXL\I]2M%5];GR)*$2TTG=0?KRH=&LV5)G,I4
MA" KA,6\FJO-O=9,^!J/(@\#.VM+ 4GLU#_ @Z2IP?J:?)";"2:@H?ZB[U,
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MN'@&'6XT:0YQ!)K[DE?(!TN&B>9SE_"E#D&G];"E%@F>*E&2J B[%K&M[\:
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M<&7*V5JU;1%+&2+3E?".D=BJIA38++VWKSB R37E%+X ^VID>JTZ3,Q\R3L
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MNI9)6.9.\UWF>T4>9'Z=LZ&B":BEHA #IHIZ+B'EG(X DG"!FHNO%=%].0_
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MP+3&%'-[8MEP:EQL-3^!=6DRP^"[@HLBACT?@*%.BS@,(]B.),:*\'N67CS
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M*7*X*!5+B=3@5(8.UA+,;ZC$S(E[M."Y6%:."4+S3ZF!.%T+3C+=&"4X2FV
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ML<]S#9X(NS03W$5?SR4GRVOVL9Z)P,\%%K.Q>]"I@U2GWN;:5;T\$]_O=GY
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M^CLYIY?TY9FXSJ4K_N<W@</N-X&Q:SG4^='L]O()G,;1U</-]<4W4$L#!!0
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M>K;S3_[+)(H-"\27_#D\'2)5EQELA,IE,*8Z'&$>\9ZZK.'TK:;3QSC*J5K
M L>P18=\/2L_OFI6\B+^()W U&91@'.+*MMPX$7(BA=^5@R!Y.$?SH$CP_8C
M."RX]1=^%N[$:?H9B<+9^V+F%[#'YVE\#@<0Y9]YK642J P?QM4/@$/"V'
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M/">!WN_1^I/J4G-_HHJEEA;$8?7+@ 9F?"6T,,<M/Q=EFKZ=*J2C @BN5#M
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ME:(2/9RSKW/EG?M9A+PHEY8<#EB.*BU6<]B,^LZ%/TWBJ0"DEU*="8NY(]#
M*?0K!R^S84(F&HSF3,::D)S6(+7!J7J7J:*!73R H'ST. \P&Y-J:[XY\H@4
M6/BVN&:6W+F'"I,0S<DJ.$&4=4=Q2_9[XI>48B",DG96;M.KL8A%$"U(WZ2$
MW[$N8*I" \A9X1VOK=*WI5E0MYW4\Y)=U*:[P8S>Q VF1D UUZH4(9*R.8Z_
MWVHJF/Q*^@TO[H).TED'E86AU-BP,K #<K>!>UO!0PY9Z:3GJW=AZ!!6@E6;
M-$C$'F>_IR6B<5O44L^VJ<K*I9GL1$YN$8Y+ZF]@]>]8%STI@2;C!G31QGQT
MT9$:D+&.^>:]K\!F&WO?M+J&_=ZQU#NYUAOJB8/<[X'63?E#W'+,;\F&QS(=
ML#'Y+%H,&DG?5#2_FNEML[MU1@65*=6-36JE/)KC!?["*0V@HQ658QA487P@
MT(S3>=  6VT3H7Y%Y=/]!YZEMO\PL]2^G0KDEL%V.:FJ%IZJZ.)8JDC*1NN+
MS5WUM.O3*6 DI6\NL'2?E#_#VC7(<[G,*$L]/W>*Q1@6[O*C-G;>[PDC ;V&
MZQ9&A5O+@@6MJA=5,M7ZL+B(SQ8E2F_T381J7-AJ1+F5^U)7RQ.!7:FX7W5]
ML!Y?*QEO7Z2S*0*&-/N53F,DS4&;*+EPI]3U4A7MH<1("6IUEN/C5O9[_'Y?
MU^W!$N-.L7?X\9RS3Q@J,_2,Z)GX49S;P?12FV.X+_>E\!:6QQD0P2A=\@<Y
M^5)J9J>U^B&D@#'26WECY% P#.7OZ;HC-956!'"SNHLXD*A\W,JJ8=LD-U;<
MT5<J\,O<E()*2M@*+#@OS?%JMJ6Y&LX>ZJL=Y0YA87V8C%'28/V%4< %V\72
M0#*9IZ74Y&C6?"$TL^*.=A.7<P#QVA&HT@_5O=4F;[7LS]![BTV=S!NPU+(\
MW*@FI*\ZA]M0Y9&RP?J-L6HCZ<:/:#I8#]1NA>0@U$H280$HM\?L&'NS48FT
M9-5E-41<)4:7'Q8:7X:]I."$F$6."=<6L)HE';?0'H([BW44ZRQLFZCZBI9Z
MS>9)ZHNX/0(_GU')HKW#X1[P%*FFY)L"2)ZM[-9L_WG]2G2\7*<<G6[!V5*3
MCOI3V*)TE9YV4J'NC5.A#BO3Z2IU7*%N8*Y)M2P6LG7WE+'YK[YLQ *%*;-I
M&:'+'7NS68<0&PD%-G7("U!O=(TJLWRT.!IZ.YX)7FSX&^F(Q$BL@>HTYJP5
ML6+,#YY"OV=*7Y'3@-(:PZ%3VW!,O(.*#2/<<TY-EO @\W*^< "<>)^XSQU=
M7.\B2[4MH#L^4U7K+S,?VPSC;OGG<-'I^LD&X:9HHSI/049D7-&[8O-@*U6U
MZAC?1["IH0[1OI9]/]%O=8\4?^!4* 2&[+WST<TF-%4E#^37_=Z)M:>JA_'.
M[/KK2K];.P-[V#@)VS]XDXT[;ZLA:.OEN.W>H#!NK?OQQD9<W5(51CQS6E$C
M7WDM92[?:9;"1'V"2BM(=B[7>+H L;/A67Y;!I]X1XL,-/W]:OU-4BI5J)T5
M?TA7<UN/DGAXI66[;>0-4VC4H91RR"5U^-4^V1R8:#[Q#9[GPJ=.,J)%V8K(
MU%T/F!L6@4JXIJJ,9B;4TJ.>F#CU8Z_U>]]8FWHP;B[K4\]S 2Z;-+NNZW'9
M:\5B1?K:VZV-".&99J&-/9")4!W V81^KVWCY]C0@2T/X.L%-2,3[0A?$-:V
MI]&87;:JV;!]K'2U8KL/Z#[':K,RQ<I#PSMO^@Z&G_/^]9J^\QG8T*6SXQ'Z
MW*20*W:L@+L2<2U26Z65"VRK4 >S]&NQ_"TYCRO?XBMC[F16*[U=:SS(E=7F
MTJ.[I:&Q:?Q*NG6Z0&OA;]7H5H):DE.*O-*K%Y3T.?:?U:9'E&;ZRE:=WH7#
M1)E^;)4T721?&QY(8M9$UKH2W&JLIIU7[$FGN*#8''DI+2*Y:BUI6US6C1)2
MZ-_2'5W'QG)D0E0G%Q[8'^R/1H.GS_>Y;Q[=(+18,?V..'NJPQ/TKF>[AX/]
MPUTY"N+$6.Z!"T#SOR^H<G9!R$JT>W.=^4(/C^!A.Y*Y[&:\ 5GXB=&U0C-9
M;&@6<57A'Y\\&3X9>8]^/!P>'E:/(0*B"0I]!)D(*5Y*CD+J,2J!/ 6.([4,
MY55'VN.1#G@DKIU__:%D/P9&"?6G4VSWCNV]C)7ZX^AIO:"R[K/(OAK8KV;-
M96(FQE; ?F<1&-?4VT&J1%^[*#,#YX,@*Y5TU,6^TW@JZ#I)]"]XI:P$<FGB
MG.9!_''_^=,!=H&X['PK]9K7LF2J/7A)AF%"GI)V$_*0X:_"6&^IUO$(/=-W
MI8L<-Z6=&VDGV8H^$[:XN?9X0SS.U.4BLG(P;_6[3_#=IHCVHZ:E*CZS16L]
M=*<<.AF0 U<,G#D>1'NVT2K^^E8GA= &#KQ'T6/NLRQ7V;"I*O<J"VHV3&JK
MQ4PX'TL@#5FCTJ8:TCYP@,*4FR<&>QE5"R/&8IH!9B2SYF9V"76_((NX=8*S
MY=06QJD83S=Q3Y>Q:3%E-3>@JL1OOU!G%N_Y\^%(7(UB$M,LKK")5[QIWW((
MDK]&WKX6,7*BR&N.S86Q*]:SG7_B$[JF>F1>UN_!VPZD-ZV?%>@]4+J74U9H
M'9HX2C2=%>P](K[E[#5^C>H&W[2:J.!!Z:T-!7H. H,2-+G(QGDDC2%S"?*O
M)#0MMA]%=0J3@S<UZR]K4'#A4RN1JY=*NI2\\M5EKZ09Z2FE"VL:D'@AQ4*+
M+Y= =1U_K&Q_G?GXR14OIPG?X3D@83^*SF7A5MMHG5S[)=5[8&ZIM\8EO?;&
M73$WF$2%JN5^5;;REL75+;H45H]YC<CQP0./'!]TD>,[4ZKT*&V^AS:Q]RKU
M,^H]_D90B&XK'<3 S=F;+%V%"E:-D8=CV+"0QI(M3A!]_R7;%341# ONP''N
M%!<*6[.UV!0KI#/WTI%IN-I-NU4W!.,>!#.R-M.'<LR-E^G[&1B3U,N]L4G&
M"N#9X!MX 61M]WNG:@$*QAA4Q'WM5P?^FF*_8(-8U!!!T J\<S\NE37)<&)5
MUJBHLU:1<;=GBFLML#U<B_^1ND,7.]HG1S$O3WHYIPO%.V]?U)CJT#L"H\*M
M0./@A]IHHRH%*PJAL8+)IU_3)N'+4/=!8S5U(8D'TM9.>TRLJ<JF(OR"(M-C
MI7!R1992K5@J<Q(B\)GG.D5YQ,>BK4[LL78E;5$4)HXE3$(698Z\+[R]F-U=
M2"9Z_;&QUMU0!])!U:WTT00J[XLK^\]$/$+%4M^\:9R.,1X'>DTZ7^ISKJ!-
M@6XI1M\(]>BV:T,;]W:4/L=A+#%^,J_T#"*&*[>I7]I--?>#+.6918&GDO,H
M2Q-QXEH+3H?U&0Z+#CONGIE%MCLL>C"HZ^Q VNYZ8S_Y3.'U,L-/IRI=@(I
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M,@6:H,!44FX1O.8\ZMV$.V34]E^0.L-;^X)4"=O%GM9OAO1)UL*@TN'X-JM
M?INNF)]4O0FJ9_J?'IO^I_V>-.[MNF5VW3([=-'7HXOXVO&4L,60S @Q1(UF
MQ!991*@CYUKR3XJ4O[CG%?X>> ],%VKU-?&]JI+"=:.J97-&NYL-:G==,6\
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M2<@L!@4+31#\6DI64\UHRV)877FZ!F:Q;+=J%K6,TR($2<V["IPM904;"J#
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MF!/TMA9;0F\ZJL?RIZL>5R9Y9T?_RZN/;_Y-@<[?S_YX_]O_!U!+ P04
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M2RKZCJR'J9PGG)64'^M!SJ/*:5Q9.0^S):08!GK;,@PT=VT,#)%T:;A1<<.
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M;<$ ]ASK'>'UZ<!W\-98-^'#3#<U<Z+#):B;]"',9VY^_NWR2^E0<@JPGL;
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MA1#5!PE/#1P7!R039'6^&<5?6Z(MHXG6DP!H;C25H,9!?K4=)!/'!]>:4$
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M#D159+&>JQNL+01CF[W44773\5@H>R U1?1T'K,27HE@5XQ3!9(R,$!:>2^
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MM=\J?*O"K!MTDU"#?9H<[L1B#*/X)OGWAU1[O6+FEF3/R$MPG/HA"B+((8B
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MJJH.YE]U<!"IB+[3JH./)&06\(OJ.OJ$B<>ZX:%$C)T.:0PK5MBF18*51Y!
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MNB7G3"ZHSGLID9IW53A^SQP/UJ@$G+V2V.^!%S F[ 0R9JAO1TR46U(L-RO
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MZ?7Y_WW!#[_??__VY?\#4$L#!!0    ( $N*)5G#?W6&.0,  -8,   1
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M']UK8$>D-[&&U#^U/&D12$V:M5A]Y*^C'='?2!LRX$>[!BPVF%+]_ >Q7G=
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M XMEU8U*(XL0%-/;$"92'P22TRWG'==PCP-+?6$R9%9S NFB &7 G$E*+>^
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M=0H9AF9CE_2?)@NM/[I+XO1!\[I_SJL5SG)0EYJ1*$,8()U'1=_WW]'@:O-
M9U29A1F/=!U?Z8:>W*=5@.)0J[!3ZQ<3*7'LO%N0J)M\TI]N/S&_S$/T]3O_
M E!+ 0(4 Q0    ( $N*)5E> F9'DYT  &B*!  ;              "  0
M  !E83 R,3,Q.3,M.&M?;W)U:V%T:&5R82YH=&U02P$"% ,4    " !+BB59
M S4<CYM0  !YOP$ '               @ ',G0  96$P,C$S,3DS,#%E>#$P
M+3$P7V]R=6MA+FAT;5!+ 0(4 Q0    ( $N*)5D;-=*LTS8  '-# 0 <
M          "  :'N  !E83 R,3,Q.3,P,65X,3 M,3%?;W)U:V$N:'1M4$L!
M A0#%     @ 2XHE6?M(3+3."0  )BT  !P              ( !KB4! &5A
M,#(Q,S$Y,S Q97@Q,"TQ,U]O<G5K82YH=&U02P$"% ,4    " !+BB59F(K*
MYK$:  !UAP  '               @ &V+P$ 96$P,C$S,3DS,#%E>#$P+3$V
M7V]R=6MA+FAT;5!+ 0(4 Q0    ( $N*)5FTQN-.1S<  (LL 0 <
M      "  :%* 0!E83 R,3,Q.3,P,65X,3 M,C5?;W)U:V$N:'1M4$L! A0#
M%     @ 2XHE69LV/0QV,0  *U4! !L              ( !(H(! &5A,#(Q
M,S$Y,S Q97@Q-"TQ7V]R=6MA+FAT;5!+ 0(4 Q0    ( $N*)5F1PH6S^P(
M $0*   ;              "  =&S 0!E83 R,3,Q.3,P,65X,38M,5]O<G5K
M82YH=&U02P$"% ,4    " !+BB59Q-%&L"D"  !0"   &P
M@ $%MP$ 96$P,C$S,3DS,#%E>#(Q+3%?;W)U:V$N:'1M4$L! A0#%     @
M2XHE65:?[T&(!@  /1T  !H              ( !9[D! &5A,#(Q,S$Y,S Q
M97@S+3%?;W)U:V$N:'1M4$L! A0#%     @ 2XHE662=X'9S!@  .AT  !H
M             ( !)\ ! &5A,#(Q,S$Y,S Q97@S+3)?;W)U:V$N:'1M4$L!
M A0#%     @ 2XHE69U<+)91!0  U1@  !H              ( !TL8! &5A
M,#(Q,S$Y,S Q97@S+3-?;W)U:V$N:'1M4$L! A0#%     @ 2XHE63Z9HFS@
M!P  9B(  !H              ( !6\P! &5A,#(Q,S$Y,S Q97@S+31?;W)U
M:V$N:'1M4$L! A0#%     @ 2XHE6=G9"L[G$@  "&D  !H
M ( !<]0! &5A,#(Q,S$Y,S Q97@S+35?;W)U:V$N:'1M4$L! A0#%     @
M2XHE6805Y6?F:@  &5L" !H              ( !DN<! &5A,#(Q,S$Y,S Q
M97@S+39?;W)U:V$N:'1M4$L! A0#%     @ 2XHE68P[O6;*!P  %20  !H
M             ( !L%(" &5A,#(Q,S$Y,S Q97@S+3A?;W)U:V$N:'1M4$L!
M A0#%     @ 2XHE6?UE(F>=-P  GQ<! !H              ( !LEH" &5A
M,#(Q,S$Y,S Q97@S+3E?;W)U:V$N:'1M4$L! A0#%     @ 2XHE67CZP/QN
M#P  QS(  !L              ( !AY(" &5A,#(Q,S$Y,S Q97@Y.2TQ7V]R
M=6MA+FAT;5!+ 0(4 Q0    ( $N*)5F1NX=]/R@  ,S/   ;
M  "  2ZB @!E83 R,3,Q.3,P,65X.3DM,E]O<G5K82YH=&U02P$"% ,4
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M P!O<FMA+3(P,C0P.#(Y7W!R92YX;6Q02P4&     !H &@!+!P  #?\#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>ea0213193-8k_orukathera_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="orka-20240829.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="From2024-08-292024-08-29_dei_FormerAddressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2024-08-29" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-29" id="Fact000005">0000907654</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-08-29" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-08-29" id="Fact000011">2024-08-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-29" id="Fact000012">Oruka Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-29" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-08-29" id="Fact000014">000-22873</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-29" id="Fact000015">36-3855489</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-29" id="Fact000016">855 Oak Grove Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-29" id="Fact000017">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-29" id="Fact000018">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-29" id="Fact000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-29" id="Fact000020">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-08-29" id="Fact000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-08-29" id="Fact000022">606-7910</dei:LocalPhoneNumber>
    <dei:EntityRegistrantName
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000023">ARCA biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000024">10170 Church Ranch Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000025">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000026">Westminster</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000027">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-08-292024-08-29_dei_FormerAddressMember"
      id="Fact000028">80021</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications contextRef="AsOf2024-08-29" id="Fact000029">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-08-29" id="Fact000030">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-08-29" id="Fact000031">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-08-29" id="Fact000032">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-08-29" id="Fact000033">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-08-29" id="Fact000034">ORKA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-08-29" id="Fact000035">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-29" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
